<SEC-DOCUMENT>0001628280-23-017564.txt : 20230511
<SEC-HEADER>0001628280-23-017564.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511161152
ACCESSION NUMBER:		0001628280-23-017564
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		49
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		23911135

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>advm-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:2ac3d0ca-e198-4bf8-a580-7d7820b89131,g:8a36a30e-c5fc-4cb1-8f5a-19bb971faa82,d:367b8e12c33c498fa919b5dac5350798--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:advm="http://www.adverum.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF8zLTEtMS0xLTQwMjgz_8ad9576b-bf24-4b79-b211-b5b12c877d72">false</ix:nonNumeric><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF80LTEtMS0xLTQwMjgz_b9e2a688-5ee0-4d87-98e9-de4e44e40507">2023</ix:nonNumeric><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF81LTEtMS0xLTQwMjgz_cdcf07de-b63f-4c1b-80f9-4e024a80017f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF82LTEtMS0xLTQwMjgz_359503e5-ac6d-4ddf-a224-33751158acf5">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF83LTEtMS0xLTQwMjgz_27500ae7-fdee-43b6-8a5b-7af7fe673602">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908731d3af1f43f28a6d4584a8940cf0_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b74848539634879bcde0f1b19053254_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i824fb6df85304dfbb00b9685d592e775_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib749589928be4d0190f40c3411ccb77e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aec62f8dd8c4f48b6d57236a9bb5cc6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a6ba63d466b43e2b0636ae42f70cab2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb942d212c94ff995b15db583ad3d3e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27d3c6628b86457f8a81acd0630f6416_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2885fb914d4a9fb1475dfd39b35ea1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34050bca04e849e2bd858606a28d821f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeee002c84444ba69bca37d55ddd1ece_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6aa1b2007db4438822cc804626038a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f44c0916af45cb8434366c7f852d47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4ffbe5f1764673b5760d7479fc4039_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b77532d5ff487084fcf175a884a30d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0300483de0d645a3a3bb07bb05d84161_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f92cbd913c34c3f97e0fdd54f7f49f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4e264e0eb94410a047fa84fb28d5ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8291885aaa4357958e19254cd61ce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3700930922134893b6263b8067f724c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa5921d28f3a4035bde41b23af227eab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acd8b1998ed4efc85109c235f6f88d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff760a046acd449e902d35ee4ca193bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99b06b0ddf94978a7ff951eed4a978b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b3ee54be714adca5246d416f27fc07_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0de0cd99e31943a7a3398bfb2471b8ec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95892d79c3ab4995b59ef11e3ea7942d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4e308e31564406905c98313e33a603_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369a173705184a7cab09ad2a6180ed79_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf7996366cc460d899c0a0ab6b1917b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifecee66b5209450f86b53dd83c818354_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230f68b10a814c8f895274e0ac72fafe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1730a9dcc0e4334888e861a0228a1b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84cb988cff74c13804946bc088788c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71a70a3d2404129bd447bda21043c37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa47672f93c844228fcf48e2ea805f97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8efd9f62836f463e824a62629a695c2d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec0ca6f1e334c53bb5d986390d410e4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb3ac51c130c4ddd85a7143df0208a5a_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15e5013c42c4501aecb2878f6bbe3c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>advm:contract</xbrli:measure></xbrli:unit><xbrli:context id="icb41c12aa72a45c0acb2793e962d957a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee913767de5c457eb0abe869f1ccf788_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb926656b3e1496e8ae5e68b8a88bcaa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b02a910cfa446ca03e773f9c23dfd4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i231f853a0b294f85b3d8e11f4d5f56b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d414f59c1bb438296e4a6a98a09a90c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1325acb65c4d3ba80692faaa31ac8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb83a86ea384dff87bc2c6a80c8dc12_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ae0052ee0c4d30a61a5234d6eeb925_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c3989caf254e88ba282f8751412f5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie74324103edc4f0da546ee3853453605_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e5816500fc04144b5ebb1566cc9f4f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ee695f35b04c92841b271089b16400_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea5ef805f8c40038f3b3e1ec4ca4f7a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic17577b3961e43a4b40b169a76ff83db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a6eb7c0dd44b829c120e24f1ea5e32_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69031cdc433a468695993438b2b429d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1cc5fc2435e4ec3a7f02439a9d618fb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406b3e1f97ba43e9b9a0eba636ce617a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea30e1fafcc7467796344a1b9ed739a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97678bdca6e84570bb323a2f04cf2272_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5622823987bd4b5b9eaeed2cfac2dc62_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6a763430794cf4a5b4d713e9cfcccc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i367b8e12c33c498fa919b5dac5350798_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDIz_6ac1f656-467d-44e6-9d42-75eb1705b732">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6OWIzYzNiNDYxMjlkNDI5Mjk3ZTMxZDIzNTk3YWUwNDEvdGFibGVyYW5nZTo5YjNjM2I0NjEyOWQ0MjkyOTdlMzFkMjM1OTdhZTA0MV8wLTAtMS0xLTQwMjgz_367eadce-a410-46f3-b921-1152c9c2b5b6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNjY_0f258a89-bfb7-444c-a8ea-c883a214c0fb">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6N2I4ZjhiNWUwNjJhNGM4OThmMWVlZjJmODYwYTQyMjMvdGFibGVyYW5nZTo3YjhmOGI1ZTA2MmE0Yzg5OGYxZWVmMmY4NjBhNDIyM18wLTAtMS0xLTQwMjgz_48457769-f427-4eea-9d62-680bdbda2690">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI3_b266ea2c-b5ab-4c71-afa0-0d9a8646dc51">001-36579</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDMx_3ba8b803-f796-4489-90dd-2330c4d10f71">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NjcyNWU5NWY1MDJjNDY3OWE1MzJhZDEyNGJhMWFlOTcvdGFibGVyYW5nZTo2NzI1ZTk1ZjUwMmM0Njc5YTUzMmFkMTI0YmExYWU5N18wLTAtMS0xLTQwMjgz_f723e93c-6e53-406c-8705-d4fcebd79983">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NjcyNWU5NWY1MDJjNDY3OWE1MzJhZDEyNGJhMWFlOTcvdGFibGVyYW5nZTo2NzI1ZTk1ZjUwMmM0Njc5YTUzMmFkMTI0YmExYWU5N18wLTItMS0xLTQwMjgz_d0b60760-0c08-414f-acbd-779fff4fda70">20-5258327</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDMy_0f55d3d1-4b6b-4b2e-a5ec-06ca11ef05c4">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI0_644fab36-f0da-4e96-9dba-af16cb54e6d2">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDM0_ace94636-64b0-44d9-a288-36417725ccb9">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI1_acb026fb-e357-4739-9b4e-6a8a2b74b881">94063</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF82OTk_b96d19ce-7fd6-47b1-9bcb-700145e17b9b">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDM1_f06bbf11-528c-465c-88df-0fa28edf8b69">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Trading symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6ZTdhYjllMzc0YzJjNGFmYjhjYWQ2MTA4NTJmOGU0ODMvdGFibGVyYW5nZTplN2FiOWUzNzRjMmM0YWZiOGNhZDYxMDg1MmY4ZTQ4M18xLTAtMS0xLTQwMjgz_8f2afb32-0cea-4a6b-a1a1-b87999853358">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6ZTdhYjllMzc0YzJjNGFmYjhjYWQ2MTA4NTJmOGU0ODMvdGFibGVyYW5nZTplN2FiOWUzNzRjMmM0YWZiOGNhZDYxMDg1MmY4ZTQ4M18xLTEtMS0xLTQwMjgz_31b6e40a-4dcb-4839-b337-ed6597356a4b">ADVM</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6ZTdhYjllMzc0YzJjNGFmYjhjYWQ2MTA4NTJmOGU0ODMvdGFibGVyYW5nZTplN2FiOWUzNzRjMmM0YWZiOGNhZDYxMDg1MmY4ZTQ4M18xLTItMS0xLTQwMjgz_91ea0891-efe5-4d3d-a473-cc2eeb3f249f">The Nasdaq Global Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDM2_16a1f274-9638-43e5-b63d-8cb3ed16a6df">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI5_ea101041-d88a-47b9-8185-7e6bcd041c05">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NDVhZjMyODA0NWZjNDc5N2E3NmI4ZDM0ZjUzODhhMWMvdGFibGVyYW5nZTo0NWFmMzI4MDQ1ZmM0Nzk3YTc2YjhkMzRmNTM4OGExY18xLTAtMS0xLTQwMjgz_0c5a7baf-bda7-4812-a0ef-5acb89217a41">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NDVhZjMyODA0NWZjNDc5N2E3NmI4ZDM0ZjUzODhhMWMvdGFibGVyYW5nZTo0NWFmMzI4MDQ1ZmM0Nzk3YTc2YjhkMzRmNTM4OGExY18xLTQtMS0xLTQwMjgz_066992f4-1915-4b1e-bb8e-f32470713d6c">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NDVhZjMyODA0NWZjNDc5N2E3NmI4ZDM0ZjUzODhhMWMvdGFibGVyYW5nZTo0NWFmMzI4MDQ1ZmM0Nzk3YTc2YjhkMzRmNTM4OGExY18yLTQtMS0xLTQwMjgz_0890789e-15aa-4ba5-b4ca-f626c3f34f70">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI2_c288aade-7c0e-46b6-b569-d983c1e3e652">x</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of May&#160;5, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i908731d3af1f43f28a6d4584a8940cf0_I20230505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yMzM4_e70870ba-b59d-40c1-947c-fbc28727d43f">100,574,949</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_13">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_13">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_19">Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_22">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_28">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_73">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_73">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_103">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_103">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_106">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_106">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_109">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_109">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_112">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_112">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_115">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_115">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_142">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_142">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_145">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_145">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_148">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_148">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_151">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_151">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_154">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_154">68</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_157">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i367b8e12c33c498fa919b5dac5350798_157">70</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i367b8e12c33c498fa919b5dac5350798_10"></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in Part II, Item 1A. &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are not currently in compliance with Nasdaq&#8217;s continued listing standards, and if we are not able to regain compliance with Nasdaq&#8217;s continued listing standards our common stock may be delisted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, whether in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to produce sufficient quantities of our product candidates at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of our research and development, including vector production, process development, assay development, product candidates and product manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities, and these third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare and other reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and, if approved, may affect the prices we may obtain.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to licensing, collaboration or other arrangements, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i367b8e12c33c498fa919b5dac5350798_16"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span><br/></span></div><div id="i367b8e12c33c498fa919b5dac5350798_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMy0xLTEtMS00MDI4Mw_30ae8286-70f0-4723-ade7-34bc46d48ec8">67,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMy0zLTEtMS00MDI4Mw_2a713564-ac6e-49dd-8ba4-049b89f5fa52">68,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNC0xLTEtMS00MDI4Mw_b8cb4f7c-67d9-4935-9861-af8d7954213d">96,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNC0zLTEtMS00MDI4Mw_b0de5e37-c3f4-4e71-8232-a66932bd6d84">117,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNi0xLTEtMS00MDI4Mw_a04a4fa4-0a73-4f5f-ad2b-0deb5b1e4425">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNi0zLTEtMS00MDI4Mw_c7ceb578-b4d1-4fb0-9ba4-b6b194652041">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNy0xLTEtMS00MDI4Mw_0f70396c-cbbe-4265-b41d-7727fed0c443">168,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNy0zLTEtMS00MDI4Mw_6cf4228a-c923-4854-aef1-6d36b593d835">190,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOC0xLTEtMS00MDI4Mw_a978b8c4-353d-4124-b015-e3183348020e">69,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOC0zLTEtMS00MDI4Mw_e5f2fadf-eea9-411d-abdc-8ea5a04e6f85">78,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOS0xLTEtMS00MDI4Mw_d7b93803-033e-4ec9-ac0d-c3e142576e70">33,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOS0zLTEtMS00MDI4Mw_954da343-22da-4628-b592-4d1f2c88d423">34,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTEtMS0xLTEtNDAyODM_25d00985-55bc-471d-8fba-62ec6814304d">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTEtMy0xLTEtNDAyODM_d589849b-5106-4e15-9331-6b7fc85026eb">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposit and other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTMtMS0xLTEtNDAyODM_a2724fe9-77fb-4630-84f3-6cae5150366c">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTMtMy0xLTEtNDAyODM_9d5cb8cf-40c9-4061-861a-ae666dc751c9">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTQtMS0xLTEtNDAyODM_50fc6f07-7f21-48c2-a401-7e4fdc4ef373">275,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTQtMy0xLTEtNDAyODM_22d1e7b4-66d8-4235-b470-774fee17b2d4">308,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTctMS0xLTEtNDAyODM_c5d5fa92-9594-494f-a8f5-9d569902dc43">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTctMy0xLTEtNDAyODM_dda0289a-6387-424c-b988-9336b5c19955">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTgtMS0xLTEtNDAyODM_7696c905-5df8-4e0d-aff9-774ca62b6c58">17,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTgtMy0xLTEtNDAyODM_9aca8aec-ee20-4b84-a38c-748bc3214c36">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTktMS0xLTEtNDAyODM_e4aa1894-2cc2-4ac8-b643-55d361eb7ca7">26,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTktMy0xLTEtNDAyODM_fa13dd2e-8c27-41da-8040-0c0448779fae">13,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjEtMS0xLTEtNDAyODM_3bbe443b-9af1-478c-9cb7-7423082bf7d9">46,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjEtMy0xLTEtNDAyODM_199fd79c-d2b9-4a44-919f-9028c97e23ec">32,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, net of current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjMtMS0xLTEtNDAyODM_3d33942e-3191-49a3-b5ad-b943fc3d8f53">71,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjMtMy0xLTEtNDAyODM_233dc98f-e1ba-4aa4-9985-cf5601fc266c">93,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMS0xLTEtNDM4MDE_f35ecedb-c0fc-43ec-bcac-119a4a9960f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMy0xLTEtNDM4MDk_8a65784f-44cf-4923-bb19-eb7a4f2fb511">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMS0xLTEtNDAyODM_61db9d77-8c5a-4d32-b27f-3e90d57c9199">117,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMy0xLTEtNDAyODM_543e5a6a-8066-47e1-985a-063dd3e0e3fe">126,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjgtMS0xLTEtNDAyODM_435f0985-cd76-4a6f-a3f6-7bf59d0c7170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjgtMy0xLTEtNDAyODM_7f9272f1-a58f-4e85-99bf-8721b7386afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjktMS0xLTEtNDAyODM_b5f9e9e1-e87c-4543-a7df-0a89de644d7d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjktMy0xLTEtNDAyODM_61537f26-df66-4c50-bbc3-804d63f41f83">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzAtMS0xLTEtNDAyODM_47b01613-59e1-4b77-ac1c-0c612dfef571">990,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzAtMy0xLTEtNDAyODM_3c4422b5-3458-42a4-9c4b-8d6b025c16ea">985,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzEtMS0xLTEtNDAyODM_179dd2b5-d2f7-43a7-afd3-482f67a62da3">799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzEtMy0xLTEtNDAyODM_fe4ec57c-642d-4b7b-a9b1-d1cbebf3a739">1,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzItMS0xLTEtNDAyODM_c916feb9-ac62-448d-861f-76c13de31bc0">831,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzItMy0xLTEtNDAyODM_7685f52b-d88b-4b57-9fab-ddb876fb5a71">802,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzMtMS0xLTEtNDAyODM_7123b59f-e966-4b5a-86bb-75c7b2ca8671">157,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzMtMy0xLTEtNDAyODM_325552b1-628f-42e5-8ab6-8f2dc08b2854">181,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzQtMS0xLTEtNDAyODM_c645c9e8-d176-46ec-b4f7-e92aeca8510b">275,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzQtMy0xLTEtNDAyODM_53636c26-9dfa-441d-82c2-0bd1ecf179f6">308,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:70.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.480%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMi0xLTEtMS00MDI4Mw_c02cedda-e5c5-4f55-88e8-b7d9cd3bc2f7">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMi0zLTEtMS00MDI4Mw_96cb16a6-86cf-4229-a961-459a7db91206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNS0xLTEtMS00MDI4Mw_aeb9f701-8783-4659-b45f-00dbda85908c">21,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNS0zLTEtMS00MDI4Mw_dd0dfb85-eb72-470d-895f-efa677747964">22,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNi0xLTEtMS00MDI4Mw_76c41b15-7f4c-4209-8140-a7fed09f9173">12,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNi0zLTEtMS00MDI4Mw_ae9dd4f9-9cd2-4ff6-8508-77ad21de3492">15,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOC0xLTEtMS00MDI4Mw_56574182-9413-401a-b557-04fb89f1317e">33,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOC0zLTEtMS00MDI4Mw_0039f0bc-bdcd-4ed3-8141-b2f97f3cde08">38,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOS0xLTEtMS00MDI4Mw_7c1e9598-3e1c-4917-9c6d-1237bb95cb2c">30,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOS0zLTEtMS00MDI4Mw_6e057251-b142-41af-906d-2aa72c953e32">38,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTAtMS0xLTEtNDAyODM_5c053755-d209-46d4-bf18-510b6abcb0e8">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTAtMy0xLTEtNDAyODM_8e43509e-445d-4eb5-a072-81bf9ef4967d">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTEtMS0xLTEtNDAyODM_ae61b5a0-6d33-4f63-89da-68ad0703d049">29,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTEtMy0xLTEtNDAyODM_834926b7-b02d-433d-afe5-8a49a636196f">37,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTItMS0xLTEtNDAyODM_b5d44854-a385-4ab6-9064-27e3b6de794b">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTItMy0xLTEtNDAyODM_19d0bfbc-906f-4c38-8667-5368c466432d">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTMtMS0xLTEtNDAyODM_e8c3501c-4aed-4f3b-8862-c5e767cca726">29,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTMtMy0xLTEtNDAyODM_c6068bfe-3ebc-44a0-8cd0-3182c26d7019">37,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTUtMS0xLTEtNDAyODM_cff0f130-cf46-4f0a-a434-f471b79b3d02">739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTUtMy0xLTEtNDAyODM_349d497a-1e37-4c26-af5a-b3aefc65c8de">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTYtMS0xLTEtNDAyODM_70b09ac8-036b-42e2-a8b9-4459111de855">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTYtMy0xLTEtNDAyODM_c003c629-e6cd-4acc-af0a-e532c200fe99">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTctMS0xLTEtNDAyODM_ad27777c-6c36-49c0-9f13-a93b2f55ef2a">28,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTctMy0xLTEtNDAyODM_d131ae80-3989-41b1-ade3-abaca71bb443">38,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMS0xLTEtNDAyODM_89aaaf34-8670-45d0-b9db-740cfcb2cfbd"><ix:nonFraction unitRef="usdPerShare" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMS0xLTEtNDAyODM_df913f46-4fa7-4ef8-8c55-f6c4ff759d21">0.29</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMy0xLTEtNDAyODM_854cb7c0-53d9-483c-bb84-c1ef6340430e"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMy0xLTEtNDAyODM_8eaf0973-aad1-4840-95cf-2c21cb646fea">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute net loss per share - basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMS0xLTEtNDAyODM_ab1e7b9c-0663-4687-b672-66d85ad2d075"><ix:nonFraction unitRef="shares" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMS0xLTEtNDAyODM_b840eaa4-f42e-4252-acdd-287c4e0be22a">100,304</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMy0xLTEtNDAyODM_586e4189-8a28-4335-b818-e2da77e155cc"><ix:nonFraction unitRef="shares" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMy0xLTEtNDAyODM_67deb29b-36f2-4781-9619-08ec24db8a8c">98,596</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>(Loss)/Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i824fb6df85304dfbb00b9685d592e775_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi0xLTEtMS00MDI4Mw_afecb0ac-323f-4b2e-9d65-2b1a52cf421d">100,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824fb6df85304dfbb00b9685d592e775_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi0zLTEtMS00MDI4Mw_1094ba82-fd7f-48a6-b4e9-2986f0c89067">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib749589928be4d0190f40c3411ccb77e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi01LTEtMS00MDI4Mw_5d15aebb-8d00-4b80-9cd0-9f22b5b56410">985,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aec62f8dd8c4f48b6d57236a9bb5cc6_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi03LTEtMS00MDI4Mw_4b4fbb6b-ae85-4790-b38d-0227ccfe3e86">1,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6ba63d466b43e2b0636ae42f70cab2_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi05LTEtMS00MDI4Mw_bdc6b2e0-aa96-4137-a469-dde51a6b7aeb">802,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi0xMS0xLTEtNDAyODM_347b7339-7caa-405b-bb04-b65f14538a39">181,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb942d212c94ff995b15db583ad3d3e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMy01LTEtMS00MDI4Mw_1bf6ee8a-6b6c-41fa-81ba-80df13e7ca77">4,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMy0xMS0xLTEtNDAyODM_5ccd0b09-85bb-4042-b4fe-f1552ed0bcfc">4,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27d3c6628b86457f8a81acd0630f6416_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfNS0xLTEtMS00MDI4Mw_93702dcb-3054-4dec-a87c-cc4a196acb58">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a2885fb914d4a9fb1475dfd39b35ea1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfNy03LTEtMS00MDI4Mw_aac5895d-6c67-4531-8262-baa5f8dc8543">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfNy0xMS0xLTEtNDAyODM_f487d3b3-d8c7-4533-b399-361ac30653ff">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2885fb914d4a9fb1475dfd39b35ea1_D20230101-20230331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOC03LTEtMS00MDI4Mw_5c284542-5e56-4a22-b459-7c5ef9b27e75">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOC0xMS0xLTEtNDAyODM_d451b801-fdb4-4c6d-98cc-ff9a02b64eee">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34050bca04e849e2bd858606a28d821f_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOS05LTEtMS00MDI4Mw_896a4d92-ee63-411c-a326-124493933cba">29,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOS0xMS0xLTEtNDAyODM_98a0a572-60cc-46b0-8a8f-63b2ae371aa9">29,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeee002c84444ba69bca37d55ddd1ece_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtMS0xLTEtNDAyODM_8fd95acc-f9bf-41d1-92bd-dd520707a878">100,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeee002c84444ba69bca37d55ddd1ece_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtMy0xLTEtNDAyODM_bf328750-c1a5-4486-b171-21a7256aec08">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aa1b2007db4438822cc804626038a5_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtNS0xLTEtNDAyODM_27cede14-585f-433f-b034-b4851e38d88b">990,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f44c0916af45cb8434366c7f852d47_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtNy0xLTEtNDAyODM_28e2965a-4b16-4adf-923d-cb0aaac93235">799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b4ffbe5f1764673b5760d7479fc4039_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtOS0xLTEtNDAyODM_5a1d6224-781d-4132-a001-e94e9b86014b">831,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtMTEtMS0xLTQwMjgz_e5062d97-83cf-468c-9eda-9ac7a4a5f086">157,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31b77532d5ff487084fcf175a884a30d_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi0xLTEtMS00MDI4Mw_2b8e4ad2-56cd-4d5a-8696-8b0dc9995850">98,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b77532d5ff487084fcf175a884a30d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi0zLTEtMS00MDI4Mw_364722a0-dd4d-4caa-bf3a-97a91346f009">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300483de0d645a3a3bb07bb05d84161_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi01LTEtMS00MDI4Mw_14c2a7b5-3616-48e3-b862-ff60ac3d56c1">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f92cbd913c34c3f97e0fdd54f7f49f0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi03LTEtMS00MDI4Mw_79f3f442-aa69-424a-afc7-01a265e43940">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4e264e0eb94410a047fa84fb28d5ac_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi05LTEtMS00MDI4Mw_eb573560-4129-45df-9cf9-75eefc9e41b3">648,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8291885aaa4357958e19254cd61ce3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi0xMS0xLTEtNDAyODM_c2c8f487-a5a9-4d6e-ba65-ff51ed3441f8">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3700930922134893b6263b8067f724c5_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMy01LTEtMS00MDI4Mw_bbc015c0-7072-477f-a54f-87bde33ba422">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMy0xMS0xLTEtNDAyODM_1116c756-1996-4473-953d-9958c82f30c0">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa5921d28f3a4035bde41b23af227eab_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNS0xLTEtMS00MDI4Mw_ae31a709-5b0d-44b6-85c5-f84f3e369668">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3700930922134893b6263b8067f724c5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNS01LTEtMS00MDI4Mw_7110cbb3-ad4f-4452-83ea-a1bf1a0991e2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNS0xMS0xLTEtNDAyODM_3bb671ad-ba0a-49af-8c2d-58d984206a22">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa5921d28f3a4035bde41b23af227eab_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNi0xLTEtMS00MDI4Mw_211a7e55-4dc7-4311-af2b-e19c8e276ebd">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd8b1998ed4efc85109c235f6f88d4_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOC03LTEtMS00MDI4Mw_45a21ae2-d128-4408-a6aa-c3f8cdb3ae7e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOC0xMS0xLTEtNDAyODM_7e8b9cf0-15fa-4a1d-a941-6b5b01553ca2">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acd8b1998ed4efc85109c235f6f88d4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOS03LTEtMS00MDI4Mw_6b015c91-69fb-4950-9f33-4a9cb777936d">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOS0xMS0xLTEtNDAyODM_76c47d88-2768-4498-981f-4fbac99d12e6">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff760a046acd449e902d35ee4ca193bf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTAtOS0xLTEtNDAyODM_3a79cde3-b8ca-43b9-8532-fea265589cb9">37,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTAtMTEtMS0xLTQwMjgz_3f2e4a4e-a277-41ee-9afe-2e3fe9ba6936">37,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id99b06b0ddf94978a7ff951eed4a978b_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtMS0xLTEtNDAyODM_70bb10ad-da7e-4f28-9110-510d6a83a966">98,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99b06b0ddf94978a7ff951eed4a978b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtMy0xLTEtNDAyODM_37442a71-42e2-48a9-9a0e-0da266f5ce72">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b3ee54be714adca5246d416f27fc07_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtNS0xLTEtNDAyODM_319ef6ef-2f06-4305-9cfd-8c2e0972ac63">970,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de0cd99e31943a7a3398bfb2471b8ec_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtNy0xLTEtNDAyODM_5c7240b9-9ff8-4ac4-beeb-730510f15bb0">1,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95892d79c3ab4995b59ef11e3ea7942d_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtOS0xLTEtNDAyODM_5c77964a-390f-4030-a87f-4a67a45c03e5">685,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtMTEtMS0xLTQwMjgz_8a81b887-ab87-4d97-8304-3689048d354d">282,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMy0xLTEtMS00MDI4Mw_82812d62-8d44-438b-9b8a-99d053046682">29,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMy0zLTEtMS00MDI4Mw_ea99f443-5921-4cc2-9801-c5748e2dac7e">37,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNS0xLTEtMS00MDI4Mw_0a927404-9abc-4d10-8844-40bd96a51e34">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNS0zLTEtMS00MDI4Mw_bd2061a2-ce1f-4bb6-88ec-70a85c1a7beb">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNi0xLTEtMS00MDI4Mw_8ccbcbc3-b188-41bd-a05d-ff69b61ad035">4,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNi0zLTEtMS00MDI4Mw_3f403b21-e4fd-46ba-baca-8929d25254b4">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (accretion) amortization of (discount) premium on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOC0xLTEtMS00MDI4Mw_f8a1a0c6-7383-49cb-af7a-dc65886a2173">960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOC0zLTEtMS00MDI4Mw_0e085338-8916-4912-9bd3-825c43379343">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOS0xLTEtMS00NTIyOA_f7a7c5b1-37ac-453a-8f4c-0e77ac32b2af">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOS0zLTEtMS00NTIyOA_9545890d-fa01-4943-be3a-ebd0d1a8f242">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTEtMS0xLTEtNDAyODM_303b37c5-6981-4960-a4bb-c9d0c5fdc558">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTEtMy0xLTEtNDAyODM_9c8dea53-d055-440a-8a06-935584c0ac43">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTMtMS0xLTEtNDAyODM_0112d8e9-7ebc-44d3-8e4b-3c144be6c6f1">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTMtMy0xLTEtNDAyODM_372b64bc-623c-43b3-94eb-0a8d764953ed">2,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTQtMS0xLTEtNDAyODM_12ca3e5a-c253-4e19-ae29-5ce310e62010">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTQtMy0xLTEtNDAyODM_6378374a-e8a2-4315-a5f1-d7130e21b2cf">1,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTYtMS0xLTEtNDAyODM_87cf1d29-22c0-4d60-a062-4809a81f897d">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTYtMy0xLTEtNDAyODM_74472a4d-2a81-4815-a021-3e4f9be34223">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTctMS0xLTEtNDAyODM_bbdc0b08-b702-4573-9b2c-ea24be7c2a3e">749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTctMy0xLTEtNDAyODM_63970e88-399b-48a4-a97e-768350f08368">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability and lease incentive receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjAtMS0xLTEtNDAyODM_ba0d5123-ed7b-4967-83ae-10aae4070049">865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjAtMy0xLTEtNDAyODM_86ae9974-8141-4679-be93-d44a3da62f8c">5,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjItMS0xLTEtNDAyODM_99ea8dbc-a8e5-40fb-a451-b8768de68273">22,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjItMy0xLTEtNDAyODM_a842303e-b69b-4e3f-8e25-12dd437a91c4">28,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjQtMS0xLTEtNDAyODM_ec313ea3-a363-4c7a-9a4b-e310440f62e4">20,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjQtMy0xLTEtNDAyODM_bd05713e-7531-429f-af60-26c33e9a73cb">29,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjUtMS0xLTEtNDAyODM_8f172707-9af3-4b50-8d40-8cab9018fb3e">41,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjUtMy0xLTEtNDAyODM_8571b5e2-7ca1-45a0-88b5-f73a6096c5b3">118,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjctMS0xLTEtNDAyODM_d7547dbc-050a-4ea6-9b5c-290960d7be33">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjctMy0xLTEtNDAyODM_48a77708-9495-44ea-ae69-98d0a7fdc6ff">4,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjgtMS0xLTEtNDAyODM_6cf4b6e6-32aa-4a8b-8949-d7ec12e6979d">21,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjgtMy0xLTEtNDAyODM_a5cf3451-a68a-47b4-8d4e-c3b635cc1306">84,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzItMS0xLTEtNDAyODM_46ef1640-bdc6-41bb-8c31-2e08c8a520d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzItMy0xLTEtNDAyODM_510e8941-b7f8-4fb0-bdd5-1cefa8b8a47a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzctMS0xLTEtNDAyODM_858ec624-0b8f-4cbd-bbdf-8429d0ae42a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzctMy0xLTEtNDAyODM_ece2b2bd-416e-40b5-841c-72c505c4922d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzgtMS0xLTEtNDAyODM_a9775bc0-783f-4ee3-b4b1-fb8bb59bc05d">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzgtMy0xLTEtNDAyODM_eef26a8c-d9cf-40bf-a392-7c982bdc07de">55,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzktMS0xLTEtNDAyODM_09902fee-4652-4e6f-901a-638227b626eb">70,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8291885aaa4357958e19254cd61ce3_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzktMy0xLTEtNDAyODM_007fe05d-9b53-4795-9293-965a9921a2dd">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDAtMS0xLTEtNDAyODM_0adf15b6-7cb7-4b7b-8416-e9dc72d7780f">70,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDAtMy0xLTEtNDAyODM_c08bc916-619b-4780-a9d9-c50ad7c7c2ee">92,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDEtMS0xLTEtNDAyODM_30ae8286-70f0-4723-ade7-34bc46d48ec8">67,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDEtMy0xLTEtNDAyODM_54326313-f36e-4cf5-ba88-6310a47e9e79">89,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDItMS0xLTEtNDAyODM_25d00985-55bc-471d-8fba-62ec6814304d">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDItMy0xLTEtNDAyODM_0faba1e0-bd8f-413f-a0dd-4db708585ef4">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDMtMS0xLTEtNDAyODM_78bcbddd-613e-4215-bf84-da9dd20098bc">70,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDMtMy0xLTEtNDAyODM_4a20396a-e5b0-4bc5-a79d-4d24c9b011f4">92,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of noncash investing and financing information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="advm:RemeasurementOfOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDYtMS0xLTEtNDAyODM_334e5848-6bc4-40b1-abbd-b62e88f4882e">8,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="advm:RemeasurementOfOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDYtMy0xLTEtNDAyODM_b6bb3343-9ba4-48ec-8dfc-e0f28da2c48d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets in accounts payable, accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDctMS0xLTEtNDAyODM_33d81230-2e4b-4a6d-bb14-59557dd6cfae">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDctMy0xLTEtNDAyODM_9c208e20-7fcb-4b4f-890e-da9d2b446cc5">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i367b8e12c33c498fa919b5dac5350798_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfMjU4MQ_07a1f4ae-6d85-494f-a723-78487b845f5a" continuedAt="iba9fe255427b4d248922e2d6efce301f" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="iba9fe255427b4d248922e2d6efce301f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfNjg2_add11bd8-bae9-4e5f-aee4-50dac2d9cce9">831.7</ix:nonFraction> million as of March&#160;31, 2023. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of March&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfOTM1_3df1e74c-8b45-4732-a8b1-2e5275fdd800">164.3</ix:nonFraction> million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfMjU4MA_0850f085-df60-435b-82ae-61c7a835089b" continuedAt="i8bf932f7b11742659548ec147e1c45dc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2022 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8bf932f7b11742659548ec147e1c45dc">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC</ix:continuation>.</span></div></ix:continuation><div id="i367b8e12c33c498fa919b5dac5350798_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfMjI1MA_2d46ad78-b5b6-494d-b84d-779ac7b43ae8" continuedAt="i1b7ccced7e114926ad1e5384bb52c26b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i1b7ccced7e114926ad1e5384bb52c26b" continuedAt="i2c785a05907c44778986b155499a1790"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfMjI1MQ_55ed0592-ef58-4795-b631-78c99510aa6e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfNDM5ODA0NjUyMDc2Nw_3605dc97-662f-4f5b-9b95-bb18f1c8e2c0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Interest Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#8217;s condensed consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><ix:continuation id="i2c785a05907c44778986b155499a1790"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfMjI1Mw_e7b14af5-d3e4-41c5-91e0-d911c985975f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January&#160;1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i367b8e12c33c498fa919b5dac5350798_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfMzEwNQ_38b585a6-a7d3-4f6c-80f6-9934e9420915" continuedAt="i221a617d8fa248c0bdbfa00247967026" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i221a617d8fa248c0bdbfa00247967026" continuedAt="i2bf2d0bc440849f78f6ace6107d96a7a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfMzEwNg_a894b043-a6a9-4a3d-8d23-dadb6cef430c" continuedAt="i03adb0f44fce43c48d9a6a37d098e1f3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4e308e31564406905c98313e33a603_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC0xLTEtMS00MDI4Mw_fc6200ee-3e21-40e4-b231-bddb8c209fa5">10,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4e308e31564406905c98313e33a603_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC0zLTEtMS00MDI4Mw_af3988ce-37e0-4fb2-8702-c5915184c082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4e308e31564406905c98313e33a603_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC01LTEtMS00MDI4Mw_13043dc7-f020-42f3-ae24-0b9a533fd507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4e308e31564406905c98313e33a603_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC03LTEtMS00MDI4Mw_2b763d7a-af60-41ec-911f-68ad6b752f86">10,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0xLTEtMS00NDEwOQ_581d82b0-a6d6-4527-b33a-16af19e6a332">72,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0zLTEtMS00NDEwOQ_a303fd43-ee33-4a89-b63f-e8c22ed68698">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi01LTEtMS00NDEwOQ_350e10c1-f766-44a5-b51e-2e9cae45d869">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi03LTEtMS00NDEwOQ_246781f9-4388-4e12-bc91-c06cf99f6106">72,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0xLTEtMS00MDI4Mw_bb50a32f-27cb-466e-b036-9cc39b58ee03">71,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0zLTEtMS00MDI4Mw_d9ec78b1-bc16-4961-ad34-4168722d9764">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi01LTEtMS00MDI4Mw_7a2bc0c6-2dfd-499c-909f-ea9f70a7fe00">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi03LTEtMS00MDI4Mw_23995e3b-ae89-4bb3-a67d-91e5c03f354b">71,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecee66b5209450f86b53dd83c818354_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC0xLTEtMS00MDI4Mw_32d35355-fbb2-40ea-acb8-425fbbd08b7e">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecee66b5209450f86b53dd83c818354_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC0zLTEtMS00MDI4Mw_2bcb15f2-7045-4a3d-af5e-98e95f8a9968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifecee66b5209450f86b53dd83c818354_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC01LTEtMS00MDI4Mw_b277adac-3900-4a4b-a7cd-e60bb4c6ebe2">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecee66b5209450f86b53dd83c818354_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC03LTEtMS00MDI4Mw_39fd93bb-b2fa-48b5-9e97-9c455023b446">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS0xLTEtMS00MDI4Mw_c8389c5b-a8b2-41e2-874e-e6ccc5d372c3">157,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS0zLTEtMS00MDI4Mw_48463433-d747-42e2-a8bd-053c73bb8a0f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS01LTEtMS00MDI4Mw_da52d604-8b20-49e6-973a-daa8765f0397">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS03LTEtMS00MDI4Mw_79e881ea-f07b-420e-bc87-f375f305f052">157,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtMS0xLTEtNDAyODM_9951d162-13c5-4728-a3be-6f4c913621a9">60,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtMy0xLTEtNDAyODM_baa83f2a-69c7-41b4-b1a2-c074cbe427f4">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtNS0xLTEtNDAyODM_52e66c0b-87fe-4cda-9d1c-b81ab9213768">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtNy0xLTEtNDAyODM_8f46306a-b53d-4f23-a3b6-77fe50fc1a5a">60,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtMS0xLTEtNDAyODM_da4aed9b-8987-4812-9e77-55d8465c63d3">97,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtMy0xLTEtNDAyODM_c68e28f7-80d3-4bd0-af9f-b49afabda10b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtNS0xLTEtNDAyODM_ddaee408-6c3b-4e1e-82dc-41d4b1dd2bfd">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtNy0xLTEtNDAyODM_34f083e7-5bc3-4b59-95e7-c0e1ab2ae4b5">96,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><ix:continuation id="i2bf2d0bc440849f78f6ace6107d96a7a"><div><ix:continuation id="i03adb0f44fce43c48d9a6a37d098e1f3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC0xLTEtMS00MDI4Mw_73579a34-c38b-4bba-ba88-c6a7495c535d">10,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC0zLTEtMS00MDI4Mw_a0429e28-cc0e-4f64-b2d2-a0e5bf14d340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC01LTEtMS00MDI4Mw_5114c942-a6bb-4249-bd95-1da47b6c0538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC03LTEtMS00MDI4Mw_d497b8b0-6195-4b2e-b88c-88a1f813f037">10,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0xLTEtMS00NDEyMQ_c081f900-dd62-423d-88d5-040d1340d734">102,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0zLTEtMS00NDEyMQ_d5ba3396-fbf5-4b08-a65f-e5093412f080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi01LTEtMS00NDEyMQ_676516b1-eb03-4c1e-894a-f642566e7b9c">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi03LTEtMS00NDEyMQ_7133a684-acbb-408e-9cbb-acd8c501417a">102,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84cb988cff74c13804946bc088788c7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0xLTEtMS00MDI4Mw_e58d54ed-af0d-40b7-a298-1c9a725bd3b8">59,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84cb988cff74c13804946bc088788c7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0zLTEtMS00MDI4Mw_34d26304-0133-4baa-baa6-8386aa8f5c7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if84cb988cff74c13804946bc088788c7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi01LTEtMS00MDI4Mw_5e5beed3-c25a-4ef1-a803-045b9b3add73">824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84cb988cff74c13804946bc088788c7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi03LTEtMS00MDI4Mw_a9a1fda1-903c-4c03-82b5-723708304d11">58,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC0xLTEtMS00MDI4Mw_3bb64711-fe41-44cc-bf03-337f507fd40b">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC0zLTEtMS00MDI4Mw_310e3da5-77f5-454f-95c6-7a47a2eb69bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC01LTEtMS00MDI4Mw_03899bb6-a44e-461d-89b5-64e79dd0ac4f">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC03LTEtMS00MDI4Mw_d190a660-a275-4780-958b-b4aea64620be">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtMS0xLTEtNDAyODM_7aded149-c1e2-4dfb-ad3e-304ca4ae9ef5">174,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtMy0xLTEtNDAyODM_f373b5fd-7c3c-4752-a99e-583bde9a9b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtNS0xLTEtNDAyODM_bf340ffc-d615-47cd-8eef-fdaec7a9610e">1,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtNy0xLTEtNDAyODM_ffda041b-3995-4863-a693-8e52ad3f71c0">173,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtMS0xLTEtNDAyODM_9d188e53-8eeb-4ded-ac66-fd61775d453a">56,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtMy0xLTEtNDAyODM_1e07e0fd-5bc7-4aee-8568-ca5b2141ed5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtNS0xLTEtNDAyODM_00b6f841-12b7-4618-a4e4-f0ad0424d41f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtNy0xLTEtNDAyODM_23df0a2c-95f9-4e17-bc93-0ba022b68c99">56,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItMS0xLTEtNDAyODM_7659d5bb-f08b-4d1d-a6a4-1192c469ff06">118,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItMy0xLTEtNDAyODM_a7e09124-605e-4cb5-85d8-080d896b441a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItNS0xLTEtNDAyODM_6aa55ef9-8806-437a-b242-2d654a448d54">1,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItNy0xLTEtNDAyODM_6397fa18-7a1b-45a9-bcd1-1f122c07c2c9">117,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, all marketable securities have a remaining maturity of less than one year. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2023 and December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfNDM5ODA0NjUyNDc2MA_7db8db9b-c68f-4cab-99e5-68d8e00f3d9f">105.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfNDM5ODA0NjUyNDc3Ng_a675a0a6-bfe7-4383-abbb-4085bf31732b">155.5</ix:nonFraction>&#160;million, respectively, which are highly liquid funds with high credit ratings that have final maturity of less than two years from date of purchase. The Company has not recorded an allowance for credit losses as of March&#160;31, 2023 and December&#160;31, 2022 related to these securities. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recorded any impairment charges on available-for-sale securities.</span></div></ix:continuation><div id="i367b8e12c33c498fa919b5dac5350798_61"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF82MS9mcmFnOmU1ODg5N2ExZTRiOTQ2ZWZhZjM0ZGExYzljMDk5NWEwL3RleHRyZWdpb246ZTU4ODk3YTFlNGI5NDZlZmFmMzRkYTFjOWMwOTk1YTBfMTM5Mw_044057c5-3a76-46c9-8d07-21d820e57e2b" continuedAt="i8dfba6fed04a470f91753e3595ad8852" escape="true">License Revenue</ix:nonNumeric></span></div><ix:continuation id="i8dfba6fed04a470f91753e3595ad8852"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Lexeo notified the Company that it achieved the first development milestone; accordingly the Company is eligible to receive additional payments. Therefore, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8efd9f62836f463e824a62629a695c2d_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF82MS9mcmFnOmU1ODg5N2ExZTRiOTQ2ZWZhZjM0ZGExYzljMDk5NWEwL3RleHRyZWdpb246ZTU4ODk3YTFlNGI5NDZlZmFmMzRkYTFjOWMwOTk1YTBfNDM5ODA0NjUxODMxOQ_4752d1b6-81c1-4656-86b2-867c65fcc187">3.5</ix:nonFraction>&#160;million of license revenue during the three months ended March 31, 2023.</span></div></ix:continuation><div id="i367b8e12c33c498fa919b5dac5350798_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfMTA3NQ_bcece813-efe9-4ea1-81ee-6bd984623f5c" continuedAt="ifb976a9f868b482fbf1dd9d55ce067c8" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ifb976a9f868b482fbf1dd9d55ce067c8" continuedAt="if6c774989dce403d914cce20d3c633f6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Redwood City, California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for facilities in Redwood City, California. Related to this lease, the Company provided the landlord with a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="idec0ca6f1e334c53bb5d986390d410e4_I20230331" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ1Mg_1901b8e7-5347-4dc3-9720-d86a19fbc291">2.5</ix:nonFraction>&#160;million, which is classified as restricted cash under long term assets on the Company's condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into an amendment to accelerate the expiration of one of its Redwood City premises under the existing lease from December 31, 2031 to September 30, 2023. Concurrently, the Company entered into an agreement for additional tenant improvement allowance towards its other Redwood City premises. As a result of the modification the Company revalued the lease liability based on the new and remaining lease terms, which resulted in a reduction to the lease liability of $<ix:nonFraction unitRef="usd" contextRef="idb3ac51c130c4ddd85a7143df0208a5a_D20230301-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ2Ng_3baa7104-e321-44e5-9c2c-bce35f44721b">8.3</ix:nonFraction>&#160;million, and recognized the remeasurement to the lease liabilities as an adjustment to the right-of-use asset. The estimated value of non-cash consideration, composed primarily of leasehold improvements and furniture and fixtures, was $<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-5" name="advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ4MQ_b3e3009a-d5dc-4cb8-9db8-b2df677e4616">14.9</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><ix:continuation id="if6c774989dce403d914cce20d3c633f6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Durham, North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has an operating lease agreement for a building in Durham, North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with <ix:nonFraction unitRef="contract" contextRef="ic15e5013c42c4501aecb2878f6bbe3c8_D20230101-20230331" decimals="INF" name="advm:LesseeOperatingLeaseNumberOfRenewalContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ5NQ_8c7bf22e-c4d1-470a-892e-fbb529edbabf">two</ix:nonFraction> options to extend the lease term for a period of <ix:nonNumeric contextRef="icb41c12aa72a45c0acb2793e962d957a_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODUwMg_18891c96-ef2c-4f02-b712-b5761495cd7f">five years</ix:nonNumeric> each. In April 2023, the Company entered into an amendment to reduce the rent payments for the NC Premises, which will be effective as of May 1, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the NC Premises through October 2037, the remainder of the lease term. In line with the amendment to the NC Premises' lease, sublease rent payments were correspondingly reduced. Sublease income for operating leases is recognized on a cash basis over the lease term based on assessment of probability of collection. Sublease income were $<ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODk4NQ_d3aa61bd-5cb3-46ec-b8a3-834bb52f49e6">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyOTA1Mw_0fe2c66e-731d-4994-af46-430e58cc308d">1.7</ix:nonFraction>&#160;million for the three months ended March 31, 2023 and 2022, respectively, and is classified as a reduction of rent expense in operating expenses.</span></div><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ1MA_40ed6503-ca4b-4a14-af2f-68563ea79811" escape="true"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ1MA_4f686816-1d8a-4c54-bb9c-6d326b02979b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payments Receivable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMS0xLTEtMS00MzUzMw_3d910bc2-54c9-4276-85db-f3b7a3d7c7f9">24,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMS0zLTEtMS00MzUyNQ_f0f9bedd-049e-47f8-9b51-135562e99122">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMi0xLTEtMS00MzU0Mw_2edb2bcf-6308-4d91-b53b-0f650f066de6">10,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMi0zLTEtMS00MzU0Nw_c2294c2c-93fd-4a26-8e1f-f467fb55cb76">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMy0xLTEtMS00MzU0Mw_f997e58f-b3b2-447b-a70f-23d100362826">11,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMy0zLTEtMS00MzU0Nw_97d234fd-2539-4e55-845d-4e4b5a7296d9">5,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNC0xLTEtMS00MzU0Mw_814086d9-f7aa-46b5-9594-a75702b9a675">11,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNC0zLTEtMS00MzU0Nw_5e968b92-3fb3-474c-bcd6-1bbccc2561df">5,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNS0xLTEtMS00MzU0Mw_84f5ee8f-71ae-4360-85a3-41ecd70861eb">11,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNS0zLTEtMS00MzU0Nw_7cd9cefe-cb07-41f4-be8a-b192bfa71801">5,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNi0xLTEtMS00MzU0Mw_88e8fd77-6e15-4283-b48f-e45d4cc5cc11">91,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:LessorOperatingLeasePaymentToBeReceivedAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNi0zLTEtMS00MzU0Nw_c7a4cbb0-33e8-4de9-8369-680a51e1e911">63,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNy0yLTEtMS00NDk1MQ_9c1e094b-6b77-4793-86b1-47586a5346d5">161,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNy00LTEtMS00NDk1Mw_ec5d4e10-a0ff-40dc-ab91-f4c8b97ece64">87,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i367b8e12c33c498fa919b5dac5350798_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RleHRyZWdpb246MDRjZWJhMmYxNDM4NDZmOGJkZjkwNWVlYTBkZjI0ZDBfNzM1_c33a7abc-c872-4d22-886b-34be8583557c" continuedAt="ied96e0ade987410da370bd264fa2695f" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ied96e0ade987410da370bd264fa2695f" continuedAt="id932b8ab59be4c5f93a3d98574337f13"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RleHRyZWdpb246MDRjZWJhMmYxNDM4NDZmOGJkZjkwNWVlYTBkZjI0ZDBfNzMz_d4540bb3-bf43-43c4-ae0e-c45fe6af0a83" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee913767de5c457eb0abe869f1ccf788_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0xLTEtMS00MDI4Mw_70f7708c-48c3-4f12-9f12-3af345f556de">34,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb926656b3e1496e8ae5e68b8a88bcaa_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0zLTEtMS00MDI4Mw_67f79833-eba8-470e-ad74-ad21e20d6b26">34,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b02a910cfa446ca03e773f9c23dfd4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNC0xLTEtMS00NTEzNg_66215cd7-0e62-4df7-95f1-ee407dd9bfd1">14,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231f853a0b294f85b3d8e11f4d5f56b0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNC0zLTEtMS00NTEzNg_5b2aeb0f-ae2d-4125-a7d4-1ffc662c5ab1">14,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d414f59c1bb438296e4a6a98a09a90c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0xLTEtMS00NDA1Mg_e2d1c744-9683-4709-989b-9d31a605444c">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1325acb65c4d3ba80692faaa31ac8c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0zLTEtMS00NDA1Mg_c930f0f8-d694-4714-b03e-29e56f9fbffd">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb83a86ea384dff87bc2c6a80c8dc12_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0xLTEtMS00NDYwNw_51318280-e2da-4648-b638-26b235468290">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ae0052ee0c4d30a61a5234d6eeb925_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0zLTEtMS00NDYwNw_cb41f67d-27e4-4df3-b7b7-4e7d61d73c98">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c3989caf254e88ba282f8751412f5c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0xLTEtMS00MDI4Mw_13e05667-8371-4639-87b1-448467f853e6">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74324103edc4f0da546ee3853453605_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0zLTEtMS00MDI4Mw_a63788f6-fd9e-4c3b-8127-b92dbbfb944d">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNy0xLTEtMS00MDI4Mw_c3b07f33-3268-47bc-8130-71773cbd01c8">51,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNy0zLTEtMS00MDI4Mw_ed75998b-69bb-4141-be3c-3ba38aa59d4f">51,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOC0xLTEtMS00MDI4Mw_2bd6d928-8827-4f63-a304-d860b7f915d5">18,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOC0zLTEtMS00MDI4Mw_52780398-fd14-4354-9918-ab2f235d9f01">16,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOS0xLTEtMS00MDI4Mw_1e03808c-dbde-49bd-a591-b690439b6b78">33,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOS0zLTEtMS00MDI4Mw_89a8394e-a91d-4811-8e85-54dae29153fd">34,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><ix:continuation id="id932b8ab59be4c5f93a3d98574337f13"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RleHRyZWdpb246MDRjZWJhMmYxNDM4NDZmOGJkZjkwNWVlYTBkZjI0ZDBfNzM0_02a1f626-5a73-4f26-8064-c6106b7443e1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0xLTEtMS00NDUwNQ_1a562356-aed9-4083-89ac-9e6942d48569">8,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0zLTEtMS00NDUwNQ_7aa33c58-68e5-40e2-870c-b7300e5a2e44">6,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0xLTEtMS00MDI4Mw_fd0ae188-d030-4021-9ead-842debb5a18f">5,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0zLTEtMS00MDI4Mw_20129846-0545-4755-86c2-9fd580e19b27">8,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNS0xLTEtMS00MDI4Mw_99768422-0f46-495a-b39c-d5b456101593">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNS0zLTEtMS00MDI4Mw_558b950f-ee10-45ed-bb2f-b4fdeb282efe">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0xLTEtMS00NDA5Nw_3b35760f-1821-4544-91c4-9e8420ae6fb9">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0zLTEtMS00NDA5Nw_61831003-0d22-41c2-8e0b-61ab15d80dde">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNi0xLTEtMS00MDI4Mw_f1f9da66-9dbc-41f7-a7ad-48f126999133">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNi0zLTEtMS00MDI4Mw_be867a5f-055c-43bb-a8cf-c4471627169e">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0xLTEtMS00MDI4Mw_c8af027a-6333-437f-9cc7-a893206dfff5">17,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0zLTEtMS00MDI4Mw_0d633a2e-b1b6-4aac-be86-1995bd2de809">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i367b8e12c33c498fa919b5dac5350798_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjgz_5dcd043b-7265-4673-9fec-26311d6c4907" continuedAt="i2773337e0e2e407fb9a181424813f38a" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="i2773337e0e2e407fb9a181424813f38a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjg0_af7fed9d-92a7-4cdb-bdda-f9b257bebb6c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMS0xLTEtMS00MDI4Mw_58939d2d-d6de-4fb1-85fb-01eb3694bfdb">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMS0zLTEtMS00MDI4Mw_176ec132-cefc-4725-aa87-10960c6c65d8">5.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMi0xLTEtMS00MDI4Mw_ba36ee67-bdec-49d7-9775-441f6518c791">4,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMi0zLTEtMS00MDI4Mw_89d7cad5-99cc-475a-9ea2-a04066dd9f9e">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMy0xLTEtMS00MDI4Mw_77009e83-3cc3-4efd-8cd7-512d056ed5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMy0zLTEtMS00MDI4Mw_7f982c8f-b00e-4ffc-b1f1-a7c051336b52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNC0xLTEtMS00MDI4Mw_dd9241d6-83e5-4c8d-bbba-e52d8c908f18">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNC0zLTEtMS00MDI4Mw_a4abfba3-0134-4980-b37b-f2998932af60">6.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNS0xLTEtMS00MDI4Mw_0e7b407a-cc35-4157-b9a0-0a4a86ebb57d">23,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNS0zLTEtMS00MDI4Mw_55c15c04-f3d9-4532-9d5e-3362b59b0d50">4.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNi0xLTEtMS00MDI4Mw_58dfadd0-7c7d-4623-8b54-ae83c076855a">7,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNi0zLTEtMS00MDI4Mw_d642fe22-488d-4307-87ba-69751000fede">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjgx_0cf2fd14-e500-4edd-9b09-a78d290f508a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e5816500fc04144b5ebb1566cc9f4f0_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMS0xLTEtMS00MDI4Mw_e7210e2f-a481-4d30-931c-af17c50512a2">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e5816500fc04144b5ebb1566cc9f4f0_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMS0zLTEtMS00MDI4Mw_6fcc593d-e14a-4294-a58b-05f841e1154e">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMi0xLTEtMS00MDI4Mw_5c824d9c-e700-4c07-9d03-9b8980025f5e">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMi0zLTEtMS00MDI4Mw_6e7c902f-7aec-4d5f-854b-7e8ae4020e76">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMy0xLTEtMS00MDI4Mw_824ee487-27ed-4417-b284-ac30f0a6514e">456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMy0zLTEtMS00MDI4Mw_be482d62-dd0a-40df-bbdf-e4f91c64e284">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNC0xLTEtMS00MDI4Mw_93670eb5-a726-4022-a705-8c0e7566f6ca">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNC0zLTEtMS00MDI4Mw_9273f75d-a9d4-4c1b-b544-752dcee9fb54">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03ee695f35b04c92841b271089b16400_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNS0xLTEtMS00MDI4Mw_149937b4-85b7-49b8-9a5d-923d7e7b7bc7">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03ee695f35b04c92841b271089b16400_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNS0zLTEtMS00MDI4Mw_dbb18dde-f4be-4583-b8ca-25b47cc5029c">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjgy_ce4b9a81-39e7-41b4-9712-387f935ea5f4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea5ef805f8c40038f3b3e1ec4ca4f7a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfMy0xLTEtMS00MDI4Mw_20097a85-eb2b-46a6-9c45-f61e2b0d2ab4">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic17577b3961e43a4b40b169a76ff83db_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfMy0zLTEtMS00MDI4Mw_d0ef155b-279e-483a-b59e-813b1f68e7a7">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a6eb7c0dd44b829c120e24f1ea5e32_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNC0xLTEtMS00MDI4Mw_53191d23-90d8-4e0e-a8ac-42df129a8445">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69031cdc433a468695993438b2b429d7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNC0zLTEtMS00MDI4Mw_57d1be4d-59e2-4618-b4ab-e28413dcef6b">3,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNS0xLTEtMS00MDI4Mw_12ac8c78-0869-4f24-96f3-3bf9524e35c9">4,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNS0zLTEtMS00MDI4Mw_a67aaf1c-678a-45a4-989b-8496be89b94b">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RleHRyZWdpb246MGNlMjkwMWE3ZmZmNDBjM2JmODU2ZjEwNDVhZTQzMzRfODM0_08e36e14-ebdb-49bc-b4e4-d6b614d27492" continuedAt="i603900092e8143c2a80246c6e3e8b66b" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="i603900092e8143c2a80246c6e3e8b66b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RleHRyZWdpb246MGNlMjkwMWE3ZmZmNDBjM2JmODU2ZjEwNDVhZTQzMzRfODM2_1874b195-a674-4799-a911-ffb4d0f502bb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1cc5fc2435e4ec3a7f02439a9d618fb_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMi0xLTEtMS00MDI4Mw_b239bfa4-7826-4c14-aa26-604e73fd852e">23,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406b3e1f97ba43e9b9a0eba636ce617a_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMi0zLTEtMS00MDI4Mw_59a38f9a-2fd8-466e-aaf5-eebe3978aa87">16,171</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea30e1fafcc7467796344a1b9ed739a5_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMy0xLTEtMS00MDI4Mw_17b60d3c-1ae7-473c-a5f9-72943b9c76f8">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97678bdca6e84570bb323a2f04cf2272_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMy0zLTEtMS00MDI4Mw_79cbb715-4334-49d4-b6f5-8654b8e03aea">2,522</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5622823987bd4b5b9eaeed2cfac2dc62_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNC0xLTEtMS00MDI4Mw_867ff56e-9efe-4392-83e8-6a3849933d66">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a6a763430794cf4a5b4d713e9cfcccc_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNC0zLTEtMS00MDI4Mw_90d83dc4-9a59-405c-9c4c-bf9ca26a8ed6">887</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNi0xLTEtMS00MDI4Mw_68149ff5-6fc4-4d2f-81ef-d80b7bbe45d5">26,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNi0zLTEtMS00MDI4Mw_0b5b3679-f6fa-41cc-b331-74ee04e77f71">19,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The interim financial statements included in this Quarterly Report on Form 10-Q and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2022, and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC) on March&#160;30, 2023. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These forward-looking and other statements are subject to risks and uncertainties, including those discussed in the section titled &#8220;Risk Factors,&#8221; set forth in Part II &#8211; Other Information, Item&#160;1A below and elsewhere in this report that could cause actual results to differ materially from historical results or anticipated results. </span></div><div id="i367b8e12c33c498fa919b5dac5350798_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector evaluation, cassette engineering, and ocular IND-enabling nonclinical and clinical development. In addition, we have in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;GMP&#8221;) quality control.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ixo-vec (ADVM-022)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, is a single, in-office intravitreal (&#8220;IVT&#8221;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) IVT injections. Ixo-vec utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a single in-office IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. Ixo-vec is currently being developed for the treatment of patients with wet age-related macular degeneration (&#8220;wet AMD&#8221;) who are responsive to anti-VEGF therapy. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. Age-related macular degeneration (&#8220;AMD&#8221;) is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the OPTIC trial, designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of Ixo-vec in subjects with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Subjects in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. We completed enrollment for OPTIC in July 2020 and will continue to present updated efficacy, aflibercept protein levels and safety data from the trial through two years and into the extension study as we continue to follow our subjects for an additional three years for a total of five years.  To date, we have seen strong signals of therapeutic efficacy in OPTIC in both the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) and 2 x 10&#94;11 vg/eye (&#8220;2E11&#8221;) doses, including continuous stable aflibercept protein levels from 10 weeks to three years, maintenance to improvement in best-corrected visual acuity and central subfield thickness (&#8220;CST&#8221;), a measure of fluid in and beneath the retina, as well as a reduction in CST fluctuations. Ixo-vec has been generally well tolerated, with the most common adverse events being</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dose-dependent adeno-associated virus (&#8220;AAV&#8221;) associated ocular inflammation that has been responsive to topical corticosteroid therapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical studies have indicated that a 6 x 10&#94;10 vg/eye (&#8220;6E10&#8221;) dose has the potential to achieve therapeutic levels of aflibercept. In April 2022, we announced we received feedback from the FDA via a Type C meeting written response related to our planned Phase 2 trial of Ixo-vec in wet AMD. We requested the FDA&#8217;s feedback to ensure alignment with the regulatory agency ahead of filing the Investigational New Drug (&#8220;IND&#8221;) amendment for our Phase 2 trial, which IND amendment was submitted on May 26, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we dosed the first subject in our Phase 2 LUNA (&#8220;LUNA&#8221;) trial of Ixo-vec. The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec - 2E11, the lower dose used in the OPTIC trial, and a new, lower 6E10 dose - in up to 72 subjects with wet AMD. The LUNA trial will assess four new enhanced prophylactic corticosteroid regimens, including local corticosteroids and combinations of local and systemic corticosteroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (&#8220;Durezol&#174;&#8221;), dexamethasone intravitreal implant (&#8220;Ozurdex&#174;&#8221;), and a combination of either topical Durezol&#174; or IVT Ozurdex&#174; with oral prednisone.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses and will be conducted at approximately 40 sites in the U.S. and Europe. Four prophylactic corticosteroid regimens will be studied. The primary endpoints will be similar to the OPTIC trial and focus on mean change in best-corrected visual acuity and CST from baseline to one year, and incidence and severity of adverse events. Other endpoints will include aflibercept protein levels starting at 14 weeks, an interim efficacy and safety analysis at 26 weeks and will include a reduction in fluctuations in CST and in treatment burden. The study will also evaluate the effectiveness and tolerability of the prophylactic corticosteroid regimens.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we announced that the European Medicines Agency (&#8220;EMA&#8221;) has granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated preliminary safety and efficacy and thus the potential to target a significant unmet medical need and bring a major therapeutic advantage to patients.  This regulatory program offers developers of promising medicines enhanced interaction and early dialogue and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. In November 2022, a PRIME kickoff meeting was held to initiate interaction with the EMA experts and to familiarize EMA with the product, development program, and planned regulatory strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced that the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) has granted Ixo-vec an Innovation Passport under the Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;). The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence and the National Health Service England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenicity to AAV therapy has been broadly reported to be associated both with systemic and ocular gene therapies, regardless of route of administration, and is generally understood to be dose-related. Based on an extensive evaluation of data from all of our subjects treated with Ixo-vec and all of our nonclinical data by internal and external experts, we believe that utilizing the 2E11 and 6E10 doses, along with the new enhanced prophylactic corticosteroid regimens, which include local corticosteroids and a combination of local and systemic corticosteroids, will allow us to minimize post-prophylaxis inflammation in our trial subjects going forward. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we initiated the INFINITY trial, a multi-center, Phase 2, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of Ixo-vec in subjects with diabetic macular edema (&#8220;DME&#8221;). A dose limiting toxicity at the 6E11 dose in this population with poorly controlled diabetes and micro vascular complications was identified in April of 2021. Consequently, we are no longer pursuing Ixo-vec for DME, nor are we evaluating the 6E11 dose in wet AMD. We have not seen similar subject safety concerns in any of our subjects at either the 2E11 dose in the INFINITY or OPTIC trials or the 6E11 dose in the OPTIC trial. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADVM-062</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8. In January 2022, we announced that the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by the absence of function in the L and the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM and to our knowledge, no other therapies to treat BCM are in development. We are collaborating with the families of patients affected with BCM (BCM Families Foundation) to help advance our therapies. In an effort to prioritize Ixo-vec clinical development and focus on establishing gene therapy as a new standard of care for highly prevalent ocular diseases, we are in the process of identifying a suitable partner to further develop this product candidate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Restructuring</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we announced we had taken measures to restructure our operations, including reductions in both headcount and expenses to prioritize Ixo-vec&#8217;s clinical development, and focus our pipeline strategy on certain highly prevalent ocular diseases. The restructuring was completed in the fourth quarter of 2022. We expect these restructuring measures will be sufficient to extend our cash runway into 2025. See, however, Part II, Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy program into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations and financial condition for the three months ended March 31, 2023 were not significantly impacted by the COVID-19 pandemic. We are actively monitoring and managing our response to the COVID-19 pandemic and assessing actual and potential impacts to these areas. Please refer to the Part II, Item 1A.&#8220;Risk Factors&#8221; for further discussion of the risks we face as a result of the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously evaluating and addressing potential impacts of the COVID-19 pandemic on our operations, and are committed to the health and safety of our employees and their families. We have reopened our offices to allow our employees more flexibility to mix virtual and in-person work and to advance our culture and corporate goals. We believe this will also enable greater balance and well-being of our employees. We continue to update our policies and implement new practices to align with the current guidance from state and federal governments and health authorities. We believe these measures and others have allowed us to mitigate, but not eliminate, the effects and risks on our on-site operations posed by the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Clinical Trials</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our ongoing and planned clinical trials is uncertain and subject to change. To date, we believe we have experienced limited impact due to COVID-19 on our ongoing clinical programs, including the OPTIC and LUNA clinical trials. We are working closely with our clinical trial sites to monitor and attempt to address or limit the potential negative impacts of the evolving COVID-19 outbreak and the emergence of COVID-19 variants on subject safety, trial enrollment, continued participation and follow-up of subjects already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity. Despite these efforts, we are unsure as to whether the COVID-19 pandemic will significantly impact future trial enrollment or completion of our current or planned clinical studies.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Supply Chain and Manufacturing</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not yet experienced significant disruptions to our supply chain and manufacturing as a result of the COVID-19 pandemic, we cannot be certain that this trend will continue. Based on current information, we believe that our partners in our supply chain have been and will continue to serve us continuously. The COVID-19 pandemic and other factors have adversely impacted the global supply chain for other supplies and materials which could impact our future operations. To mitigate against future potential delays in supplies and materials we use in our operations, including product supply, we are continuously implementing additional measures to address potential risks as we identify them, including securing additional supplies and manufacturing capacity reserve, which have resulted in additional expenses and may result in other additional expenses in the future. Given the uncertainty regarding the impact delays and disruption in the global supply chain may have on our operations, we are unable to quantify the ultimate impact on our future results at this time.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and, as of March&#160;31, 2023, we had an accumulated deficit of $831.7 million. We expect to incur substantial expenses and continuing losses from operations in the foreseeable future as we conduct our research and development efforts, advance our product candidates through nonclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may in the future generate revenue from a variety of sources, including license fees, milestone and research and development payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved, to date we have not generated any revenue from product sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party contract research organizations (&#8220;CROs&#8221;) to carry out our clinical development and we do not have a sales organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through nonclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $164.3 million in cash, cash equivalents and short-term investments. We believe that our cash, cash equivalents and short-term investments are sufficient to fund operations into 2025. However, we may need to raise additional funds sooner as a result of a number of risks and uncertainties, including those set forth in Part II, Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage nonclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will need to adjust the accrual accordingly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We may require increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily comprises interest income on our cash equivalents and investments in marketable securities.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Except as noted below, there have been no significant changes in our critical accounting judgments and estimates during the three months ended March 31, 2023 as compared to the critical accounting judgments and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our most recent Annual Report on Form 10-K filed with the SEC on March 30, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a right-of-use asset and a lease liability on our condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or lease modification date, as applicable. In order to determine the incremental borrowing rate, we estimate our credit rating, adjust the credit rating for the nature of the collateral, and benchmark the borrowing rate against observable yields on comparable securities with a similar term. We base the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent and initial direct costs. We determine the lease term at the commencement date or lease modification date, as applicable, by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses and is recognized on a cash basis based on assessment of probability of collection.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2023 and 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,294)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,239)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,133)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,039)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,889)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,056)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,908)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.6 million of license revenue for the three months ended March&#160;31, 2023 was primarily related to a milestone payment received from Lexeo Therapeutics, Inc.(&#8220;Lexeo&#8221;) pursuant to a license agreement we had entered into with Lexeo in January 2021, pursuant to which we granted Lexeo an exclusive license to the intellectual property rights, pre-clinical data and knowhow associated with our Friedreich's Ataxia program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $1.9 million to $21.1 million for the three months ended March&#160;31, 2023 from $23.0&#160;million for the three months ended March&#160;31, 2022. The overall decrease was primarily due to a $3.3 million decrease in personnel-associated costs due to lower headcount following the restructuring in the prior year, and a $0.9 million decrease in laboratory expenses as the company prioritize its effort in the clinical development of Ixo-vec, partially offset by a $1.3&#160;million increase in material production and bioanalytic expenses driven by the Ixo-vec clinical trial, and a $1.3 million increase in license costs driven by the Lexeo revenue. Stock-based compensation expense included in research and development expenses was $1.4&#160;million for the three months ended March&#160;31, 2023, compared to $1.9 million for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, our research and development activities were attributable to our Ixo-vec and earlier-stage research programs. We expect that research and development expenses will fluctuate in future periods as we focus on advancing Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense decreased $2.4 million to $12.8 million for the three months ended March&#160;31, 2023 from $15.2&#160;million for the three months ended March&#160;31, 2022, primarily related to decreases of $1.3 million in personnel-associated costs driven by lower headcount, $0.6 million in professional services driven by legal fees related to our patents, and $0.5&#160;million in recruiting costs driven by prior year hiring. Stock-based compensation expense included in general and administrative expenses was $3.2&#160;million for the three months ended March&#160;31, 2023, compared to $3.4 million for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that general and administrative expenses will decrease in future periods as we streamline our operations. We are expecting further year over year decreases for the second and third quarter until we get past the anniversary of the restructuring.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $1.2 million for the three months ended March&#160;31, 2023 and $0.2 million for the three months ended March&#160;31, 2022. The increase is from higher average yields in investments, partially offset by declining investment balances.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized an income tax provision of $17,000 for the three months ended March&#160;31, 2023 and $19,000 for the three months ended March&#160;31, 2022 related to foreign operations. </span></div><div id="i367b8e12c33c498fa919b5dac5350798_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of March&#160;31, 2023, we had an accumulated deficit of $831.7 million. As of March&#160;31, 2023, we had $164.3 million in cash, cash equivalents and short-term investments compared to $185.6 million as of December&#160;31, 2022. We believe that our existing cash and cash equivalents and short-term investments as of March&#160;31, 2023 will be sufficient to fund our operations and meet our existing contractual obligations and other cash requirements into 2025. However, we may need to raise additional funds sooner as a result of a number of risks and uncertainties, including those set forth in Part II, Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned nonclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to expand our research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and cost of our commercialization of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (decrease) increase in cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,457&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, net cash used in operating activities was $22.4 million, primarily as a result of net loss of $29.1 million due to the continued activities developing our product candidates partially offset by $6.6 million of non-cash charges mainly related to $4.6 million of stock-based compensation expense and $1.6 million of depreciation and amortization expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, net cash used in operating activities was $28.9 million, primarily as a result of net loss of $37.9 million due to the continued activities developing our product candidates partially offset by $2.1 million of change in operating assets and liabilities and by $6.9 million of non-cash charges mainly related to $5.4 million of stock-based compensation expense and $1.4 million of depreciation and amortization expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2023 consisted of $21.6 million of net maturities from our marketable securities, partially offset by $0.1 million of purchases of property and equipment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2022 consisted of $88.8 million of net maturities from marketable securities, partially offset by $4.4 million of purchases of property and equipment primarily related to laboratory equipment and facility construction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2022 consisted mainly of $3,000 of proceeds from the exercise of stock options.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_103"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div><span><br/></span></div><div id="i367b8e12c33c498fa919b5dac5350798_106"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Management, including our Chief Executive Officer and Acting Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March&#160;31, 2023. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Quarterly Report on Form 10-Q. We conduct this type of evaluation quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Previously Reported Material Weakness in Internal Control over Financial Reporting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the potential magnitude of the error(s) that could arise from the operating deficiency as potentially material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remediation Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address our material weaknesses, we have implemented and continue to implement increased rigor to ensure controls operate with regard to material non-routine transactions. Consistent with past practice, preparation of technical accounting memos should operate for all material non-routine transactions, including modifications of existing agreements. We intend to continue to take steps to remediate the material weakness, including engaging additional outside financial reporting and technical accounting expertise to assist in the determination and analysis of potential accounting and statutory reporting impacts taking into consideration complexity of transactions to ensure we bridge and improve the knowledge and expertise within Finance on such specific non-routine transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our remediation activities are not complete and we continue to seek ways to strengthen the operation of our controls over our financial statement close process. While we believe that these efforts will improve our internal control over financial reporting, the implementation of our remediation is ongoing and will require validation and testing of the design and operating effectiveness of our internal controls over a sustained period of financial reporting cycles. The actions that we are taking are subject to ongoing senior management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate the material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the existence of the material weakness, our Chief Executive Officer and Acting Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described under the Remediation Plan above, we continue to implement increased rigor to ensure controls operated over material non-routine transactions during the quarter ended March&#160;31, 2023. Such remediation actions were changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i367b8e12c33c498fa919b5dac5350798_112"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_115"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales, marketing and other activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years or longer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into 2025. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials, investments into our manufacturing capabilities, the scope of our research and development activities, continued compliance with and receipt of rent under our sublease, and changing circumstances beyond our control, that may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned through collaboration agreements and public or private financings. If we run low on capital and are unable to successfully raise additional funds on terms acceptable to us, we may need to significantly curtail some or all of our development activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial future capital in order to complete the nonclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or ongoing clinical trials of our product candidates could cause an increase in our spending levels, as would other corporate activities, such as expenses related to manufacturing supply of our product candidates. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the type, number, scope, progress, costs, results of and timing of any future nonclinical studies and clinical trials of any of our product candidates that we are pursuing or may choose to pursue in the future;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the United States Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities outside the United States (&#8220;U.S.&#8221;), including any additional clinical trials or nonclinical studies the FDA or other regulatory authorities outside the U.S. may require evaluating the safety of our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including internal and external commercial manufacturing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability and cost of acquiring and shipping of supplies necessary for manufacturing and clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing sales, marketing, distribution and other commercial capabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain partnering arrangements for development; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing enhanced internal controls over financial reporting; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. General market conditions resulting from rising interest rates, inflation, bank failures, global supply chain issues, Russia&#8217;s invasion of Ukraine, the COVID-19 pandemic, as well as other market conditions, as well as our ability to maintain our Nasdaq listing, may make it difficult for us to obtain adequate additional financing when needed or on attractive terms, or at all. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we may be unable to complete any current or future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not currently in compliance with Nasdaq&#8217;s continued listing standards, and if we are not able to regain compliance with Nasdaq&#8217;s continued listing standards our common stock may be delisted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on The Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ADVM.&#8221; On November 18, 2022, we received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying us that we were out of compliance with the Nasdaq $1.00 per share minimum closing bid price rule. We have until May 17, 2023, to regain compliance with the minimum bid price rule. We will not be able to achieve compliance by May 17, 2023. We may be eligible for an additional 180-day period to regain compliance if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary, which we intend to do. However, if it appears to the Nasdaq staff that we will not be able to cure the deficiency, or if we do not meet the other listing standards, Nasdaq could provide notice that our common stock will become subject to delisting. In the event we receive notice that our common stock is being delisted, Nasdaq rules permit us to appeal any delisting determination by the Nasdaq staff to a Hearings Panel. Accordingly, our common stock is subject to the risk of being delisted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions could adversely affect our current financial condition and projected business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;), where we held a small portion of our cash and cash equivalents, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), as receiver.  On March 12, 2023, the Department of the Treasury, the Federal Reserve, and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those funds in excess of the standard FDIC insurance limits, under a systemic risk exception and, as a result, we had access to our cash and cash equivalents at SVB.  Since then, several other banks have failed and there is uncertainty in the markets regarding the stability of regional banks and the safety of deposits in excess of the FDIC insured deposit limits. The ultimate outcome of these events cannot be predicted, but these events could have a material adverse effect on our business operations if our ability to access funds at SVB or any other banks we use is compromised.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one product candidate in clinical trials, and if that product candidate is not successful our business could be materially impacted. Our other product candidates are in the early stages of development and will require substantial nonclinical and/or clinical development and testing, manufacturing process improvement and validation, clinical studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of nonclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers, partnering with a pharmaceutical licensee with manufacturing capabilities, or developing our own manufacturing capabilities that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing market share while competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA or marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (&#8220;EMA&#8221;), and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution, or be conditional on future development activities and clinical results. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development has inherent risk. Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, for the treatment of wet age-related macular degeneration (&#8220;wet AMD&#8221;), uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may generate unexpected results in clinical trials in the future, such as the dose-limiting toxicity at the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) dose tested in the INFINITY trial in diabetic macular edema (&#8220;DME&#8221;) subjects. Although we will be bound by the generally applicable laws governing approval, the fact that our product is a gene therapy and the broad patient population that it is intended to treat means that the safety and efficacy of our product and the related clinical data will be under increased scrutiny by competent authorities. There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors is safe and effective for use in its target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, whether in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of nonclinical studies and clinical trials, animal models and human subjects may experience changes in their health, including illnesses, injuries and discomforts. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. In addition, subjects may not comply with the requirements of the study, such as missing physician visits or not taking eye drops as prescribed, which may result in changes to their health or vision that are then attributed to the product candidate. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. For example, a dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial in DME subjects resulted in our announcement on July 22, 2021 that we were discontinuing development of Ixo-vec for the DME indication. It is possible that as we test Ixo-vec and other product candidates, in current and future clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, including the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. In some cases, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that one or more of our product candidates causes serious or life-threatening side effects, or side effects that outweigh the therapeutic benefit of the product candidate, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to understand the safety of our product candidates, when a subject experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate. The subjects we enroll in our clinical trials for our current product candidates are generally less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the subjects enrolled in our wet AMD trials are often geriatric and have other health conditions unrelated to wet AMD. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a subject in any of these or subsequent trials was related to Ixo-vec, nor can we assure you that the FDA or other regulatory authorities outside the U.S. responsible for reviewing the safety of Ixo-vec will agree with our determination. If a subject in one of our clinical trials experiences a negative health event, and that event is misattributed to Ixo-vec, the trial and other trials of Ixo-vec may be placed on clinical hold, and regulatory approval of Ixo-vec may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a subject enrolled in one of our clinical trials experiences a negative health event, the subject may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because subjects we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC that enroll a small number of subjects, this risk is increased.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates built on adeno-associated viral vector (&#8220;AAV&#8221;) vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, dose-related ocular inflammation is a known side effect of Ixo-vec administration, but the duration of inflammation caused by Ixo-vec, our ability to prevent or manage that inflammation using corticosteroids or other anti-inflammatory or immunomodulatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. The primary purpose of our LUNA trial is to identify the best combination of a prophylactic corticosteroid regimen and dose of Ixo-vec that minimizes post-prophylactic inflammation while at the same time providing efficacy. If we are unable to manage this inflammation appropriately, we may not be able to further develop Ixo-vec and the FDA or other regulatory authorities outside the U.S. may not approve Ixo-vec. Even if we achieve marketing approval, doctors may not prescribe, and patients may not use, Ixo-vec or our other product candidates if they deem the levels or risk of inflammation to be unacceptable or if they are unwilling or unable to use the required prophylactic corticosteroid regimen. Further, patients treated with Ixo-vec could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies in the future. In addition, patients previously treated with or exposed to other AAV-based gene therapies could develop antibodies against AAV.7m8 and/or the aflibercept protein, which could reduce or eliminate the effectiveness of Ixo-vec or could cause unanticipated adverse reactions to Ixo-vec. Studies have also found that intravenous delivery of certain AAV vectors at high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any therapeutic protein or injection of gene therapies that express a therapeutic protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to intravitreal injection, such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our lead product candidate, Ixo-vec, is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though EYLEA&#174; (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed via a gene therapy treatment modality. If such side effects are serious or life threatening, the development of our product candidate and future product candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology or product candidates. Promising nonclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a nonclinical model, including non-human primate models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. Success in nonclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through nonclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may become apparent only when the product candidate is tested in human subjects suffering from the relevant disease. Furthermore, the initiation of future trials for a product candidate will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. We will still need to conduct Phase 3 pivotal trials in which we anticipate Ixo-vec will be compared to available therapies and utilize longer term endpoints in order to support submission and approval of a BLA or equivalent outside of the U.S. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, the FDA and/or other regulatory authorities outside the U.S. may still conclude that the product candidate has not demonstrated a beneficial risk/benefit profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and the time, cost and probability of subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on our gene therapy platform and in product candidates based on this platform, and our future success depends on the successful development of such product candidates. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to external commercial manufacturing sites, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, EMA and other regulatory authorities outside the U.S. and the criteria these regulators may use to determine the quality, safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other treatment modalities, which are better known or more extensively studied to date. In 2017 and 2019, the FDA approved the first two products in vivo gene therapy. To date, approvals for gene therapy products by the FDA have been generally for rare diseases with limited treatment options. Because we are targeting a broad population of patients with wet AMD, for which there is an approved and widely adopted standard of care, the benefit-risk profile of Ixo-vec may be subject to greater scrutiny by regulatory authorities. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience, including, for example, reevaluating whether to require a companion diagnostic for gene therapy products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a clinical trial can begin to enroll at a clinical site, the site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee must review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory agencies, review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change chemistry, manufacturing, and controls requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so or the consultations take longer than we expect, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating and patient&#8217;s safety concerns over participating in a clinical trial, including during a pandemic. We will be required to identify and enroll a sufficient number of patients for any clinical trial for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval of our product candidates in the U.S. and/or Europe and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA, the EMA or other regulatory authorities outside the U.S. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if patients and investigators are unwilling to participate in our gene therapy studies because of the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, or because of negative publicity from other adverse events in the biotechnology or gene therapy sector or inadequate results in our nonclinical studies or clinical trials or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, or conduct of clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an AAV delivery system, with which host integration has been less of a concern. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may choose not to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nonclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities outside the U.S. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities outside the U.S. can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S. that a product candidate is safe and effective for any indication;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S. or the other regulatory authorities outside the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in our manufacturing processes, analytical testing, or facilities or the manufacturing processes, analytical testing or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable regulatory authorities outside the U.S. in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues or further subject follow up occurs and more subject data become available. For example, although we have periodically announced interim data from subjects in our OPTIC trial, which showed all Ixo-vec related adverse events as mild to moderate in severity, there is no guarantee that in the future, we will not have more severe drug- or treatment-related adverse events in subjects treated with Ixo-vec, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of subjects were enrolled with different dosages and other treatment conditions under our protocol. These different doses, populations, and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of supplemental injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation by the FDA, PRIME designation by the EMA for Ixo-vec and the Innovation Passport by the MHRA may not lead to a faster development, regulatory review or approval, and it does not increase the likelihood that Ixo-vec will receive marketing approval in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for Ixo-vec in September 2018 for the treatment of wet AMD. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including pre-investigational new drug application (&#8220;IND&#8221;) meetings, end-of-phase 1 meetings, and end-of-phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Medicines Agency EMA granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation in June 2022 for the treatment of wet AMD. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated preliminary safety and efficacy and thus the potential to target a significant unmet medical need and bring a major therapeutic advantage to patients.  This regulatory program offers developers of promising medicines enhanced interaction and early dialogue with the EMA and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) granted Ixo-vec an Innovation Passport under the Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) in April 2023. The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence and the National Health Service England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom (&#8220;UK&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, Fast Track, PRIME and ILAP designations for Ixo-vec may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA or the EMA. In addition, the FDA may rescind the Fast Track designation for Ixo-vec if FDA later determines that Ixo-vec no longer meets the qualifying criteria for Fast Track designation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve, is often very expensive and may require extended periods of time. As we develop, seek to optimize, and operate the Ixo-vec manufacturing process, internally or through third parties, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical manufacturing campaigns or process validation campaigns. For example, all Good Manufacturing Practices (&#8220;GMP&#8221;) activities at our Redwood City facility, and external manufacturing, testing, and distribution partners are subject to significant health authority regulation with respect to manufacturing and testing our product candidates. If we are unable to satisfy these regulatory requirements, or if we are unable to solve the technical, scientific, and other challenges described above, we may be unable to manufacture a sufficient supply of our product candidates for our clinical trials and may be forced to delay or terminate our development programs. Additionally, changes in manufacturing processes (including cell lines), equipment or facilities (including moving manufacturing or testing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to conduct additional studies to demonstrate comparability in order to receive regulatory approval of any manufacturing modifications. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may revise the process that we use to manufacture Ixo-vec for clinical trials. Before we use a revised process in clinical trials, we must submit analytical comparability data to the FDA and comparable regulatory authorities outside the U.S. to demonstrate that the process changes have not altered Ixo-vec in a manner that undermines the applicability of the clinical data from our clinical trials. If the FDA and comparable regulatory authorities outside the U.S. do not find our analytical comparability data sufficient, the FDA and comparable regulatory authorities outside the U.S. could place our IND or equivalent on clinical hold until we conduct additional nonclinical or clinical comparability studies demonstrating that the Ixo-vec manufactured by our revised process and our previous process are materially equivalent, which could substantially delay the development process. If we make further changes to the manufacturing process, equipment or facilities of Ixo-vec in the future, the FDA and comparable regulatory authorities outside the U.S. may require us to demonstrate comparability between Ixo-vec manufactured before and after the change. For example, the FDA and comparable regulatory authorities outside the U.S. could require comparability studies to demonstrate that Ixo-vec manufactured in its current facilities is comparable to Ixo-vec manufactured at future commercial supply sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any required comparability studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If the results of these comparability studies are not positive or are only modestly positive or if there are safety concerns, we may be delayed in obtaining marketing approval for Ixo-vec or not obtain marketing approval at all. Our product development costs also will increase if we experience delays in testing or regulatory approvals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to produce sufficient quantities of our products and product candidates at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our products, we may not be able to manufacture sufficient quantities to meet clinical or potential commercial demand. Our inability to produce enough of a product meeting all release acceptance criteria at acceptable costs may cause us to be unable to meet clinical or potential commercial demand, to lose potential revenue, to have reduced margins, or to be forced to discontinue such product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop, seek to optimize and operate the Ixo-vec manufacturing process internally or through third parties, we will likely face technical and scientific challenges, considerable costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from commercializing Ixo-vec, if approved, on a profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing processes will subject us to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use, as well as comparable legislation and regulations outside of the U.S. We will incur significant costs in complying with these laws and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy products are novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. If we are unable to secure adequate manufacturing capacity from our contract manufacturing partners, or if our contracted slots are cancelled or delayed in order to prioritize other projects, we may be unable to produce sufficient quantities of our product candidates for our development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product used in clinical trials or approved for commercial sale must be manufactured and tested in accordance with GMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GMP regulations enforced by the FDA through its facilities inspection program as well as other regulations enforced by other regulatory authorities outside the U.S. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with GMP regulations to the satisfaction of the FDA or other regulatory authorities outside the U.S. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. If the facility does not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect any manufacturing facility we may have or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authorities outside the U.S. determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and governmental policies may have an effect on regulations. For example, on January 31, 2020, the UK withdrew from the European Union (&#8220;EU&#8221;), commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK-EU Trade and Cooperation Agreement, which has applied since the end of the Transition Period, provides for tariff-free trade of goods, but not services, between the UK and the EU, but there may however be additional non-tariff costs which did not exist prior to the end of the Transition Period. Further, should the UK further diverge from the EU from a regulatory perspective in relation to medical products, tariffs could be put into place in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extend to procedures such as batch release certification, and Great Britain (England, Scotland and Wales) is treated as a third country. Northern Ireland, with regard to EU regulations, continues to follow the EU regulatory rules. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK continues to accept EU batch testing and batch release, but has recently conducted a consultation as to the future strategy for batch testing policy; two years notice will be provided of any change to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland is, however, covered by centralized marketing authorizations granted by the European Commission (&#8220;EC&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently delays on cross-border trade between the UK and the EU as businesses and governmental bodies adapt to the arrangements. We and our contract vendors currently rely on other contractors based in the UK. The implementation of new governmental policies associated with Brexit may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time, inspect any manufacturing facility we may have or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party contractors fail to maintain regulatory compliance, the FDA or other regulatory authorities outside the U.S. can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, revocation of a pre-existing approval, injunction, seizure of product, or other civil or criminal penalties or closing one or more manufacturing or testing facilities. As a result, our business, financial condition and results of operations may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. Alternative contractors could need to be qualified through a BLA supplement which could result in further delay. The regulatory authorities may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Changing contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the complexity of manufacturing our product candidates, we may not be able to manufacture sufficient quantities to support our clinical trials. Delays in manufacture and supply by our contract manufacturing partners may also cause delays in their ability to supply the amount of our product that we have ordered and on which we have based our expected development timelines. Our inability to produce enough of a product candidate at acceptable costs may result in the delay or termination of development programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, or transportation or storage conditions of the product. Even minor deviations from prescribed manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contract manufacturers must comply with the FDA&#8217;s GMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable regulatory authorities in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow GMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, storage, or distribution of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to develop the manufacturing process for late-stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of our research and development, including vector production, process development, assay development, product candidates and product manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our vector production, product and product candidate manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements or partnerships with these third parties and if we do enter into agreements with these third parties, we cannot be assured these agreements will be on favorable economic terms or that any of these third parties will be successful at fulfilling their contractual obligations, and it is possible they may choose to terminate their engagements with us. If we need to enter into alternative arrangements, it could delay or jeopardize our product development activities or be more costly. Our reliance on these third parties for vector production, process development, assay development, product and product candidate manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies,  research and related activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vector production, product and product candidate manufacturing and testing are conducted in accordance with applicable GMP requirements and other applicable regulatory requirements; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research, process development, and assay development are conducted in accordance with applicable industry and regulatory standards and norms;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of which we may not be able to do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to rely on third-party manufacturers and suppliers, and may enter into partnerships and other business development arrangements, which entails risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing, supplier agreements, partnerships or other agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control as a result of using third-party manufacturers or partners for some or all aspects of manufacturing activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements, partnerships, or supplier agreements with third parties in a manner or at a time that is costly or damaging to us; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer, supplier or partner, or their commitments to other vaccine and therapeutics production projects that may reduce available manufacturing capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our nonclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct nonclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to conduct research and to develop and manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that they become known by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, academic institutions that we collaborate with often require rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, including through breach of our agreements with third parties, failure of our security measures or publication of information by any of our third-party collaborators, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, in 2019 we received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. Although no further action has been taken in that matter, it illustrates that if one of our licenses were to be terminated, we may be unable to obtain a new license to that technology on commercially reasonable terms, if at all.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Hatch-Waxman exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Further, following Russia&#8217;s invasion of Ukraine in February 2022, the U.S. government has levied sanctions against Russia and Belarus, Russia has issued a decree that removes protections for some patent holders who are registered in unfriendly countries, including the U.S., and the USPTO has terminated its engagement with officials from intellectual property agencies in Russia, Belarus and Eurasia, so we are not currently maintaining certain intellectual property filings in these jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system will likely be introduced by the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer a patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;). Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Hatch-Waxman Act permits a patent restoration term of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the U.S., patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. Similar extensions of patent term are available in Europe and other jurisdictions. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation by the regulatory authorities in the EU of applicable EU regulations governing data and market exclusivity may impact our entitlement to data and market exclusivity. The revisions to the orphan drug legislation in the EU and the EU rules governing Supplementary Protection Certificates that are currently being discussed may also impact our entitlement to this exclusivity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed or may in-license may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights we have licensed, including certain rights related to our proprietary AAV.7m8 capsid, were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability, or that of our sublicensees, to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement, what activities satisfy those diligence obligations, and to what extent those obligations are relieved or delayed by external factors beyond our control, such as the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of our payment obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rights upon termination of such agreement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one product candidate in clinical trials. Before we can initiate clinical trials for other product candidates in the U.S., we need to submit the results of nonclinical testing to the FDA, along with other information including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. We may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary nonclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA or other regulatory authorities may require us to conduct additional nonclinical testing for any of our product candidates before they allow us to initiate clinical testing under any IND or equivalent, or at any stage of clinical development of Ixo-vec or other new product candidates based on concerns that arise as the clinical program progresses or if significant manufacturing process changes are made to the program, which may lead to additional delays and increase the costs of our nonclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any clinical trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities outside the U.S. to temporarily or permanently shut down due to violations of GMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process, or in the manufacturing facilities in which our product candidates are made;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of non-investigational materials or supplies required for the clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of non-investigational materials or supplies required for manufacturing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses, permits or resources necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection, sample testing or analysis in a timely and accurate manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or other regulatory authorities outside the U.S., or the finding of regulatory violations by the FDA or other regulatory authorities outside the U.S., or an IRB that requires us to undertake corrective action resulting in suspension or termination of one or more clinical sites or the imposition of a clinical hold on the IND or that prohibits us from using some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities outside the U.S. for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs refusing to approve, suspending or terminating the trial at a clinical site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs will increase if we have delays in testing or approval of any of our product candidates, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of our clinical trials, or if we, the FDA or other regulatory authorities outside the U.S., the IRB, other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have amended our protocol and from time to time may further amend our protocol based on a variety of factors, and these changes may have unanticipated consequences on our clinical trial outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical trials and submit a BLA, and/or an MAA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in policies from the FDA or other regulatory authorities outside the U.S. during the period of product development, clinical trials and FDA regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from product sales, if any, could be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical efficacy, including duration of efficacy, and safety compared to other more-established products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any labeling approved for our products by the FDA or other applicable regulatory authorities outside the U.S., including the possible inclusion of a &#8220;black box warning&#8221; from the FDA or other applicable regulatory authorities outside the U.S. alerting health care providers to potential serious side effects associated with using a product or the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new therapeutic options by health care providers and their patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new procedures or methods of treatment that may be more effective in treating or may reduce the incidence of wet AMD, or other conditions that our product candidates are intended to treat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to the product candidate; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products and defend and enforce our intellectual property rights relating to our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering a gene encoding a therapeutic antibody fragment similar to ranibizumab (LUCENTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of wet AMD and diabetic retinopathy, which competes for the same patients, study site resources, and personnel as Ixo-vec. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New developments, including the development of other biotechnology and gene therapy technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, LUCENTIS and EYLEA are currently available in the U.S. for treatment of wet AMD. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, Ixo-vec for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long-acting delivery devices and gene therapy. LUCENTIS and EYLEA are anti-VEGF therapies that are well established and widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of wet AMD. There are several other companies with marketed products or products in development for the treatment of wet AMD, including 4D Molecular Therapeutics, Bayer, Hoffmann-La Roche Ltd., Novartis, Regeneron and REGENXBIO. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities outside the U.S. for compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">institute import holds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA and other regulatory authorities outside the U.S. strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the competent regulatory authority as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and regulatory and enforcement authorities outside the U.S. actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the U.S., private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for gene therapy products, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the U.S., even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans. or, if they do, the level of payment may not be sufficient to allow the company to sell its products at a profit. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to executive, Congressional, and judicial challenges as well as efforts to repeal, replace, or otherwise modify them or alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act of 2017 included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Reduction Act&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare and other reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and, if approved, may affect the prices we may obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect until 2032 unless additional congressional action is taken. Further, Congress is considering additional health reform measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. The Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, the Inflation Reduction Act, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. The Inflation Reduction Act permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the Inflation Reduction Act will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market for Ixo-vec, if approved, in the treatment of wet AMD or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, or if this occurs for any of our other product candidates, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of Ixo-vec for the treatment of wet AMD, a disease we believe to be the most common cause of vision loss in adults over the age of 50 in developed countries. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate, we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with Ixo-vec or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effort to identify patients with diseases we seek to treat is in early stages.  We cannot accurately predict the number of patients for whom treatment for wet AMD using Ixo-vec or any of our other product candidates might be possible or whether the FDA or other regulatory authorities may approve indications for Ixo-vec or any of our other product candidates that are more limited than we expect due to efficacy or safety concerns. For example, some patients have neutralizing antibodies at titer levels that may prevent them from benefiting from Ixo-vec. If this patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic corticosteroid treatment will be required to manage inflammation associated with treatment with Ixo-vec, and certain patients cannot be treated with prophylactic corticosteroids. If this proportion of the patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into development or other strategic collaborations with biotechnology and pharmaceutical companies in the past and may do so again in the future. Research activities under our collaboration agreements are subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments may impose price controls, which may adversely affect our future profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, including Member States of the European Economic Area (&#8220;EEA&#8221;), the pricing of prescription pharmaceuticals is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. Publication of discounts by third-party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no sales, marketing, distribution, or market access and reimbursement capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, distribution, or market access and reimbursement capabilities. If any of our product candidates ultimately receive regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, marketing, distribution, or market access and reimbursement capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing, distribution, or market access and reimbursement functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing, distribution, or market access and reimbursement functions ourselves, we could face a number of additional related risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to attract and build an effective marketing department, sales force, or distribution capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial, remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, Ixo-vec, expresses the aflibercept protein, which is also the active component in EYLEA. If safety or efficacy issues occur relating to EYLEA, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment or consulting agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize expected operational efficiencies and the cost savings from the restructuring, our operating results and financial condition would be adversely affected. Due to our restructuring, we may not be able to effectively manage our operations or retain qualified personnel, which may result in weaknesses to our infrastructure and operations, increased risk that we may be unable to comply with legal and regulatory requirements, increased risks to our internal controls and disclosure controls, and loss of employees and reduced productivity among remaining employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring resulted in the loss of institutional knowledge and expertise and the reallocation of and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Further, the restructuring and possible additional cost-containment measures may yield unintended consequences, such as attrition beyond our intended workforce reduction and reduced employee morale. We may be required to rely more heavily on temporary or part-time employees, third party contractors and consultants to assist with managing our operations. These consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We will have only limited control over the activities of these consultants and in many instances can expect these individuals to devote only limited time to our activities. Failure of any of these persons to devote sufficient time and resources to our business could harm our business. Employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to successfully manage this transition and these restructuring activities, our expenses may be more than expected and we may be unable to fund our Ixo-vec development plan or implement our business strategy. As a result, our business, prospects, financial condition and results of operations could be negatively affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Russia&#8217;s invasion of Ukraine and current adverse economic conditions could adversely affect our revenue, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global disruption to, and potential impacts on, the health of the global economy arising from, related to, or resulting from Russia&#8217;s invasion of Ukraine in February 2022 could affect our business and operations. For example, the credit and financial markets have been adversely affected by the war and measures taken in response thereto, potentially impacting our ability to raise adequate additional capital when needed or on favorable terms. In addition, current economic conditions, such as recent global supply chain disruptions, labor shortages, rising interest rates and inflation, may adversely impact our operations, for example by increasing our costs, disrupting our suppliers&#8217; ability to provide us with materials and supplies needed for both our manufacturing and clinical trials, or causing delays to our clinical trial and manufacturing timelines, which may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the emergence of new variants have caused us to modify our business practices, including the adoption of a hybrid mix of virtual and in-person work, updating our policies and implementing new practices to align with guidance from state and federal governments and health authorities. We may take further actions that may be required by government authorities or that we determine are in the best interests of our employees, customers, and business partners. We are uncertain that such measures will be sufficient to mitigate future risks posed by the virus and its variants or otherwise be satisfactory to government authorities and how long we will be required to continue these measures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, an increased reliance by us and the companies with which we do business on information technology systems to support a hybrid workforce may increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also affect our current and planned trials, development programs and our timelines for commercialization. We and our CROs, clinical sites and contract manufacturing organizations (&#8220;CMOs&#8221;) may face disruptions that may affect our ability to conduct and timely complete ongoing clinical trials, nonclinical studies, obtain clinical supplies, and conduct other research and development activities. The response to the COVID-19 pandemic also could redirect resources with respect to regulatory and intellectual property matters in a way that could adversely impact our ability to progress regulatory approvals and protect our intellectual property.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our relationships with our manufacturers, service providers, suppliers, or other vendors are terminated, materially altered, or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative manufacturers, service providers, suppliers, or other vendors or do so on commercially reasonable terms or in a timely or cost-effective manner. Further, delays could occur which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. The COVID-19 pandemic may also affect the operations of the FDA or other health regulatory authorities outside the U.S., which could result in delays of meetings, reviews and approvals, including with respect to our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, the recent recession or market correction, which has been attributed in part to the COVID-19 pandemic, could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are taking steps to mitigate all of these effects, the occurrence of any of these disruptions, including of our own operations, could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact our business, results of operations, and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the duration and spread or any future resurgence of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may experience materially adverse impacts to our business as a result of its global human and economic impact, or as a result of our actions taken and not taken as mitigation measures during the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and other third parties on which we rely collect, receive, use, process, generate, transfer, make accessible, protect, secure, dispose of, transmit, share, and store sensitive, confidential, and proprietary information, including personal information (such as health-related information and medical information), intellectual property, trade secrets, research and development information, financial information, and other business information.  As a result, we and the third parties upon which we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our confidential, sensitive, and proprietary data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent, continue to rise, are becoming increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivist,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products and services. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and data and those of third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruptions of clinical trials, loss of confidential, sensitive, or proprietary data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting payments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations.  Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations.  We rely on third-party service providers and technologies to operate critical business systems to process confidential, sensitive, or proprietary data in a variety of contexts, including, without limitation, CROs, CMOs, collaborators, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions.  We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business.  Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place.  If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.  In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our confidential, sensitive, or proprietary information or our information technology systems, or those of third parties upon which we rely. A security incident or other interruption could result in delays to the development and commercialization of our product candidates, disruption of our programs, negative publicity and financial loss. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents.  Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and confidential, sensitive, or proprietary information. For example, the loss of clinical trial information from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective.  Furthermore, because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security incidents that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, such as governmental authorities, partners, and affected individuals, of security incidents. Such disclosures may involve inconsistent requirements and are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing confidential, sensitive, or proprietary information (including personal information); litigation (including class-action claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security incident could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business, delay or impede the development of our products, and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, there can be no assurance that we will promptly detect any such disruption or security incident, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer confidential, sensitive, or proprietary information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including research and marketing, in the pharmaceutical industry. These laws include anti-kickback, false claims, and healthcare professional payment transparency laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, arranging for, or recommending the purchase, lease or order of any healthcare item or service for which payment may be made, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices may be subject to scrutiny if they do not qualify for an exception or safe harbor. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (such as a physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states and localities also mandate implementation of commercial compliance programs, restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs, impose restrictions on drug manufacturer marketing practices, require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products or product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, policies, and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; interruption of our clinical trials; and other adverse business consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share sensitive, proprietary, and confidential information, including personal information, business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our processing activities may subject us to numerous data privacy and security obligations, such as laws, regulations, guidance, industry standards, external and internal policies, contractual requirements, and other obligations relating to data privacy and security and that govern processing of confidential, sensitive, or proprietary data (including personal information ) by us or on our behalf, including information that we collect or will collect about subjects and healthcare providers in connection with clinical trials. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws and regulations, including those relating to data breach notification, personal information privacy, consumer protection (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services for them involving individually identifiable health information, as well as their covered subcontractors. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or the CPRA (collectively, "CCPA") applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain rights related to their personal information.  The CCPA provides for administrative fines for noncompliance (up to $7,500 per violation) and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. Additionally, the CPRA&#8217;s recent amendments expand the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia and Colorado, have also passed comprehensive data privacy and security laws, and similar laws are being considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the EU GDPR, the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal information, including health-related information. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing; other corrective actions; private litigation related to processing of personal information brought by classes of data subjects or consumer protection organizations authorized by law to represent their interests; and/or fines up to the greater of &#8364;20 million or 4% of annual global revenue, and separately &#163;17.5 million or 4% of annual global revenue under the UK GDPR. EU member states are also able to legislate separately on health and genetic information, and we must comply with these local laws where we operate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, we may be unable to transfer personal information from Europe and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal information to other countries.  In particular, the European Economic Area (&#8220;EEA&#8221;) and the United Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal information to the U.S. and other countries whose data privacy and security laws they believe are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal information from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal information to the U.S.  If there is no lawful manner for us to transfer personal information from the EEA and the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal information necessary to operate our business.  Additionally, companies that transfer personal information out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activities groups.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal information out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process confidential, sensitive, or proprietary information on our behalf.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and imprisonment of company officials (for example, under HIPAA). Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our development partners, third-party manufacturer and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and any of our future development partners or CROs are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal and state health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted on December 22, 2017, known as the Tax Cuts &amp; Jobs Act (&#8220;TCJA&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law in March 2020. The CARES Act modifies certain of the changes made by the TCJA. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the TCJA, as amended by the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. For example, the recently enacted Inflation Reduction Act of 2022 includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock. In addition, it is uncertain if and to what extent various states will conform to the TCJA, as amended by the CARES Act, the Inflation Reduction Act, or other newly enacted federal tax legislation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TCJA, federal NOLs incurred in taxable years beginning after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs for taxable years beginning after 2022 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. We may have experienced an ownership change as a result of the February 2018 underwritten public offering of our common stock, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the amount of the NOLs and research credit carryforwards presented in our financial statements could be limited and may expire unutilized. In addition, state suspensions of the ability to use NOLs, and research credits, may limit our ability to use our NOLs and research credits to offset state taxable income and taxes.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to enroll and dose subjects in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct nonclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of any clinical trials of our product candidates and the results of trials of competing product candidates or of other companies in our market sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial results, variations in our financial results and the adequacy of our cash runway to achieve key milestones, or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing adequate supply of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to gene therapy and to biotechnology generally, including with respect to other products and potential products in such markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our Nasdaq listing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our stock by insiders and stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing effects of the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to licensing, collaboration or other arrangements, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants, debt and other financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the removal of directors by the stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting. If we fail to remediate this material weakness or if we discover or develop additional material weaknesses or otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected and our financial statements may need to be restated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. During the year ended December 31, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the magnitude of the potential errors that could arise from the operating deficiency as potentially material. As a result, we are unable to assert that our internal control over financial reporting is effective as of March 31, 2023. For so long as we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected and we could become subject to litigation or investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been subject to securities class action lawsuits in the past and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management&#8217;s time and attention from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we and certain of our former officers were involved in purported securities class action lawsuits, which have since been settled. The purported securities class action lawsuits asserted that the defendants violated the Exchange Act and the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and alleged that the defendants, who are no longer at Adverum, made materially false and misleading statements and omitted allegedly material information related to, among other things, the Phase 2a clinical trial for AVA&#8209;101, a program which was discontinued in 2015, and the prospects of AVA-101. We settled these lawsuits for $13.0 million, of which we contributed $1.0 million to cover our indemnification obligations to the underwriters, and the remainder was contributed by our insurers. Any future litigation of this type could result in payment of damages or settlement fees and diversion of management&#8217;s attention and resources, any of which could adversely impact our business. Monitoring and defending against legal actions are time-consuming for our management and detract from our ability to focus fully on our business activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, which may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition, termination or modification of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature and terms of stock-based compensation grants; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">derivative instruments recorded at fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America. will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation and bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional costs associated with resolving the dispute in other jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could seriously harm our business.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_142"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i367b8e12c33c498fa919b5dac5350798_145"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_148"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i367b8e12c33c498fa919b5dac5350798_151"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2023, we, through our subsidiary Adverum NC, LLC, ARE-NC REGION NO. 21, LLC (&#8220;Landlord&#8221;), and JAGUAR GENE THERAPY, LLC (&#8220;Subtenant&#8221;), entered into a Third Amendment to Lease Agreement and First Amendment to Consent to Sublease (the &#8220;Lease Amendment&#8221;), which amends the lease relating to building we lease in Durham, North Carolina (the &#8220;NC Premises&#8221;). The Lease Amendment primarily reduces the rent payments for the NC Premises effective as of May 1, 2023, and modifies the tenant improvement allowances provided by the Landlord to us and the Subtenant. The Lease Amendment is filed as Exhibit 10.3 to this Form 10-Q.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>OR ITEM<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> through </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023009899/advm-20221231xexx104d.htm">Third Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of March 24, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023009899/advm-20221231xexx104e.htm">Fourth Amendment to Lease between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of March 24, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4E</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex103.htm">Third Amendment to Lease and First Amendment to Consent to Sublease between Adverum NC, LLC (a wholly owned subsidiary of the Company), ARE-NC REGION NO. 21, LLC and Jaguar Gene Therapy, LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex103.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex103.htm"> dated as of April 3, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex103.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex103.htm"> </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex312.htm">Certification of Principal Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20230331ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>OR ITEM<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL tags for the cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, are embedded with the Inline XBRL document.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i367b8e12c33c498fa919b5dac5350798_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i367b8e12c33c498fa919b5dac5350798_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 11, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 11, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda Rubinstein</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Accounting Officer)</span></div></td></tr></table></div><div style="padding-left:54pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>advm-20230331ex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic0ea302be3b844a990b2f403094b28c7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO LEASE AGREEMENT AND FIRST AMENDMENT TO CONSENT TO SUBLEASE</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Third Amendment to Lease and First Amendment to Consent to Sublease (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is made as of April </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, 2023 but effective as of March 1, 2023, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-NC REGION NO. 21, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADVERUM NC, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAGUAR GENE THERAPY, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Landlord and Tenant are parties to that certain Lease Agreement dated as of January&#160;8, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as amended by that certain letter agreement dated as of January 8, 2021, that certain First Amendment to Lease Agreement dated as of April 15, 2021 and that certain Acknowledgment of Commencement Date dated as of April 23, 2021 and by that certain Consent to Sublease and Second Amendment to Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) dated as of October&#160;26, 2021 among Landlord, Tenant and Sublessee (the Original Lease as amended is herein the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160; Pursuant to the Lease, Landlord leased to Tenant certain premises constituting the entire building located at 14 TW Alexander Drive, Durham, North Carolina as more particularly described in the Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Tenant has sublet the entire Premises to Sublessee pursuant to that certain Sublease dated October 26, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Sublease has been consented to by Landlord subject to and in accordance with the terms of the Consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Landlord and Tenant desire to amend the terms of the Lease and Landlord, Tenant and Sublessee desire to amend the terms of the Consent as provided in this Amendment subject to the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree to amend the Lease and Landlord, Tenant and Sublessee agree to amend the Consent as provided herein&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of March 1, 2023, Base Rent under the Lease shall be reduced from $32.00 per rentable square foot of the Premises per year to $27.90 per rentable square foot of the Premises per year. Commencing on May 1, 2023 (the next occurring Adjustment Date under the Lease) and on each Adjustment Date thereafter, Base Rent shall be adjusted by multiplying the Base Rent payable immediately before such Adjustment Date by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable immediately before such Adjustment Date, as currently provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Lease. For the avoidance of doubt, on May 1, 2023, the rate of Base Rent payable under this Lease shall be $ $29.60 per rentable square foot of the Premises per year.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained in the Lease or the Consent or the Amended and Restated Work Letter (as defined in the Consent), the Tenant Improvement Allowance to be provided by Landlord under the Lease, the Consent and the Amended and Restated Work Letter is hereby reduced from $23,465,700.00 to $16,790,488.00.  The forgoing reduced allowance amount is inclusive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751349118.7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the separate $2,000,000.00 Warm Shell Improvement Allowance which has been fully disbursed by Landlord plus that portion of the original Tenant Improvement Allowance (i.e. $14,790,488.00) which has been spent to date by Tenant and&#47;or Sublessee and disbursed by Landlord pursuant to the original Work Letter and&#47;or Amended and Restated Work Letter.  Tenant and Sublessee acknowledge and agree that the Warm Shell Improvement Allowance and the balance of the funds constituting the Tenant Improvement Allowance have been fully disbursed and Landlord has no further obligation with respect to the disbursement of the Warm Shell Improvement Allowance and the Tenant Improvement Allowance.  Landlord and Tenant further acknowledge the Tenant Improvement Allowance is included in the Base Rent amount as amended by this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">First Additional TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to the Additional Tenant Improvement Allowance (renamed herein below the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Second Additional Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Landlord shall provide to Tenant and Sublessee a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Additional Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; in the amount of $8,675,212.00 (which amount equates to the difference between the Tenant Improvement Allowance plus the Warm Shell Improvement Allowance provided in the Original Lease and the current amount of the Tenant Improvement Allowance as reduced by this Amendment &#8211; i.e. ($23,465,700.00 + $2,000,000.00) - $16,790,488.00 &#61; $8,675,212.00). As of the date hereof, the First Additional Tenant Improvement Allowance remains undisbursed and available for use. The First Additional Tenant Improvement Allowance shall be made available for use and shall be disbursed by Landlord on all of the same terms and conditions under the Lease, the Consent and the Amended and Restated Work Letter as are applicable to the Second Additional Tenant Improvement Allowance except that the computation of TI Rent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Lease with respect to requested disbursements of the First Additional Tenant Improvement Allowance shall be based on an interest rate of 6.25% per annum instead of the rate of 8% per annum applicable to requested disbursements of the Second Additional Tenant Improvement Allowance. As with the Second Additional Tenant Improvement Allowance, monthly TI Rent shall commence to be due and payable and interest shall commence to accrue on the date that Landlord first disburses funds constituting such Second Additional Tenant Improvement Allowance or any portion(s) thereof.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Second Additional TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord shall continue to provide to Tenant (and to Sublessee pursuant to and in accordance with the terms and conditions of the Consent and the Amended and Restated Work Letter), the Additional Tenant Improvement Allowance in the amount of $17,382,000.00 (for clarity such allowance is hereby renamed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Second Additional Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and all references in the Lease, the Consent and the Amended and Restated Work Letter shall be revised accordingly). As of the date hereof, the Second Additional Tenant Improvement Allowance remains undisbursed and available for use.  All terms and conditions in the Lease, in the Consent and in the Amended and Restated Work Letter pertaining to the use and disbursement of the Second Additional Tenant Improvement Allowance and to the computation and charging of TI Rent upon the disbursement of funds constituting such allowance shall remain in effect and unchanged by this Amendment. The parties acknowledge that the interest rate which shall be used in computing the TI Rent for disbursements of the Second Additional Tenant Improvement Allowance shall be eight percent (8%) per annum. The defined term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in the Lease, the Consent and the Amended and Restated Work Letter is hereby amended to add and include the First Additional Tenant  Improvement Allowance and the Second Additional Tenant  Improvement Allowance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Election to Use the TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The two sentences in the Amended and Restated Work Letter which immediately follow </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Amended and Restated Work Letter and which provide that Tenant and Sublessee have made an irrevocable election upfront and in advance of any request for such funds to receive the full amount of the Second Additional Tenant Improvement Allowance are hereby deleted. Tenant and Sublessee shall not be deemed to have elected to receive disbursements of the First Additional Tenant Improvement Allowance or the Second Additional Tenant Improvement Allowance until such time as Tenant or Sublessee, as the case may be, has submitted a draw request to Landlord in accordance with the provisions of the Amended and Restated Work. The submission of the draw request shall be deemed a binding irrevocable election by the Tenant and Sublessee to receive the requested funds (and only the requested funds) and once made, such election may not thereafter be modified by either party without Landlord&#8217;s consent, which consent may not be unreasonably withheld, conditioned or delayed.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Deadline for Use of TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The deadline for the use of the TI Allowance is hereby extended until June 30, 2024.  Notwithstanding anything to the contrary contained in the Lease, the Consent or the Amended and Restated Work  Letter, Tenant and Sublessee shall have no right to any portion of the TI Allowance that is not requested for disbursement  in accordance with the disbursement conditions set forth in the Lease, the Consent and the Amended and Restated Work Letter before June 30, 2024.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">This Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Each of Tenant with respect to the Lease and Sublessee with respect to the Sublease and the Consent represents and warrants that it is currently (a) in compliance with and shall at all times during the Term of the Lease and Sublease, respectively remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OFAC Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (b) not listed on, and shall not during the Term of the Lease and Sublease, respectively be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">Each of Tenant and Sublessee agree that for itself, its employees, agents, and any subtenant, that it shall not disclose to any person or entity the terms of this Amendment, except as may be required by law or to agents or professionals of Tenant or Sublessee respectively, provided that such agents or professionals are bound by confidentiality agreements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Each party represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in connection with the transaction reflected in this Amendment and that no Broker brought about this transaction.  Each party hereby agrees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to indemnify and hold the other parties harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with the indemnifying party with regard to this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">Time is of the essence in this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.&#160; Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">Except as amended and&#47;or modified by this Amendment, the Lease and the Consent are each hereby ratified and confirmed and all other terms of the Lease and Consent shall remain in full force and effect, unaltered and unchanged by this Amendment. In the event of any conflict between the provisions of this Amendment and the provisions of the Lease and&#47;or the Consent, the provisions of this Amendment shall prevail Whether or not specifically amended by this Amendment, all of the terms and provisions of the Lease and the Consent are hereby amended to the extent necessary to give effect to the purpose and intent of this Amendment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Signatures are on the next page.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><div id="ic0ea302be3b844a990b2f403094b28c7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the parties hereto have executed this Amendment as of the day and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.921%"><tr><td style="width:1.0%"></td><td style="width:42.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TENANT&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADVERUM NC, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited liability company</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">                                            </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer, Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> I hereby certify that the signature, name, and<br>title above are my signature, name and title.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLESSEE&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAGUAR GENE THERAPY, LLC<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andrew Knudten                                         </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Andrew Knudten, COO                                   </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> I hereby certify that the signature, name, and<br>title above are my signature, name and title.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LANDLORD&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-NC REGION NO. 21, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited partnership, </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">managing member</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARE-QRS CORP.,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Maryland corporation,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">general partner</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Hikin                         </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VP Real Estate Legal Affairs          </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned as Guarantor of the Lease hereby consents to this Amendment and hereby reaffirms all of the undersigned&#8217;s obligations under the Guaranty of Lease and affirms that the undersigned shall be liable for all obligations thereunder including, without limitation, those arising in connection with the Amendment and Consent.  All references in the Guaranty of Lease to the Lease shall refer to the Lease as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:494.25pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:205.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:21.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:40pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited liability company</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">                                     </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer                                          </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer                             </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> I hereby certify that the signature, name, and<br>title above are my signature, name and title.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>advm-20230331ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7844526e48d24eca99474526a3f51aea_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laurent Fischer, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;11, 2023 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.844%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>advm-20230331ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8a69bb524cbc4958915b8d4a5fb93a42_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Linda Rubinstein, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;11, 2023</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.894%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Linda Rubinstein</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>advm-20230331ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idc001c7f0a0f4ca8a1de01fbe0d3990e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Laurent Fischer, in his capacity as Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.508%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>advm-20230331ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibbc2d3809fd947f1a170b7b13a310a84_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Linda Rubinstein, in her capacity as Chief Financial Officer, of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Linda Rubinstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>advm-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2ac3d0ca-e198-4bf8-a580-7d7820b89131,g:8a36a30e-c5fc-4cb1-8f5a-19bb971faa82-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000006 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>0000008 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseRevenue" roleURI="http://www.adverum.com/role/LicenseRevenue">
        <link:definition>0000009 - Disclosure - License Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.adverum.com/role/Leases">
        <link:definition>0000010 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>0000011 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.adverum.com/role/EquityIncentiveAwards">
        <link:definition>0000012 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>0000013 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000014 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>0000015 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.adverum.com/role/LeasesTables">
        <link:definition>0000016 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>0000017 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables">
        <link:definition>0000018 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>0000019 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetail" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail">
        <link:definition>0000020 - Disclosure - Organization and Basis of Presentation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails">
        <link:definition>0000021 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseRevenueDetail" roleURI="http://www.adverum.com/role/LicenseRevenueDetail">
        <link:definition>0000023 - Disclosure - License Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetail" roleURI="http://www.adverum.com/role/LeasesDetail">
        <link:definition>0000024 - Disclosure - Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail" roleURI="http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail">
        <link:definition>0000025 - Disclosure - Leases - Schedule of Undiscounted Future Lease Payments under Operating Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>0000026 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000027 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofStockOptionsActivityDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails">
        <link:definition>0000028 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails">
        <link:definition>0000029 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>0000030 - Disclosure - Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails">
        <link:definition>0000031 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" abstract="false" name="LessorOperatingLeasePaymentToBeReceivedAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseNumberOfRenewalContracts" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" abstract="false" name="AccruedNonclinicalClinicalAndDevelopmentProcessCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LexeoTherapeuticsIncMember" abstract="true" name="LexeoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_RemeasurementOfOperatingLeaseRightOfUseAssets" abstract="false" name="RemeasurementOfOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" abstract="false" name="OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" abstract="false" name="IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>advm-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2ac3d0ca-e198-4bf8-a580-7d7820b89131,g:8a36a30e-c5fc-4cb1-8f5a-19bb971faa82-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c0336ada-05a5-4dca-bba4-c5c2d6990356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f344569-9f74-468f-83f3-f3db32b89a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0336ada-05a5-4dca-bba4-c5c2d6990356" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f344569-9f74-468f-83f3-f3db32b89a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_50ff5b68-de33-4037-bd37-ccd23fa2bb69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0336ada-05a5-4dca-bba4-c5c2d6990356" xlink:to="loc_us-gaap_ShortTermInvestments_50ff5b68-de33-4037-bd37-ccd23fa2bb69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d6ef4a9-2085-4d85-9d2f-38dd2839694d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0336ada-05a5-4dca-bba4-c5c2d6990356" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d6ef4a9-2085-4d85-9d2f-38dd2839694d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5226f224-e902-48ae-a418-09ec4a21e137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_baebedc1-0378-430e-8179-c42a28b471ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5226f224-e902-48ae-a418-09ec4a21e137" xlink:to="loc_us-gaap_LiabilitiesCurrent_baebedc1-0378-430e-8179-c42a28b471ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe669f3e-e824-4e36-879c-0a84c14ce239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5226f224-e902-48ae-a418-09ec4a21e137" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe669f3e-e824-4e36-879c-0a84c14ce239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c8f8d380-15ef-4ebe-b6ce-5b93f341a217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5226f224-e902-48ae-a418-09ec4a21e137" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c8f8d380-15ef-4ebe-b6ce-5b93f341a217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f94d36c6-3cc9-4e53-94a2-7efd6ccec585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0a522d43-b9d0-4090-b985-f87cdd4926be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f94d36c6-3cc9-4e53-94a2-7efd6ccec585" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0a522d43-b9d0-4090-b985-f87cdd4926be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4242caad-5757-4031-8d29-034c311af447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f94d36c6-3cc9-4e53-94a2-7efd6ccec585" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4242caad-5757-4031-8d29-034c311af447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b4064ca2-1692-4e48-abff-ec18d914370d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f94d36c6-3cc9-4e53-94a2-7efd6ccec585" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b4064ca2-1692-4e48-abff-ec18d914370d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9759d912-d90a-47c9-b53b-6d8fa22b9ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f94d36c6-3cc9-4e53-94a2-7efd6ccec585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9759d912-d90a-47c9-b53b-6d8fa22b9ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7270cc88-7c0e-4762-a68b-504b7ce9fb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f94d36c6-3cc9-4e53-94a2-7efd6ccec585" xlink:to="loc_us-gaap_AssetsCurrent_7270cc88-7c0e-4762-a68b-504b7ce9fb34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6294edd7-81cd-400f-990e-3c33742f2bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_09378989-5a11-4dc4-91e0-dad833a26945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6294edd7-81cd-400f-990e-3c33742f2bcf" xlink:to="loc_us-gaap_Liabilities_09378989-5a11-4dc4-91e0-dad833a26945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d8b2657-ef8e-4a03-8fe7-373c754e4231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6294edd7-81cd-400f-990e-3c33742f2bcf" xlink:to="loc_us-gaap_StockholdersEquity_9d8b2657-ef8e-4a03-8fe7-373c754e4231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b9e8809f-0d5a-4123-9bd0-a9b42304da6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_aa8a9422-42dc-4795-9da7-71e4ebcbbc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b9e8809f-0d5a-4123-9bd0-a9b42304da6e" xlink:to="loc_us-gaap_PreferredStockValue_aa8a9422-42dc-4795-9da7-71e4ebcbbc7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8d368236-2d40-4fcd-aba8-2620abc23c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b9e8809f-0d5a-4123-9bd0-a9b42304da6e" xlink:to="loc_us-gaap_CommonStockValue_8d368236-2d40-4fcd-aba8-2620abc23c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_996badca-206c-48bb-a0e9-c44f7c3dac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b9e8809f-0d5a-4123-9bd0-a9b42304da6e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_996badca-206c-48bb-a0e9-c44f7c3dac3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9a54e0e-928b-429b-bb19-22df60c9307e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b9e8809f-0d5a-4123-9bd0-a9b42304da6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9a54e0e-928b-429b-bb19-22df60c9307e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14cc0874-3d3f-41f3-ab32-2ab610c37ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b9e8809f-0d5a-4123-9bd0-a9b42304da6e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14cc0874-3d3f-41f3-ab32-2ab610c37ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16698f25-7977-4b15-863b-b22a96f0bff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3a7893d0-fffc-454f-af39-7ab0f937fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16698f25-7977-4b15-863b-b22a96f0bff5" xlink:to="loc_us-gaap_AccountsPayableCurrent_3a7893d0-fffc-454f-af39-7ab0f937fcd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_60c1dd05-9e2f-4f3c-ac0d-661aef7d61da" xlink:href="advm-20230331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16698f25-7977-4b15-863b-b22a96f0bff5" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_60c1dd05-9e2f-4f3c-ac0d-661aef7d61da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc9ac8f5-abca-4dbd-9fe6-7424db584704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16698f25-7977-4b15-863b-b22a96f0bff5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc9ac8f5-abca-4dbd-9fe6-7424db584704" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bdc349f9-d376-4960-9dbc-c65b39170cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f5773434-b0c6-4c94-9755-b876803866b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bdc349f9-d376-4960-9dbc-c65b39170cc7" xlink:to="loc_us-gaap_NetIncomeLoss_f5773434-b0c6-4c94-9755-b876803866b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_5cc50266-b5bd-48db-a37a-29baea0b8db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bdc349f9-d376-4960-9dbc-c65b39170cc7" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_5cc50266-b5bd-48db-a37a-29baea0b8db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_14a9449f-0be8-4f70-aabb-6cf948f44c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bdc349f9-d376-4960-9dbc-c65b39170cc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_14a9449f-0be8-4f70-aabb-6cf948f44c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0e6148fe-090e-4c14-892c-b62fec777e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_57af02c6-bd52-4e29-9cdf-9d6a2d0f52b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0e6148fe-090e-4c14-892c-b62fec777e67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_57af02c6-bd52-4e29-9cdf-9d6a2d0f52b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6d85a3d2-efca-4830-b688-38d5b0f203de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0e6148fe-090e-4c14-892c-b62fec777e67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6d85a3d2-efca-4830-b688-38d5b0f203de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2a8b65a4-6f17-4988-81d1-c1ed4ff435f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adb75d10-897f-4857-9cdb-c6518598ad78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a8b65a4-6f17-4988-81d1-c1ed4ff435f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adb75d10-897f-4857-9cdb-c6518598ad78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c7970abf-a1a2-4d4d-b2fa-6bcf7afc86be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a8b65a4-6f17-4988-81d1-c1ed4ff435f1" xlink:to="loc_us-gaap_OperatingExpenses_c7970abf-a1a2-4d4d-b2fa-6bcf7afc86be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_330598dd-1a22-4b96-8770-85fe862a4e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9bcb9b80-2523-45ba-9530-3409c7379f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_330598dd-1a22-4b96-8770-85fe862a4e65" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9bcb9b80-2523-45ba-9530-3409c7379f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21e66961-9642-4d50-8da9-c8da1601dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_330598dd-1a22-4b96-8770-85fe862a4e65" xlink:to="loc_us-gaap_OperatingIncomeLoss_21e66961-9642-4d50-8da9-c8da1601dc67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6aa020fc-0910-48fc-94d2-2bb913ed0341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_99f0c891-9223-41c1-962a-429b48bbc540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6aa020fc-0910-48fc-94d2-2bb913ed0341" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_99f0c891-9223-41c1-962a-429b48bbc540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_37d57f31-4c28-4f00-b168-ad6d3a8769cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6aa020fc-0910-48fc-94d2-2bb913ed0341" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_37d57f31-4c28-4f00-b168-ad6d3a8769cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_560bc194-c98b-493c-a60b-aacee5a4edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c54e02d3-a48b-4da0-a911-3ec5c0f71cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_560bc194-c98b-493c-a60b-aacee5a4edfd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c54e02d3-a48b-4da0-a911-3ec5c0f71cb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_eb3fc753-2229-483a-ac17-08bfe8268388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_560bc194-c98b-493c-a60b-aacee5a4edfd" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_eb3fc753-2229-483a-ac17-08bfe8268388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89b7e35a-b363-43e9-bca9-716222ba8a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_560bc194-c98b-493c-a60b-aacee5a4edfd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89b7e35a-b363-43e9-bca9-716222ba8a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6d1d7182-6fa7-4da4-b863-324b7b49c856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6d1d7182-6fa7-4da4-b863-324b7b49c856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a4bcee55-6f04-4fdc-8835-061961b923a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_ShareBasedCompensation_a4bcee55-6f04-4fdc-8835-061961b923a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72b25e98-bd20-468d-9821-d4f3d4859005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_NetIncomeLoss_72b25e98-bd20-468d-9821-d4f3d4859005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_91d81b25-7e8a-444d-a82a-50729923a751" xlink:href="advm-20230331.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_91d81b25-7e8a-444d-a82a-50729923a751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_307903dd-7894-4474-860a-30ac61f11bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_DepreciationAndAmortization_307903dd-7894-4474-860a-30ac61f11bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f9fd5b60-83c7-4e22-811a-608aefa1f4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f9fd5b60-83c7-4e22-811a-608aefa1f4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_623b63f1-abec-4730-af3e-c156dc69a239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_623b63f1-abec-4730-af3e-c156dc69a239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_60930ff1-ebc4-4941-a62b-22db10b867e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_60930ff1-ebc4-4941-a62b-22db10b867e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f7c64380-6bad-4e62-b405-b12d2efdc0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f7c64380-6bad-4e62-b405-b12d2efdc0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_24118d23-10f2-4980-824c-f66f2561857d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_24118d23-10f2-4980-824c-f66f2561857d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7d791ce3-1e82-4a95-9128-e75fcbf7340a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2daf7aff-eeaf-4da7-b30b-8f96662cd464" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7d791ce3-1e82-4a95-9128-e75fcbf7340a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cafb6ded-04c4-4f5e-9da6-8567a46b1780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02378945-6cbd-447b-aace-a7621f19149e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cafb6ded-04c4-4f5e-9da6-8567a46b1780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02378945-6cbd-447b-aace-a7621f19149e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0fdeaa7-05cd-4669-bb6f-9036c8029d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cafb6ded-04c4-4f5e-9da6-8567a46b1780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0fdeaa7-05cd-4669-bb6f-9036c8029d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e11a8b4d-186c-4068-a2a3-f2bdf8b1a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cafb6ded-04c4-4f5e-9da6-8567a46b1780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e11a8b4d-186c-4068-a2a3-f2bdf8b1a13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e355890-6ae8-401d-a9c5-7f04fe0d65d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7766e10-cedc-4ef9-b623-726ee70ba5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e355890-6ae8-401d-a9c5-7f04fe0d65d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7766e10-cedc-4ef9-b623-726ee70ba5ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bd9b4544-b0e6-4c1e-86c0-265f85f61dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e355890-6ae8-401d-a9c5-7f04fe0d65d4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bd9b4544-b0e6-4c1e-86c0-265f85f61dc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e5a7315-2a19-4d74-8af9-e1b1948ca9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5646ea5f-7cf6-4f66-875e-b467eb013178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e5a7315-2a19-4d74-8af9-e1b1948ca9c7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5646ea5f-7cf6-4f66-875e-b467eb013178" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a776fac-b1ff-4a24-9813-9bb04cbb2991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_97f4b2de-b236-4f4b-8702-9b742182953e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a776fac-b1ff-4a24-9813-9bb04cbb2991" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_97f4b2de-b236-4f4b-8702-9b742182953e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3966e64d-42ac-44fa-a3ce-ab0cf9236266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a776fac-b1ff-4a24-9813-9bb04cbb2991" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3966e64d-42ac-44fa-a3ce-ab0cf9236266" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_84b57668-fd1a-4db5-9a53-99d5710611b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a776fac-b1ff-4a24-9813-9bb04cbb2991" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_84b57668-fd1a-4db5-9a53-99d5710611b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_a047b469-584a-49f8-bc88-95edb7c7644b" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_94cf3492-7571-4e5f-a8db-99b78dc354fb" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_a047b469-584a-49f8-bc88-95edb7c7644b" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_94cf3492-7571-4e5f-a8db-99b78dc354fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_78deed85-29e7-4bd5-938e-ba571d24bf77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_a047b469-584a-49f8-bc88-95edb7c7644b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_78deed85-29e7-4bd5-938e-ba571d24bf77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_8a1684a6-4a46-4877-8338-78697696b518" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_a047b469-584a-49f8-bc88-95edb7c7644b" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_8a1684a6-4a46-4877-8338-78697696b518" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_bf20e11f-980d-4b8c-8be2-f4e48eb74858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_bf20e11f-980d-4b8c-8be2-f4e48eb74858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_968c5db6-7370-4cc6-b6a5-6b77582cc1b0" xlink:href="advm-20230331.xsd#advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:to="loc_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_968c5db6-7370-4cc6-b6a5-6b77582cc1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_ecae4cf8-f778-4770-a8ff-6fd32b3819ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_ecae4cf8-f778-4770-a8ff-6fd32b3819ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4c31383a-087e-4a4d-aadd-49b6e505fd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4c31383a-087e-4a4d-aadd-49b6e505fd9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_820fc12c-06fd-43f0-b06e-ae45b7d70c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_820fc12c-06fd-43f0-b06e-ae45b7d70c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_f266c422-e940-409a-a8b2-2bdf3773c330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1507733a-1464-4379-87ca-4278b12a1b7b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_f266c422-e940-409a-a8b2-2bdf3773c330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bfb58f82-f299-457f-a1a3-db7934e8afac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bfb58f82-f299-457f-a1a3-db7934e8afac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d6fee733-9207-4661-8680-a4861c425044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d6fee733-9207-4661-8680-a4861c425044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_79ca7266-3f11-40db-9459-95e0748ca14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_79ca7266-3f11-40db-9459-95e0748ca14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_647aa1a4-040d-4bbe-9152-e20bec639faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_647aa1a4-040d-4bbe-9152-e20bec639faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_235e7902-9efb-418b-ae31-14722fa29d75" xlink:href="advm-20230331.xsd#advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:to="loc_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_235e7902-9efb-418b-ae31-14722fa29d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_885d5f23-47f4-4df6-952c-2560f2895646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_24cfe054-bc16-459d-8a85-ffcacca378fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_885d5f23-47f4-4df6-952c-2560f2895646" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_58bb5d86-4cb1-4b52-ad1b-498880c5a223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8698efa1-1639-413e-9564-d533bc8e45a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_58bb5d86-4cb1-4b52-ad1b-498880c5a223" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8698efa1-1639-413e-9564-d533bc8e45a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_43f04cb6-5b4a-47c4-adfd-fa79647b5e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_58bb5d86-4cb1-4b52-ad1b-498880c5a223" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_43f04cb6-5b4a-47c4-adfd-fa79647b5e73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ebb63801-5486-4efa-b4f3-99535a6b0d43" xlink:href="advm-20230331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e7a28cb9-c95e-4755-b376-88d5f122d934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ebb63801-5486-4efa-b4f3-99535a6b0d43" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e7a28cb9-c95e-4755-b376-88d5f122d934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_750ceb59-de81-44d5-a30f-f79a2e577c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ebb63801-5486-4efa-b4f3-99535a6b0d43" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_750ceb59-de81-44d5-a30f-f79a2e577c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_2a53bbd6-a8f3-463c-9745-cea62553cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ebb63801-5486-4efa-b4f3-99535a6b0d43" xlink:to="loc_us-gaap_TaxesPayableCurrent_2a53bbd6-a8f3-463c-9745-cea62553cddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_bb672b83-e37a-47ef-a702-84b4548b353a" xlink:href="advm-20230331.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ebb63801-5486-4efa-b4f3-99535a6b0d43" xlink:to="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_bb672b83-e37a-47ef-a702-84b4548b353a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_16569fc6-9cdc-4f5a-a806-63eb376ce272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ebb63801-5486-4efa-b4f3-99535a6b0d43" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_16569fc6-9cdc-4f5a-a806-63eb376ce272" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>advm-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2ac3d0ca-e198-4bf8-a580-7d7820b89131,g:8a36a30e-c5fc-4cb1-8f5a-19bb971faa82-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ie305b36212824a0c95539dacf781eba0_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4fbb22f-b5cd-48d1-879e-c282e947bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4fbb22f-b5cd-48d1-879e-c282e947bd0f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ce3c95f6-34c5-43e3-80d6-651441e8a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_SharesOutstanding_ce3c95f6-34c5-43e3-80d6-651441e8a21a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05baf2b5-54e3-4375-b17a-50666118d67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockholdersEquity_05baf2b5-54e3-4375-b17a-50666118d67b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_87ab84fd-6f6b-44ea-a0c1-0f48b427bfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_87ab84fd-6f6b-44ea-a0c1-0f48b427bfec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8d7be309-2257-4122-8f81-c2ae561a07fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8d7be309-2257-4122-8f81-c2ae561a07fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_796fbef2-cb89-45d0-b4c6-b8ff9455e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_796fbef2-cb89-45d0-b4c6-b8ff9455e0a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3c58db97-bcf9-40e1-b00c-50a2e9f976ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3c58db97-bcf9-40e1-b00c-50a2e9f976ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3d2a16dd-de4a-469b-9fed-d7f6caa4be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3d2a16dd-de4a-469b-9fed-d7f6caa4be4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e426fb2b-9fa2-41f6-ae03-c7432fc5851f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e426fb2b-9fa2-41f6-ae03-c7432fc5851f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_35abbdfb-f8e8-4321-8af2-724ef5f3ab6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_NetIncomeLoss_35abbdfb-f8e8-4321-8af2-724ef5f3ab6a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_72a0939b-348c-4e92-8364-e8447e9eef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0975b04-c9d6-4104-b043-82aa966fe7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a4fbb22f-b5cd-48d1-879e-c282e947bd0f" xlink:to="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8e6e1f01-f85f-4537-9d12-86016ae822c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:to="loc_us-gaap_EquityComponentDomain_8e6e1f01-f85f-4537-9d12-86016ae822c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:to="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f248b5c6-6385-4742-a96e-13fcf8203c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_CommonStockMember_f248b5c6-6385-4742-a96e-13fcf8203c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29f88202-0c33-4579-b1c8-ec90368ef469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29f88202-0c33-4579-b1c8-ec90368ef469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77201f99-285e-4b0c-9ffc-e1e6033496d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77201f99-285e-4b0c-9ffc-e1e6033496d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f262e5d6-b775-47b0-8a78-ce149ed53fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_RetainedEarningsMember_f262e5d6-b775-47b0-8a78-ce149ed53fa8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended" id="iaede258e6e5f472784a9064c0b398930_FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38373570-c7c4-4d11-97bf-7ec50ec259f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38373570-c7c4-4d11-97bf-7ec50ec259f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e752b90-79f2-47ba-8202-15a616e260af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e752b90-79f2-47ba-8202-15a616e260af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8df77b4-8dd7-49d2-9bb0-ccf6c21e2442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8df77b4-8dd7-49d2-9bb0-ccf6c21e2442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_999e6a0f-48c7-4cfb-871f-5b7ff0ec1e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_999e6a0f-48c7-4cfb-871f-5b7ff0ec1e9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_49957c39-f9d4-48dd-ba1b-15ee1992b7ba" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_49957c39-f9d4-48dd-ba1b-15ee1992b7ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_bd9a6cd4-77e4-4ed0-9117-790a76861c10" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_bd9a6cd4-77e4-4ed0-9117-790a76861c10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_3d1bd2d7-9892-427d-b18b-1143fc455734" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_3d1bd2d7-9892-427d-b18b-1143fc455734" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62d04fef-b741-4f73-8bfb-4a49e2b444bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62d04fef-b741-4f73-8bfb-4a49e2b444bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:to="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_50086f6f-b778-4181-b6c0-400b85062058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_MoneyMarketFundsMember_50086f6f-b778-4181-b6c0-400b85062058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_21dcec74-7b9a-4466-8019-b9bc19e1c972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_CommercialPaperMember_21dcec74-7b9a-4466-8019-b9bc19e1c972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abb2339a-2264-464b-8c89-bdf6e6eb1e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abb2339a-2264-464b-8c89-bdf6e6eb1e3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_94fa7157-3416-4409-946e-2fef9bbc1827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_94fa7157-3416-4409-946e-2fef9bbc1827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_638b8aff-0d34-4549-8d0c-503c006026cb" xlink:href="advm-20230331.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_638b8aff-0d34-4549-8d0c-503c006026cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa77a0c5-2dcf-44c0-9dc1-f29aea650787_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa77a0c5-2dcf-44c0-9dc1-f29aea650787_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_25446a1c-922c-4cfe-902b-5b89333f363c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_25446a1c-922c-4cfe-902b-5b89333f363c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55de2ac0-1905-4168-a402-81902442101a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55de2ac0-1905-4168-a402-81902442101a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LicenseRevenueDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#LicenseRevenueDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/LicenseRevenueDetail" xlink:type="extended" id="if45ac07534bc44dfb132f353ca6b5ccf_LicenseRevenueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_64055171-fbc5-4e66-a19c-2d0d94f0e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_061e06ed-917e-4a6c-a0aa-73f935250fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_64055171-fbc5-4e66-a19c-2d0d94f0e7b6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_061e06ed-917e-4a6c-a0aa-73f935250fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_64055171-fbc5-4e66-a19c-2d0d94f0e7b6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:to="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0aecadc2-0be2-490d-860b-b86c46730588" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0aecadc2-0be2-490d-860b-b86c46730588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_e7971147-dc20-4831-a6e8-8de095b3f357" xlink:href="advm-20230331.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0aecadc2-0be2-490d-860b-b86c46730588" xlink:to="loc_advm_LexeoTherapeuticsIncMember_e7971147-dc20-4831-a6e8-8de095b3f357" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#LeasesDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/LeasesDetail" xlink:type="extended" id="ia414f4412e8d47239916b2c23a9d0fe3_LeasesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_68d5c37b-4a19-4704-9dc4-552a9ba8268c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_68d5c37b-4a19-4704-9dc4-552a9ba8268c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fc6e8442-76f2-469e-aee2-8e120542bf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fc6e8442-76f2-469e-aee2-8e120542bf79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_32a2cb3e-7923-44e6-b9d3-742ded3a8081" xlink:href="advm-20230331.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_32a2cb3e-7923-44e6-b9d3-742ded3a8081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_9518ca8c-e2e6-4800-bbe9-c5a73a25964d" xlink:href="advm-20230331.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_9518ca8c-e2e6-4800-bbe9-c5a73a25964d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b2b707bb-bae8-4f06-9925-d89ece25a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b2b707bb-bae8-4f06-9925-d89ece25a74d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0f720135-75b8-4abb-beb3-699513d32447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_SubleaseIncome_0f720135-75b8-4abb-beb3-699513d32447" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32fe192c-76ad-4292-ad9a-b5269f7bcae6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32fe192c-76ad-4292-ad9a-b5269f7bcae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_64747bec-c2be-4d7f-a421-48a8d1924fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:to="loc_us-gaap_BuildingMember_64747bec-c2be-4d7f-a421-48a8d1924fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_96d74e88-4a6a-4ce1-b496-9de064bc37c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:to="loc_us-gaap_ManufacturingFacilityMember_96d74e88-4a6a-4ce1-b496-9de064bc37c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="i89e7e28f36374f3d891dedd85f0166d9_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cffb062d-0992-44cf-b514-17c5c718f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cffb062d-0992-44cf-b514-17c5c718f18d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74a539df-9c5d-4832-8d12-fc5182c22363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74a539df-9c5d-4832-8d12-fc5182c22363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_285aea03-bc20-4a33-8b59-51f7fab072ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_285aea03-bc20-4a33-8b59-51f7fab072ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b07df44b-0fc1-4296-9c99-a714d880ec9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b07df44b-0fc1-4296-9c99-a714d880ec9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9a4fbe26-fa0a-436e-8852-8ae3e48bd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9a4fbe26-fa0a-436e-8852-8ae3e48bd5c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6afade2a-a47c-4324-acf8-26e45074ca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_EquipmentMember_6afade2a-a47c-4324-acf8-26e45074ca1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_238f4fa1-6a6d-48ac-b21c-4cc95a84819f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_ComputerEquipmentMember_238f4fa1-6a6d-48ac-b21c-4cc95a84819f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8e2e5c64-8689-4b82-baaf-e83462c952f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8e2e5c64-8689-4b82-baaf-e83462c952f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e21bcbbc-f271-40fe-88eb-7b47553d855c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_ConstructionInProgressMember_e21bcbbc-f271-40fe-88eb-7b47553d855c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i910dac6805834cc2800e175217d261e4_EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dddd833f-715e-467e-aa29-f15e2e86ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dddd833f-715e-467e-aa29-f15e2e86ae2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_adb50951-b65f-4944-a1cb-76000fb8f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_adb50951-b65f-4944-a1cb-76000fb8f6ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6ea37a35-ae73-4a19-b187-1463a3357c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6ea37a35-ae73-4a19-b187-1463a3357c9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a352db45-4bac-44ef-ac82-23472ad49af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a352db45-4bac-44ef-ac82-23472ad49af0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_476b49d5-0dce-41ea-b026-19d0fdf2e356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8c5900-b859-4292-8405-fc90704970a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8c5900-b859-4292-8405-fc90704970a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fc292c2-d57f-4a52-94a7-e10df772fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fc292c2-d57f-4a52-94a7-e10df772fe70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c1d455c0-a6d7-4f10-807b-28f2fa1ea26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c1d455c0-a6d7-4f10-807b-28f2fa1ea26c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_186797e3-bdb9-44cf-9950-3803a551147a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_186797e3-bdb9-44cf-9950-3803a551147a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b762a85-3fd2-4189-8d76-cab15dea6210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:to="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36356a8e-6043-4167-86f1-f28489dac900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36356a8e-6043-4167-86f1-f28489dac900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b4b97d9-7475-489f-bee6-d2bafc507a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b4b97d9-7475-489f-bee6-d2bafc507a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_04d03fb7-5e77-4d84-844c-4ce965551051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b4b97d9-7475-489f-bee6-d2bafc507a71" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_04d03fb7-5e77-4d84-844c-4ce965551051" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended" id="ie35ad19fb6aa4b4296d4914cef62eec5_EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ca4fc1-15d8-4cde-a94e-bc8beebfa824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b417e4d7-0789-4e62-b409-58d4f0e0bc58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ca4fc1-15d8-4cde-a94e-bc8beebfa824" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b417e4d7-0789-4e62-b409-58d4f0e0bc58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ca4fc1-15d8-4cde-a94e-bc8beebfa824" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_962df312-c0cd-408a-89c0-4c16c6a44478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_962df312-c0cd-408a-89c0-4c16c6a44478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f863b75d-ed77-4525-9e78-f245afd716b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f863b75d-ed77-4525-9e78-f245afd716b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a22e656-e3f9-4edd-94b0-a3b534d02728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a22e656-e3f9-4edd-94b0-a3b534d02728" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="extended" id="i213ffbdaae6848e48e7218faa685f341_NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ee71a12-28a6-42b3-96d5-553fb40f291a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7581553b-b639-4922-9eee-2994653cda8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ee71a12-28a6-42b3-96d5-553fb40f291a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7581553b-b639-4922-9eee-2994653cda8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ee71a12-28a6-42b3-96d5-553fb40f291a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f9ecbc51-fd15-4117-b185-d758b28911c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f9ecbc51-fd15-4117-b185-d758b28911c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_48a44f7e-11d7-4e62-95f2-e012e7a51a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_48a44f7e-11d7-4e62-95f2-e012e7a51a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8723f2c8-31a8-4c95-93f3-9a362dbaa2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8723f2c8-31a8-4c95-93f3-9a362dbaa2cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a764a3a4-4f3e-4414-a701-8b00f3ea2302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:to="loc_us-gaap_EmployeeStockMember_a764a3a4-4f3e-4414-a701-8b00f3ea2302" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>advm-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2ac3d0ca-e198-4bf8-a580-7d7820b89131,g:8a36a30e-c5fc-4cb1-8f5a-19bb971faa82-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e00df335-3d0a-4316-b0a3-8d9350b01cdc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b216d3eb-5a7b-4305-9d25-3ea699e85b90_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_34a94249-504c-41fd-afcc-7de82e945b72_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7cb8fb8d-eaa1-4e2b-a6e0-da1c0a4c924a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4c6449c1-d21b-4aa6-811b-1d167fe1b45b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5fd61fb5-ada5-4570-8c62-5410eefeeec0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4c9ea095-8be3-4aeb-9d88-f218c741be02_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5057aaed-e8e7-4dbc-b571-77014bfcbcb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_372e43f2-dea3-42f8-9829-0b87581b1097_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a61f2754-7cdc-4866-a0a8-c2c211bb4b17_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_994780aa-1c4f-4e96-bf8a-875a7840b6ca_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_eb2686ca-ec64-4c0a-9008-419090e623c3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4c866c1-ec52-4d3b-bf29-ff023de1bdad_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2afc9e5-a54f-4898-a25d-4bd98d3a55a6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_3aa8cf32-ba9a-4ec4-ab5c-ae76512ae370_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_82b68d44-3b5f-4a33-9ce8-0df99ebd77d6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9454d67c-860d-4df0-9258-113a31a92151_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_c1d0f971-2a35-4576-844d-eed3b7e9683d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_dd83712a-6afa-4de7-b531-c6dd919c93be_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5e221536-5fc9-4886-a76c-c9f472c02103_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f251d7a3-83a6-4a9c-92ba-ab340037d579_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_471e2486-daa8-419a-a96c-74261be38d8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a1a2a83a-6d50-4af9-a50d-fabc8cddeac0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e37d427-33c2-47a8-8ce0-969d34b9bfcb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_392b8eeb-fc67-4bde-8bf5-728eceeaaa79_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_8f107df9-4313-477e-9943-a87453748dc8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca245932-4f5a-4c14-afb5-939c4b3502af_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_35cd6dae-a56c-4b06-9aec-f882d97fec23_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ccc50ef-8b43-4748-ab2e-dfa73d163033_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03f8fce5-d778-4a6c-a4a7-c2910e10987b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32bb4de1-6e2f-41b8-80bf-10daf61cc15f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7a9f8f67-92b6-4cb8-b235-5aded597efe9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9bbee2b2-faa1-4c54-a111-488a9034c5ee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2b344b76-eb60-4d52-9259-d8cd7bd1762a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1955c1c-3928-4914-95b8-3e8b6467e1e9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f12be1da-848b-415e-bca8-04e09ce0136d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c8495772-d78f-477e-9437-3cf02483a506_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9d66d3a-63c5-48cb-96b9-44fba8c18456_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b630f8c9-7c6e-4a16-9c37-fb7197ab7189_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6ca0cbbb-7b0a-4fed-acfe-390e8c748951_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets in accounts payable, accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_77883064-dfe6-4d4b-b82a-5306e9f0a610_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Payments Receivable</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d09b1ea0-8196-473f-9f52-43fff95c28b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1511edd9-5a9e-4048-8145-9c4d68aa89c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c6fe50c7-4ca7-4678-9174-c9306d585a62_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities in an unrealized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3ca7696b-d2ce-43ed-88d0-550ca93f3cbc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3c752f7e-2386-48cb-9bc2-c94562a097cd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94e0d08-0829-472e-bbae-2daa259bece0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_670fed1c-b7cb-4a34-bd4c-2f46e4b57b88_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_bbaecc74-f8f6-4f6c-bcf0-7663967af7b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_14ef6b3d-3207-4d95-8134-7173c7381c9e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_ce619faf-17b2-4ece-a7fc-f510926b1200_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e9a8520-a0e2-4fe5-bc2d-41d315f23ef1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dc45a5a2-a43b-409d-b9dc-586adc406e1d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_dccf3ac0-1895-4ca3-bc6b-f1d00368a73c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3322fd6a-7275-46a8-9171-907bfb1335ac_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_07124408-9ef2-4477-a3e6-d1c8e3dbfae4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_344a2c38-b3d8-437d-b0bb-eadfec4bcfd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0340ace6-38d8-4ee5-a0b5-43e9d62e1434_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_607ffd54-9178-4c30-a0cc-2e2d6bcaedc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5c073512-7d89-40e3-b787-63a43461ba7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_bf621ee5-fd12-4494-83ce-bd4cff010274_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_47c8a7d8-7fd8-4ac8-b666-416742a2a495_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0bfe420c-dc66-469b-b954-a46d8d9ee85f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_91a685c0-f814-4440-85c1-673a95d7ad85_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_58931ef0-d804-4242-a56a-798cac8eddef_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_423575da-9130-4f6a-9ace-217768317f90_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b7e6548d-5240-4779-9d2b-97a23ef88dd9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_366bf66b-7032-46b1-9a4c-e1f4ae73a829_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_a4add8f2-d90d-42d9-bae0-36c07adbb366_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20230331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_04d4de0a-0ec3-49bd-a382-782438685130_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_31fb3b23-355b-4e29-b35f-42087f7b4478_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9c37d0e7-1430-4f17-a886-8cf5b7907eb4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_37a2a5f0-77d5-448f-96f7-8b1faba906a5_terseLabel_en-US" xlink:label="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_label_en-US" xlink:label="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Four</link:label>
    <link:label id="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_documentation_en-US" xlink:label="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:href="advm-20230331.xsd#advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:to="lab_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_44ba46de-31bd-429b-92e0-2123e4616041_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ac931787-11af-4c95-98c4-81e670a36a7b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f64f6f5d-1593-4f03-af17-a2d0f5fd3e2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_42f3055d-0047-4917-b518-6d42e963b157_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_20b69cf9-3d2c-4928-aef4-c463e426501e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fcebc7ee-1e1e-4923-af9c-87dca6cbf842_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c802221b-159e-44cd-aa93-63ea5d1ce45e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3a8986d2-94e2-43b0-804d-56639c6af1d5_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="advm-20230331.xsd#advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_07c300ab-448c-4467-930f-59926803353f_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:href="advm-20230331.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:to="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eec8f7a1-8b1c-4d2d-be5f-af5df9b59a33_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9860dbaa-5496-4a0e-b78e-2c52b8390474_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_31537d5b-6084-4de6-bfdf-d1c09c17c49f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f41988e0-f560-458d-9891-3eeb68763545_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb45435-4a00-4a6c-a31d-b6b511be1a6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2a208afe-1f16-4834-b7d8-a4756a76e5c0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2976e16d-b22e-4a78-8c52-264527512928_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c8b622c4-f8c4-4ca4-9c9a-ac7204ef05e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9a63b77f-6f0d-4be0-ae88-937c7d8cab19_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e524526-ef56-4652-b12f-6ff22462adc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_58e87900-b272-47a2-92c0-07aa14d2af47_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0756a75c-2762-4769-bcb3-03380174fad9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_4a59b13e-c042-4bc3-b8c8-3b03e8029db1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2ce58a8c-8206-48d5-b3c9-d4fd794cbd4b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce5ca777-3075-441f-a228-04f1a8baa6d6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e12c4e66-b566-4493-a043-b6b7f601b576_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant- Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_14ad80a2-b59f-4ff8-abee-60c2765fac75_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_70d09c13-4817-473a-9ec3-09bc9fa4999f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_5236df24-55af-4bf8-a852-985ef87d848e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_55908f4e-e98f-49f8-a25e-7be64ecf1435_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_49a7e760-cf3c-4a54-b9b9-0fe8515400fc_negatedTotalLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, amortized cost basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7eef0813-1ca4-4a46-82a6-446abcdbed58_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6459842-08df-4560-80e7-434d6c4b88ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7d7173b2-2bc0-4dfe-bfb8-d950b8577308_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96609c9d-6d9c-4ebc-ba04-a1524078ee09_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_bf57c974-627c-4328-889a-fa39c924d724_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_96931303-d3ca-4130-8348-1ad178aaaae8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_927ac65e-9bab-40b9-8af7-cfed839bcf40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5f6ab07b-e9e0-4b59-a3f8-f081cd938f56_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee4e096e-6285-419a-935c-ea8c2c6ffe3d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_f20290a1-5821-46cf-bfa4-078a7aaefa8c_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80178d4-731e-4905-98cf-821805bf0263_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3e90562a-ef96-4b4d-b2ef-a2f0a173c6d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fd2907e6-1453-466b-8047-a7adcaced9ad_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_82277305-ec7b-427f-899a-23c1664a69f6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_f9fadcf6-9be8-4525-982a-e90c01d4cd5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4a3a2f55-700f-4dcc-b128-e34ae554e44d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_48496428-4262-4cbb-bd5b-9f1834d669e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bc08e0ca-b1d5-43c9-bd1c-a709d11f3d06_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a95722c8-bc06-42c5-b42c-768122bf1902_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (accretion) amortization of (discount) premium on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b3a1c5c3-2f97-47a2-826b-f2b38dfc3363_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_655f4350-c7da-4aa0-b592-8be7c8250a6d_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_48d4a49d-0a74-49e4-a7a8-221e13a69e2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_53bc22f6-7970-45d7-8ff4-565168b036f7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c27e6cd5-3303-4a40-9893-4ee86743be74_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d48561e-decd-4c7e-a9bc-e2088c1d07b6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9b0a5388-8f3d-493f-8f3a-eb06509462e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_55174f5e-e93d-4361-b91d-3fd4259fbaf6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_74718589-2d74-4dcf-a940-7049b5f36dcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bf28cffb-b122-4249-b82c-82cedc5ae759_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13e9dbd4-45a4-46e6-908c-390dcb367577_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e75c39f-2330-4ebe-bbab-23282e5cc261_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_45f7f191-b109-4070-ab40-556b36e62b55_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_43a0ab10-c542-4ae5-8750-8e0963052282_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_216a783a-acde-4459-a5cd-13507e66158e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a75188a3-3d01-4dde-8eb7-79d280dd6c84_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8d0ccc44-3386-4e95-b560-64d5e4b0d6b4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_58ec1085-caf2-488e-9ed7-b35e667e9fff_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ea56ce5c-14b3-41d5-8c07-622793c686ec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_d1e83397-caae-4c14-9f3f-d85eff9ce150_terseLabel_en-US" xlink:label="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of operating lease right-of-use assets</link:label>
    <link:label id="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:href="advm-20230331.xsd#advm_RemeasurementOfOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:to="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_43508659-2a76-4c0c-a224-44739c4dec3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9f770a7a-a5d3-4cc3-970b-8c1454acb665_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bce613f7-ded9-4d69-8213-a30fb7495fa5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb2c8908-73bd-4483-90b0-c7f79ea63f7b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1fe19472-811c-44a0-a929-282c1e996449_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_ffaae59c-356d-42bd-8b87-0e3d80f3a6d3_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_746963ce-6225-420a-b38d-eb7e559f9b24_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7ed0d569-1e64-4a5e-a30a-bea4d299a112_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_beeda5d9-c9ca-46ea-bc1e-105ff6ffb660_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fa583fab-1d74-40e2-8f1d-598a48d8f7bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_625981b7-6ddd-497c-9902-47d940cb861b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_08ea7577-7de3-43a8-b9e1-74ba6c83e9f7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_b174dee0-c29f-4bad-87c4-7985b2f803b8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e75f5cbb-1976-416c-a9ac-09c41e5f403e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2960d39-c30e-482a-be9a-a2e5849cc69e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_3dcf7b7b-afab-4a7b-8209-1fb49f7042c1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f5d31c4c-82b0-4da9-9e57-9ee77f3c54be_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_55c2234b-0bab-45c7-8118-76c26de507a8_terseLabel_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_label_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember" xlink:href="advm-20230331.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LexeoTherapeuticsIncMember" xlink:to="lab_advm_LexeoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_bd049045-9b20-4cd6-b673-59ee1b1f7fc5_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ee331540-cb64-4c94-8c04-0cb8dbff8dc5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_edbd7251-b0ef-4475-8f73-ebe8e6747d0e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_84068267-ff9b-4dd8-ab88-4d2833f57370_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_bccf25db-9ad6-4da5-88cd-8ca8569e8853_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cd6b2d2d-12f4-4b53-b4fb-a52c2a02023d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2f15e865-466e-423c-b4de-5215bf78f6bf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_9b931fb4-b778-4dbd-b10e-60d1dd737639_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_09df03c7-460b-4df4-a649-8d3b2bf7295b_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c124da2f-ea27-4bf8-bedb-f40bf6e80d09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_de5c8a1e-511b-43f0-9ad7-4585d63f1566_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_28e76a5b-2a94-4966-9d17-f3e318e13c31_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c47a56f9-787b-4b4f-b40a-fc317393d27e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0f74df93-eb2b-44b7-8e01-f1f17a2eb079_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d26f08ca-9f1a-46ae-80a1-224482711ff4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_58ccb462-3e3a-4ddf-9df2-64e843be2641_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1baa4bb5-c059-4834-bf09-a5327c769701_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_835f1178-c9ee-4a23-8af7-b2f8ad806cb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a5b8961b-deff-4488-8d3c-7b627225711b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ebd62338-bdf3-4d52-a020-70cf6610efdd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9ad62c78-c526-4c17-a4b1-2853e1e17da0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_208f893e-d23d-4aeb-bfe5-53a03124e88c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cfd2056c-f1e0-4fe4-8e19-2e811f17e01b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f7192dad-3e16-4285-99e5-8c6ea4304a9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_00b4dfd4-e7d5-48a9-94c6-6325703332bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7919942b-496f-4e34-8f78-c2a790b8a746_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4bb71454-4506-411b-b79d-a8c91fa3fdb6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_9646be3d-1127-45b9-885a-c2b121dd5c86_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63307a3e-5241-4e50-9564-e0498f1c7db8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_689f6faa-3449-4a01-b43b-a29427dd248b_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Facility</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96af05af-5c01-464d-a318-f9a0f64acaf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_00a4877c-9a35-4eac-966b-6c17ff70fb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_74ac5d14-8c2b-4209-9dc1-b5a6fe71da6c_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Future Sublease Payments Receivable under Operating Lease</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3361fe5d-b470-4869-9d70-d3dfe5207f43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_665190e4-e601-44ba-8ad8-3116e98d9843_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f26abbbd-e505-4b5d-a08a-c6b76abfdcf4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Future Lease Payments under Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3d5ccac0-5ca5-4ed4-a96f-511304d9ba77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_65716935-32a0-48d6-ae22-3096a26d4980_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a134510a-3024-4fd0-8c1c-a5ca1ab9b4cd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c5312a0b-4c58-4f7a-8ae7-bacdde77f78f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0dc55fbd-27e4-4e53-8f9a-a11e7d24a410_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_26002e96-e6b1-40b3-a294-8ece637a0e91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e60b01a0-5423-4803-bb74-013cd96f14c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_34c9e8cc-889e-429b-9d21-367ac59be898_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_2abf7f93-9605-453a-a2d0-de7ba2062e50_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_86b989f1-9ab0-4513-9750-f4f39fee2a60_terseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability and lease incentive receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liabilities And Lease Incentive Receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in lease liabilities and lease incentive receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:href="advm-20230331.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:to="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_326ed266-fb5d-4de7-8fdb-3ca0cbdec197_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ef73b99c-40ed-4463-88d8-1185c1460fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_77a74fdd-7077-43dd-89d2-bc381c352290_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1af397f5-7446-4aa4-8867-04f5597262f8_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6057fcc8-75d9-4120-b496-49482dbcfb06_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c8d32684-a7b9-4eea-9ea7-3329a90123bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e4092d27-0d04-4f64-9463-09255d7ddecd_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fac1b956-1113-49d1-9659-4d18078cf010_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_512e6214-39f8-48e4-8a62-f5e724cf5cab_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_54e21ad9-3b05-41fd-aeeb-a59a69925884_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_75972ba0-3d6a-48ca-aec7-643d01ff8e74_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_215034c0-1822-419d-b73c-9724c8a1503f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7c431e55-6dce-4b32-82f4-fe8d0eb9428d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fc7e0721-c276-45ab-8ef7-39671051e66a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_73f32b41-d8e4-4cd9-a51e-796502b72ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_31e3bce8-1b17-416e-8320-75e9e02513aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_54346234-fa4d-40f1-bfc6-dc2871f29bc8_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0e658faa-fafa-4f46-a225-45c960837e7f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8c439fac-d429-43b5-add5-ddc94a181170_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_be437d98-d27c-4519-9dbf-d8c6f68a88a0_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a4afd9ec-fbd0-4cce-a3a9-d705ea611d1e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ea6bb6e8-7895-42c9-a37e-364a3cbb9e7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e791158c-2cfa-4042-bf39-366dc4e16078_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0200e15c-9b02-4dfb-b6e8-c856ecb456bf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c25cf86a-307b-44a8-8b96-500795a89b85_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_45e960ec-9b15-4964-8ccb-0b4cc3673adc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_a4a8e847-d86c-46d5-8549-e790fa7f856a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_926f0b5d-b43f-4549-b3d8-adc1937f1026_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_95c799c4-a211-4117-8a27-8bb823e4a9fe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_29e7c52c-3adf-4322-a9a5-423de5e465ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_8d64af85-f99a-4dd1-95cc-60e2585291c7_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20230331.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1d4840-e4d7-4d86-845f-9e1c4aa8361a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8e44828a-aeab-4f15-bb88-f3eaa2d5f610_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_63534c34-682e-4164-8bbf-254527fb7ca9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c6f6db90-63fa-4a11-93a5-8466141d3f8c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_1c3648ad-cc0b-438d-85bc-be08ce256077_terseLabel_en-US" xlink:label="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated value of non-cash consideration</link:label>
    <link:label id="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_label_en-US" xlink:label="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</link:label>
    <link:label id="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_documentation_en-US" xlink:label="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:href="advm-20230331.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:to="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887ab5d2-9f03-4f6f-88cd-ffa0a011556e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8cc896f0-9ba0-4fff-9710-4b8808c3534d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2881c11d-9b4c-46c7-b000-31437856cae2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_64db6f2a-1e76-4da0-937a-e0f9058a210d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cefc4038-1490-4a8c-9f39-4d33be4fe22a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b9bb984e-e783-49bb-9473-a6811a99812a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7de69f3a-7ecb-45e1-a372-089e152d4a11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91f55fee-c365-4b59-8470-368d0ea4d90b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0db1232e-be98-4b80-83d7-32b1c01fdabf_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_210bfbb5-6dab-4552-8455-c5310f3c77d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c63ca614-8fe6-4a8b-8d4f-ee83a960351b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_49f35539-a0f4-4f57-bb86-505a29845bef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7a1d7e1-530b-459b-8c71-f80ab2c1ead0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d0f1433e-2a76-4e2b-9af1-503e5e2717e3_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_38adb00a-63cd-45b6-8014-7ca46b602c00_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_82f1f908-ec46-4461-bb8c-e155cbca2ffb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)/Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f1cb1285-fde8-4f3d-9986-02bc573b45c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_36b6b412-b609-4e43-9cca-35cc01e13da2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_e786faed-9e4e-4864-92f9-b5831c0cdaf3_terseLabel_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued nonclinical, clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_label_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Nonclinical, Clinical, And Development Process Costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_documentation_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical clinical and development process costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:href="advm-20230331.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:to="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_93197f90-e63e-495c-ae0b-2daa56e5fafc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f331e010-3d68-44bd-ba23-e3078d8a060c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2b95b2a6-6ef3-4e60-84f3-3b66df78ee37_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_edad3f8c-c2b5-4e64-834c-9eef66410db8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92fa91d4-e6ea-487c-be55-e0153c0e2cb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4eeaa6b9-fd65-4822-870a-a2157b4e1dce_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6e4d270c-8f82-4d92-9ede-f60f2b78a940_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4ffe6cfd-8c96-42fd-9558-fe2687452d7a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97236453-bb66-4d0d-ab1a-0ac3e9de5f29_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_29826282-eece-40f4-9027-3ff986dd05b0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_1d24bfbf-2b51-497c-a851-30031d642564_negatedTerseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, unrealized gains</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized gain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7c89e986-4f4d-40e1-81aa-39e00b8fb863_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>advm-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2ac3d0ca-e198-4bf8-a580-7d7820b89131,g:8a36a30e-c5fc-4cb1-8f5a-19bb971faa82-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4095d2e8-6505-4803-babb-7f9793124daf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_DocumentType_4095d2e8-6505-4803-babb-7f9793124daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4fe6a2b2-141a-4477-82f8-7797e57eb199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_DocumentQuarterlyReport_4fe6a2b2-141a-4477-82f8-7797e57eb199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e13452a5-5477-4838-927c-46c1f3ad5e1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_DocumentPeriodEndDate_e13452a5-5477-4838-927c-46c1f3ad5e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9bf77806-88b5-4c47-a803-1867c1853f89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_DocumentTransitionReport_9bf77806-88b5-4c47-a803-1867c1853f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_48ee0fa9-49d1-4520-84a2-e78e0f90948e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityFileNumber_48ee0fa9-49d1-4520-84a2-e78e0f90948e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cb4f3001-bce1-4e82-baa6-83d857fce3b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityRegistrantName_cb4f3001-bce1-4e82-baa6-83d857fce3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_efef4bc3-4919-491d-9131-8e3794ae6673" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityIncorporationStateCountryCode_efef4bc3-4919-491d-9131-8e3794ae6673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_23f1cc88-f36d-46ed-bb7b-126861fac9df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityTaxIdentificationNumber_23f1cc88-f36d-46ed-bb7b-126861fac9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_df9eb219-90dc-408a-91ca-512ee6b11f6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityAddressAddressLine1_df9eb219-90dc-408a-91ca-512ee6b11f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ca851de3-3848-4ea8-b2d1-e2ae3c721810" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityAddressCityOrTown_ca851de3-3848-4ea8-b2d1-e2ae3c721810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b255b739-1807-4fed-b375-438327881862" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityAddressStateOrProvince_b255b739-1807-4fed-b375-438327881862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_70200097-d756-4402-9016-24eba1392c3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityAddressPostalZipCode_70200097-d756-4402-9016-24eba1392c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ef30ad78-8b5d-4e08-aeff-7b5a82f850e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_CityAreaCode_ef30ad78-8b5d-4e08-aeff-7b5a82f850e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d98059a-6e7b-4cff-b92b-16497f54bab5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_LocalPhoneNumber_3d98059a-6e7b-4cff-b92b-16497f54bab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7da31473-fbe1-4920-b1e7-665cac5c79de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_Security12bTitle_7da31473-fbe1-4920-b1e7-665cac5c79de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7425d339-c35b-4e5f-9352-50167c6e290a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_TradingSymbol_7425d339-c35b-4e5f-9352-50167c6e290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a5612e5b-4406-4de9-b069-f89a2b299f73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_SecurityExchangeName_a5612e5b-4406-4de9-b069-f89a2b299f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_95bf9e6e-0674-4e42-ab50-e8a0f6d6d713" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityCurrentReportingStatus_95bf9e6e-0674-4e42-ab50-e8a0f6d6d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_677340bb-31aa-4b60-91a5-d4e75bb5f2b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityInteractiveDataCurrent_677340bb-31aa-4b60-91a5-d4e75bb5f2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_328d9c56-9772-48a9-9300-df01a2ab95df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityFilerCategory_328d9c56-9772-48a9-9300-df01a2ab95df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_44822da9-d679-4140-97f5-5bc7c03ac2e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntitySmallBusiness_44822da9-d679-4140-97f5-5bc7c03ac2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3a359d90-7920-4e65-8cc4-6b102dc7a669" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityEmergingGrowthCompany_3a359d90-7920-4e65-8cc4-6b102dc7a669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c1c7bbcf-f902-4537-9b50-6fa732288e09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityShellCompany_c1c7bbcf-f902-4537-9b50-6fa732288e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0fd545de-48f7-457a-820f-07e464de7469" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0fd545de-48f7-457a-820f-07e464de7469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_74e398df-658c-4786-9901-afc1040d1057" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_AmendmentFlag_74e398df-658c-4786-9901-afc1040d1057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f4a6b318-cc2a-4f7d-b29d-e8e993da6527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_DocumentFiscalYearFocus_f4a6b318-cc2a-4f7d-b29d-e8e993da6527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_03562e91-46ca-42c7-bdd8-e337d2e778ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_DocumentFiscalPeriodFocus_03562e91-46ca-42c7-bdd8-e337d2e778ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b4ca073f-cfeb-4e3f-a6cb-040e16306993" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_EntityCentralIndexKey_b4ca073f-cfeb-4e3f-a6cb-040e16306993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_90356a3f-0587-4ed7-a320-f50dd25c7c63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_491d78bf-6b98-4532-8629-e446d72de4af" xlink:to="loc_dei_CurrentFiscalYearEndDate_90356a3f-0587-4ed7-a320-f50dd25c7c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0f0df457-e932-4ab4-8657-94e61f9dce33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f0df457-e932-4ab4-8657-94e61f9dce33" xlink:to="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_75f810eb-2275-49d3-b903-78638eab9354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_75f810eb-2275-49d3-b903-78638eab9354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4dbf25f1-40db-46a9-92a9-dc4d889514ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_75f810eb-2275-49d3-b903-78638eab9354" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4dbf25f1-40db-46a9-92a9-dc4d889514ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_34fa050e-b33b-4c9a-9f17-9132912dd6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_75f810eb-2275-49d3-b903-78638eab9354" xlink:to="loc_us-gaap_ShortTermInvestments_34fa050e-b33b-4c9a-9f17-9132912dd6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_221b1316-d2ae-4c8d-9b17-eb557282647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_75f810eb-2275-49d3-b903-78638eab9354" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_221b1316-d2ae-4c8d-9b17-eb557282647b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f48fc1d1-9237-485f-9db5-4f27b9b44f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_75f810eb-2275-49d3-b903-78638eab9354" xlink:to="loc_us-gaap_AssetsCurrent_f48fc1d1-9237-485f-9db5-4f27b9b44f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d31e7dc7-4530-4dee-b2b8-ab59874d2988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d31e7dc7-4530-4dee-b2b8-ab59874d2988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e4be7f6c-e5df-4f68-85e1-5a4da665371a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e4be7f6c-e5df-4f68-85e1-5a4da665371a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d1cdd588-2c12-4a69-9941-93a822df751c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d1cdd588-2c12-4a69-9941-93a822df751c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1559d0dd-ff39-4f01-b8f9-53b3837d9e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1559d0dd-ff39-4f01-b8f9-53b3837d9e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7369e399-16d7-4b13-9275-e2608a21b717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26648198-50b4-4518-bd72-9dedc66156c6" xlink:to="loc_us-gaap_Assets_7369e399-16d7-4b13-9275-e2608a21b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f0df457-e932-4ab4-8657-94e61f9dce33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ca346e7d-bad6-4610-8632-af97b222e461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ca346e7d-bad6-4610-8632-af97b222e461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5bba9a7f-0aad-4132-90ce-cd9105cca454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca346e7d-bad6-4610-8632-af97b222e461" xlink:to="loc_us-gaap_AccountsPayableCurrent_5bba9a7f-0aad-4132-90ce-cd9105cca454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_d8327650-2b07-41e1-9cbb-ec15b262f137" xlink:href="advm-20230331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca346e7d-bad6-4610-8632-af97b222e461" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_d8327650-2b07-41e1-9cbb-ec15b262f137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b0f014ed-0b0a-4a74-9601-3117e9edf4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca346e7d-bad6-4610-8632-af97b222e461" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b0f014ed-0b0a-4a74-9601-3117e9edf4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1073f8ee-31bb-4480-b3e0-0c3494c9a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca346e7d-bad6-4610-8632-af97b222e461" xlink:to="loc_us-gaap_LiabilitiesCurrent_1073f8ee-31bb-4480-b3e0-0c3494c9a0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_11ec2f1c-74a1-499f-8691-a6e8a7fac40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_11ec2f1c-74a1-499f-8691-a6e8a7fac40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_637d6b28-47f0-4568-affc-97641f15872d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_637d6b28-47f0-4568-affc-97641f15872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b83245e0-4c8b-4d83-8444-9cfb39bbc2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:to="loc_us-gaap_Liabilities_b83245e0-4c8b-4d83-8444-9cfb39bbc2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7f4afa97-6824-4e62-8f44-5ea48d5a575a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:to="loc_us-gaap_PreferredStockValue_7f4afa97-6824-4e62-8f44-5ea48d5a575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59c37722-3b9e-432e-a375-eb86dbe906be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:to="loc_us-gaap_CommonStockValue_59c37722-3b9e-432e-a375-eb86dbe906be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9bc6954f-6044-452e-a676-c70696463e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9bc6954f-6044-452e-a676-c70696463e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e53d9d2-ea77-442c-a2cd-06e1a4d34350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e53d9d2-ea77-442c-a2cd-06e1a4d34350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_42ee8e88-9463-46d7-a4a3-da13e3319423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_42ee8e88-9463-46d7-a4a3-da13e3319423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ab40b0a-cd73-4c55-a252-5902af3a1e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5a9549e-dd21-471b-8674-a393b12bdaea" xlink:to="loc_us-gaap_StockholdersEquity_5ab40b0a-cd73-4c55-a252-5902af3a1e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff8dd8d3-f34d-4626-95ca-a018e24ecdb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be3585db-4bc3-4289-b5b3-e4fa6ca886c9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff8dd8d3-f34d-4626-95ca-a018e24ecdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a6bb8a19-3371-43e9-bece-d5c66850e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a6bb8a19-3371-43e9-bece-d5c66850e84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7022076d-a4a9-400b-a3a7-2def65df7476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7022076d-a4a9-400b-a3a7-2def65df7476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c99021da-ded6-4f88-b9ae-20629791c7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7022076d-a4a9-400b-a3a7-2def65df7476" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c99021da-ded6-4f88-b9ae-20629791c7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e615ed73-b898-4b7c-9c11-d23cfddbc324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7022076d-a4a9-400b-a3a7-2def65df7476" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e615ed73-b898-4b7c-9c11-d23cfddbc324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_07ea94cd-c23a-49d3-a456-7a078b880e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7022076d-a4a9-400b-a3a7-2def65df7476" xlink:to="loc_us-gaap_OperatingExpenses_07ea94cd-c23a-49d3-a456-7a078b880e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ea99914d-f09c-47d3-b893-d1c86acd17e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_OperatingIncomeLoss_ea99914d-f09c-47d3-b893-d1c86acd17e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2afd03f1-abaf-4409-adc8-980bd7c94a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2afd03f1-abaf-4409-adc8-980bd7c94a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ae94aa2-5663-45d4-934a-19a681409214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ae94aa2-5663-45d4-934a-19a681409214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a91a524-ffdb-4158-9375-dda90d93c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3a91a524-ffdb-4158-9375-dda90d93c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50fb8d48-fe8e-4d84-9999-2a8a14bc0cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_NetIncomeLoss_50fb8d48-fe8e-4d84-9999-2a8a14bc0cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_f54650a1-0541-4ea5-a9f3-daf8cdec6767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_f54650a1-0541-4ea5-a9f3-daf8cdec6767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_a94452c3-5cd3-4e15-b6f5-2dff0b06ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_f54650a1-0541-4ea5-a9f3-daf8cdec6767" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_a94452c3-5cd3-4e15-b6f5-2dff0b06ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3b4d841d-f821-4d17-8247-dac91c965f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_f54650a1-0541-4ea5-a9f3-daf8cdec6767" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3b4d841d-f821-4d17-8247-dac91c965f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499c40c1-db8d-427a-aa6c-50e5eec13847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_499c40c1-db8d-427a-aa6c-50e5eec13847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019b818d-289e-49e6-ae23-4fd1c66e96cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_EarningsPerShareBasic_019b818d-289e-49e6-ae23-4fd1c66e96cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9186532d-5b5d-4c11-b7db-ead8cbfff72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9186532d-5b5d-4c11-b7db-ead8cbfff72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50c147ec-d0fb-4217-bcb5-affcf90f3e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50c147ec-d0fb-4217-bcb5-affcf90f3e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04a0ce63-8e21-45d4-b96c-325220fffed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76c4317a-3fc9-491c-a15b-7e3efdbfa186" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04a0ce63-8e21-45d4-b96c-325220fffed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_72007603-f27c-49a8-bc48-b439536e4a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_72007603-f27c-49a8-bc48-b439536e4a19" xlink:to="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8e6e1f01-f85f-4537-9d12-86016ae822c6" xlink:to="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f248b5c6-6385-4742-a96e-13fcf8203c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_CommonStockMember_f248b5c6-6385-4742-a96e-13fcf8203c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29f88202-0c33-4579-b1c8-ec90368ef469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29f88202-0c33-4579-b1c8-ec90368ef469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77201f99-285e-4b0c-9ffc-e1e6033496d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77201f99-285e-4b0c-9ffc-e1e6033496d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f262e5d6-b775-47b0-8a78-ce149ed53fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4d1217c-1b74-469e-bdd0-87044c11b3e6" xlink:to="loc_us-gaap_RetainedEarningsMember_f262e5d6-b775-47b0-8a78-ce149ed53fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4fbb22f-b5cd-48d1-879e-c282e947bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_625620c3-0478-4f94-8cf2-eeb8232d2631" xlink:to="loc_us-gaap_StatementLineItems_a4fbb22f-b5cd-48d1-879e-c282e947bd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4fbb22f-b5cd-48d1-879e-c282e947bd0f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ce3c95f6-34c5-43e3-80d6-651441e8a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_SharesOutstanding_ce3c95f6-34c5-43e3-80d6-651441e8a21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05baf2b5-54e3-4375-b17a-50666118d67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockholdersEquity_05baf2b5-54e3-4375-b17a-50666118d67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_87ab84fd-6f6b-44ea-a0c1-0f48b427bfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_87ab84fd-6f6b-44ea-a0c1-0f48b427bfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8d7be309-2257-4122-8f81-c2ae561a07fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8d7be309-2257-4122-8f81-c2ae561a07fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_796fbef2-cb89-45d0-b4c6-b8ff9455e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_796fbef2-cb89-45d0-b4c6-b8ff9455e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3c58db97-bcf9-40e1-b00c-50a2e9f976ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3c58db97-bcf9-40e1-b00c-50a2e9f976ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3d2a16dd-de4a-469b-9fed-d7f6caa4be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3d2a16dd-de4a-469b-9fed-d7f6caa4be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e426fb2b-9fa2-41f6-ae03-c7432fc5851f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e426fb2b-9fa2-41f6-ae03-c7432fc5851f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_35abbdfb-f8e8-4321-8af2-724ef5f3ab6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_NetIncomeLoss_35abbdfb-f8e8-4321-8af2-724ef5f3ab6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_72a0939b-348c-4e92-8364-e8447e9eef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_SharesOutstanding_72a0939b-348c-4e92-8364-e8447e9eef4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0975b04-c9d6-4104-b043-82aa966fe7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46572923-3234-4bcc-a540-6062a3ef9857" xlink:to="loc_us-gaap_StockholdersEquity_b0975b04-c9d6-4104-b043-82aa966fe7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_318abb41-6a73-4cd7-a503-0c13d305df97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_318abb41-6a73-4cd7-a503-0c13d305df97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5bcd0a37-6950-4f70-ae32-c85f6811c93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_318abb41-6a73-4cd7-a503-0c13d305df97" xlink:to="loc_us-gaap_NetIncomeLoss_5bcd0a37-6950-4f70-ae32-c85f6811c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_318abb41-6a73-4cd7-a503-0c13d305df97" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b10f4922-4787-4c5e-9216-6075ab98c036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:to="loc_us-gaap_DepreciationAndAmortization_b10f4922-4787-4c5e-9216-6075ab98c036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_465a2f6b-cf0e-4e93-90cb-053d42a49fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:to="loc_us-gaap_ShareBasedCompensation_465a2f6b-cf0e-4e93-90cb-053d42a49fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3df31279-4a30-48fb-ade6-9274af92c1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3df31279-4a30-48fb-ade6-9274af92c1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ad71ac07-4dfe-4a79-9ad1-54a9bc20d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ad71ac07-4dfe-4a79-9ad1-54a9bc20d11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_af7831da-bee8-4bea-af86-ee4498fff3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_696468fb-10f4-4871-9883-e6f134ba84fd" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_af7831da-bee8-4bea-af86-ee4498fff3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_318abb41-6a73-4cd7-a503-0c13d305df97" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6a8b6951-fc3b-4dfe-b4a2-857b35f951c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6a8b6951-fc3b-4dfe-b4a2-857b35f951c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_23edcc11-1522-44fc-b586-c6e0401ee59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_23edcc11-1522-44fc-b586-c6e0401ee59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_71558f24-23ee-42dd-9668-0cdba59166b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_71558f24-23ee-42dd-9668-0cdba59166b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3a63e4b5-4735-4e0c-b72d-8de3f88442b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3a63e4b5-4735-4e0c-b72d-8de3f88442b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_4127aaa4-535c-46c6-812a-8a6f00e0c29e" xlink:href="advm-20230331.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36431d9d-b1e7-4a69-8fcb-b5aa6f52ab7d" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_4127aaa4-535c-46c6-812a-8a6f00e0c29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f1fdf14-52ac-48b2-ab8d-dfd60873414b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_318abb41-6a73-4cd7-a503-0c13d305df97" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f1fdf14-52ac-48b2-ab8d-dfd60873414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96127a61-368a-4f9a-8686-fe5523bc20fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96127a61-368a-4f9a-8686-fe5523bc20fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bc8d650f-abaa-4c33-ac5c-8e2a447bfaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96127a61-368a-4f9a-8686-fe5523bc20fe" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bc8d650f-abaa-4c33-ac5c-8e2a447bfaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9733958b-4443-4f91-a189-aaedb321d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96127a61-368a-4f9a-8686-fe5523bc20fe" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9733958b-4443-4f91-a189-aaedb321d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_360d4ad1-ac38-4a9d-ba9c-4751d2cf98fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96127a61-368a-4f9a-8686-fe5523bc20fe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_360d4ad1-ac38-4a9d-ba9c-4751d2cf98fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17c20ffc-1de4-4fcc-854d-d9911a00c585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96127a61-368a-4f9a-8686-fe5523bc20fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17c20ffc-1de4-4fcc-854d-d9911a00c585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7fe7f5d4-d4e2-46be-bf8f-65938ac7c188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7fe7f5d4-d4e2-46be-bf8f-65938ac7c188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a645d27d-e6e7-4a2f-addb-6dc0e694a11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7fe7f5d4-d4e2-46be-bf8f-65938ac7c188" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a645d27d-e6e7-4a2f-addb-6dc0e694a11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7fcf76f4-5cd9-4150-961a-e48bc8485361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7fe7f5d4-d4e2-46be-bf8f-65938ac7c188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7fcf76f4-5cd9-4150-961a-e48bc8485361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa7b7011-a281-4b2b-91bf-25b7c8afb47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa7b7011-a281-4b2b-91bf-25b7c8afb47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55e5941d-fa39-4d5e-804c-86878245a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55e5941d-fa39-4d5e-804c-86878245a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f852b5b-866b-4547-8173-fc7a58f3914c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f852b5b-866b-4547-8173-fc7a58f3914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a530aab7-daa3-4225-a9d7-1c878eae5d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a530aab7-daa3-4225-a9d7-1c878eae5d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6bfa46a5-2ae4-466a-96da-58032c71595c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6bfa46a5-2ae4-466a-96da-58032c71595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50184c13-165e-4ecd-9adc-488c1fd5f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50184c13-165e-4ecd-9adc-488c1fd5f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d353f9ae-7785-428a-890e-6c1a7bc8a509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f819e9db-f118-4432-9499-dad6321a3057" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d353f9ae-7785-428a-890e-6c1a7bc8a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_0234382c-a8ba-4131-b33a-494b23c435b0" xlink:href="advm-20230331.xsd#advm_RemeasurementOfOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d353f9ae-7785-428a-890e-6c1a7bc8a509" xlink:to="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_0234382c-a8ba-4131-b33a-494b23c435b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_899588a7-9514-4146-8364-94e19c4671d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d353f9ae-7785-428a-890e-6c1a7bc8a509" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_899588a7-9514-4146-8364-94e19c4671d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="advm-20230331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ffac6aa-60b3-486c-872a-14484ec56463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_42a93044-94e0-41ec-8b92-6b080991dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ffac6aa-60b3-486c-872a-14484ec56463" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_42a93044-94e0-41ec-8b92-6b080991dca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_391d6991-1b62-4741-8d4b-0770c484891f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e885f805-1c81-4230-9d1c-6ea34860cfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_391d6991-1b62-4741-8d4b-0770c484891f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e885f805-1c81-4230-9d1c-6ea34860cfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20230331.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6353c7d0-1a79-4c35-b6b2-1f2070e78b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8ec75f9a-4e60-4313-83ed-52077e6e788d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6353c7d0-1a79-4c35-b6b2-1f2070e78b3d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8ec75f9a-4e60-4313-83ed-52077e6e788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LicenseRevenue" xlink:type="simple" xlink:href="advm-20230331.xsd#LicenseRevenue"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LicenseRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_06b96f84-c12c-498b-96a6-27c93905b36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0edac42a-53b5-4cd8-8837-2a82fe637b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_06b96f84-c12c-498b-96a6-27c93905b36d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0edac42a-53b5-4cd8-8837-2a82fe637b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Leases" xlink:type="simple" xlink:href="advm-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b60be8b9-fe23-45ae-a4e6-32aa20ef047b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ecbfb7ff-dd09-458b-93b8-479d279940de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b60be8b9-fe23-45ae-a4e6-32aa20ef047b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ecbfb7ff-dd09-458b-93b8-479d279940de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7f23845e-4b0e-4df4-8d26-54643af03915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ef9a8440-b8c1-42fb-8b3b-d4db7f2eb9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7f23845e-4b0e-4df4-8d26-54643af03915" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ef9a8440-b8c1-42fb-8b3b-d4db7f2eb9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_756b5328-3e88-4dd4-ac6c-26568f194711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e66b421c-8a8b-496b-8720-9782c580651d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_756b5328-3e88-4dd4-ac6c-26568f194711" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e66b421c-8a8b-496b-8720-9782c580651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20230331.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8bb98e89-9ef5-4b86-8891-d541acddae19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f5a8f3c7-a93c-45e1-bd3e-194851348f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bb98e89-9ef5-4b86-8891-d541acddae19" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f5a8f3c7-a93c-45e1-bd3e-194851348f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5b68a7da-68da-46de-a2cc-259a2ae3c8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_05951d7e-b48f-4abd-a2e5-e36bd2c211d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b68a7da-68da-46de-a2cc-259a2ae3c8f9" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_05951d7e-b48f-4abd-a2e5-e36bd2c211d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_34312d50-a07c-41af-84ad-04556d66313d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b68a7da-68da-46de-a2cc-259a2ae3c8f9" xlink:to="loc_us-gaap_UseOfEstimates_34312d50-a07c-41af-84ad-04556d66313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f0359240-43f9-4e75-9487-3f85bb65f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b68a7da-68da-46de-a2cc-259a2ae3c8f9" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f0359240-43f9-4e75-9487-3f85bb65f5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dcf223f0-2a4d-43ee-883f-e6c4fb525481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b68a7da-68da-46de-a2cc-259a2ae3c8f9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dcf223f0-2a4d-43ee-883f-e6c4fb525481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20230331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_292e51d2-bf30-488a-b3b6-c2e5405e9be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fdf81eb9-7d60-40da-b65e-5a33dc6291be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_292e51d2-bf30-488a-b3b6-c2e5405e9be2" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fdf81eb9-7d60-40da-b65e-5a33dc6291be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesTables" xlink:type="simple" xlink:href="advm-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f5ebc52e-2296-4ed8-830b-14f36f9916e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7eb9fd68-6320-4ae6-afba-6d1e63d2fc79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f5ebc52e-2296-4ed8-830b-14f36f9916e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7eb9fd68-6320-4ae6-afba-6d1e63d2fc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_83e17382-c95a-4ca3-8f65-5f86ebf523e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f5ebc52e-2296-4ed8-830b-14f36f9916e3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_83e17382-c95a-4ca3-8f65-5f86ebf523e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_88ca2cc6-dd39-4586-8553-fe0f19a9bb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3259ad54-a272-4066-8e1b-2a801a35d355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_88ca2cc6-dd39-4586-8553-fe0f19a9bb8c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3259ad54-a272-4066-8e1b-2a801a35d355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dd255056-a4f4-49f8-8b6f-13643ec6fd65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_88ca2cc6-dd39-4586-8553-fe0f19a9bb8c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dd255056-a4f4-49f8-8b6f-13643ec6fd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e154e579-9c6f-4204-959b-42c815f5d7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4e60e26f-450d-421c-a1bc-413cf4642fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e154e579-9c6f-4204-959b-42c815f5d7e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4e60e26f-450d-421c-a1bc-413cf4642fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e63a4ed5-e23d-49ce-8cd0-607034561c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e154e579-9c6f-4204-959b-42c815f5d7e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e63a4ed5-e23d-49ce-8cd0-607034561c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_01df58ed-9e98-4334-8dda-e56aacdd8781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e154e579-9c6f-4204-959b-42c815f5d7e9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_01df58ed-9e98-4334-8dda-e56aacdd8781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20230331.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5d98aba6-75dc-4217-a927-5254d3adcde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_962211dc-6b32-49b0-a404-d10d4aa05937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5d98aba6-75dc-4217-a927-5254d3adcde6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_962211dc-6b32-49b0-a404-d10d4aa05937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#OrganizationandBasisofPresentationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af3e017f-3529-4c50-82ab-1b439a70291f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a427b8fe-403b-4884-8eca-2b5668c40063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af3e017f-3529-4c50-82ab-1b439a70291f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a427b8fe-403b-4884-8eca-2b5668c40063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d5a82c37-5e49-4c4e-95a2-b3f689fefce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af3e017f-3529-4c50-82ab-1b439a70291f" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d5a82c37-5e49-4c4e-95a2-b3f689fefce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7f83ee1d-46a0-45e4-9190-242c01d6f071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7f83ee1d-46a0-45e4-9190-242c01d6f071" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:to="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09d8d9a9-ec41-4d12-9fd2-04f1e7cfdf7e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_50086f6f-b778-4181-b6c0-400b85062058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_MoneyMarketFundsMember_50086f6f-b778-4181-b6c0-400b85062058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_21dcec74-7b9a-4466-8019-b9bc19e1c972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_CommercialPaperMember_21dcec74-7b9a-4466-8019-b9bc19e1c972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abb2339a-2264-464b-8c89-bdf6e6eb1e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abb2339a-2264-464b-8c89-bdf6e6eb1e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_94fa7157-3416-4409-946e-2fef9bbc1827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_94fa7157-3416-4409-946e-2fef9bbc1827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_638b8aff-0d34-4549-8d0c-503c006026cb" xlink:href="advm-20230331.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad75cdd7-2f2c-4eb1-9621-14040132f134" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_638b8aff-0d34-4549-8d0c-503c006026cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa77a0c5-2dcf-44c0-9dc1-f29aea650787" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_25446a1c-922c-4cfe-902b-5b89333f363c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_25446a1c-922c-4cfe-902b-5b89333f363c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55de2ac0-1905-4168-a402-81902442101a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89e31cff-6de0-4b23-bae4-1759765ee482" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55de2ac0-1905-4168-a402-81902442101a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_257a2fbd-eab2-4959-87f2-bb5c1ac5f300" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38373570-c7c4-4d11-97bf-7ec50ec259f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38373570-c7c4-4d11-97bf-7ec50ec259f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e752b90-79f2-47ba-8202-15a616e260af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e752b90-79f2-47ba-8202-15a616e260af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8df77b4-8dd7-49d2-9bb0-ccf6c21e2442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8df77b4-8dd7-49d2-9bb0-ccf6c21e2442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_999e6a0f-48c7-4cfb-871f-5b7ff0ec1e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_999e6a0f-48c7-4cfb-871f-5b7ff0ec1e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_49957c39-f9d4-48dd-ba1b-15ee1992b7ba" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_49957c39-f9d4-48dd-ba1b-15ee1992b7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_bd9a6cd4-77e4-4ed0-9117-790a76861c10" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_bd9a6cd4-77e4-4ed0-9117-790a76861c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_3d1bd2d7-9892-427d-b18b-1143fc455734" xlink:href="advm-20230331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_3d1bd2d7-9892-427d-b18b-1143fc455734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62d04fef-b741-4f73-8bfb-4a49e2b444bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b63d1dde-7fcb-435c-8bc5-a1d9ea164a62" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62d04fef-b741-4f73-8bfb-4a49e2b444bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d242d2de-ead4-4dbb-b89b-f4815beecdad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cbd180be-1023-4138-9a9f-e08efbf27024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d242d2de-ead4-4dbb-b89b-f4815beecdad" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cbd180be-1023-4138-9a9f-e08efbf27024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LicenseRevenueDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#LicenseRevenueDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LicenseRevenueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29119b24-8f80-4cc8-9c4a-083204a14e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29119b24-8f80-4cc8-9c4a-083204a14e94" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:to="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0aecadc2-0be2-490d-860b-b86c46730588" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3d54bd40-d0bf-4d07-a0ab-2026cbfc2929" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0aecadc2-0be2-490d-860b-b86c46730588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_e7971147-dc20-4831-a6e8-8de095b3f357" xlink:href="advm-20230331.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0aecadc2-0be2-490d-860b-b86c46730588" xlink:to="loc_advm_LexeoTherapeuticsIncMember_e7971147-dc20-4831-a6e8-8de095b3f357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_64055171-fbc5-4e66-a19c-2d0d94f0e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_000a1425-cea7-42e4-8512-990dc9285b6d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_64055171-fbc5-4e66-a19c-2d0d94f0e7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_061e06ed-917e-4a6c-a0aa-73f935250fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_64055171-fbc5-4e66-a19c-2d0d94f0e7b6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_061e06ed-917e-4a6c-a0aa-73f935250fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#LeasesDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9b66e552-2f59-46b6-a260-f292e05a518d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9b66e552-2f59-46b6-a260-f292e05a518d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_32fe192c-76ad-4292-ad9a-b5269f7bcae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_64747bec-c2be-4d7f-a421-48a8d1924fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:to="loc_us-gaap_BuildingMember_64747bec-c2be-4d7f-a421-48a8d1924fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_96d74e88-4a6a-4ce1-b496-9de064bc37c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2ca720-346b-476f-9846-9d6bed1670fe" xlink:to="loc_us-gaap_ManufacturingFacilityMember_96d74e88-4a6a-4ce1-b496-9de064bc37c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9d8979ac-36f1-4c80-9de8-3b704666d340" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_68d5c37b-4a19-4704-9dc4-552a9ba8268c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_68d5c37b-4a19-4704-9dc4-552a9ba8268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fc6e8442-76f2-469e-aee2-8e120542bf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fc6e8442-76f2-469e-aee2-8e120542bf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_32a2cb3e-7923-44e6-b9d3-742ded3a8081" xlink:href="advm-20230331.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_32a2cb3e-7923-44e6-b9d3-742ded3a8081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_9518ca8c-e2e6-4800-bbe9-c5a73a25964d" xlink:href="advm-20230331.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_9518ca8c-e2e6-4800-bbe9-c5a73a25964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b2b707bb-bae8-4f06-9925-d89ece25a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b2b707bb-bae8-4f06-9925-d89ece25a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0f720135-75b8-4abb-beb3-699513d32447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_be687811-0004-4690-8553-d78c4731f89b" xlink:to="loc_us-gaap_SubleaseIncome_0f720135-75b8-4abb-beb3-699513d32447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail" xlink:type="simple" xlink:href="advm-20230331.xsd#LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8334a7fb-ac30-45b0-a93a-d5cc3b17fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8334a7fb-ac30-45b0-a93a-d5cc3b17fba0" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_051037f4-34ee-4d2b-90b1-a2105a57ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_051037f4-34ee-4d2b-90b1-a2105a57ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9820f9dd-f85b-4fa1-8b20-dbb4cbec73f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9820f9dd-f85b-4fa1-8b20-dbb4cbec73f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0bbf3488-a9da-412f-8021-4e7ca21e5c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0bbf3488-a9da-412f-8021-4e7ca21e5c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b3cefd7d-fed2-470a-988d-af47abb3d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b3cefd7d-fed2-470a-988d-af47abb3d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6bf47ce4-e423-4840-bcb0-8885dd068616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6bf47ce4-e423-4840-bcb0-8885dd068616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9e2f0e70-0ced-4059-837c-c3422c536e07" xlink:href="advm-20230331.xsd#advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9e2f0e70-0ced-4059-837c-c3422c536e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1e85950-6daa-4252-aaeb-944d29094410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9db2423-3a33-4b71-849a-16ffdd4e6e2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1e85950-6daa-4252-aaeb-944d29094410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8334a7fb-ac30-45b0-a93a-d5cc3b17fba0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_e2db5a89-19dc-4498-a58f-c1070e282236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_e2db5a89-19dc-4498-a58f-c1070e282236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_ee9026ef-2e66-4357-ae35-b89b7b33d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_ee9026ef-2e66-4357-ae35-b89b7b33d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_dbf99bb0-c12f-4548-9206-697bf30bc221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_dbf99bb0-c12f-4548-9206-697bf30bc221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_a7b7c0af-7fc7-4aa6-b059-2c9ad0ec9815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_a7b7c0af-7fc7-4aa6-b059-2c9ad0ec9815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4d83d5ec-9528-41bd-8d1b-39235f393b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4d83d5ec-9528-41bd-8d1b-39235f393b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_ba5bee65-d348-4794-ba45-85f2bb5358ab" xlink:href="advm-20230331.xsd#advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_ba5bee65-d348-4794-ba45-85f2bb5358ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_aa78df0d-55ba-4041-bc08-dadafa6aa749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_79054e36-f13e-413e-b2e9-3a8bc0809ba7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_aa78df0d-55ba-4041-bc08-dadafa6aa749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_91488ddf-4f37-4988-9bc1-f22d189cfe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_91488ddf-4f37-4988-9bc1-f22d189cfe70" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b07df44b-0fc1-4296-9c99-a714d880ec9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9a4fbe26-fa0a-436e-8852-8ae3e48bd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9a4fbe26-fa0a-436e-8852-8ae3e48bd5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6afade2a-a47c-4324-acf8-26e45074ca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_EquipmentMember_6afade2a-a47c-4324-acf8-26e45074ca1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_238f4fa1-6a6d-48ac-b21c-4cc95a84819f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_ComputerEquipmentMember_238f4fa1-6a6d-48ac-b21c-4cc95a84819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8e2e5c64-8689-4b82-baaf-e83462c952f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8e2e5c64-8689-4b82-baaf-e83462c952f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e21bcbbc-f271-40fe-88eb-7b47553d855c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ed51bc4-380a-4cd8-a313-dbeda079ddcc" xlink:to="loc_us-gaap_ConstructionInProgressMember_e21bcbbc-f271-40fe-88eb-7b47553d855c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a0aca983-b401-4509-82bc-02df7913cdbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cffb062d-0992-44cf-b514-17c5c718f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cffb062d-0992-44cf-b514-17c5c718f18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74a539df-9c5d-4832-8d12-fc5182c22363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74a539df-9c5d-4832-8d12-fc5182c22363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_285aea03-bc20-4a33-8b59-51f7fab072ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d962130-35b6-4b86-ae72-2d7a5e66aad1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_285aea03-bc20-4a33-8b59-51f7fab072ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_1961b228-4339-4bbd-a347-60649b073c1f" xlink:href="advm-20230331.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:to="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_1961b228-4339-4bbd-a347-60649b073c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b6b930f9-883c-4f0a-a29b-ea7fc7bf3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b6b930f9-883c-4f0a-a29b-ea7fc7bf3c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a0028115-63c1-449d-a2cb-e75b8839ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a0028115-63c1-449d-a2cb-e75b8839ec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_5efd79b8-280a-4382-81e1-ab7e184dc670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:to="loc_us-gaap_TaxesPayableCurrent_5efd79b8-280a-4382-81e1-ab7e184dc670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a31af8ea-536a-4fb6-b5f1-08a8e5463221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a31af8ea-536a-4fb6-b5f1-08a8e5463221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_3d48643b-a5b2-4315-82eb-0afb0711fee3" xlink:href="advm-20230331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c73f45c4-19f5-422c-be10-9be01d067320" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_3d48643b-a5b2-4315-82eb-0afb0711fee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d6c9c3a-954c-49b3-8c56-82fe6f8a7894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d6c9c3a-954c-49b3-8c56-82fe6f8a7894" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9b70ac6-a7ef-49eb-a477-7da90eac6584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9b70ac6-a7ef-49eb-a477-7da90eac6584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_59d87801-10a4-4b98-bb33-28055ece73a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_59d87801-10a4-4b98-bb33-28055ece73a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aed3deb9-76e5-405c-883b-c65f9b9b7e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aed3deb9-76e5-405c-883b-c65f9b9b7e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e3b15972-492f-4c6c-bad6-77129d862b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e3b15972-492f-4c6c-bad6-77129d862b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ec6bb0a-98db-4dc4-a3d6-c72af853bbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ec6bb0a-98db-4dc4-a3d6-c72af853bbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_db8c14a8-168d-4a75-8fc1-29e8773f43a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4851d0e9-a035-41b1-aad3-d989679849b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_db8c14a8-168d-4a75-8fc1-29e8773f43a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d6c9c3a-954c-49b3-8c56-82fe6f8a7894" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_56dbd7c7-fe55-4f73-8183-8a574dc2386f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_56dbd7c7-fe55-4f73-8183-8a574dc2386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6e2b275-f863-40c5-9d4b-cb0e250f9f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6e2b275-f863-40c5-9d4b-cb0e250f9f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be0ce11d-dbbe-441e-b8a4-537ffdd95be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be0ce11d-dbbe-441e-b8a4-537ffdd95be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4bf2d771-b512-4e40-90d9-9589e42ac6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4bf2d771-b512-4e40-90d9-9589e42ac6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bad2c7a7-0977-403e-af88-dfcb3e102b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bad2c7a7-0977-403e-af88-dfcb3e102b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b79e29cc-df01-43f1-9d62-15a8bb1f90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e04f5604-4277-4f1a-9c1b-33ed3e35a2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b79e29cc-df01-43f1-9d62-15a8bb1f90e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89cd1c55-da85-4800-947a-91f6073be303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89cd1c55-da85-4800-947a-91f6073be303" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:to="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b4b97d9-7475-489f-bee6-d2bafc507a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_36356a8e-6043-4167-86f1-f28489dac900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b4b97d9-7475-489f-bee6-d2bafc507a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_04d03fb7-5e77-4d84-844c-4ce965551051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b4b97d9-7475-489f-bee6-d2bafc507a71" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_04d03fb7-5e77-4d84-844c-4ce965551051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_178662cc-a51a-4564-ad14-3454b78c6a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dddd833f-715e-467e-aa29-f15e2e86ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dddd833f-715e-467e-aa29-f15e2e86ae2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_adb50951-b65f-4944-a1cb-76000fb8f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_adb50951-b65f-4944-a1cb-76000fb8f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6ea37a35-ae73-4a19-b187-1463a3357c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6ea37a35-ae73-4a19-b187-1463a3357c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a352db45-4bac-44ef-ac82-23472ad49af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a352db45-4bac-44ef-ac82-23472ad49af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_476b49d5-0dce-41ea-b026-19d0fdf2e356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b880fcc-240d-4baa-bc84-31c2bd6b76c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_476b49d5-0dce-41ea-b026-19d0fdf2e356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9dd8492-16ac-4a0e-8426-a7374a44bd59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8c5900-b859-4292-8405-fc90704970a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8c5900-b859-4292-8405-fc90704970a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fc292c2-d57f-4a52-94a7-e10df772fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fc292c2-d57f-4a52-94a7-e10df772fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c1d455c0-a6d7-4f10-807b-28f2fa1ea26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c1d455c0-a6d7-4f10-807b-28f2fa1ea26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_186797e3-bdb9-44cf-9950-3803a551147a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_186797e3-bdb9-44cf-9950-3803a551147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b762a85-3fd2-4189-8d76-cab15dea6210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210a7190-de23-40a0-b08a-66305a645d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b762a85-3fd2-4189-8d76-cab15dea6210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_484a8b06-69ba-4a57-b8ee-14c1cfe83a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_484a8b06-69ba-4a57-b8ee-14c1cfe83a95" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_962df312-c0cd-408a-89c0-4c16c6a44478" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f863b75d-ed77-4525-9e78-f245afd716b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f863b75d-ed77-4525-9e78-f245afd716b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a22e656-e3f9-4edd-94b0-a3b534d02728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4094a0a-2374-4299-8e63-02c21871a9c2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a22e656-e3f9-4edd-94b0-a3b534d02728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ca4fc1-15d8-4cde-a94e-bc8beebfa824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0697ba54-e194-45c7-8bc8-1fbaf74ed783" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ca4fc1-15d8-4cde-a94e-bc8beebfa824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b417e4d7-0789-4e62-b409-58d4f0e0bc58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ca4fc1-15d8-4cde-a94e-bc8beebfa824" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b417e4d7-0789-4e62-b409-58d4f0e0bc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="simple" xlink:href="advm-20230331.xsd#NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1d502dd9-112f-4348-935f-5ab1636ab4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d502dd9-112f-4348-935f-5ab1636ab4e9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f9ecbc51-fd15-4117-b185-d758b28911c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_48a44f7e-11d7-4e62-95f2-e012e7a51a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_48a44f7e-11d7-4e62-95f2-e012e7a51a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8723f2c8-31a8-4c95-93f3-9a362dbaa2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8723f2c8-31a8-4c95-93f3-9a362dbaa2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a764a3a4-4f3e-4414-a701-8b00f3ea2302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a3ae3f1-ca1a-495f-95f8-dfc43c38a2bf" xlink:to="loc_us-gaap_EmployeeStockMember_a764a3a4-4f3e-4414-a701-8b00f3ea2302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ee71a12-28a6-42b3-96d5-553fb40f291a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd822b79-3667-4b0c-8b40-4b658fbf839a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ee71a12-28a6-42b3-96d5-553fb40f291a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7581553b-b639-4922-9eee-2994653cda8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ee71a12-28a6-42b3-96d5-553fb40f291a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7581553b-b639-4922-9eee-2994653cda8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336888176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,574,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363334975072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 67,552<span></span>
</td>
<td class="nump">$ 68,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">96,733<span></span>
</td>
<td class="nump">117,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,588<span></span>
</td>
<td class="nump">5,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">168,873<span></span>
</td>
<td class="nump">190,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">69,503<span></span>
</td>
<td class="nump">78,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,347<span></span>
</td>
<td class="nump">34,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other long-term assets</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">275,577<span></span>
</td>
<td class="nump">308,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">2,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">17,344<span></span>
</td>
<td class="nump">16,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">26,265<span></span>
</td>
<td class="nump">13,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">46,472<span></span>
</td>
<td class="nump">32,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">71,348<span></span>
</td>
<td class="nump">93,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">117,820<span></span>
</td>
<td class="nump">126,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">990,214<span></span>
</td>
<td class="nump">985,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(799)<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(831,668)<span></span>
</td>
<td class="num">(802,612)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">157,757<span></span>
</td>
<td class="nump">181,518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 275,577<span></span>
</td>
<td class="nump">$ 308,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336805280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,059<span></span>
</td>
<td class="nump">22,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,780<span></span>
</td>
<td class="nump">15,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">33,839<span></span>
</td>
<td class="nump">38,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(30,239)<span></span>
</td>
<td class="num">(38,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(29,039)<span></span>
</td>
<td class="num">(37,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,056)<span></span>
</td>
<td class="num">(37,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized gain/(loss) on marketable securities</a></td>
<td class="nump">739<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (28,324)<span></span>
</td>
<td class="num">$ (38,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8212; basic (in USD per share)</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8212; diluted (in USD per share)</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share - basic (in shares)</a></td>
<td class="nump">100,304<span></span>
</td>
<td class="nump">98,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute net loss per share - diluted (in shares)</a></td>
<td class="nump">100,304<span></span>
</td>
<td class="nump">98,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363335390448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)/Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 964,965<span></span>
</td>
<td class="num">$ (714)<span></span>
</td>
<td class="num">$ (648,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">282,952<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">970,349<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(685,984)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">181,518<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">985,651<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
<td class="num">(802,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,056)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 157,757<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 990,214<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
<td class="num">$ (831,668)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336693088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,056)<span></span>
</td>
<td class="num">$ (37,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,563<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net (accretion) amortization of (discount) premium on marketable securities</a></td>
<td class="num">(960)<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">924<span></span>
</td>
<td class="num">(2,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(749)<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable', window );">Lease liability and lease incentive receivable</a></td>
<td class="num">(865)<span></span>
</td>
<td class="nump">5,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,412)<span></span>
</td>
<td class="num">(28,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(20,232)<span></span>
</td>
<td class="num">(29,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">41,850<span></span>
</td>
<td class="nump">118,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(4,374)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">21,533<span></span>
</td>
<td class="nump">84,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents and restricted cash</a></td>
<td class="num">(879)<span></span>
</td>
<td class="nump">55,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">70,934<span></span>
</td>
<td class="nump">36,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">70,055<span></span>
</td>
<td class="nump">92,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">67,552<span></span>
</td>
<td class="nump">89,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">70,055<span></span>
</td>
<td class="nump">92,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_RemeasurementOfOperatingLeaseRightOfUseAssets', window );">Remeasurement of operating lease right-of-use assets</a></td>
<td class="nump">8,004<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable, accrued expenses and other current liabilities</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 2,616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities and lease incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_RemeasurementOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement Of Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_RemeasurementOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340382800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $831.7 million as of March&#160;31, 2023. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of March&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $164.3 million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2022 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340186048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Interest Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#8217;s condensed consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January&#160;1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363337649056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, all marketable securities have a remaining maturity of less than one year. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2023 and December&#160;31, 2022 was $105.9&#160;million and $155.5&#160;million, respectively, which are highly liquid funds with high credit ratings that have final maturity of less than two years from date of purchase. The Company has not recorded an allowance for credit losses as of March&#160;31, 2023 and December&#160;31, 2022 related to these securities. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recorded any impairment charges on available-for-sale securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340489552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">License Revenue</a></td>
<td class="text">License Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Lexeo notified the Company that it achieved the first development milestone; accordingly the Company is eligible to receive additional payments. Therefore, the Company recognized $3.5&#160;million of license revenue during the three months ended March 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340404496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Redwood City, California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for facilities in Redwood City, California. Related to this lease, the Company provided the landlord with a letter of credit in the amount of $2.5&#160;million, which is classified as restricted cash under long term assets on the Company's condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into an amendment to accelerate the expiration of one of its Redwood City premises under the existing lease from December 31, 2031 to September 30, 2023. Concurrently, the Company entered into an agreement for additional tenant improvement allowance towards its other Redwood City premises. As a result of the modification the Company revalued the lease liability based on the new and remaining lease terms, which resulted in a reduction to the lease liability of $8.3&#160;million, and recognized the remeasurement to the lease liabilities as an adjustment to the right-of-use asset. The estimated value of non-cash consideration, composed primarily of leasehold improvements and furniture and fixtures, was $14.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Durham, North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has an operating lease agreement for a building in Durham, North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each. In April 2023, the Company entered into an amendment to reduce the rent payments for the NC Premises, which will be effective as of May 1, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the NC Premises through October 2037, the remainder of the lease term. In line with the amendment to the NC Premises' lease, sublease rent payments were correspondingly reduced. Sublease income for operating leases is recognized on a cash basis over the lease term based on assessment of probability of collection. Sublease income were $1.4&#160;million and $1.7&#160;million for the three months ended March 31, 2023 and 2022, respectively, and is classified as a reduction of rent expense in operating expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payments Receivable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340378560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336878032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,812&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363341910752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,171</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336865552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2022 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span>The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accrued Interest Receivable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Interest Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#8217;s condensed consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January&#160;1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340210656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336853872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Future Lease Payments under Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payments Receivable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Undiscounted Future Sublease Payments Receivable under Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payments Receivable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340233648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363334887696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,812&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340246592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,171</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340643184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 831,668<span></span>
</td>
<td class="nump">$ 802,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 164,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363337349568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 97,101<span></span>
</td>
<td class="nump">$ 118,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">96,733<span></span>
</td>
<td class="nump">117,158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: cash equivalents, amortized cost basis</a></td>
<td class="num">(60,485)<span></span>
</td>
<td class="num">(56,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: cash equivalents, unrealized gains</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: cash equivalents, unrealized losses</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: cash equivalents, estimated fair value</a></td>
<td class="num">(60,487)<span></span>
</td>
<td class="num">(56,240)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">10,984<span></span>
</td>
<td class="nump">10,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,984<span></span>
</td>
<td class="nump">10,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">72,594<span></span>
</td>
<td class="nump">102,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">72,529<span></span>
</td>
<td class="nump">102,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">71,949<span></span>
</td>
<td class="nump">59,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">71,655<span></span>
</td>
<td class="nump">58,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">157,586<span></span>
</td>
<td class="nump">174,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 157,220<span></span>
</td>
<td class="nump">$ 173,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363340192048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Marketable securities in an unrealized loss</a></td>
<td class="nump">$ 105.9<span></span>
</td>
<td class="nump">$ 155.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363337010512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember', window );">Lexeo Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336819616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">$ 2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Reduction in lease liability</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue', window );">Estimated value of non-cash consideration</a></td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts', window );">Number of renewal contracts | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseNumberOfRenewalContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336805168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Undiscounted Future Lease Payments under Operating Lease (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining nine months)</a></td>
<td class="nump">$ 24,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">10,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">11,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">11,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">11,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">91,538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">161,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Payments Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">2023 (remaining nine months)</a></td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">5,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2025</a></td>
<td class="nump">5,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2026</a></td>
<td class="nump">5,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2027</a></td>
<td class="nump">5,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour', window );">Thereafter</a></td>
<td class="nump">63,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted lease payments</a></td>
<td class="nump">$ 87,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Payment to be Received, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336759936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 51,933<span></span>
</td>
<td class="nump">$ 51,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(18,586)<span></span>
</td>
<td class="num">(16,994)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,347<span></span>
</td>
<td class="nump">34,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">34,375<span></span>
</td>
<td class="nump">34,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">14,419<span></span>
</td>
<td class="nump">14,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336726992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts', window );">Accrued nonclinical, clinical and process development costs</a></td>
<td class="nump">$ 8,475<span></span>
</td>
<td class="nump">$ 6,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation</a></td>
<td class="nump">5,946<span></span>
</td>
<td class="nump">8,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">State income tax payable</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 17,344<span></span>
</td>
<td class="nump">$ 16,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical clinical and development process costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363336828368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Stock Options Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">19,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">4,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares) | shares</a></td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">23,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">7,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 5.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share) | $ / shares</a></td>
<td class="nump">0.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">6.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">4.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363337671264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details) - Restricted stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share) | $ / shares</a></td>
<td class="nump">3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 2.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363337390624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,563<span></span>
</td>
<td class="nump">$ 5,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,182<span></span>
</td>
<td class="nump">$ 3,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140363337712832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">26,198<span></span>
</td>
<td class="nump">19,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">23,307<span></span>
</td>
<td class="nump">16,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>advm-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20230331.xsd" xlink:type="simple"/>
    <context id="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i908731d3af1f43f28a6d4584a8940cf0_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b74848539634879bcde0f1b19053254_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i824fb6df85304dfbb00b9685d592e775_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib749589928be4d0190f40c3411ccb77e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0aec62f8dd8c4f48b6d57236a9bb5cc6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a6ba63d466b43e2b0636ae42f70cab2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8eb942d212c94ff995b15db583ad3d3e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i27d3c6628b86457f8a81acd0630f6416_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9a2885fb914d4a9fb1475dfd39b35ea1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34050bca04e849e2bd858606a28d821f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaeee002c84444ba69bca37d55ddd1ece_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6aa1b2007db4438822cc804626038a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i11f44c0916af45cb8434366c7f852d47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b4ffbe5f1764673b5760d7479fc4039_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i31b77532d5ff487084fcf175a884a30d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0300483de0d645a3a3bb07bb05d84161_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f92cbd913c34c3f97e0fdd54f7f49f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b4e264e0eb94410a047fa84fb28d5ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba8291885aaa4357958e19254cd61ce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3700930922134893b6263b8067f724c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa5921d28f3a4035bde41b23af227eab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4acd8b1998ed4efc85109c235f6f88d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff760a046acd449e902d35ee4ca193bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id99b06b0ddf94978a7ff951eed4a978b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3b3ee54be714adca5246d416f27fc07_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0de0cd99e31943a7a3398bfb2471b8ec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95892d79c3ab4995b59ef11e3ea7942d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2b4e308e31564406905c98313e33a603_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i369a173705184a7cab09ad2a6180ed79_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icbf7996366cc460d899c0a0ab6b1917b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifecee66b5209450f86b53dd83c818354_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i230f68b10a814c8f895274e0ac72fafe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1730a9dcc0e4334888e861a0228a1b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if84cb988cff74c13804946bc088788c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie71a70a3d2404129bd447bda21043c37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa47672f93c844228fcf48e2ea805f97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8efd9f62836f463e824a62629a695c2d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idec0ca6f1e334c53bb5d986390d410e4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb3ac51c130c4ddd85a7143df0208a5a_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic15e5013c42c4501aecb2878f6bbe3c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icb41c12aa72a45c0acb2793e962d957a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iee913767de5c457eb0abe869f1ccf788_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibb926656b3e1496e8ae5e68b8a88bcaa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68b02a910cfa446ca03e773f9c23dfd4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i231f853a0b294f85b3d8e11f4d5f56b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d414f59c1bb438296e4a6a98a09a90c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d1325acb65c4d3ba80692faaa31ac8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8eb83a86ea384dff87bc2c6a80c8dc12_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i08ae0052ee0c4d30a61a5234d6eeb925_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49c3989caf254e88ba282f8751412f5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie74324103edc4f0da546ee3853453605_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e5816500fc04144b5ebb1566cc9f4f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03ee695f35b04c92841b271089b16400_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifea5ef805f8c40038f3b3e1ec4ca4f7a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic17577b3961e43a4b40b169a76ff83db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5a6eb7c0dd44b829c120e24f1ea5e32_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i69031cdc433a468695993438b2b429d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1cc5fc2435e4ec3a7f02439a9d618fb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i406b3e1f97ba43e9b9a0eba636ce617a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea30e1fafcc7467796344a1b9ed739a5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i97678bdca6e84570bb323a2f04cf2272_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5622823987bd4b5b9eaeed2cfac2dc62_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a6a763430794cf4a5b4d713e9cfcccc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="contract">
        <measure>advm:contract</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF8zLTEtMS0xLTQwMjgz_8ad9576b-bf24-4b79-b211-b5b12c877d72">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF80LTEtMS0xLTQwMjgz_b9e2a688-5ee0-4d87-98e9-de4e44e40507">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF81LTEtMS0xLTQwMjgz_cdcf07de-b63f-4c1b-80f9-4e024a80017f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF82LTEtMS0xLTQwMjgz_359503e5-ac6d-4ddf-a224-33751158acf5">0001501756</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80L2ZyYWc6MTg2NThlMWM5NGY5NGQzODhiMGQxMmY5YWMzZDljN2EvdGFibGU6ZWNkZjJkMDZlOWRhNGI3NjkxYThlMjQzYzgzMTNmMzAvdGFibGVyYW5nZTplY2RmMmQwNmU5ZGE0Yjc2OTFhOGUyNDNjODMxM2YzMF83LTEtMS0xLTQwMjgz_27500ae7-fdee-43b6-8a5b-7af7fe673602">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDIz_6ac1f656-467d-44e6-9d42-75eb1705b732">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6OWIzYzNiNDYxMjlkNDI5Mjk3ZTMxZDIzNTk3YWUwNDEvdGFibGVyYW5nZTo5YjNjM2I0NjEyOWQ0MjkyOTdlMzFkMjM1OTdhZTA0MV8wLTAtMS0xLTQwMjgz_367eadce-a410-46f3-b921-1152c9c2b5b6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNjY_0f258a89-bfb7-444c-a8ea-c883a214c0fb">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6N2I4ZjhiNWUwNjJhNGM4OThmMWVlZjJmODYwYTQyMjMvdGFibGVyYW5nZTo3YjhmOGI1ZTA2MmE0Yzg5OGYxZWVmMmY4NjBhNDIyM18wLTAtMS0xLTQwMjgz_48457769-f427-4eea-9d62-680bdbda2690">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI3_b266ea2c-b5ab-4c71-afa0-0d9a8646dc51">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDMx_3ba8b803-f796-4489-90dd-2330c4d10f71">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NjcyNWU5NWY1MDJjNDY3OWE1MzJhZDEyNGJhMWFlOTcvdGFibGVyYW5nZTo2NzI1ZTk1ZjUwMmM0Njc5YTUzMmFkMTI0YmExYWU5N18wLTAtMS0xLTQwMjgz_f723e93c-6e53-406c-8705-d4fcebd79983">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NjcyNWU5NWY1MDJjNDY3OWE1MzJhZDEyNGJhMWFlOTcvdGFibGVyYW5nZTo2NzI1ZTk1ZjUwMmM0Njc5YTUzMmFkMTI0YmExYWU5N18wLTItMS0xLTQwMjgz_d0b60760-0c08-414f-acbd-779fff4fda70">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDMy_0f55d3d1-4b6b-4b2e-a5ec-06ca11ef05c4">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI0_644fab36-f0da-4e96-9dba-af16cb54e6d2">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDM0_ace94636-64b0-44d9-a288-36417725ccb9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI1_acb026fb-e357-4739-9b4e-6a8a2b74b881">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF82OTk_b96d19ce-7fd6-47b1-9bcb-700145e17b9b">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDM1_f06bbf11-528c-465c-88df-0fa28edf8b69">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6ZTdhYjllMzc0YzJjNGFmYjhjYWQ2MTA4NTJmOGU0ODMvdGFibGVyYW5nZTplN2FiOWUzNzRjMmM0YWZiOGNhZDYxMDg1MmY4ZTQ4M18xLTAtMS0xLTQwMjgz_8f2afb32-0cea-4a6b-a1a1-b87999853358">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6ZTdhYjllMzc0YzJjNGFmYjhjYWQ2MTA4NTJmOGU0ODMvdGFibGVyYW5nZTplN2FiOWUzNzRjMmM0YWZiOGNhZDYxMDg1MmY4ZTQ4M18xLTEtMS0xLTQwMjgz_31b6e40a-4dcb-4839-b337-ed6597356a4b">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6ZTdhYjllMzc0YzJjNGFmYjhjYWQ2MTA4NTJmOGU0ODMvdGFibGVyYW5nZTplN2FiOWUzNzRjMmM0YWZiOGNhZDYxMDg1MmY4ZTQ4M18xLTItMS0xLTQwMjgz_91ea0891-efe5-4d3d-a473-cc2eeb3f249f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDM2_16a1f274-9638-43e5-b63d-8cb3ed16a6df">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI5_ea101041-d88a-47b9-8185-7e6bcd041c05">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NDVhZjMyODA0NWZjNDc5N2E3NmI4ZDM0ZjUzODhhMWMvdGFibGVyYW5nZTo0NWFmMzI4MDQ1ZmM0Nzk3YTc2YjhkMzRmNTM4OGExY18xLTAtMS0xLTQwMjgz_0c5a7baf-bda7-4812-a0ef-5acb89217a41">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NDVhZjMyODA0NWZjNDc5N2E3NmI4ZDM0ZjUzODhhMWMvdGFibGVyYW5nZTo0NWFmMzI4MDQ1ZmM0Nzk3YTc2YjhkMzRmNTM4OGExY18xLTQtMS0xLTQwMjgz_066992f4-1915-4b1e-bb8e-f32470713d6c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGFibGU6NDVhZjMyODA0NWZjNDc5N2E3NmI4ZDM0ZjUzODhhMWMvdGFibGVyYW5nZTo0NWFmMzI4MDQ1ZmM0Nzk3YTc2YjhkMzRmNTM4OGExY18yLTQtMS0xLTQwMjgz_0890789e-15aa-4ba5-b4ca-f626c3f34f70">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yNDI2_c288aade-7c0e-46b6-b569-d983c1e3e652">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i908731d3af1f43f28a6d4584a8940cf0_I20230505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xL2ZyYWc6YTcyMDNhYjE5ODJkNDVhYmEzZTVjMTA5ZTIwZmNiYTAvdGV4dHJlZ2lvbjphNzIwM2FiMTk4MmQ0NWFiYTNlNWMxMDllMjBmY2JhMF8yMzM4_e70870ba-b59d-40c1-947c-fbc28727d43f"
      unitRef="shares">100574949</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMy0xLTEtMS00MDI4Mw_30ae8286-70f0-4723-ade7-34bc46d48ec8"
      unitRef="usd">67552000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMy0zLTEtMS00MDI4Mw_2a713564-ac6e-49dd-8ba4-049b89f5fa52"
      unitRef="usd">68431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNC0xLTEtMS00MDI4Mw_b8cb4f7c-67d9-4935-9861-af8d7954213d"
      unitRef="usd">96733000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNC0zLTEtMS00MDI4Mw_b0de5e37-c3f4-4e71-8232-a66932bd6d84"
      unitRef="usd">117158000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNi0xLTEtMS00MDI4Mw_a04a4fa4-0a73-4f5f-ad2b-0deb5b1e4425"
      unitRef="usd">4588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNi0zLTEtMS00MDI4Mw_c7ceb578-b4d1-4fb0-9ba4-b6b194652041"
      unitRef="usd">5006000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNy0xLTEtMS00MDI4Mw_0f70396c-cbbe-4265-b41d-7727fed0c443"
      unitRef="usd">168873000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfNy0zLTEtMS00MDI4Mw_6cf4228a-c923-4854-aef1-6d36b593d835"
      unitRef="usd">190595000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOC0xLTEtMS00MDI4Mw_a978b8c4-353d-4124-b015-e3183348020e"
      unitRef="usd">69503000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOC0zLTEtMS00MDI4Mw_e5f2fadf-eea9-411d-abdc-8ea5a04e6f85"
      unitRef="usd">78934000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOS0xLTEtMS00MDI4Mw_d7b93803-033e-4ec9-ac0d-c3e142576e70"
      unitRef="usd">33347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfOS0zLTEtMS00MDI4Mw_954da343-22da-4628-b592-4d1f2c88d423"
      unitRef="usd">34927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTEtMS0xLTEtNDAyODM_25d00985-55bc-471d-8fba-62ec6814304d"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTEtMy0xLTEtNDAyODM_d589849b-5106-4e15-9331-6b7fc85026eb"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTMtMS0xLTEtNDAyODM_a2724fe9-77fb-4630-84f3-6cae5150366c"
      unitRef="usd">1351000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTMtMy0xLTEtNDAyODM_9d5cb8cf-40c9-4061-861a-ae666dc751c9"
      unitRef="usd">1413000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTQtMS0xLTEtNDAyODM_50fc6f07-7f21-48c2-a401-7e4fdc4ef373"
      unitRef="usd">275577000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTQtMy0xLTEtNDAyODM_22d1e7b4-66d8-4235-b470-774fee17b2d4"
      unitRef="usd">308372000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTctMS0xLTEtNDAyODM_c5d5fa92-9594-494f-a8f5-9d569902dc43"
      unitRef="usd">2863000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTctMy0xLTEtNDAyODM_dda0289a-6387-424c-b988-9336b5c19955"
      unitRef="usd">2238000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTgtMS0xLTEtNDAyODM_7696c905-5df8-4e0d-aff9-774ca62b6c58"
      unitRef="usd">17344000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTgtMy0xLTEtNDAyODM_9aca8aec-ee20-4b84-a38c-748bc3214c36"
      unitRef="usd">16767000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTktMS0xLTEtNDAyODM_e4aa1894-2cc2-4ac8-b643-55d361eb7ca7"
      unitRef="usd">26265000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMTktMy0xLTEtNDAyODM_fa13dd2e-8c27-41da-8040-0c0448779fae"
      unitRef="usd">13241000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjEtMS0xLTEtNDAyODM_3bbe443b-9af1-478c-9cb7-7423082bf7d9"
      unitRef="usd">46472000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjEtMy0xLTEtNDAyODM_199fd79c-d2b9-4a44-919f-9028c97e23ec"
      unitRef="usd">32246000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjMtMS0xLTEtNDAyODM_3d33942e-3191-49a3-b5ad-b943fc3d8f53"
      unitRef="usd">71348000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjMtMy0xLTEtNDAyODM_233dc98f-e1ba-4aa4-9985-cf5601fc266c"
      unitRef="usd">93561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMS0xLTEtNDM4MDE_f35ecedb-c0fc-43ec-bcac-119a4a9960f2"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMy0xLTEtNDM4MDk_8a65784f-44cf-4923-bb19-eb7a4f2fb511"
      unitRef="usd">1047000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMS0xLTEtNDAyODM_61db9d77-8c5a-4d32-b27f-3e90d57c9199"
      unitRef="usd">117820000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjUtMy0xLTEtNDAyODM_543e5a6a-8066-47e1-985a-063dd3e0e3fe"
      unitRef="usd">126854000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjgtMS0xLTEtNDAyODM_435f0985-cd76-4a6f-a3f6-7bf59d0c7170"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjgtMy0xLTEtNDAyODM_7f9272f1-a58f-4e85-99bf-8721b7386afe"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjktMS0xLTEtNDAyODM_b5f9e9e1-e87c-4543-a7df-0a89de644d7d"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMjktMy0xLTEtNDAyODM_61537f26-df66-4c50-bbc3-804d63f41f83"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzAtMS0xLTEtNDAyODM_47b01613-59e1-4b77-ac1c-0c612dfef571"
      unitRef="usd">990214000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzAtMy0xLTEtNDAyODM_3c4422b5-3458-42a4-9c4b-8d6b025c16ea"
      unitRef="usd">985651000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzEtMS0xLTEtNDAyODM_179dd2b5-d2f7-43a7-afd3-482f67a62da3"
      unitRef="usd">-799000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzEtMy0xLTEtNDAyODM_fe4ec57c-642d-4b7b-a9b1-d1cbebf3a739"
      unitRef="usd">-1531000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzItMS0xLTEtNDAyODM_c916feb9-ac62-448d-861f-76c13de31bc0"
      unitRef="usd">-831668000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzItMy0xLTEtNDAyODM_7685f52b-d88b-4b57-9fab-ddb876fb5a71"
      unitRef="usd">-802612000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzMtMS0xLTEtNDAyODM_7123b59f-e966-4b5a-86bb-75c7b2ca8671"
      unitRef="usd">157757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzMtMy0xLTEtNDAyODM_325552b1-628f-42e5-8ab6-8f2dc08b2854"
      unitRef="usd">181518000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzQtMS0xLTEtNDAyODM_c645c9e8-d176-46ec-b4f7-e92aeca8510b"
      unitRef="usd">275577000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8xOS9mcmFnOjBmYzMzN2IxOGUxNTRlOTBhYmM4MjAwOTI0NGM3NTRiL3RhYmxlOjYxZGFiZjgyNWE0ZTRjZWQ5MmY5MmUzMDRjMWY4NzVhL3RhYmxlcmFuZ2U6NjFkYWJmODI1YTRlNGNlZDkyZjkyZTMwNGMxZjg3NWFfMzQtMy0xLTEtNDAyODM_53636c26-9dfa-441d-82c2-0bd1ecf179f6"
      unitRef="usd">308372000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMi0xLTEtMS00MDI4Mw_c02cedda-e5c5-4f55-88e8-b7d9cd3bc2f7"
      unitRef="usd">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMi0zLTEtMS00MDI4Mw_96cb16a6-86cf-4229-a961-459a7db91206"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNS0xLTEtMS00MDI4Mw_aeb9f701-8783-4659-b45f-00dbda85908c"
      unitRef="usd">21059000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNS0zLTEtMS00MDI4Mw_dd0dfb85-eb72-470d-895f-efa677747964"
      unitRef="usd">22964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNi0xLTEtMS00MDI4Mw_76c41b15-7f4c-4209-8140-a7fed09f9173"
      unitRef="usd">12780000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfNi0zLTEtMS00MDI4Mw_ae9dd4f9-9cd2-4ff6-8508-77ad21de3492"
      unitRef="usd">15169000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOC0xLTEtMS00MDI4Mw_56574182-9413-401a-b557-04fb89f1317e"
      unitRef="usd">33839000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOC0zLTEtMS00MDI4Mw_0039f0bc-bdcd-4ed3-8141-b2f97f3cde08"
      unitRef="usd">38133000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOS0xLTEtMS00MDI4Mw_7c1e9598-3e1c-4917-9c6d-1237bb95cb2c"
      unitRef="usd">-30239000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfOS0zLTEtMS00MDI4Mw_6e057251-b142-41af-906d-2aa72c953e32"
      unitRef="usd">-38133000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTAtMS0xLTEtNDAyODM_5c053755-d209-46d4-bf18-510b6abcb0e8"
      unitRef="usd">1200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTAtMy0xLTEtNDAyODM_8e43509e-445d-4eb5-a072-81bf9ef4967d"
      unitRef="usd">244000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTEtMS0xLTEtNDAyODM_ae61b5a0-6d33-4f63-89da-68ad0703d049"
      unitRef="usd">-29039000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTEtMy0xLTEtNDAyODM_834926b7-b02d-433d-afe5-8a49a636196f"
      unitRef="usd">-37889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTItMS0xLTEtNDAyODM_b5d44854-a385-4ab6-9064-27e3b6de794b"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTItMy0xLTEtNDAyODM_19d0bfbc-906f-4c38-8667-5368c466432d"
      unitRef="usd">19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTMtMS0xLTEtNDAyODM_e8c3501c-4aed-4f3b-8862-c5e767cca726"
      unitRef="usd">-29056000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTMtMy0xLTEtNDAyODM_c6068bfe-3ebc-44a0-8cd0-3182c26d7019"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTUtMS0xLTEtNDAyODM_cff0f130-cf46-4f0a-a434-f471b79b3d02"
      unitRef="usd">739000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTUtMy0xLTEtNDAyODM_349d497a-1e37-4c26-af5a-b3aefc65c8de"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTYtMS0xLTEtNDAyODM_70b09ac8-036b-42e2-a8b9-4459111de855"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTYtMy0xLTEtNDAyODM_c003c629-e6cd-4acc-af0a-e532c200fe99"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTctMS0xLTEtNDAyODM_ad27777c-6c36-49c0-9f13-a93b2f55ef2a"
      unitRef="usd">-28324000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTctMy0xLTEtNDAyODM_d131ae80-3989-41b1-ade3-abaca71bb443"
      unitRef="usd">-38617000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMS0xLTEtNDAyODM_89aaaf34-8670-45d0-b9db-740cfcb2cfbd"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMS0xLTEtNDAyODM_df913f46-4fa7-4ef8-8c55-f6c4ff759d21"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMy0xLTEtNDAyODM_854cb7c0-53d9-483c-bb84-c1ef6340430e"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTgtMy0xLTEtNDAyODM_8eaf0973-aad1-4840-95cf-2c21cb646fea"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMS0xLTEtNDAyODM_ab1e7b9c-0663-4687-b672-66d85ad2d075"
      unitRef="shares">100304000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMS0xLTEtNDAyODM_b840eaa4-f42e-4252-acdd-287c4e0be22a"
      unitRef="shares">100304000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMy0xLTEtNDAyODM_586e4189-8a28-4335-b818-e2da77e155cc"
      unitRef="shares">98596000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yMi9mcmFnOmJiZTdkYzgxNjg0YzQ3NTc4OTdmOGZiOTY3YzljODc5L3RhYmxlOjZkNTM2ZjhhYTg2YjRjYTk4ODYyZWM5MzhmZGEwMDQwL3RhYmxlcmFuZ2U6NmQ1MzZmOGFhODZiNGNhOTg4NjJlYzkzOGZkYTAwNDBfMTktMy0xLTEtNDAyODM_67deb29b-36f2-4781-9619-08ec24db8a8c"
      unitRef="shares">98596000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i824fb6df85304dfbb00b9685d592e775_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi0xLTEtMS00MDI4Mw_afecb0ac-323f-4b2e-9d65-2b1a52cf421d"
      unitRef="shares">100117000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i824fb6df85304dfbb00b9685d592e775_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi0zLTEtMS00MDI4Mw_1094ba82-fd7f-48a6-b4e9-2986f0c89067"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib749589928be4d0190f40c3411ccb77e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi01LTEtMS00MDI4Mw_5d15aebb-8d00-4b80-9cd0-9f22b5b56410"
      unitRef="usd">985651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0aec62f8dd8c4f48b6d57236a9bb5cc6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi03LTEtMS00MDI4Mw_4b4fbb6b-ae85-4790-b38d-0227ccfe3e86"
      unitRef="usd">-1531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a6ba63d466b43e2b0636ae42f70cab2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi05LTEtMS00MDI4Mw_bdc6b2e0-aa96-4137-a469-dde51a6b7aeb"
      unitRef="usd">-802612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMi0xMS0xLTEtNDAyODM_347b7339-7caa-405b-bb04-b65f14538a39"
      unitRef="usd">181518000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8eb942d212c94ff995b15db583ad3d3e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMy01LTEtMS00MDI4Mw_1bf6ee8a-6b6c-41fa-81ba-80df13e7ca77"
      unitRef="usd">4563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMy0xMS0xLTEtNDAyODM_5ccd0b09-85bb-4042-b4fe-f1552ed0bcfc"
      unitRef="usd">4563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i27d3c6628b86457f8a81acd0630f6416_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfNS0xLTEtMS00MDI4Mw_93702dcb-3054-4dec-a87c-cc4a196acb58"
      unitRef="shares">456000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9a2885fb914d4a9fb1475dfd39b35ea1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfNy03LTEtMS00MDI4Mw_aac5895d-6c67-4531-8262-baa5f8dc8543"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfNy0xMS0xLTEtNDAyODM_f487d3b3-d8c7-4533-b399-361ac30653ff"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i9a2885fb914d4a9fb1475dfd39b35ea1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOC03LTEtMS00MDI4Mw_5c284542-5e56-4a22-b459-7c5ef9b27e75"
      unitRef="usd">739000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOC0xMS0xLTEtNDAyODM_d451b801-fdb4-4c6d-98cc-ff9a02b64eee"
      unitRef="usd">739000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i34050bca04e849e2bd858606a28d821f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOS05LTEtMS00MDI4Mw_896a4d92-ee63-411c-a326-124493933cba"
      unitRef="usd">-29056000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfOS0xMS0xLTEtNDAyODM_98a0a572-60cc-46b0-8a8f-63b2ae371aa9"
      unitRef="usd">-29056000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iaeee002c84444ba69bca37d55ddd1ece_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtMS0xLTEtNDAyODM_8fd95acc-f9bf-41d1-92bd-dd520707a878"
      unitRef="shares">100573000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaeee002c84444ba69bca37d55ddd1ece_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtMy0xLTEtNDAyODM_bf328750-c1a5-4486-b171-21a7256aec08"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6aa1b2007db4438822cc804626038a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtNS0xLTEtNDAyODM_27cede14-585f-433f-b034-b4851e38d88b"
      unitRef="usd">990214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11f44c0916af45cb8434366c7f852d47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtNy0xLTEtNDAyODM_28e2965a-4b16-4adf-923d-cb0aaac93235"
      unitRef="usd">-799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b4ffbe5f1764673b5760d7479fc4039_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtOS0xLTEtNDAyODM_5a1d6224-781d-4132-a001-e94e9b86014b"
      unitRef="usd">-831668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjM3YjIyNWM3MmM1NDQzOTg5ZTcwMTc0ZWIwYzdhODhlL3RhYmxlcmFuZ2U6MzdiMjI1YzcyYzU0NDM5ODllNzAxNzRlYjBjN2E4OGVfMTAtMTEtMS0xLTQwMjgz_e5062d97-83cf-468c-9eda-9ac7a4a5f086"
      unitRef="usd">157757000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i31b77532d5ff487084fcf175a884a30d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi0xLTEtMS00MDI4Mw_2b8e4ad2-56cd-4d5a-8696-8b0dc9995850"
      unitRef="shares">98381000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i31b77532d5ff487084fcf175a884a30d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi0zLTEtMS00MDI4Mw_364722a0-dd4d-4caa-bf3a-97a91346f009"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0300483de0d645a3a3bb07bb05d84161_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi01LTEtMS00MDI4Mw_14c2a7b5-3616-48e3-b862-ff60ac3d56c1"
      unitRef="usd">964965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f92cbd913c34c3f97e0fdd54f7f49f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi03LTEtMS00MDI4Mw_79f3f442-aa69-424a-afc7-01a265e43940"
      unitRef="usd">-714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b4e264e0eb94410a047fa84fb28d5ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi05LTEtMS00MDI4Mw_eb573560-4129-45df-9cf9-75eefc9e41b3"
      unitRef="usd">-648076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba8291885aaa4357958e19254cd61ce3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMi0xMS0xLTEtNDAyODM_c2c8f487-a5a9-4d6e-ba65-ff51ed3441f8"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3700930922134893b6263b8067f724c5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMy01LTEtMS00MDI4Mw_bbc015c0-7072-477f-a54f-87bde33ba422"
      unitRef="usd">5381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMy0xMS0xLTEtNDAyODM_1116c756-1996-4473-953d-9958c82f30c0"
      unitRef="usd">5381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaa5921d28f3a4035bde41b23af227eab_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNS0xLTEtMS00MDI4Mw_ae31a709-5b0d-44b6-85c5-f84f3e369668"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3700930922134893b6263b8067f724c5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNS01LTEtMS00MDI4Mw_7110cbb3-ad4f-4452-83ea-a1bf1a0991e2"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNS0xMS0xLTEtNDAyODM_3bb671ad-ba0a-49af-8c2d-58d984206a22"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iaa5921d28f3a4035bde41b23af227eab_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfNi0xLTEtMS00MDI4Mw_211a7e55-4dc7-4311-af2b-e19c8e276ebd"
      unitRef="shares">371000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4acd8b1998ed4efc85109c235f6f88d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOC03LTEtMS00MDI4Mw_45a21ae2-d128-4408-a6aa-c3f8cdb3ae7e"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOC0xMS0xLTEtNDAyODM_7e8b9cf0-15fa-4a1d-a941-6b5b01553ca2"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i4acd8b1998ed4efc85109c235f6f88d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOS03LTEtMS00MDI4Mw_6b015c91-69fb-4950-9f33-4a9cb777936d"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfOS0xMS0xLTEtNDAyODM_76c47d88-2768-4498-981f-4fbac99d12e6"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff760a046acd449e902d35ee4ca193bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTAtOS0xLTEtNDAyODM_3a79cde3-b8ca-43b9-8532-fea265589cb9"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTAtMTEtMS0xLTQwMjgz_3f2e4a4e-a277-41ee-9afe-2e3fe9ba6936"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id99b06b0ddf94978a7ff951eed4a978b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtMS0xLTEtNDAyODM_70bb10ad-da7e-4f28-9110-510d6a83a966"
      unitRef="shares">98767000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id99b06b0ddf94978a7ff951eed4a978b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtMy0xLTEtNDAyODM_37442a71-42e2-48a9-9a0e-0da266f5ce72"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3b3ee54be714adca5246d416f27fc07_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtNS0xLTEtNDAyODM_319ef6ef-2f06-4305-9cfd-8c2e0972ac63"
      unitRef="usd">970349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0de0cd99e31943a7a3398bfb2471b8ec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtNy0xLTEtNDAyODM_5c7240b9-9ff8-4ac4-beeb-730510f15bb0"
      unitRef="usd">-1423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95892d79c3ab4995b59ef11e3ea7942d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtOS0xLTEtNDAyODM_5c77964a-390f-4030-a87f-4a67a45c03e5"
      unitRef="usd">-685984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yNS9mcmFnOjFjMWJiMzVlNTFkMDQ2YTRiMTk2MzhkN2IyNWQ0NThhL3RhYmxlOjRhNWZmYmUwZTk1MzQxYThhYjIwZDU1MWIxYzRiMDNlL3RhYmxlcmFuZ2U6NGE1ZmZiZTBlOTUzNDFhOGFiMjBkNTUxYjFjNGIwM2VfMTEtMTEtMS0xLTQwMjgz_8a81b887-ab87-4d97-8304-3689048d354d"
      unitRef="usd">282952000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMy0xLTEtMS00MDI4Mw_82812d62-8d44-438b-9b8a-99d053046682"
      unitRef="usd">-29056000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMy0zLTEtMS00MDI4Mw_ea99f443-5921-4cc2-9801-c5748e2dac7e"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNS0xLTEtMS00MDI4Mw_0a927404-9abc-4d10-8844-40bd96a51e34"
      unitRef="usd">1592000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNS0zLTEtMS00MDI4Mw_bd2061a2-ce1f-4bb6-88ec-70a85c1a7beb"
      unitRef="usd">1425000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNi0xLTEtMS00MDI4Mw_8ccbcbc3-b188-41bd-a05d-ff69b61ad035"
      unitRef="usd">4563000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNi0zLTEtMS00MDI4Mw_3f403b21-e4fd-46ba-baca-8929d25254b4"
      unitRef="usd">5381000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOC0xLTEtMS00MDI4Mw_f8a1a0c6-7383-49cb-af7a-dc65886a2173"
      unitRef="usd">960000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOC0zLTEtMS00MDI4Mw_0e085338-8916-4912-9bd3-825c43379343"
      unitRef="usd">-212000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOS0xLTEtMS00NTIyOA_f7a7c5b1-37ac-453a-8f4c-0e77ac32b2af"
      unitRef="usd">1427000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfOS0zLTEtMS00NTIyOA_9545890d-fa01-4943-be3a-ebd0d1a8f242"
      unitRef="usd">1126000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTEtMS0xLTEtNDAyODM_303b37c5-6981-4960-a4bb-c9d0c5fdc558"
      unitRef="usd">-19000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTEtMy0xLTEtNDAyODM_9c8dea53-d055-440a-8a06-935584c0ac43"
      unitRef="usd">92000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTMtMS0xLTEtNDAyODM_0112d8e9-7ebc-44d3-8e4b-3c144be6c6f1"
      unitRef="usd">-924000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTMtMy0xLTEtNDAyODM_372b64bc-623c-43b3-94eb-0a8d764953ed"
      unitRef="usd">2916000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTQtMS0xLTEtNDAyODM_12ca3e5a-c253-4e19-ae29-5ce310e62010"
      unitRef="usd">-62000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTQtMy0xLTEtNDAyODM_6378374a-e8a2-4315-a5f1-d7130e21b2cf"
      unitRef="usd">1658000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTYtMS0xLTEtNDAyODM_87cf1d29-22c0-4d60-a062-4809a81f897d"
      unitRef="usd">631000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTYtMy0xLTEtNDAyODM_74472a4d-2a81-4815-a021-3e4f9be34223"
      unitRef="usd">1437000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTctMS0xLTEtNDAyODM_bbdc0b08-b702-4573-9b2c-ea24be7c2a3e"
      unitRef="usd">-749000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMTctMy0xLTEtNDAyODM_63970e88-399b-48a4-a97e-768350f08368"
      unitRef="usd">-1188000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjAtMS0xLTEtNDAyODM_ba0d5123-ed7b-4967-83ae-10aae4070049"
      unitRef="usd">-865000</advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable>
    <advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjAtMy0xLTEtNDAyODM_86ae9974-8141-4679-be93-d44a3da62f8c"
      unitRef="usd">5252000</advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjItMS0xLTEtNDAyODM_99ea8dbc-a8e5-40fb-a451-b8768de68273"
      unitRef="usd">-22412000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjItMy0xLTEtNDAyODM_a842303e-b69b-4e3f-8e25-12dd437a91c4"
      unitRef="usd">-28929000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjQtMS0xLTEtNDAyODM_ec313ea3-a363-4c7a-9a4b-e310440f62e4"
      unitRef="usd">20232000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjQtMy0xLTEtNDAyODM_bd05713e-7531-429f-af60-26c33e9a73cb"
      unitRef="usd">29750000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjUtMS0xLTEtNDAyODM_8f172707-9af3-4b50-8d40-8cab9018fb3e"
      unitRef="usd">41850000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjUtMy0xLTEtNDAyODM_8571b5e2-7ca1-45a0-88b5-f73a6096c5b3"
      unitRef="usd">118507000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjctMS0xLTEtNDAyODM_d7547dbc-050a-4ea6-9b5c-290960d7be33"
      unitRef="usd">85000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjctMy0xLTEtNDAyODM_48a77708-9495-44ea-ae69-98d0a7fdc6ff"
      unitRef="usd">4374000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjgtMS0xLTEtNDAyODM_6cf4b6e6-32aa-4a8b-8949-d7ec12e6979d"
      unitRef="usd">21533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMjgtMy0xLTEtNDAyODM_a5cf3451-a68a-47b4-8d4e-c3b635cc1306"
      unitRef="usd">84383000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzItMS0xLTEtNDAyODM_46ef1640-bdc6-41bb-8c31-2e08c8a520d5"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzItMy0xLTEtNDAyODM_510e8941-b7f8-4fb0-bdd5-1cefa8b8a47a"
      unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzctMS0xLTEtNDAyODM_858ec624-0b8f-4cbd-bbdf-8429d0ae42a4"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzctMy0xLTEtNDAyODM_ece2b2bd-416e-40b5-841c-72c505c4922d"
      unitRef="usd">3000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzgtMS0xLTEtNDAyODM_a9775bc0-783f-4ee3-b4b1-fb8bb59bc05d"
      unitRef="usd">-879000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzgtMy0xLTEtNDAyODM_eef26a8c-d9cf-40bf-a392-7c982bdc07de"
      unitRef="usd">55457000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzktMS0xLTEtNDAyODM_09902fee-4652-4e6f-901a-638227b626eb"
      unitRef="usd">70934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba8291885aaa4357958e19254cd61ce3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfMzktMy0xLTEtNDAyODM_007fe05d-9b53-4795-9293-965a9921a2dd"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDAtMS0xLTEtNDAyODM_0adf15b6-7cb7-4b7b-8416-e9dc72d7780f"
      unitRef="usd">70055000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDAtMy0xLTEtNDAyODM_c08bc916-619b-4780-a9d9-c50ad7c7c2ee"
      unitRef="usd">92155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDEtMS0xLTEtNDAyODM_30ae8286-70f0-4723-ade7-34bc46d48ec8"
      unitRef="usd">67552000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDEtMy0xLTEtNDAyODM_54326313-f36e-4cf5-ba88-6310a47e9e79"
      unitRef="usd">89652000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDItMS0xLTEtNDAyODM_25d00985-55bc-471d-8fba-62ec6814304d"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDItMy0xLTEtNDAyODM_0faba1e0-bd8f-413f-a0dd-4db708585ef4"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDMtMS0xLTEtNDAyODM_78bcbddd-613e-4215-bf84-da9dd20098bc"
      unitRef="usd">70055000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iefe6c0d87a224d0fbb1cca8f042cf3c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDMtMy0xLTEtNDAyODM_4a20396a-e5b0-4bc5-a79d-4d24c9b011f4"
      unitRef="usd">92155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <advm:RemeasurementOfOperatingLeaseRightOfUseAssets
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDYtMS0xLTEtNDAyODM_334e5848-6bc4-40b1-abbd-b62e88f4882e"
      unitRef="usd">8004000</advm:RemeasurementOfOperatingLeaseRightOfUseAssets>
    <advm:RemeasurementOfOperatingLeaseRightOfUseAssets
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDYtMy0xLTEtNDAyODM_b6bb3343-9ba4-48ec-8dfc-e0f28da2c48d"
      unitRef="usd">0</advm:RemeasurementOfOperatingLeaseRightOfUseAssets>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDctMS0xLTEtNDAyODM_33d81230-2e4b-4a6d-bb14-59557dd6cfae"
      unitRef="usd">17000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8yOC9mcmFnOmM0Y2I3YmMxYTY5ZjRhYTY4OTdkOTEwNWI0YmFhZDJmL3RhYmxlOjE3YmRhODdhNjM5MTRmZmFhNjViMjg2MzIyMDE4OTg4L3RhYmxlcmFuZ2U6MTdiZGE4N2E2MzkxNGZmYWE2NWIyODYzMjIwMTg5ODhfNDctMy0xLTEtNDAyODM_9c208e20-7fcb-4b4f-890e-da9d2b446cc5"
      unitRef="usd">2616000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfMjU4MQ_07a1f4ae-6d85-494f-a723-78487b845f5a">Organization and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or &#x201c;Adverum&#x201d;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $831.7 million as of March&#160;31, 2023. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of March&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $164.3 million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2022 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfNjg2_add11bd8-bae9-4e5f-aee4-50dac2d9cce9"
      unitRef="usd">-831700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfOTM1_3df1e74c-8b45-4732-a8b1-2e5275fdd800"
      unitRef="usd">164300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNC9mcmFnOmNmMzAzMjE5ZTRjMzQ5YzQ4OTMyZTFlNmU5MDE5YjFiL3RleHRyZWdpb246Y2YzMDMyMTllNGMzNDljNDg5MzJlMWU2ZTkwMTliMWJfMjU4MA_0850f085-df60-435b-82ae-61c7a835089b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2022 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfMjI1MA_2d46ad78-b5b6-494d-b84d-779ac7b43ae8">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Interest Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable related to the Company&#x2019;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#x2019;s condensed consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January&#160;1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfMjI1MQ_55ed0592-ef58-4795-b631-78c99510aa6e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfNDM5ODA0NjUyMDc2Nw_3605dc97-662f-4f5b-9b95-bb18f1c8e2c0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Interest Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable related to the Company&#x2019;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#x2019;s condensed consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF8zNy9mcmFnOjkzZWVjNDA4NmNjNTRkMmU5Y2ZlOTA4NjE0Y2E0ODU5L3RleHRyZWdpb246OTNlZWM0MDg2Y2M1NGQyZTljZmU5MDg2MTRjYTQ4NTlfMjI1Mw_e7b14af5-d3e4-41c5-91e0-d911c985975f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January&#160;1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfMzEwNQ_38b585a6-a7d3-4f6c-80f6-9934e9420915">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, all marketable securities have a remaining maturity of less than one year. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2023 and December&#160;31, 2022 was $105.9&#160;million and $155.5&#160;million, respectively, which are highly liquid funds with high credit ratings that have final maturity of less than two years from date of purchase. The Company has not recorded an allowance for credit losses as of March&#160;31, 2023 and December&#160;31, 2022 related to these securities. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not recorded any impairment charges on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfMzEwNg_a894b043-a6a9-4a3d-8d23-dadb6cef430c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b4e308e31564406905c98313e33a603_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC0xLTEtMS00MDI4Mw_fc6200ee-3e21-40e4-b231-bddb8c209fa5"
      unitRef="usd">10984000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b4e308e31564406905c98313e33a603_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC0zLTEtMS00MDI4Mw_af3988ce-37e0-4fb2-8702-c5915184c082"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b4e308e31564406905c98313e33a603_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC01LTEtMS00MDI4Mw_13043dc7-f020-42f3-ae24-0b9a533fd507"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b4e308e31564406905c98313e33a603_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNC03LTEtMS00MDI4Mw_2b763d7a-af60-41ec-911f-68ad6b752f86"
      unitRef="usd">10984000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0xLTEtMS00NDEwOQ_581d82b0-a6d6-4527-b33a-16af19e6a332"
      unitRef="usd">72594000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0zLTEtMS00NDEwOQ_a303fd43-ee33-4a89-b63f-e8c22ed68698"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi01LTEtMS00NDEwOQ_350e10c1-f766-44a5-b51e-2e9cae45d869"
      unitRef="usd">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i369a173705184a7cab09ad2a6180ed79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi03LTEtMS00NDEwOQ_246781f9-4388-4e12-bc91-c06cf99f6106"
      unitRef="usd">72529000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0xLTEtMS00MDI4Mw_bb50a32f-27cb-466e-b036-9cc39b58ee03"
      unitRef="usd">71949000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi0zLTEtMS00MDI4Mw_d9ec78b1-bc16-4961-ad34-4168722d9764"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi01LTEtMS00MDI4Mw_7a2bc0c6-2dfd-499c-909f-ea9f70a7fe00"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbf7996366cc460d899c0a0ab6b1917b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfNi03LTEtMS00MDI4Mw_23995e3b-ae89-4bb3-a67d-91e5c03f354b"
      unitRef="usd">71655000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifecee66b5209450f86b53dd83c818354_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC0xLTEtMS00MDI4Mw_32d35355-fbb2-40ea-acb8-425fbbd08b7e"
      unitRef="usd">2059000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifecee66b5209450f86b53dd83c818354_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC0zLTEtMS00MDI4Mw_2bcb15f2-7045-4a3d-af5e-98e95f8a9968"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifecee66b5209450f86b53dd83c818354_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC01LTEtMS00MDI4Mw_b277adac-3900-4a4b-a7cd-e60bb4c6ebe2"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifecee66b5209450f86b53dd83c818354_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOC03LTEtMS00MDI4Mw_39fd93bb-b2fa-48b5-9e97-9c455023b446"
      unitRef="usd">2052000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS0xLTEtMS00MDI4Mw_c8389c5b-a8b2-41e2-874e-e6ccc5d372c3"
      unitRef="usd">157586000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS0zLTEtMS00MDI4Mw_48463433-d747-42e2-a8bd-053c73bb8a0f"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS01LTEtMS00MDI4Mw_da52d604-8b20-49e6-973a-daa8765f0397"
      unitRef="usd">373000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i230f68b10a814c8f895274e0ac72fafe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfOS03LTEtMS00MDI4Mw_79e881ea-f07b-420e-bc87-f375f305f052"
      unitRef="usd">157220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtMS0xLTEtNDAyODM_9951d162-13c5-4728-a3be-6f4c913621a9"
      unitRef="usd">60485000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtMy0xLTEtNDAyODM_baa83f2a-69c7-41b4-b1a2-c074cbe427f4"
      unitRef="usd">6000</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtNS0xLTEtNDAyODM_52e66c0b-87fe-4cda-9d1c-b81ab9213768"
      unitRef="usd">4000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTAtNy0xLTEtNDAyODM_8f46306a-b53d-4f23-a3b6-77fe50fc1a5a"
      unitRef="usd">60487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtMS0xLTEtNDAyODM_da4aed9b-8987-4812-9e77-55d8465c63d3"
      unitRef="usd">97101000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtMy0xLTEtNDAyODM_c68e28f7-80d3-4bd0-af9f-b49afabda10b"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtNS0xLTEtNDAyODM_ddaee408-6c3b-4e1e-82dc-41d4b1dd2bfd"
      unitRef="usd">369000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOmNmOWMwOWZhMGY2MTQ4ZDdiNjQ1ZTlmZmNjYWUyZDcyL3RhYmxlcmFuZ2U6Y2Y5YzA5ZmEwZjYxNDhkN2I2NDVlOWZmY2NhZTJkNzJfMTEtNy0xLTEtNDAyODM_34f083e7-5bc3-4b59-95e7-c0e1ab2ae4b5"
      unitRef="usd">96733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC0xLTEtMS00MDI4Mw_73579a34-c38b-4bba-ba88-c6a7495c535d"
      unitRef="usd">10235000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC0zLTEtMS00MDI4Mw_a0429e28-cc0e-4f64-b2d2-a0e5bf14d340"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC01LTEtMS00MDI4Mw_5114c942-a6bb-4249-bd95-1da47b6c0538"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7a62a1f62c14a66b61b2e95c77e7922_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNC03LTEtMS00MDI4Mw_d497b8b0-6195-4b2e-b88c-88a1f813f037"
      unitRef="usd">10235000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0xLTEtMS00NDEyMQ_c081f900-dd62-423d-88d5-040d1340d734"
      unitRef="usd">102722000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0zLTEtMS00NDEyMQ_d5ba3396-fbf5-4b08-a65f-e5093412f080"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi01LTEtMS00NDEyMQ_676516b1-eb03-4c1e-894a-f642566e7b9c"
      unitRef="usd">246000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic1730a9dcc0e4334888e861a0228a1b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi03LTEtMS00NDEyMQ_7133a684-acbb-408e-9cbb-acd8c501417a"
      unitRef="usd">102476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if84cb988cff74c13804946bc088788c7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0xLTEtMS00MDI4Mw_e58d54ed-af0d-40b7-a298-1c9a725bd3b8"
      unitRef="usd">59487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if84cb988cff74c13804946bc088788c7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi0zLTEtMS00MDI4Mw_34d26304-0133-4baa-baa6-8386aa8f5c7f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if84cb988cff74c13804946bc088788c7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi01LTEtMS00MDI4Mw_5e5beed3-c25a-4ef1-a803-045b9b3add73"
      unitRef="usd">824000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if84cb988cff74c13804946bc088788c7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfNi03LTEtMS00MDI4Mw_a9a1fda1-903c-4c03-82b5-723708304d11"
      unitRef="usd">58663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC0xLTEtMS00MDI4Mw_3bb64711-fe41-44cc-bf03-337f507fd40b"
      unitRef="usd">2059000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC0zLTEtMS00MDI4Mw_310e3da5-77f5-454f-95c6-7a47a2eb69bb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC01LTEtMS00MDI4Mw_03899bb6-a44e-461d-89b5-64e79dd0ac4f"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie71a70a3d2404129bd447bda21043c37_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfOC03LTEtMS00MDI4Mw_d190a660-a275-4780-958b-b4aea64620be"
      unitRef="usd">2024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtMS0xLTEtNDAyODM_7aded149-c1e2-4dfb-ad3e-304ca4ae9ef5"
      unitRef="usd">174503000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtMy0xLTEtNDAyODM_f373b5fd-7c3c-4752-a99e-583bde9a9b35"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtNS0xLTEtNDAyODM_bf340ffc-d615-47cd-8eef-fdaec7a9610e"
      unitRef="usd">1105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa47672f93c844228fcf48e2ea805f97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTAtNy0xLTEtNDAyODM_ffda041b-3995-4863-a693-8e52ad3f71c0"
      unitRef="usd">173398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtMS0xLTEtNDAyODM_9d188e53-8eeb-4ded-ac66-fd61775d453a"
      unitRef="usd">56256000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtMy0xLTEtNDAyODM_1e07e0fd-5bc7-4aee-8568-ca5b2141ed5c"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtNS0xLTEtNDAyODM_00b6f841-12b7-4618-a4e4-f0ad0424d41f"
      unitRef="usd">16000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTEtNy0xLTEtNDAyODM_23df0a2c-95f9-4e17-bc93-0ba022b68c99"
      unitRef="usd">56240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItMS0xLTEtNDAyODM_7659d5bb-f08b-4d1d-a6a4-1192c469ff06"
      unitRef="usd">118247000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItMy0xLTEtNDAyODM_a7e09124-605e-4cb5-85d8-080d896b441a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItNS0xLTEtNDAyODM_6aa55ef9-8806-437a-b242-2d654a448d54"
      unitRef="usd">1089000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RhYmxlOjkzODMyYmJmZTNmNTQ1MDM5OWYyM2VjZDgxZTdjNjg0L3RhYmxlcmFuZ2U6OTM4MzJiYmZlM2Y1NDUwMzk5ZjIzZWNkODFlN2M2ODRfMTItNy0xLTEtNDAyODM_6397fa18-7a1b-45a9-bcd1-1f122c07c2c9"
      unitRef="usd">117158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfNDM5ODA0NjUyNDc2MA_7db8db9b-c68f-4cab-99e5-68d8e00f3d9f"
      unitRef="usd">105900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80My9mcmFnOjM4NTg4MTJjYzMzYjQ4ZDliMDQzZTNlYzE2MmEyMjJhL3RleHRyZWdpb246Mzg1ODgxMmNjMzNiNDhkOWIwNDNlM2VjMTYyYTIyMmFfNDM5ODA0NjUyNDc3Ng_a675a0a6-bfe7-4383-abbb-4085bf31732b"
      unitRef="usd">155500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF82MS9mcmFnOmU1ODg5N2ExZTRiOTQ2ZWZhZjM0ZGExYzljMDk5NWEwL3RleHRyZWdpb246ZTU4ODk3YTFlNGI5NDZlZmFmMzRkYTFjOWMwOTk1YTBfMTM5Mw_044057c5-3a76-46c9-8d07-21d820e57e2b">License Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lexeo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#x201c;Lexeo&#x201d;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, Lexeo notified the Company that it achieved the first development milestone; accordingly the Company is eligible to receive additional payments. Therefore, the Company recognized $3.5&#160;million of license revenue during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8efd9f62836f463e824a62629a695c2d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF82MS9mcmFnOmU1ODg5N2ExZTRiOTQ2ZWZhZjM0ZGExYzljMDk5NWEwL3RleHRyZWdpb246ZTU4ODk3YTFlNGI5NDZlZmFmMzRkYTFjOWMwOTk1YTBfNDM5ODA0NjUxODMxOQ_4752d1b6-81c1-4656-86b2-867c65fcc187"
      unitRef="usd">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfMTA3NQ_bcece813-efe9-4ea1-81ee-6bd984623f5c">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redwood City, California&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease for facilities in Redwood City, California. Related to this lease, the Company provided the landlord with a letter of credit in the amount of $2.5&#160;million, which is classified as restricted cash under long term assets on the Company's condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company entered into an amendment to accelerate the expiration of one of its Redwood City premises under the existing lease from December 31, 2031 to September 30, 2023. Concurrently, the Company entered into an agreement for additional tenant improvement allowance towards its other Redwood City premises. As a result of the modification the Company revalued the lease liability based on the new and remaining lease terms, which resulted in a reduction to the lease liability of $8.3&#160;million, and recognized the remeasurement to the lease liabilities as an adjustment to the right-of-use asset. The estimated value of non-cash consideration, composed primarily of leasehold improvements and furniture and fixtures, was $14.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Durham, North Carolina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, the Company has an operating lease agreement for a building in Durham, North Carolina (&#x201c;NC Premises&#x201d;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each. In April 2023, the Company entered into an amendment to reduce the rent payments for the NC Premises, which will be effective as of May 1, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the NC Premises through October 2037, the remainder of the lease term. In line with the amendment to the NC Premises' lease, sublease rent payments were correspondingly reduced. Sublease income for operating leases is recognized on a cash basis over the lease term based on assessment of probability of collection. Sublease income were $1.4&#160;million and $1.7&#160;million for the three months ended March 31, 2023 and 2022, respectively, and is classified as a reduction of rent expense in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payments Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="idec0ca6f1e334c53bb5d986390d410e4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ1Mg_1901b8e7-5347-4dc3-9720-d86a19fbc291"
      unitRef="usd">2500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idb3ac51c130c4ddd85a7143df0208a5a_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ2Ng_3baa7104-e321-44e5-9c2c-bce35f44721b"
      unitRef="usd">-8300000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ4MQ_b3e3009a-d5dc-4cb8-9db8-b2df677e4616"
      unitRef="usd">14900000</advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue>
    <advm:LesseeOperatingLeaseNumberOfRenewalContracts
      contextRef="ic15e5013c42c4501aecb2878f6bbe3c8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ5NQ_8c7bf22e-c4d1-470a-892e-fbb529edbabf"
      unitRef="contract">2</advm:LesseeOperatingLeaseNumberOfRenewalContracts>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="icb41c12aa72a45c0acb2793e962d957a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODUwMg_18891c96-ef2c-4f02-b712-b5761495cd7f">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:SubleaseIncome
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODk4NQ_d3aa61bd-5cb3-46ec-b8a3-834bb52f49e6"
      unitRef="usd">1400000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyOTA1Mw_0fe2c66e-731d-4994-af46-430e58cc308d"
      unitRef="usd">1700000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ1MA_40ed6503-ca4b-4a14-af2f-68563ea79811">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payments Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RleHRyZWdpb246YjQzNDU1YmZkZGJiNDZhMWJhNmFmNjBjMTM0MTg2ZjlfNDM5ODA0NjUyODQ1MA_4f686816-1d8a-4c54-bb9c-6d326b02979b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, including the impact of the NC Premises subsequent event, undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payments Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMS0xLTEtMS00MzUzMw_3d910bc2-54c9-4276-85db-f3b7a3d7c7f9"
      unitRef="usd">24118000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMS0zLTEtMS00MzUyNQ_f0f9bedd-049e-47f8-9b51-135562e99122"
      unitRef="usd">3747000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMi0xLTEtMS00MzU0Mw_2edb2bcf-6308-4d91-b53b-0f650f066de6"
      unitRef="usd">10840000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMi0zLTEtMS00MzU0Nw_c2294c2c-93fd-4a26-8e1f-f467fb55cb76"
      unitRef="usd">5002000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMy0xLTEtMS00MzU0Mw_f997e58f-b3b2-447b-a70f-23d100362826"
      unitRef="usd">11194000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfMy0zLTEtMS00MzU0Nw_97d234fd-2539-4e55-845d-4e4b5a7296d9"
      unitRef="usd">5152000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNC0xLTEtMS00MzU0Mw_814086d9-f7aa-46b5-9594-a75702b9a675"
      unitRef="usd">11560000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNC0zLTEtMS00MzU0Nw_5e968b92-3fb3-474c-bcd6-1bbccc2561df"
      unitRef="usd">5306000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNS0xLTEtMS00MzU0Mw_84f5ee8f-71ae-4360-85a3-41ecd70861eb"
      unitRef="usd">11938000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNS0zLTEtMS00MzU0Nw_7cd9cefe-cb07-41f4-be8a-b192bfa71801"
      unitRef="usd">5466000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <advm:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNi0xLTEtMS00MzU0Mw_88e8fd77-6e15-4283-b48f-e45d4cc5cc11"
      unitRef="usd">91538000</advm:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <advm:LessorOperatingLeasePaymentToBeReceivedAfterYearFour
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNi0zLTEtMS00MzU0Nw_c7a4cbb0-33e8-4de9-8369-680a51e1e911"
      unitRef="usd">63300000</advm:LessorOperatingLeasePaymentToBeReceivedAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNy0yLTEtMS00NDk1MQ_9c1e094b-6b77-4793-86b1-47586a5346d5"
      unitRef="usd">161188000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80OS9mcmFnOmI0MzQ1NWJmZGRiYjQ2YTFiYTZhZjYwYzEzNDE4NmY5L3RhYmxlOmFhZTMwZDI2YTJiYjRkNWY5MWEwNDQxOTFiNGM1YTNlL3RhYmxlcmFuZ2U6YWFlMzBkMjZhMmJiNGQ1ZjkxYTA0NDE5MWI0YzVhM2VfNy00LTEtMS00NDk1Mw_ec5d4e10-a0ff-40dc-ab91-f4c8b97ece64"
      unitRef="usd">87973000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RleHRyZWdpb246MDRjZWJhMmYxNDM4NDZmOGJkZjkwNWVlYTBkZjI0ZDBfNzM1_c33a7abc-c872-4d22-886b-34be8583557c">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RleHRyZWdpb246MDRjZWJhMmYxNDM4NDZmOGJkZjkwNWVlYTBkZjI0ZDBfNzMz_d4540bb3-bf43-43c4-ae0e-c45fe6af0a83">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee913767de5c457eb0abe869f1ccf788_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0xLTEtMS00MDI4Mw_70f7708c-48c3-4f12-9f12-3af345f556de"
      unitRef="usd">34375000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibb926656b3e1496e8ae5e68b8a88bcaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0zLTEtMS00MDI4Mw_67f79833-eba8-470e-ad74-ad21e20d6b26"
      unitRef="usd">34336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68b02a910cfa446ca03e773f9c23dfd4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNC0xLTEtMS00NTEzNg_66215cd7-0e62-4df7-95f1-ee407dd9bfd1"
      unitRef="usd">14419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i231f853a0b294f85b3d8e11f4d5f56b0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNC0zLTEtMS00NTEzNg_5b2aeb0f-ae2d-4125-a7d4-1ffc662c5ab1"
      unitRef="usd">14382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5d414f59c1bb438296e4a6a98a09a90c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0xLTEtMS00NDA1Mg_e2d1c744-9683-4709-989b-9d31a605444c"
      unitRef="usd">1325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d1325acb65c4d3ba80692faaa31ac8c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0zLTEtMS00NDA1Mg_c930f0f8-d694-4714-b03e-29e56f9fbffd"
      unitRef="usd">1325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8eb83a86ea384dff87bc2c6a80c8dc12_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0xLTEtMS00NDYwNw_51318280-e2da-4648-b638-26b235468290"
      unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i08ae0052ee0c4d30a61a5234d6eeb925_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNS0zLTEtMS00NDYwNw_cb41f67d-27e4-4df3-b7b7-4e7d61d73c98"
      unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i49c3989caf254e88ba282f8751412f5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0xLTEtMS00MDI4Mw_13e05667-8371-4639-87b1-448467f853e6"
      unitRef="usd">946000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie74324103edc4f0da546ee3853453605_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNi0zLTEtMS00MDI4Mw_a63788f6-fd9e-4c3b-8127-b92dbbfb944d"
      unitRef="usd">1010000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNy0xLTEtMS00MDI4Mw_c3b07f33-3268-47bc-8130-71773cbd01c8"
      unitRef="usd">51933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfNy0zLTEtMS00MDI4Mw_ed75998b-69bb-4141-be3c-3ba38aa59d4f"
      unitRef="usd">51921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOC0xLTEtMS00MDI4Mw_2bd6d928-8827-4f63-a304-d860b7f915d5"
      unitRef="usd">18586000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOC0zLTEtMS00MDI4Mw_52780398-fd14-4354-9918-ab2f235d9f01"
      unitRef="usd">16994000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOS0xLTEtMS00MDI4Mw_1e03808c-dbde-49bd-a591-b690439b6b78"
      unitRef="usd">33347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI3ZjdiNTNkYzE3MzQ2OGU4NzQyYTBmYWJiZGVjNDk0L3RhYmxlcmFuZ2U6YjdmN2I1M2RjMTczNDY4ZTg3NDJhMGZhYmJkZWM0OTRfOS0zLTEtMS00MDI4Mw_89a8394e-a91d-4811-8e85-54dae29153fd"
      unitRef="usd">34927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RleHRyZWdpb246MDRjZWJhMmYxNDM4NDZmOGJkZjkwNWVlYTBkZjI0ZDBfNzM0_02a1f626-5a73-4f26-8064-c6106b7443e1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0xLTEtMS00NDUwNQ_1a562356-aed9-4083-89ac-9e6942d48569"
      unitRef="usd">8475000</advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts>
    <advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0zLTEtMS00NDUwNQ_7aa33c58-68e5-40e2-870c-b7300e5a2e44"
      unitRef="usd">6854000</advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0xLTEtMS00MDI4Mw_fd0ae188-d030-4021-9ead-842debb5a18f"
      unitRef="usd">5946000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfMi0zLTEtMS00MDI4Mw_20129846-0545-4755-86c2-9fd580e19b27"
      unitRef="usd">8710000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNS0xLTEtMS00MDI4Mw_99768422-0f46-495a-b39c-d5b456101593"
      unitRef="usd">764000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNS0zLTEtMS00MDI4Mw_558b950f-ee10-45ed-bb2f-b4fdeb282efe"
      unitRef="usd">532000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0xLTEtMS00NDA5Nw_3b35760f-1821-4544-91c4-9e8420ae6fb9"
      unitRef="usd">264000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0zLTEtMS00NDA5Nw_61831003-0d22-41c2-8e0b-61ab15d80dde"
      unitRef="usd">254000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNi0xLTEtMS00MDI4Mw_f1f9da66-9dbc-41f7-a7ad-48f126999133"
      unitRef="usd">1895000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNi0zLTEtMS00MDI4Mw_be867a5f-055c-43bb-a8cf-c4471627169e"
      unitRef="usd">417000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0xLTEtMS00MDI4Mw_c8af027a-6333-437f-9cc7-a893206dfff5"
      unitRef="usd">17344000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF80Ni9mcmFnOjA0Y2ViYTJmMTQzODQ2ZjhiZGY5MDVlZWEwZGYyNGQwL3RhYmxlOmI2MTBmZDFhZGRmYzQzNmM5ZDMyZjk5N2Q4MzY5NDVmL3RhYmxlcmFuZ2U6YjYxMGZkMWFkZGZjNDM2YzlkMzJmOTk3ZDgzNjk0NWZfNy0zLTEtMS00MDI4Mw_0d633a2e-b1b6-4aac-be86-1995bd2de809"
      unitRef="usd">16767000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjgz_5dcd043b-7265-4673-9fec-26311d6c4907">Equity Incentive Awards&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjg0_af7fed9d-92a7-4cdb-bdda-f9b257bebb6c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMS0xLTEtMS00MDI4Mw_58939d2d-d6de-4fb1-85fb-01eb3694bfdb"
      unitRef="shares">19320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie2d33e9095ba4947ab6c48b484ad49f9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMS0zLTEtMS00MDI4Mw_176ec132-cefc-4725-aa87-10960c6c65d8"
      unitRef="usdPerShare">5.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMi0xLTEtMS00MDI4Mw_ba36ee67-bdec-49d7-9775-441f6518c791"
      unitRef="shares">4216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMi0zLTEtMS00MDI4Mw_89d7cad5-99cc-475a-9ea2-a04066dd9f9e"
      unitRef="usdPerShare">0.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMy0xLTEtMS00MDI4Mw_77009e83-3cc3-4efd-8cd7-512d056ed5b7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfMy0zLTEtMS00MDI4Mw_7f982c8f-b00e-4ffc-b1f1-a7c051336b52"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNC0xLTEtMS00MDI4Mw_dd9241d6-83e5-4c8d-bbba-e52d8c908f18"
      unitRef="shares">229000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNC0zLTEtMS00MDI4Mw_a4abfba3-0134-4980-b37b-f2998932af60"
      unitRef="usdPerShare">6.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNS0xLTEtMS00MDI4Mw_0e7b407a-cc35-4157-b9a0-0a4a86ebb57d"
      unitRef="shares">23307000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNS0zLTEtMS00MDI4Mw_55c15c04-f3d9-4532-9d5e-3362b59b0d50"
      unitRef="usdPerShare">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNi0xLTEtMS00MDI4Mw_58dfadd0-7c7d-4623-8b54-ae83c076855a"
      unitRef="shares">7812000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmI2Mzk2OGMwY2Y0YjQ2MDFiZmE5NDg2MjQ3MjJlNmJkL3RhYmxlcmFuZ2U6YjYzOTY4YzBjZjRiNDYwMWJmYTk0ODYyNDcyMmU2YmRfNi0zLTEtMS00MDI4Mw_d642fe22-488d-4307-87ba-69751000fede"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjgx_0cf2fd14-e500-4edd-9b09-a78d290f508a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4e5816500fc04144b5ebb1566cc9f4f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMS0xLTEtMS00MDI4Mw_e7210e2f-a481-4d30-931c-af17c50512a2"
      unitRef="shares">1693000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4e5816500fc04144b5ebb1566cc9f4f0_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMS0zLTEtMS00MDI4Mw_6fcc593d-e14a-4294-a58b-05f841e1154e"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMi0xLTEtMS00MDI4Mw_5c824d9c-e700-4c07-9d03-9b8980025f5e"
      unitRef="shares">529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMi0zLTEtMS00MDI4Mw_6e7c902f-7aec-4d5f-854b-7e8ae4020e76"
      unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMy0xLTEtMS00MDI4Mw_824ee487-27ed-4417-b284-ac30f0a6514e"
      unitRef="shares">456000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfMy0zLTEtMS00MDI4Mw_be482d62-dd0a-40df-bbdf-e4f91c64e284"
      unitRef="usdPerShare">3.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNC0xLTEtMS00MDI4Mw_93670eb5-a726-4022-a705-8c0e7566f6ca"
      unitRef="shares">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i77eba6fdf0b541be83de2f8ede67d487_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNC0zLTEtMS00MDI4Mw_9273f75d-a9d4-4c1b-b544-752dcee9fb54"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i03ee695f35b04c92841b271089b16400_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNS0xLTEtMS00MDI4Mw_149937b4-85b7-49b8-9a5d-923d7e7b7bc7"
      unitRef="shares">1738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i03ee695f35b04c92841b271089b16400_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOmJlZTJlOTUzOTc4MzQyMzNiZmYyZmExNGMzOTA5YTBhL3RhYmxlcmFuZ2U6YmVlMmU5NTM5NzgzNDIzM2JmZjJmYTE0YzM5MDlhMGFfNS0zLTEtMS00MDI4Mw_dbb18dde-f4be-4583-b8ca-25b47cc5029c"
      unitRef="usdPerShare">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RleHRyZWdpb246YjgxNmMyNjU4MTY4NDgyMTkyYzQzNTFhMWQwZGQwMWZfNjgy_ce4b9a81-39e7-41b4-9712-387f935ea5f4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifea5ef805f8c40038f3b3e1ec4ca4f7a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfMy0xLTEtMS00MDI4Mw_20097a85-eb2b-46a6-9c45-f61e2b0d2ab4"
      unitRef="usd">1381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic17577b3961e43a4b40b169a76ff83db_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfMy0zLTEtMS00MDI4Mw_d0ef155b-279e-483a-b59e-813b1f68e7a7"
      unitRef="usd">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5a6eb7c0dd44b829c120e24f1ea5e32_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNC0xLTEtMS00MDI4Mw_53191d23-90d8-4e0e-a8ac-42df129a8445"
      unitRef="usd">3182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i69031cdc433a468695993438b2b429d7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNC0zLTEtMS00MDI4Mw_57d1be4d-59e2-4618-b4ab-e28413dcef6b"
      unitRef="usd">3448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNS0xLTEtMS00MDI4Mw_12ac8c78-0869-4f24-96f3-3bf9524e35c9"
      unitRef="usd">4563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81Mi9mcmFnOmI4MTZjMjY1ODE2ODQ4MjE5MmM0MzUxYTFkMGRkMDFmL3RhYmxlOjNhZjMzZGJjZWI4NzRjYzk5MTkzZDcwMTMxOTU4NjcxL3RhYmxlcmFuZ2U6M2FmMzNkYmNlYjg3NGNjOTkxOTNkNzAxMzE5NTg2NzFfNS0zLTEtMS00MDI4Mw_a67aaf1c-678a-45a4-989b-8496be89b94b"
      unitRef="usd">5381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RleHRyZWdpb246MGNlMjkwMWE3ZmZmNDBjM2JmODU2ZjEwNDVhZTQzMzRfODM0_08e36e14-ebdb-49bc-b4e4-d6b614d27492">Net Loss per Share&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#x201c;ESPP&#x201d;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RleHRyZWdpb246MGNlMjkwMWE3ZmZmNDBjM2JmODU2ZjEwNDVhZTQzMzRfODM2_1874b195-a674-4799-a911-ffb4d0f502bb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1cc5fc2435e4ec3a7f02439a9d618fb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMi0xLTEtMS00MDI4Mw_b239bfa4-7826-4c14-aa26-604e73fd852e"
      unitRef="shares">23307000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i406b3e1f97ba43e9b9a0eba636ce617a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMi0zLTEtMS00MDI4Mw_59a38f9a-2fd8-466e-aaf5-eebe3978aa87"
      unitRef="shares">16171000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iea30e1fafcc7467796344a1b9ed739a5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMy0xLTEtMS00MDI4Mw_17b60d3c-1ae7-473c-a5f9-72943b9c76f8"
      unitRef="shares">1738000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i97678bdca6e84570bb323a2f04cf2272_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfMy0zLTEtMS00MDI4Mw_79cbb715-4334-49d4-b6f5-8654b8e03aea"
      unitRef="shares">2522000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5622823987bd4b5b9eaeed2cfac2dc62_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNC0xLTEtMS00MDI4Mw_867ff56e-9efe-4392-83e8-6a3849933d66"
      unitRef="shares">1153000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a6a763430794cf4a5b4d713e9cfcccc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNC0zLTEtMS00MDI4Mw_90d83dc4-9a59-405c-9c4c-bf9ca26a8ed6"
      unitRef="shares">887000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNi0xLTEtMS00MDI4Mw_68149ff5-6fc4-4d2f-81ef-d80b7bbe45d5"
      unitRef="shares">26198000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b74848539634879bcde0f1b19053254_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2N2I4ZTEyYzMzYzQ5OGZhOTE5YjVkYWM1MzUwNzk4L3NlYzozNjdiOGUxMmMzM2M0OThmYTkxOWI1ZGFjNTM1MDc5OF81NS9mcmFnOjBjZTI5MDFhN2ZmZjQwYzNiZjg1NmYxMDQ1YWU0MzM0L3RhYmxlOjlkMTljYTJkZjRlNTRiZjY4NTA0MGY5MWUxNTRlNGI0L3RhYmxlcmFuZ2U6OWQxOWNhMmRmNGU1NGJmNjg1MDQwZjkxZTE1NGU0YjRfNi0zLTEtMS00MDI4Mw_0b5b3679-f6fa-41cc-b331-74ee04e77f71"
      unitRef="shares">19580000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>44
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M AO/Q*>)=/JT@0H5'5IO:;4LC'6C'U2' $5+H-#ZK.ZD"&S6(IX4Z_1,JN(
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M%3074%%*)>B*V18Z5LO."Z6H*S852=O;H&I$:UW,F$KB>10!D4T(V+N&;8B
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M0N70$C:4IT[-\7*7EU+=!9'EUFQE)PYLV*L,<J-C+=Z/+D<=[PVZ&-/@(C<
MUB6;2]]Z,$>W!FE[T@E7WO73?'[12Q=79ND,J),SXKEJGOK2\-@E@7\=A;#Z
MU5552[O*Q6ET:=>M_<M7Y[UE+@"+@=<-S$(9&53F$8K4Z,AH43?P+]8.*??)
ML I7Y%D.L-U%]#:<PH[+/+U)E[;EFX]]QQIE9H&S/,3)Z()0+#-]Q*Q1S)R;
M4K#=@B.W'B!\MX)E6"P\#?&'F<[-MT/H3)G#(TZH3;#V=2?(_)!YP$9<JVTG
MDHVTZ&9>,N3O4/Z@%,B!D.I#ZCILF*WKD#GA+/*#?257V(+2^JP3NQM* ^:<
M4@5%QB=Q=WPLI?8WL+8,^3RJ>\+9J5H1.W01OE ST3[K7+8::T]]SY8SY;;\
M=%6//4IM\KF",R8K8X=NZP5"@?H7865<G9ME0KZN(8!,"!:;CFPI)ICG,\ 5
M@J"2)C=@N9(4#7\)U_E$[4#-^&@'J>%?W0C-#JV^5N=8")VE:9'PX*@<<FAF
MDW"8<GF[R';;X&[2<Y"L2(8B?=W[Z'MI&.N$)W-__?DT2$9Q0?B^QLR&U0_)
ME@M1EKC_F#BX+-4N;HMV<"FIG*&</+5MH<\9.R]]^"[K%+<OWZO$=/+TUYXG
MF2*%AE\6?:D-QGO8T,'175_*XYW;4$-^E>]\W"^0['(QZD?[:^6\W*9NEI<[
M*5IAI=$MAI;8.AD=/AL(7^YYY26Z-M^M%B[BII8?^9.3/"_ / OL]H4=])?M
MTW\!4$L#!!0    ( 'B!JU;E]%%PS08  $L1   8    >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULK5A;;]RX%?XKQ"RP:(&YCY/-^@:,T\TVBP8UXKI]*/K
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M%$#GX>-4_1V! ,!NY_DC>I^!M0-8Z*!M(W 82.K!&<..PC8E,Z6]CVRT%0N
M8X',0VY9E0); K6AT18\6VV"8H'T&E8&-IH@VD%E8=O$HJN7+8.H]A6II!^8
MG/G10HN["7=NQJ-BJ"1SINK3DRM\_ <WX+C:&W 'L9=!#H8X)5DJ#@\Z&-^
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M[5R43G746-!/\I#98KWW@<<B+$,9R19H;=^1&$& @ NKC!/NU<=AXNODM]W
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MA_-TP$SXEA5NG*[]]Z.5=DZ7_K+ T"8,">#Y6F/>:V_(0/]!\>8/4$L#!!0
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M_MZL?A9U/*=D+S7*A?]L%=<F6)Q6SINB5@:"0NKXRY_J/&PIS 8O* QKA6'
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M]+O :N(H.BE2J(O7HC24B=)"Q4H5@ <(N5'9=KE<B&!1H6D](,<W^43/E".
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M!>.U"<U/0JC!FL@)Y8ORZ Q)!=FYQ1633'&$QW "KG73:H7*V5GB"-WK)'Q
MNNJ1LC>0<OBDE=M8N%4UUM_;)\3J0"W;4[O*3@)^8N8<\C2&;)3E)_#R0ZAY
MP,O_4Z@/*)G#&FZ$Y5+;SJ"%ORZ7UADZ*'^_%GZ/7KR.[B_/A6T9QWE$M\.B
M><)H\?-/:3GZY03WXL"].(7^0V4ZB?0ZS[?@X=[0]3?N&9BJX?9;)UJZD"Z&
MWTCM.QF^R!3)N*9K:PE K\!M$%9:TO47:GT!5%:^.=05;I!CLT2SW\G@_4=%
M-KJSA&O/X [ITFVTK$$TK=%/V 1F[R OXGPR'B9Y"7=LJ0USVCR_L(&TB(MT
MZH>\RD)DG2-G+PJ>O-4KMV4&(8WS;#S\?^B,$H[.15!9B9T+9Z0JJ_"[I@B=
MZ?JW12@@:FN26Y@6)2&,TA%\T8Y)+W@E33!.XVF>AR%+*4BR9)QW3=<?RQJI
M.ERP_NDB2]9HX\0__<;[M(K'57E&DS*>3HNSD\6@#.5Q7DSZ5$VS"5QR;CKR
M<KNCQ]U25-[J,Q7*P'5GC.=W)]A22.$$2??J>*RN@SH?U.61^E#\_Z'V>\=*
M*TX'67 F8]C/ @O*+O>YJ_&)&DR?6JYM."!57(3S4<;5N(#;II7Z&9'$C0^C
MS^0X]O6JX@G5:^^-,%>$26)RXF^((!<P*0L8YQD\.BH059Q@$!S;0<N>V5(B
M9*20D:,^CVE<3<=0I)/A&+ ?R^$[2"=4L\)/RGA23N"U5R0Y>O@;-.O0WGP!
M.N7Z'G#8/730R[YQO*CW[9=*LQ;*@L05F8[.)]2P3-_2^H73;6@C2^VH*87I
MAKX"T'@%DJ^T=ON%=W#XKEC\"U!+ P04    " !X@:M6Y]4%&+P#  "G"
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MH=I%$ ?'A0>^*ZU;")?SFNUP@_9[O=8T"P>4G%<H#5<2-!:+X"Z^65VY\_[
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M/(A*^5)'TK:&6SR$N #1-30=BDSY", $N8O610@%'P<]?,]=VB;,)=FQD%'
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M >9V,@)'.\+H!6$XM361[@\UFP)(T<Q5C+1O0S?IKY%22M*I*:N;?&M!E;B
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MWGS 73Z!(-?2AG_8#+;E) +>6Z?;G3,Q:(4:GFR[.X<W#O7H.P[9SB$+O(=
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M.N3=9TZW*E36@.;74IJG@0W0W=-F_P)02P,$%     @ >(&K5H(&?*#_ @
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M' 2@6U]K)U;5WDO6RI(S^6%)GP+4+H#V"Z7L?N(.Z#XNLS]02P,$%     @
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M4S8</WU%<K8%%P>D)VOU@.B> +J;@LX5R:3W" 43(V<M78"'HGQNLR4MTIT
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M*[^>LE,&%2Y%J_RMV7[%WL\D\)5&N?@+VSXV85"VSINZ!Y."6NKN*Y[Z/.P
MQL>O -(>D/XK(.L!,7.\4Q9MS84716[-%FR()K:PB+F):'(C=:CBG;=T*PGG
MBTLA+3P(U2)<HW"M12J1=R!T!3MW9@F74@M=2J'@2CMOVR[N(YQ7E0P5B1?=
MLPKU.9RC%U*Y(PJYOYO#X<$1'(#4<"V5H@"7<T_Z@PI>]EHO.JWI*UJOA1U!
M-OX :9)F>^"SM^%S+ =X^A+.*6M#ZM(A=6GDR_Z>NKETI3(A>PZ^GR\H/?0\
M?^QSV%$>[Z<,+7OF&E'BE%%/.K0;9,7[=^.3Y,L^O_^)[(7[;'"?O<4>BO%(
M%5XH!(=E:^D-D'FJK]#0:AHH2O[&"B@K>RO=D9]&\C!I-L4XF8P^YWRS:W!/
MU&0RF@Q1G7*^\_S#Z"%I*ZD=*%P2+AE]FC"P73MW&V^:V!$+XZF_XG)-$Q!M
M"*#[I3'^>1.:;)BIQ1]02P,$%     @ >(&K5K@<="J8 @  60@  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&ULM59=;YLP%/TK%JNF5NH*@81,'4%J
MDDV-U$I5NVX/TQY<N &K8#/;A.S?SS;$35H:K5KV$OQQS_$YEXMOHH;Q1Y$#
M2+0N"RHF3BYE=>ZZ(LFAQ.*,54#5SI+Q$DLUY9DK*@XX-:"R<'W/"]T2$^K$
MD5F[X7'$:ED0"C<<B;HL,?\]A8(U$V?@;!9N299+O>#&484SN -Y7]UP-7,M
M2TI*H((PBC@L)\[%X'PVUO$FX!N!1FR-D7;RP-BCGBS2B>-I05! (C4#5H\5
MS* H-)&2\:OC=.R1&K@]WK!_,=Z5EP<L8,:*[R25^<3YZ* 4EK@NY"UK+J'S
M,])\"2N$^45-&SOR')340K*R RL%):'M$Z^[/&P!%$\_P.\ _G/ \!5 T $"
M8[159FS-L<1QQ%F#N(Y6;'I@<F/0R@VA^BW>2:YVB<+)^(HDZI4 NH45T!K0
M\1PD)L4)^H#N[^;H^.@$'2%"T=><U0+35$2N5,=JL)MT1TS;(_Q7C@C0-:,R
M%^@S32'=Q;M*KM7L;S1/_;V$UYB?H6!PBGS/#WKTS/X>[N^1$]@4!H8O>(5O
M3@3.,@X9-H7)EC:9/ZY4*%I(*,7/OKRUO,-^7OW]GHL*)S!QU <J@*_ B=^_
M&X3>IS[3!R+;2<'0IF"XC]U6$6^-]WEM"4)#H*^651R$GA>YJVT/+X.>(G:$
MC:RPT7YAL :FBA<XKJ"6)!&G:$&3/H%[B=[Z,@Y$MN,YM)[#_U2/X2%3<""R
MG12,;0K&_UJ/XY?U.'I1CWM/>:L'=^N6+H%GIGD)E+":RO;RLZNV/UZ8MO!L
M?:KZ9MOFGFC:IJNNMHQ0@0I8*DKO;*SJD+>-K)U(5IE>\,"DZBQFF*O>#UP'
MJ/TE8W(ST0?8?Q/Q'U!+ P04    " !X@:M690ZQ9@($   ?%@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6RUF&UOVS80Q[\*H15#"V31DQ^2S#90
M6RI:H!F"9-U>#'M!2V>;J$1Z)&4WP#[\2$F1+5MF[(Y]8^OA[B?>_TZD>*,M
MXU_%"D"B;WE&Q=A92;F^<UV1K"#'XIJM@:H["\9S+-4I7[IBS0&GI5.>N8'G
M#=P<$^I,1N6U!SX9L4)FA,(#1Z+(<\R?IY"Q[=CQG9<+CV2YDOJ".QFM\1*>
M0'Y9/W!UYC:4E.1 !6$4<5B,G??^7>SWM$-I\0>!K=@[1CJ4.6-?]<FG=.QX
M>D2002(U JN_#<P@RS1)C>.?&NHTS]2.^\<O] ]E\"J8.18P8]F?))6KL7/C
MH!06N,CD(]M^A#J@ON8E+!/E+]I6MKW 04DA),MK9S6"G-#J'W^KA=AS"$XY
M!+5#<. 0^B<<PMHA//<)O=JA=ZY#OW8H0W>KV$OA(BSQ9,39%G%MK6CZH%2_
M]%9Z$:H+Y4ER=9<H/SGY#$IE@=Y&(#')WJ$WB%#T^XH5 M-4C%RIGJ$MW:3F
M32M><(+GHWM&Y4J@F*:0=OC/S/ZAP=]5L34!!B\!3@,C\![S:Q3Z5RCP@A!]
M>8K0VS?ONL;U'1B4J+%R5>L=O.A\7F 85FS&1)"\AFFI%C9E$9;<\&19" %P
MA<KRN$(1B(23=?EJ__59V:)/$G+Q=U=]5.!>-UC/>W=BC1,8.VIB$\ WX$Q^
M_LD?>+]V)<4F++()BRW!6MGI-=GIF>B31Q"2DT1"BA(L5EU9J "#$J 7B\TD
MZ'OAR-WLJWN.472.4?R*42O*?A-E_Y4HTZ):3=24E.E"1!G!<Y(1^=P5<D7K
M[XWA)O2\@Y"-C[RTH&S"8DNPEM2#1NJ!4>I82*(6755/&YP5@-@"449_T<6E
MYSA!4N!8IZ)+]\&1[G[O]DCXLZPBXS O5=02K*7HL%%T:%3TJ9A7)4MHPG+H
MTLT(N'2B'';(>Z3N\.@M]8>'1K&E8;54NVE4NS&J-BU(EA*Z[)++Z'FI7#9A
MD4U8; G6DO^VD?_V1ZWZMS:S8Q,6V83%EF"M[/C>[EO=^[_K?DTX6(D/)^.S
MK"+S:"Z5SA:MK=W>/L<W:G>/:;%0G^H%5_,+^H"3D]\19M"EM6R5%EFEQ;9H
M[90$NY0$/VJZJ<FV<F23%EFEQ;9H[1SM]H&^<2,S^:W(Y\#U!R$'"EN<-7M>
M@?XU[7^G9O#%*0J//G""P^G*ZO[.%JVM^VZ'YYNW>.4[T6@N@>>=&ILA??0,
MF'=U<6;?[1F9/2^6V1*MDMG=:X3EP)=E!U*H,BVHK%I&S=6FR_F^[.T=7)_Y
M=U'5J]QAJM;I/>9+0H7:D"X4TKL>JI+D53>R.I%L7;;;YDQ*EI>'*\!J Z4-
MU/T%8_+E1#^@Z0E/_@-02P,$%     @ >(&K5BVTXSPN P  ]PH  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&ULM59K;YLP%/TK%JNF5MH*YIET"=+:
MJMJD38N:=OOLPDU !<QLD[3_?C90H(TATK1] ;_N.>?BW).[V%/VR!, @9[R
MK.!+(Q&BO#!-'B60$WY.2RCDSH:RG @Y95N3EPQ(7 ?EF6E;EF_F)"V,<%&O
MK5BXH)7(T@)6#/$JSPE[OH2,[I<&-EX6;M-M(M2"&2Y*LH4UB/MRQ>3,[%#B
M-(>"I[1 ##9+XS.^N,2!"JA/_$QASP=CI%)YH/113;[&2\-2BB"#2"@((E\[
MN((L4TA2Q^\6U.@X5>!P_()^4R<ODWD@'*YH]BN-1;(T9@:*84.J3-S2_1=H
M$_(47D0S7C_1OCUK&2BJN*!Y&RP5Y&G1O,E3^R$& ;8]$F"W 7:MNR&J55X3
M0<(%HWO$U&F)I@9UJG6T%)<6ZE;6@LG=5,:)\!O(E#CZB-;RON,J T0WZ+Z(
M4Q[1JA 0HYM*5 Q0?1"MR+.\$L%15<3 T(\2&!%IL6VW3Z]!D#0[0R<H+=!=
M0BM.BI@O3"&E*D(S:F5=-K+L$5G?"3M'#OZ ;,MVT/WZ&IV>G+V&,66F7;IV
MEZY=XSHCN&\$:Y4U"*X>057)!2])!$M#E@$'M@,C?/\.^]:G"7U.I\^90@_K
M=$\9J'I2*N4#4$X+D? SG=8&S:_15 'N0MO%>+8P=QH1;B?"/2;"U9$U4=Z
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M<8ZB;05A"K*K8487,,,0Q^TL<<,27\4"+R!2*F^@B2]H.F09-RCCJU"TYVZ
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MF^LF'829H-]O.%?'@2G0M/W)OU!+ P04    " !X@:M6,0+?&% #  #F"@
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M1=TY>' >!9MS*MC^/C+[#5!+ P04    " !X@:M6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( 'B!JU9WT.B,&0,
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MB\)ECR5VV*NR84S)HTO0#DJ&>\XH62)'R3X+)70!+(+D!"3?">0TX."E$>2
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M+W=O<FMB;V]K+GAM;"YR96QSS=C-CH(P%(;A6R&] ,LY5=2)N)J-VXDW0+"
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( 'B!JU89HHD8[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( 'B!
MJU:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ >(&K5N:4IZC.!0  RQX  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( 'B!
MJU9+R4L+0@4  , 5   8              " @1$.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !X@:M6E>]8N>,$  !R$@  &
M        @(&)$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ >(&K5F/9HJIG!@  TRH  !@              ("!HA@  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( 'B!JU92D-7"L@8  $8=   8
M              " @3\?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !X@:M6A0.<?DP&  !X#P  &               @($G)@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ >(&K5N7T47#-!@
M2Q$  !@              ("!J2P  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( 'B!JU;ISN\NKP<  %P4   8              " @:PS
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !X@:M6<$>C
M"^4#  !V"   &               @(&1.P  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ >(&K5LZ)021&!@  TPX  !D
M ("!K#\  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !X
M@:M6K];K"K0#  !C"   &0              @($I1@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( 'B!JU;GU048O ,  *<(   9
M          " @11*  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#
M%     @ >(&K5@JS4-BG P  <@@  !D              ("!!TX  'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !X@:M6"$-EC)@(  "_
M%P  &0              @('E40  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;%!+ 0(4 Q0    ( 'B!JU9>N-O;W ,  &8)   9              " @;1:
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ >(&K5H;1
M6XLF P  ,PD  !D              ("!QUX  'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6Q02P$"% ,4    " !X@:M6LS;]SM #  #;"   &0
M    @($D8@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M 'B!JU:4C<CPX0,  +,)   9              " @2MF  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ >(&K5H(&?*#_ @  : 8  !D
M             ("!0VH  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !X@:M6UX%1&( "   N!@  &0              @(%Y;0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( 'B!JU8!*J<K!P8
M % A   9              " @3!P  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ >(&K5LN(^UM9 @  7P4  !D              ("!
M;G8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !X@:M6
MN!QT*I@"  !9"   &0              @('^>   >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'B!JU9E#K%F @0  !\6   9
M      " @<U[  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ >(&K5BVTXSPN P  ]PH  !D              ("!!H   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !X@:M6OCV/: $$   3%
M&0              @(%K@P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( 'B!JU;Y  :_) ,  +<(   9              " @:.'  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ >(&K5LD.^HYM
M P   @P  !D              ("!_HH  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !X@:M6,0+?&% #  #F"@  &0
M@(&BC@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( 'B!
MJU;OX)V/. ,  ,0+   9              " @2F2  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ >(&K5D?CS'AY P  %P\  !D
M         ("!F)4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !X@:M6_)F0"P\#   L$0  #0              @ %(F0  >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( 'B!JU:7BKL<P    !,"   +
M  "  8*<  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'B!JU9WT.B,&0,  #D5
M   /              "  6N=  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !X@:M6CWJT85T!   D$P  &@              @ &QH   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !X@:M6[UO*"88!  #5$P
M$P              @ %&H@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..)P G (@*  #]HP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>69</ContextCount>
  <ElementCount>170</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - License Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LicenseRevenue</Role>
      <ShortName>License Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Leases</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/EquityIncentiveAwards</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Organization and Basis of Presentation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentationDetail</Role>
      <ShortName>Organization and Basis of Presentation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - License Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LicenseRevenueDetail</Role>
      <ShortName>License Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/LicenseRevenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesDetail</Role>
      <ShortName>Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/LeasesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Leases - Schedule of Undiscounted Future Lease Payments under Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail</Role>
      <ShortName>Leases - Schedule of Undiscounted Future Lease Payments under Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails</Role>
      <ShortName>Equity Incentive Awards - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="advm-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="advm-20230331.htm">advm-20230331.htm</File>
    <File>advm-20230331.xsd</File>
    <File>advm-20230331_cal.xml</File>
    <File>advm-20230331_def.xml</File>
    <File>advm-20230331_lab.xml</File>
    <File>advm-20230331_pre.xml</File>
    <File>advm-20230331ex103.htm</File>
    <File>advm-20230331ex311.htm</File>
    <File>advm-20230331ex312.htm</File>
    <File>advm-20230331ex321.htm</File>
    <File>advm-20230331ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="322">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "advm-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 322,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 69,
   "dts": {
    "calculationLink": {
     "local": [
      "advm-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "advm-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "advm-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 258,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 11,
   "keyStandard": 159,
   "memberCustom": 2,
   "memberStandard": 22,
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.adverum.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.adverum.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Equity Incentive Awards",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.adverum.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.adverum.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "14",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.adverum.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Incentive Awards (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Organization and Basis of Presentation (Detail)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail",
     "shortName": "Organization and Basis of Presentation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - License Revenue (Detail)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.adverum.com/role/LicenseRevenueDetail",
     "shortName": "License Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8efd9f62836f463e824a62629a695c2d_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Leases (Detail)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.adverum.com/role/LeasesDetail",
     "shortName": "Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "idb3ac51c130c4ddd85a7143df0208a5a_D20230301-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Leases - Schedule of Undiscounted Future Lease Payments under Operating Lease (Detail)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail",
     "shortName": "Leases - Schedule of Undiscounted Future Lease Payments under Operating Lease (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i8f60ec22fbb74a92a9a0d6ce8dd11138_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "ie2d33e9095ba4947ab6c48b484ad49f9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails",
     "shortName": "Equity Incentive Awards - Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "ie2d33e9095ba4947ab6c48b484ad49f9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i4e5816500fc04144b5ebb1566cc9f4f0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails",
     "shortName": "Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i4e5816500fc04144b5ebb1566cc9f4f0_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails",
     "shortName": "Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i31b77532d5ff487084fcf175a884a30d_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i31b77532d5ff487084fcf175a884a30d_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000006 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "6",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - License Revenue",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.adverum.com/role/LicenseRevenue",
     "shortName": "License Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20230331.htm",
      "contextRef": "i22811799817548dcb6723a8ef7f36b9e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical clinical and development process costs.",
        "label": "Accrued Nonclinical, Clinical, And Development Process Costs",
        "terseLabel": "Accrued nonclinical, clinical and process development costs"
       }
      }
     },
     "localname": "AccruedNonclinicalClinicalAndDevelopmentProcessCosts",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent amortized cost.",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "negatedTotalLabel": "Less: cash equivalents, amortized cost basis"
       }
      }
     },
     "localname": "CashAndCashEquivalentAmortizedCost",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized gain.",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "negatedTerseLabel": "Less: cash equivalents, unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized loss.",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "terseLabel": "Less: cash equivalents, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "terseLabel": "Total cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease liabilities and lease incentive receivables.",
        "label": "Increase (Decrease) In Lease Liabilities And Lease Incentive Receivable",
        "terseLabel": "Lease liability and lease incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseNumberOfRenewalContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "label": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "terseLabel": "Number of renewal contracts"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalContracts",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "advm_LessorOperatingLeasePaymentToBeReceivedAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Payment to be Received, after Year Four",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFour",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LexeoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexeo Therapeutics, Inc",
        "label": "Lexeo Therapeutics, Inc [Member]",
        "terseLabel": "Lexeo Therapeutics, Inc"
       }
      }
     },
     "localname": "LexeoTherapeuticsIncMember",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/LicenseRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Non-cash Consideration, Leasehold Improvements, Value",
        "label": "Operating Lease, Non-cash Consideration, Leasehold Improvements, Value",
        "terseLabel": "Estimated value of non-cash consideration"
       }
      }
     },
     "localname": "OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_RemeasurementOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement Of Operating Lease Right Of Use Assets",
        "label": "Remeasurement Of Operating Lease Right Of Use Assets",
        "terseLabel": "Remeasurement of operating lease right-of-use assets"
       }
      }
     },
     "localname": "RemeasurementOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.adverum.com/20230331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r203",
      "r206",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/LicenseRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r203",
      "r206",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/LicenseRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net (accretion) amortization of (discount) premium on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r105"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r108",
      "r326",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r15",
      "r18",
      "r76",
      "r289",
      "r330",
      "r331",
      "r369",
      "r370",
      "r371",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss)/Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r376",
      "r377",
      "r378",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r69",
      "r70",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r89",
      "r107",
      "r123",
      "r160",
      "r163",
      "r167",
      "r180",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r265",
      "r267",
      "r275",
      "r358",
      "r383",
      "r384",
      "r392"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r101",
      "r109",
      "r123",
      "r180",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r265",
      "r267",
      "r275",
      "r358",
      "r383",
      "r384",
      "r392"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r176",
      "r187"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r46",
      "r175",
      "r187",
      "r321"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets in accounts payable, accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r103",
      "r337"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "negatedTerseLabel": "Less: cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r34",
      "r38"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash and cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r29",
      "r78"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r19",
      "r111",
      "r113",
      "r117",
      "r322",
      "r327"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r179",
      "r188",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "verboseLabel": "Marketable securities in an unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r32",
      "r55"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LicenseRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r218",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LicenseRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r118",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r140",
      "r142",
      "r144",
      "r145",
      "r146",
      "r150",
      "r271",
      "r272",
      "r323",
      "r328",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share \u2014 basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r118",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r142",
      "r144",
      "r145",
      "r146",
      "r150",
      "r271",
      "r272",
      "r323",
      "r328",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share \u2014 diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r60",
      "r99",
      "r114",
      "r115",
      "r116",
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r139",
      "r152",
      "r181",
      "r208",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r289",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r204",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r273",
      "r293",
      "r294",
      "r295",
      "r345",
      "r346",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r204",
      "r221",
      "r226",
      "r273",
      "r293",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r204",
      "r221",
      "r226",
      "r273",
      "r294",
      "r345",
      "r346",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r204",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r293",
      "r294",
      "r295",
      "r345",
      "r346",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r205",
      "r207",
      "r269",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r344",
      "r379",
      "r380",
      "r381",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r20",
      "r79",
      "r84",
      "r94",
      "r160",
      "r162",
      "r166",
      "r168",
      "r324",
      "r343"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r124",
      "r138",
      "r139",
      "r159",
      "r260",
      "r263",
      "r264",
      "r329"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r372",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "negatedTerseLabel": "Reduction in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Future Lease Payments under Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payments to be Received, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sublease Payments Receivable"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Future Sublease Payments Receivable under Operating Lease"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining nine months)"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r123",
      "r180",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r266",
      "r267",
      "r268",
      "r275",
      "r342",
      "r383",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r81",
      "r91",
      "r358",
      "r375",
      "r382",
      "r387"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r102",
      "r123",
      "r180",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r266",
      "r267",
      "r268",
      "r275",
      "r358",
      "r383",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing Facility"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain/(loss) on marketable securities",
        "verboseLabel": "Unrealized loss on marketable securities, net"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r33",
      "r85",
      "r93",
      "r100",
      "r110",
      "r112",
      "r116",
      "r123",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r143",
      "r160",
      "r162",
      "r166",
      "r168",
      "r180",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r272",
      "r275",
      "r343",
      "r383"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r160",
      "r162",
      "r166",
      "r168",
      "r343"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofUndiscountedFutureLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Deposit and other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r26",
      "r45",
      "r119"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r45",
      "r119",
      "r120"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r67"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r104"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r58",
      "r92",
      "r325",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r72",
      "r95",
      "r394"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r336",
      "r365",
      "r374"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails",
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r61",
      "r90",
      "r333",
      "r335",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r99",
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r139",
      "r181",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r270",
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r157",
      "r158",
      "r161",
      "r164",
      "r165",
      "r169",
      "r170",
      "r171",
      "r217",
      "r218",
      "r320"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/LicenseRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "License Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LicenseRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Grant- Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r62",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r82",
      "r83",
      "r88",
      "r366"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r39",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r60",
      "r99",
      "r114",
      "r115",
      "r116",
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r139",
      "r152",
      "r181",
      "r208",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r289",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r152",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Common stock issued upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r44",
      "r358",
      "r375",
      "r382",
      "r387"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r285",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "State income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accrued Interest Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r205",
      "r207",
      "r269",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r379",
      "r380",
      "r381",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted-average common shares used to compute net loss per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute net loss per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r362": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r363": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r364": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001628280-23-017564-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-017564-xbrl.zip
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M=LKFD[?I^<9?\->PNTFLA2/4,&:X%(F21.K0*A.R$%A'_/!L<7M/KW_5 @8
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MY>ERX8^<\(3QI8;Y.&.#E+<."XGA7V BEZ-4,N@/,K<6P"3:RA]# ?P2:(#
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M2>0MRJ-^^92\EW3;6OX2BFEMU8QF6V_G9*D :WJ =;?O2PS*18<R04[ZG6,
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M*(D,3Y(XE):2E0V\1N\F0KP\AO]TR'SC,K)*^57*[V'(>Z$35D'>C"%OLG=
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MK_!+\*LOT]>#_I'M5M]K5+F8#O"/G6[X"[AL7@C/_SQ(Y_/C8GKL5@/?[N6
MZ2&TZ;=VSW]Y7/[Z??^<O^[#W3O &U^)CX=O/^_!=^!;P#WWSCX>OF[O=]X+
MX*+PS=<5<-%V_+]OSS[^$TX<Y?(#A9;M[IWM';;;^[_O?=_?;7_>WST2>]__
M:._]\YY^//P"7+1=[?WS1]K[_)[O_?T)*TL2MQ')H 7B!NBGS3LG%;@:,/VX
M2,(VCDC5'<6P,ZP/OS(I4B$X52YGA&A#::1!QN0CR"QMM"(X!2=9V?HC,#G3
MDJJC:K_9037(8#XMIPF['<^7&7"':^-&-*^I975C0W[*+M\KY/[0%K3^-3R.
MK1P?IOC7EPTIK?]%?FWU^I,+XU>,+_R[=6IS1!,,[$FVL8"'5;>U"P3SU/;!
M8G9;?XS:9RVB-EL48UF//PS^<;3A?T>V#P#8//$VAM->#Y"U&IYMMEX"0H+7
MUZWL5NL0VC1N3,M6G1J)XR!S_VIPW#J*W=C*45)[ I<'+=OJPDC!Y6ZP_3JM
MVN=VP,ORI5''Q7[^XS&,"33KI!^;A*Y6SX_:MM\*U2 O60PN?S;$K['=.QE<
M_MI)OQ=&/M=. ?\UFX(\#D .<@45:..XFDHKC/HU>8@I@3_CSYHZZ?!DYON#
M$305I%3'?6$V#O+D@O;9\5?B")R@_*IAK+J :;>@S8\WN::'[!AD <Y,/6+-
MM,A_A>&.H,=-M<8\V0:VH57CL1RT!E6NWUC547(?ZV)BEV617YQCY/TJP@T!
MQ#UL 93FB/D5S];S[=CFKV=':]0!*>?&A C"J.H$CO]S_QG8XMJSS-_&1ORO
M;#\?<CK8N6CC;M/$VX4_Y)J9C_W/1_23S:/N@D;.1H-X%& \8N1(8& I-!CO
M8]YIR\C6?)BU!?._74^0VA+LV;X_;O@H(QFJ*+L\[?*4R_,3%+O*4:K)G&OF
MU]<(\_"H]JGK">EG:@)?) E=5%/*7Z[RYH\C\ #K1:$TZM?K/=DJY?;4+Q]C
M3YUN=/'P5FOGNG9OUHIUH2[-/I/-JW>C#(Y[_2$"%.Z,\_-J>O)P:G%C2BZP
MJ7>YC8?0Q#<7+2Q:<956P/O()Q82B8I[I!T'2J4815:[7.M34"52"!IC(,B2
M;\WO"YMHQ6;K]+B""3@]DUQL5S 7!ZU3N ?^!;8K6[0J-F5UTRA;]CQWFKD.
ME+BQNL,Z,0[N.8UM4(\.3)SCP84%R(8SS[?IVKWP]T%<,-8U9P'OE_[7'/(@
M[33KN*#9?X$#X,^:GVM-ZG<^82UP@A\H "X@SH1#FF:.3[RR&KQ';=PLJ=<N
M&4:3<B 83J4P(N<O$*XB\5P$/TOJ'\6KO-)Q:(T3*EJ/&4K)INI2('DT<>\7
MB20WELS%V,W,^,2.N7E^<3_4RGE:#8];[[?>;8V)71M(-%P&LI49WKDRP.-@
M):N3-O3P7V._H7[J]YV=O\X]ASH/O-<&,UDC03\;IWX\MT#Y;^\BV-JQN82[
M)U46,BAUJH8M3][_[M7+\S=GX,E<O%]UX+7@F.1&U383P*E3#7-KZT@@?*27
MDW9'[>P$^=C/= P>[PV;2#R\I\G!N!BNJ7QU>!K@+?L7W?RG/!CC3M0U%,][
MG%V$C)@7HLCO;=I1TPQHPM($5C<K,^L.7*DG+!"-*2"OIZOZ-0\H>+/M6WP$
M1GXSSX/\DMY)U1W[*#!I@;GD6S:AVZD-_*@%8]"RX?-H;*8WZ[=73=I_KPOC
M4V\(R&,%C^3%OIH333_0&)YZ3*,'A\CVS\;>6[)5_Z)9DQDRVZMKNC,EM8;8
M@0:/VLU$F[%8^:W#XWX\MU6-2W<%U1J+?GC>5%#L[-N!GU=3P7$3)Y\"*PF3
MH&&2N7'C;Z41#-H9,+X\*[*E'<^X45X3'>\*;MKL;+O6PL%Q!)+9,-==^'3V
M:B^UC&8?&Z8W-")<F-JI"7:3Q(?-U*Z-LQOEO0JQ\>>JNN!)K 4][MZT0EP]
M_7-/,S:UXS#>8CWKPLV=#<FLI-M[=7#H1H.V+,QN-I6WKY_OF>2/VB'/O7ZT
M-:+#6S^/N@VOKR%]P>D!GVPF=O/9\:HES-K8^$=YBH0)9,QJZ$Z#.V]K7,YP
M]1I:VB(8_;]SE:BUH5&[:^9WJMIP\;SM /[U;)F6P_8,69R[ODBL6ZUNK)O>
M>ZS[7774K7+TJCN<(;Q@F%>&[)Z-R>[G+]\__O-?(*D[?+^S#_>\_;('!/<#
M_=@^.(2_?7Z%/]!7^&#WO9@ENP>'^^V/_^SAO=TC^H'ND?W?_P:"W/[\L2;(
M1W0/R/.'P[_Y_F$;R.X; F27!BYM4!JY?*PS-SP@I^&'4L9ZY3BS4<^27>*4
M!](4  L(-Q2>)U$PS9T3U%/I9LGNNU&GD^T@ .Z4*%H7LFA-A/$34>R;&W.Y
M\=0K+2P6!BO/N5+::.F($-P8"_,,W[OK]7X0#](KX!2=''-=QUGW]R<A8@ 1
M4!23T$UU""<904I[8P3!ULHXYS(]GN&\&KA D'E*GXMR]:/;E\SU/3E6F3$U
M=*^YM5'5,==:Y)N-G<\TH!J>S7Q@0M0&4RP^\].._1+SZDHCD-K0V\%@U#EI
MZ''C[]3E[<8$(-OP[/IUFG3VO'31)+GG1Z<2UC?STLIXS;->E:DQY6@FK7V*
M6<R_^#PS?LPK%B5)PUD!UK1EJW605PF AQSU\A]KEVES>ECR$M&H6=Z!-YT/
MSN:8Z.2'QE[DF [E]"V8/SE[K37LYY;4R?VV#<_43DQ^8?S16%70QJH_<7/:
MT#;4KKE\\T#]Z1[X=T/[+=]>1W*'8((1M+X>CTX>JK&WLW?1E7QYIAN9@!V#
MA];KU^V]6%II-B!TH;'@@(P&8Z\$5/%+!,4!'R:;H0G[A#'*\>G9J3(UBN?A
MP\8+RM43>]UZ86SBB(-$J[X?=?+BG:]#W'XXJAW%QGWR-8L-%4R__L2IR<-^
MWI4K^-ZT*;Q?JW38MR'N=,-!'J:Q91Z\!?):?<V]; *#:V:L]G?WQ,'N#M[_
M_/X,VD#W3S\QB<'Y,0I)21/B23AD7+9>CNA$O([4XY4W7#OCO3IO<H@)IE_K
M0LZK;<,F#:\F#>^?-WP:O:Z,%GVU53O?B,"BH'K=-D0W; TN(G35()NL'!@=
MNV;5V-Q5/]S6- ;!WM7>XC4H?RD4,KABB;C=!%ERLL"W<<CB!YVOX<3UQM[D
M%$B?&XY.#B)^KYLQ&(X#:QG!;QZ6B5-[,NJ?]/(0Y-4.Z-.P2F>3XS":[9/-
MO\ZFX/]RQT[AC?7SZ8>=Z37+X/4XA)@7]^H,@QJ1Z[[D <_2R@$= .)V]3T_
M!X [^4;^1-.]'WPF![_Z.;,R-/&>O+C?'S1'>HSO;LS49GT;^"W?:]H$Y*=J
MUNPGLV*SCGQEL^7 >$_X3A8']+]71Z%F5S6;QN?&#F.W&9'NV8^:F\.@@Q[P
M@LGDK,W@S>*[P:A<'50H^==+!BYS??YU2:5^]*;<3RKUE=&*1X\^P%!.Q<#Z
MO2[\ZALO8R67@!\C/G'Z*2I'N$T"!18YXL0+9/)9M<$0XHT61HFY/,V5HWF9
MU76'[;/63NC5"YS3 ;=+DE]MUO<F)V%V8XMB(AL[>I&R/M6E=^.DR4'KMU[.
MG9PLK+[>>??;^<IJ3M.X/!(7C[T_J=>+)L_MO'M__EC^-")L\[X7R1?<?W4Q
M#F^Z YB%3;"@YI[DU];+AJG\66=ZO6CM73[XZ=+5>AGCJI<]9E+ N216:] /
M>R> RXS*Q]U[,I6$8-N#WF1F#T9N$/]W5#LF(,'03(FQ4U1U@8V!@(]&51VV
M>]&J)WE>F8(9KA$QFY?^8A#F<W\13<#F\E\)::C^>>;R>8"NINT70:VQMS0^
M;R7DI=I9WR1.N6%CRI^3$IM0VL7Z<Q.(@0%O7*7F^S.GFYW?/,7:&T^OB31=
M%SS://?NLO]64]AQG&HJ\%.'K48G.=+7.&$]H.MV,+P<9QPWL(F.G66' *;/
M>#60RD9VL5UULN?0K$+F;^:4E-R!L0;4'B>"UP(6QT[.5.^?I[9/!=M.C\&9
M&,?[:F?L9N^N3F@'?<\KJZGG1V,PF/A=^2WPUMKAO>S:Y4&TX^!6D_(][1E=
M))Y8#\.;HV'0,D#<.I3;;I^[5+%.;<Y)-+4_7"^U7Y)5SG&]N1O Z8[K*)QM
MHJ%7C-=TVVL!P6=&_GS(I[WB1E<FV9HS.?P38_KN_<0LU-L$+/"\+)0LV/-4
MUM&@":_F7(Q0I2KF"33L]W+\L4ZQL"<G_9[UQ\TWZG>/W<?I]^<LV&ZO3L*>
M+)[ESOCA@E&'6Z0DWLY!O-VJ,V>KN^K,[GW5^35,MKI>U<5NJ559;,9[Y[1Z
M#VCO$=\[_.-S_9W/?_./N^UJ;_?O[Q\/\WM?T;W.J[.]SW\<S]+JO>]'Y&#W
M"+ZW_WGO^WZUOWO\!;YUNK^[W]ZC__V\=_CA[,/AF[.]SNNT]_W5Z?[?GYAV
M MP?B:P*#/$D/=(X260,X]%PB@T1<^NUE%A)5(#Y1;GVV 67+,:4*R,5IG*6
MAN=A;]7C/LUX&J";N@8:=@WA67@%^N86SO3()1JP _\/:VZ2TDE:'R7!*AAI
ME5W!?5<U.(V&QV HATUNV(1"3!!H*N9X7,5^3C9K$M\NKYM-W=:9EDZ3YM=D
M4PY>W-(?F9S%@/*1*R_D><"GRN W?('8O0[8@K3QS[P1HD4>DS2^:*S3_,^_
M1[UL'DY@PL?Q^5ZUD)O5LB8$W(1\_06%@[]-+?K=-K/]"<J,KJ3,#H#G]YM(
M=M4]&0TG*YPU!1I/MK%$-X&FYJ340>M_+PDZBW4 S#/O'+Q2J)LS#\#,F$R)
MJ=3A\<:>)@S>-&+<HO.;>A>-S01ODD[<[_?<>->E.YN^J?E*CIS;II7@U8!G
MD9V7]ME%UFF]\6?,U]9M5K*5G)7ON[VY>7D^"\;.4B-M$-"PF0[=WD3>XPUB
M9^-EJ\EC4[1W[,A>3D.XL_@?T:I>[LE$;R^O2DXM@C4.Q9Q6W@*OMZYZ^3B]
M?6I+<;L"OSWDU/%X-A%+WAL%S[^>=>)G\CYJ8=5O#/6VZ#%Z-EXIR*CJ3_6V
MN7NN9S\ CG':S+A-%S RR1,?[]FH$:+9M=B_+<1,X#$/:&[%-#!>C%:]#MA$
M5.,W^&L=A.B#_)O=9X/-BWV3V=V+[4&S4'=6Q7;( 86ODV07%[O^.#=@>J$.
M6&@KH]"PWL V&;SIE.B+$%\>FGH8)^-6IP7UJT&=NM(#J7R)Z$O5#=<]G]=L
MFR;60ST:-,G5>0/ -6/4[,( \=5>\M9X%TWO:^QWF\V=.1!U!!T[NS1DT# @
MTG4#3H"E]YL!.-]NWW+@J5[J#\B@T^Q$:'HV;L-XKM>I5[FK=?NF/^2J\(L=
M?&ETHTXQFJRAYL_4,FCZ72_IG]5M'ISD3H_SQ/KQ4NKW6  KLV/OW;@FQ4&Z
M_3;3>JUJK7W.HT]6&^XP9\A*:Q"W+" =*$/!!B=]3)QA/^NA8087<>(\^<A9
M/G?8P--,!6QT)(D]\&Z^'UB/VF&J@3-'XP87B=971H5NOX7ZW 5K0IOGZ_IU
M!9 <TK0G@_AB\LNODVH:5;=N9_W0KV,%&2<#Y(7JF4/Q:HK57+Y8P]["S3KV
M^$#E\9?'E[?J2S-']377N-C2U%Q[&6^1:Z_]Z+6$;$GR<Z_]\37!KO]H:>PJ
M-I;R6[WVAN/ ;R[K2^;NO>*4V2:=Y6$.8YU-K[BZ@E*]P; UV5MXZ5C-NP[)
MU'&^U]6YPO.EKFY]*.]#GF]VXU@VB8Z3);''.XCM=@U]F==-ZGWE,\L(=Q3A
M[:?"V+S,OVI-ILK[;I,"N?ISY7<++LBSF28K!<"S,R'G2#:9';>I2;?B(_W$
M%'*R'VSE]?%B->P*I5PBBUD3N?_K30Y0]4;PBC#X]^)#NO3R@O67'WYM_4<Y
MO^,0Y(O;6X%%ZWV5=ZS@.QZZ0M(#S/RK8S)[<V'SJV?Z(AU_Y"(C-_?\Z589
MN67?%JEXY'AD6$=&A.0<2X.%-YH1%AFS$K-KCA*<JRZR,TEY>]WKO[/MN!O=
M\.(PJ7/W,+M?M??U)*J,_&P(N*DRTMGO'/RS=WKPS\?CO=\_T+W#_$RH]C__
M33X>MCL?._N?/_SS_NSCKC^;K3+R@7X0'[[OB(^=5Z<?/W_XEL/&T$^ZO_O?
M-KRO\X'N'W\\_./+_O<_TO[+IL+(WCN,]W;?\+W33\E+BG&,B$5*$,>1(T<9
M02X$ISW%)EFQL4WPIM%WKJ!9"B(5K'I>6'5Q)/#O?7!)+[S4' _X+>:LZ4/[
M;=6K:CX5[/H^@UTV,:.U!^Q2$2.>'$5:88J\,$00S3W6=&E%-0MX%?!:$_#*
MT;4"7DL&+S(#7H1ASH)7*&$*X$430S92CK S5C"6@L"J@%<!KY7HVPJ UP5P
M78:QXATN$:38#$A1IR0+RB);'Q=.HD>&D(2DMD$Z)6C2<@6]PQ*-GJ3WEVCT
M>KUC;:+1+V=R;V^8YW2Q(;B2<3QIL\QD/H2%*9P=8ZN\==C80*TD&L>@3 G>
MKKQYKBZ"M_N[KTX/_OXD- F:.HRL#!)Q015RP+(0D381$Z5EC&YL*[HIS"J9
MYR6Y$$6Y'UBY;QOM+$J]B%)_GU%J"X)*@3,4P6-"W&J3SX].*&I/:0Q22Z.!
M<Q=]?F+Z_*\GI- S$<"BT(LH-)E1:"9P)-@3E)0$*\VM0$Z0B&@TWD8N FCT
MQK:4<QK][Z+,JZK,*Z#+)2#V +K,9G29<JDT209QIC7BD5#DO"'(8^F3,4D2
M+!O&3<T*6>AG&!"[.BQPJYV[=X@57#$NSP^QO$O*&,FD])Y+'+0Q'EMLG73$
M$.5*K. )(-=LHI=S EM&$Z+*.\2EC,AA)I'QGADG=(R8 7*13</OC%Q7H\>]
MTI';!E:+<C^,<I=8P;W&"L9*'4ST*E>0=I[D"F>2(!M8/M59:D5I,$IR<"V*
M/C\Q?5XD5O#8"EUB!<N(%8P56EGJ//82T9 "*+3QR&"34+0F*6Q5BKE"/,/X
M#L&"HLWK9YU+L. A@P63[!EFC(C,(1NU0=RY?%"/"KG<@O"8)2:XJRFW%&*%
M3/0:Y1!<.JFKI!#\&)M2A#DFI1,4&RYPTO K"T$SKXF&N5S" JN.40?S^[\8
M#4PP(5!RCN;]7Q99[S3B5,!? M9.Q8UMNHG%*L4SRR+%T]3MLE_J(75]-EH
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MBSN P&SD(EA!@\0< 1O B)LHD5',HF"M5E(DS(S:V&:*W3W;H2# *B/ "@!
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M<4H>!4FR.^H#TC#_40HV>F6-)!A\%;))\%VB2P4GG@Q.K !,E+C4@R#!+'$
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M*TZV$Q-NF,61Y\9.8H/E:WBAE3+&@ SB(.X!QL9Q\H\.)\>A;:1&&NB)%SK
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MZ9>(0<H'BH\M!CB[1<'&QQQ-@C^NYJP$@JQ2"+R?3<LI\#X<MA 26^$7N"M
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MA'\.(8Y06QH\M 4U:X1R A^.\":%;D(3D)XQS8><F'Q0NZ='>3E5W=08N@5
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M?BBRG(BM?H+ZZH=/^P=O:M.N]@SO:/0GH:WA[.&9(VW(8&TG8@P$+>U@5]A
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M;+NKW!EH_N&(X5(&ENKI[<IO@A<PS-7\/0'(C@GI+?F>>).H5DVE__46A]O
M10*Z=KV]2=4D76Z'*B4$[A5Q<P5K&PX6<=] 4%B('ZN.NEG5)AH^@'X-##^U
MZTR$E5X'X\4P8>D":(USSHH80-H4KU[:P0TB%"1#J1GX%UAB)LP9N$!<_VG-
MH!%E,>$3U4AI!+[\FJL2MRS;%5!?L2&EO#"JXA%Q)5'Z(M)6=T TD!](+1#!
MK32VE5NG;)#5#C75IAG@^ HLN@6\?Z%:D]6,,,Y;00Q1@5E5!\5*,#5&\YZV
M!%-]88U+OKE5@VRKPHJZNOQ6[Q(47K=D*64:[C2;8N6A:KU.+DY\0-5%9J\M
MG'8;PJFN>WC=$DR?:IJH&PBHA@M-6Y':CV+@HA -@7;'8[RR3URDZXRUMTA,
MIJ'_+\ZG4S%17/[G-Z_%W#@Z)$,<TO8Y2OZB/CJ;K:)H[B"U]_M!4U?P3WJ>
MZAC6)F85$ED3C3@4SUY5P&6Q8&SY>Z53K_L$FC4ALD3$%&3A>!,C>"N!(;T"
MXLM5U$7$?JET?BC]!TAB8 N6 YDS/M!F<C! Q2B@5*5,KV"8$HX7E"P&SR>O
M>EX4^44#C\E\(60 D<R DR8P,R"1<E"J#+$6\A/ >H1;AMY8R#^-\H1$"S&3
MJ.EFU/ 2>SJK(1B@?46WD^IX1 $8VNSX3. AL4)J)Z7\UI4K5P@J['NI";_.
MH.G&;OVE:B8C7+^UME-;',BP^S@^0?@I)'_KW57]8!ZAVXI4RA4.Q:7CDDVZ
MVYA5S6NO9B/!)FNU)QJS-*A0G)R@11D)ZI*2V)_TIZ!_F4!*1M$SBN$5Y/"1
M#EO1DGPHG1;2^2#"?<WS%B^A1"MYO?>XV &2JO+<4"<M68@-J^(7Y(6K U0J
M=8H@EOI]4VM?$42B\& *. "=4N7-8\$>5]!\:G@)12UKY7>D(R1L6XDB,;J
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MY,&8XR+1?2'67QTW7[JF+)5K1V_\A7R4%+DM*N\(U$;82ISCACNN0-KAJ5Z
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M[N#)I>^-F/,HN6 ^L?E,V^BB*X)1I3--[&CD_J,KXRQK6'$*2I<"[2V26 F
M4BJP$S-KA?<.?PCA!ML,QHQFWCM<;V#_ [YA86.5W MM.[)XH1F;VFUY$YY.
MC>!'B0M7^BA%E-;M#/U*]D6MG,%DV>( +U2[*?L-'\RU+F^XM(P0L+[]KHNS
M"[C; :T7LNGS8MU4#;+RG_BN_R%]_&!.-Q4>GI"Z9RO^=SINWE10+!-F>\$\
MV& AB,*(7H;#[K)K5ORUYR__^9U@(U8_M*OO@[.%V.VG7SKR6&XB >K88$*
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MA509:*<IXS?6%^'V^!^7G2:'L;Q;Z3<EH8A<:'AWQ29*!C2]MA!N^ L#@^W
MY=K?(/T)V=D]<'#5;7*JJQZU]\4R^86"<D=RQ'4$3?$#0#6^MRUT%;L<@3?
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MKC!-.2I,)$HH<HDGJJ%#82Q9M]JG#UY9U$B!?&G14V)2JZVFL9<:A6]P"[>
MZPI:CPK7TL2'#F=XA!U50[C/P/$CS!) =[;L*[L!OAXM6!;=AM9D?DGT-5$@
MDNJ<D'HS:[1T// RED0N@"J:[I;+4EB2PO)9_@P'PN;DH,H<ZPS-,IYDYGEW
MJ2-K4LN?.5HD2_IIY>Z%GC7W7]1<J8/*_"VUA/$>03J. ?\SA"#0,!6&%U*/
MQ'C+G;0;Z D<P#J2@ATRL9_V&?4+@RL@FJFJMPJZFS<%WP5GL$H30&Q(VHEI
MQW/3E$C@4'IPAL?8LM\ /SX^A70V-=4QSV)^&@TVQ5;MH$,,"FT/S@_.RGI:
M9-U"^\M&A2')P$5[@@JG'9;QA[$YG/C*41!F[0X%BKT=0532GIWW3Z,4KB!?
M!:#*1_C[80?%+BF]KK+-[*?+AJY']"UCAM*4KWA9=S&^/'YXPE^C3Z?<^P[N
M#V][?P+OK5M_Y<#MKG*ZLQN%SY]C?!$ ^MSS(SIY]6Y\)5'<'$JNH/F4:#NR
MD8Y:>M:  2D&"V^7=;'N(- ,MN(:Y&G[DP_,?O)86()JXSG K=)]-0*1A./D
M-U:@L;KJ:2.,G6;T^@HHOIH1-A<LN6N +P&QBOJ&+[\/1@H=DH8<..F@1(D'
M7LW_F@F8D"!39KRIR(X-Y-K9/AS"1MH5OMR'#R(/#7Z&=G,V;.-*\5>?K+[O
M6BC?-9A;]#9"=AU$WM*-N:SHQ@Y?LAF->T4)>[-UH()2HECYN>[ /B 1=W><
M,2EN;B0R %-GT4=A"IDX)4/@C(^%+9[2,?B&ZL4=G,-V5Q#@2GLS^]4N=O\@
M8JQML8N4G8/*I?T*1EEV!-<FRH>\$ZAR>9XQXF$3=I;M/>5:W6>?G&MUYUK=
MZ>6Q%P[2LH\ 0XKM$O^'.#>0% .+/^YPK0?V^\D- +PS%E%V6AO#8-@NY/ ,
M,>C4P*@N]T!]I'M%T&G<8TBP>RJDG_B1!KGKM)4L5RG(E!_+YC#Z3K-P$)67
M4/\*_S4$QRU8&<PJ=/WFXFU5[>EG<+J,V'%38.VU8S),H)L<45(*_[^+J$EA
MP]AQCQ,SWK&>/$RO)$U%@FYQJ_&] U?Y[T+2:4C\!0?P. H5'&$P%YS(L 3!
M SW6L6P-<N%QA2U.(^2C$'S8((K$+)C!=\3& 4R''X+GS<5,4%Z9(U )LX[]
M<CG\*27-&8(:YXV%<@D<%J<O@5>9"Y.Y9*X+NIZLGBL@M0/W7&JJ5QJ5D9<*
M!6XK[A]#V'EP'91)@9^G:R50A;ST# 2;<JFX0"UUO395>TB:W^9I]"U1&QXD
M0(7B*_5Y1DT;-&^2]:;P/%N]RS5V#,72<F@AZK&FHI./$PUU]@X[%%;U>YDC
MMP:^NJ\[N(>L5GMUT53;\:O/OA 'L<8>U*\NGG[YAPTJ(AJ_>"8O\N$?(1Z;
MIY\_^0N,!8')W7QB#WL].*9K7RD#3L]@AV /1/B3>_-02&TLB8^>G2?XD2;X
M020AG,_RRO%.J[/C!NK@1&Q+9<Y[=XPJ20AD6]@7E#;A->P(.R^:QUHT[SRG
MCE$"F,IB66GRJ1B(H<TFAH"&RC14YUK1F]*?A^56-WS+GJCW@A>'"GVWU\20
M4<VZ)TCCS%!FD#@BT7=V[DH-,O#9N0C^H!<^+\''7((NM[7$6!2+"5>Y!FM?
M.9L==Q[T?I[,C^ 06C@TM.00Q=.TE[F!:C"--?@'KQ1DJS_/_!_H7Q(YEL=!
MJUP%&NK[U2'/4_A84Y@R:UYA%+LA@I9M%U%"K)1Z..;EPB8[[;A$9#539@"*
M^\#.'2(R:$W@QO401 ]-7V%7G4M,80/A4)W7P ?=Q@ 4"<:9RF[KVMH=LOW[
MI. Q3UTB_MV[=W",/^ *Z07 HZO[S06<)P=W(3A:L%)'OVK*2R@3='W2*OJ@
MHPJ[0)B5.CYYO!CI!(T*U? L7/B\0!_172SO2EP*<4>ZD&-;Q?T_"(W;0?D7
M+@*5).%[>/=D!QYJ=>MJU1\3/5)"/@\MP9 4HFS[4"1)W$T8E8'RVV7PWZY<
MS!8V2$%48LRNS*F%$BX)(QC^!F3/X)H5F%#DO'9$2R_]*V)(O# .9O6I;0S(
MK3<,]P&G8V? SGTX4+#0X1OB9S2*(-1=$E/9?T]P,TR>7W;3&$4<6^5C,5"'
M3V(CC5(#FM8':3V@D2L2W065DX*BV0B8$<1K).63=\C,(KQ)5.X6BB-*F$.O
M53@*C4PN  I_X18>=1"_2X9[QC<OY1+F3'=+C55QIQ/!U5+,5N$[P7(73 #.
MQ'1^3PLOM##W('TYPRP^ ,SBZ1EF<899G![,XG7/HC^]T0+U]<Y%L;D&!J$-
M1 JMM@WG(PD((3!RN.8\)10GX8"$_V^E5RCL5B5@R>*.#"6L/77\P[?IRQ7'
MAF+O!KCK[S>^P)^=GQ:76)RUM BB0-IG08<S86='#1ME+3TZ]PDP K.:P.-#
MV>>V4GJEM DMG-Y _$L.JE.,L=F/!4RYKYTZD F5S8)M\CT2#UU->Y)=YN.Z
M<P^(3RR$PX*[3JB^06H3:9 %CTD.%CQS8U.7VP%*0\Q1(BMN>OE18(:%0D#3
M*+N1.%6I&A6(X3:$]N@V%8.3"5^,)%W*N=1V*9UGQ*)G#>Q*@.^IMP&=<$'4
M<TP3=;'P1+4C6LX)L9D*TKNU"<"0Q6T"B:\*91&6^)JA3QUG6#SND+NYJ3<3
M@DJOB6K1A$Z)LUP[P/!UK(P2'A";%RW3:EQ:D20UD/2RSS1VP;Z(D%QT*8CN
M'?:_N.NR:"D(*3O;--[S9O^<B;,&7QJ(I\3KO.ZER.UDK*P'IR"N<V#.X5U+
M0\=M;&09BLAFS0R#"9^!1RZ#2QY_RQ@?R'HUM8"!"+=$-&IM5%,K5TVW?@N(
MNO G\."UHQ-BJ1D:F1B.;7]_)P!DQUJ1W,:3;!TSQ01L3CCYE[5V/CY>@&_+
M85S]U)?KMXR)2+%MQ>KUCZ^^^R;W*71JP<2DRIFO@M&\H6^^+H<!R;WY)]_]
MQX_/M=8E=!YAULMAC(FO(^P1A[XNM5 PD991-BOW"=P&-97KZZYC"<&(P%Q@
M<IE6.]=0=]K.QB].0VIA"OW,A/=Z X():! ^_>3IET=UO @?"($YS!2FQY=N
M@K.'B#<ZB08CD 3O "X.O0RJ2N?EIWP=Q*<;<>.E=5#K,H=;;C8H9#BUNPH:
MC?&TQEZ&P9Y]CRJR8""17GYJK4 JY/"TUT604L%!0KI6E3L6!'!OOQ?M9;/(
MP8!<N+YRS.9(AWI$S*Z$<-^_5$(XZ",.%QE0./"BVU[LD9K_J?N ^FC=AY_J
MA_;0\,I06ZR']12&!@I+!YZJ@O"K1/1+IP>.L>]$%Q)^+T6+TLZL02WM\(74
M)N!BEW6'FZB'DR(S2,:E>UE9HRCR5W*?"PUUX5 /\![T5T [])KH7"*[OR0J
M/V*^"-_%YN7+73T.?)(A V[E?W/B>QL6,+7QAGM_!XL;B8"> T_5 8VN5*QD
M>[\.VPN\1/=M66IHO'6Q^:T;;,)_@LSXIY]\^ND=YH!. )3RQG L[(NF#&[Q
MM;7OPF-A>]<UXNME.1%%N]'RI738X2X[?68T(=03Y4G\_?F<X\*E8V<:YG:"
M0<(Q]\?<:!!\FSD;=N6O-!8JD*JT%M1%2QU83U;!T-1#Q(3%0].!$SC(:V*9
M9NO4(>Q]>; VW@PYA:U->(ON:G*H1>$@]D*2D#;<CZBW'6?\FI(SF$0((_R>
MX195.TS,. U>JSU0CSZ@-14/_"0E*GD/-7I7I[]Y?FZQ+/M?X14WW4Z1%+8Y
M8%3^HX+(#W%5KP5M[KAC>;?)-@*_17=1NOW"6^9<'HH3O$,45O8_ZC4@Z;D;
MX3G1M+\NQ^O;TN[VZA_/7^O=0.%X'Z)VV*B?T?&6NUL]L(\+C,3!F]IK*W:X
MF,'0@\-\=57)[),_)IRDG"1VC'@Q:/U[.=R$O)1L.8TD7N4%#.<WOT'/+/*F
MBT>HO^3OOJGZFS 0JV_:JP:+)]R?#G?'U?X<8M%IQ]1S/3B'X;SJRLVNW,]T
M'Q*;LH.P:.Q:W\9ZU1%.F]:S= F4*@$USI:-3L;/_R53<>+GQG]TMQ#C%^X@
M%N<=A@C7@3L ALA#-+DWE<O.>.6>M#!UR9.8ROA@L:)2Q<HIO#G"IS=4'@M_
M8J=-*FTXK>+=H^Q M0(T)8JFZ75<%8F/L& D,WP0XLV&*Z]K7I7W<9RW^$N2
M]U)^]B&.*MI../; +:-]Z$C"(N:;_#T_NK QIH!QNA*<V!&9"\]Q)*2"-\CQ
M,*M[?E2-;B*PP14WS02(X :*^V&J%5,="?6@4>6(NEY*ANE:H+2"&6EB&!<&
MD0NHD\5>2"P79W. ^:<Y::*KF$;0#[_W*12RK)*V'D7YU$C])'A:U]V&*#L4
M!AFO%D]:=/2YA-_JV'>$.E[D+1O89Y8=0]\2TC=P;R]HJ*Q.^ T:I!G?D#"-
M@6A.W*467$J,3:@ !$R7F( X$(/Z4K;AQ)?Y*V7,)C>1T\*8:_?LH6%9K%D*
M[C+,!"_4G.:-BNN1F]SK6BT^$(U D? (!(<OW35^L[3$TILN,N'K]6V N!UA
MQ_C'@9LI,WEXYG5EY%G;;CT-D:DDB0+^'KQEM-+IZ;HLQD%7IAR/C1 :D<*K
MWW+GHOX'*.I_NES4AZ>O-__[W^ZN*#_]]/-_.T,!SE" QUJ[><?N1\"H!;NH
M2ES?>>3J1^>G$L\.<:%E&?"\ Z94SWUW.;%R'>2>EC6\V%TZ0B4^:_X0^O$,
M[5B#N8&ICY*5AD*+SEKEZ3:F'CU:3]RQ^.EZQBANKB]P>!T?\/&PY^)\/:R0
M,2L2+V1.2*3N):X"_$ZL)461(!WCF!N'@H4@*\'C">\K?/'\J 7Q-+IT6^$H
MI\@AM& Z\^@%I?E:8HB'6)7DEQ'=3>Q\GGZ>/<APF<J\"Y:5JXF8=0T^*F1:
MKN"'BEV$P5N7>]@C(@P0$=1[QJE:F:$E)16>!NG43+>OX&"VIC$*/G];-:(,
MZ#/\CN#=GABVASA@R!Z $M%,D6LZZ=&(K4,L489C7!P>#+6"QUP3 [Y]/L-R
M-*N_0]$O,EJKUYA;7;NL^-^_L_R:(RXOB6/CQVIS"U=Y@<2$!,4_<!E&-/D2
M#A,#[:8<(XJ\3) S/B5]S1DT!KNJN!7\_C9!*<<CA0DVZ1M88/_-VD!L>CZP
M:Q^56KW\ Y3#<[]&[#+6"\SOM67IH0ZV0B'?L0[# OGVR^ZFRIM'U]\0DZ A
MAN$(,:\:XAPOXGW,9QJUB-.=,A0[4,&2B?J38XNL<"^'2.7/!:I7L\V+>CS<
M]W<=RK3'5W9M'H0-,R5==Q4P?JVHA>>^@.&7;R:QM8U%441>Y#Y'JY>[Y)\C
M2SI%O'1S 9.T]U$@WW0/+PE^C,F&E9SB$=IU&]Q,IO1AL!5@LL7 T@EZQK]F
M)#<+<-Y/0E/>J7;*F-1=\?&(87(L"KG<05,:)#_*2$Y6IO2[4@ZY*$\D $46
M5N-?EGSIC5XWA^6Z9:TS*MOZCJAX@6#-FC&'OZ-K(-> ZU]=]C?QCD/N&1A!
M7;G'-]+@KS%(D+RP.F\F=QSA(.] >+[:_M[WVW3XU-C,AGG'H^-I%K;XO3>F
M3;9O2A;7>?7]2P2G!>,0]BU:/3?[UUVS,>JJC-%8@H?$+R';T*94I73S'ADK
MTV&6,EZ;)0^8,IOJ!^CG*&+57BC.6\6L5W3"C(FORY>40QE3B8)KE87'2WS!
MB5PZ0YR 9H('_9W3.K?PRS;\LAIO@98V/^PLN@B-2Y"ZH'V!+YWX<>]E(<HS
MY]=+S@IDGQI2U%#'8BT6-^+UX!\N7##[^W!=H5!-6B@/)/%Q^F<$6Q20SU5M
M4.*U8OQ0?HA9\ +4-"/F6<0F,^\LZF&$.9AXM+!?FD5R&+E#W5N -9FPOM#+
MV2JVTJ5ZR9W-/XXRZV&6\H;:8@&HWF(_=_!. =SI/ZVWC+I&USV6!?'>J\@<
M19U@&72A+RQV/3X,LW1GOBPOZ0DO9Y)O%'KAB"G^D1SVK'BYZS#.-JK]7Y'>
MH<&*9+U"_-J.:B9=_*#$PC/^1Z'\H6B:HNALO (R(/Z<LC#;[?=@:A#FT  $
MWK[!,F-<F KK?X+PA 9[8-)\%[1\?*F>EY/2;#G"1P!]Q?&-FQ&CIHYU*[P+
MFI_:!\X&;:VH_U*63M5B9B;B]6/$)>88^JHAU11:(IC.DR)_9N5XPMA!:S+O
MMH*@J+FPB,)'B^N(;NKB7Z?NAST#_)HGOI[NR,@]+"'W0?-Q'TD>CB@R9=$M
M9.7>=WP=]2)K=Q$$T:R042!TE%I>:%]=ED,]?#R!=@1'.L(H0DM-LH1D+$K@
M'*BY)1_]VVT%RPI2;B,>!F&U-!W,7E/>2AW92"*N '#3"H9O KU2EK[$IW%V
MU9$M!Z]\TSC.Y. 64>KENOQ7V6\@.I*(B.YX"UBQ@=>$)JK"'>N>[NGX>YW7
MW 3W<.!,9_K@XM=[3CO144/IT"B'*I*B+*D*CV 2K=F1.9?"/T I_+-S?_NY
MJ/T'6]^_YQ1J.!X,GH0),5>_T=&+(# ("X,Y$9*O-<H>HNA.&M\/P?96PRIA
MP=G7-]T8ER%F<M=/5M\"Q@@@:<&OF"1+QR1,,=<35( 8&Q@>*ZNZPWAK[+.%
MLS8$[ABZCJ02BUZ3!IFL]F=G#_S8I3?@'1IHH+C ]Y.;X%-G2TK5&HLVHKZ5
M.@_[T@E]37WN-4F6C>IE4GSR7PW#/30=S]T:_&YLXT5";@O!I8BPIZX8%%0@
MV&/?_5JMER*YA\2-N;I3MG;TT474OU2:!Y51[XX7+]]KK?*72N!_LN\,;QK<
MQ@T\"]Q(J,W"B7QP;0K8R(P2HKA=@T,3_ABFEU!U<@5C^=<UN'1MC40U6I*(
M;;%FJC!2LQRT]',@4]$2MLYY])A<3.H5XNE#>6AN;Y@^@@PB9T^;@T2H[()=
MUWO5))U/.!/-]8.VIQU94+0_2>@MN[1^0*%MN:+/:A/NAC,(+LW 95<*D&$>
MNI:8$;8:,XOIY-QB=]M:2YS=K%.I:9*("X9Y1T1/)M,9V:(PO^VPK9":;<"?
MH(P#7 &"UF#UPA,2,#2$7,CZ&L9[D&OA(*>;D:@!%.Q0^,*X@R>M!=P*FC=X
MU4)2.-Q%*K5!3@L+!QC>-'SMU'-2S\-96(E9%WT1G9^^@M#$<<%+&^"0*W@F
M\7*(D2K?-(7PWM]J6J$S6W,,.78/_9DGP0_3)8FIJBW0Q5VKH"1U+\K54;=O
M7GZU#A[NT$E>ATJSEU7B]/#.8Q7E-2CSF*[2W[]['<59S(XQ#TH7PV#.RDHK
MD,-'D K0BE6 _JR6/)%QL$00SR2F3D915Q2@PMAWY/YQ?Y%V[E"TG39UY[+&
M0SQ\,&8@N-WU>GW35D$\D+XD\  *!0+O;/L:3.CFAM8I1-O0DS<.1EH'%R\A
M&ZSJR1U*GX(F$I8'8NH+-A2, AE&5YU><&L45,YY6&A^6E/R)5R3J#02RL(3
MW_B_5-)#LN!A,PH!2W,E%JF(,>D03-UZLL6%S#C4WXS[[NM_/*<$%<- ,#E%
MYA5AI!MJ;E?D@G:D)ALEF"7.T+JN-DE+0A'2%Q];-.R\HK"APF58(F+#V:4?
M)H'PP_* *42"?><-ZI :E/-"MP8HG,IJ*45M%<O!>HU#%;'?;V9R;>EHO6_]
MCA]BM!0\9FHUQ-K<\37P7< )!=O:J-ZN1U9YWQH7R;X<J+V^NG!L)#K';)FC
M\?!8DR8VKR6KSS/;!C9K/4 '6$NK"@#31LS<<T)I=W1/6QR? W?[J(M*2:N,
MDSO3R+DPFSO09X)<<'M@\K4R'!@CN5[D \U18_IZWF_J1(G^CFE3UT$G(W$>
M%@PKN[(JP3M?/DN3'<VP3;R0S1J.];)BAX.$2)ZLWA YTSMO#>U\-62-CETM
M_#NS9\XOSB+QY"O!V6-)[;@V-:\.(2,H-%;5!LRUL%!!3N7DE<E>V"FM&6IR
MC9BL2YF?=7F&A[1&N,C+BMLPV]5_AB&&P^NSIP5P!WQ" __S?^'D;/KP!BH*
MJ'0C/[>>I^:;GP4EC8)].\R)!;M=]=SF'>S,UST4=8/+,_4#I$MD.4*7:G@!
MNE=YBRQ=/;PM\14C=?%& 4/\9&)?O_G9'M8Q V(U!&,CLFN$V&<4V<MP6F/D
M:._+6^TG^\5K_$4A=2^*];_Y>=5/D,&3()_>#?P XEOX^;\NPG?"93:T6%]T
MYEL^%PYF 8.!-C>N?,A6U; 9,'9J-V+P,H^C7$48Z)9A+6TOMB H,>(]PP^O
MNFX3ML[E-.(F&(A  ?ZR/(*7Q.C,U<%KH@? FGJ$LKN@&W(%A5XB;#J\#T8O
ME$G3*/#(FX1%2&"V0OC@^+$$X[8!C?.KRJV\GP5X[)E4@G.Q9YDLK(PVRC8E
MO"T&%Z"G=SM_/R&Q4\=0Q @-=Z[Y?(":S^?GFL^YYO.'9WF8UA7V_F6W42#V
MO6PYYW#"XU"IO$'LE:J\880HQLA'PL$<72%5*I*% /D"8!<Q)WF!]1L B3#T
MHA[$[%,2)=R^;:O?Q,SJL] 11)_I.0$0\G)7W7;]6TV.0FKDJE6/'\(E\\FY
MO",TFK\)[2[D/@S%!-X75C_"*\'O)>YE6KU@HH'?6(*!0LX4)I@3YA=)VP@9
MZ64YHH V>7C Z:J]&N3!_1UY K\.WB> (?^DK$!OUMW8X".&__L%BFQ_1IXC
M9J/%*(?@.J3%$([K[SL\:-K5*S#<+>)-,0]Z!4IZX?G@L/?.J%$,HP0$4@KS
MP>13_. ?(.X% H$'K:5"+B=',WI@Q$,)\_6O:C95Z^ J@?L D@R<"B!__35&
M(7*A^TP<K;9-YC(/<&T(652U890!'C(XUF1/P=E=AL.'X=N,G^(\&W(*00>1
M-2AA2@I0)<2YP+FO*L9T.$2\ IDBB$B?)$)XZ8690HD.'"6 Q6*BYG*H>*QV
M$Z;/_8Z!C"LM5"DI("N<7[HR8O&:86G(,(IW_)P<,G /H;V)I%E,*U*&B?.7
MFMY@\#@E1:Y(62J^$<8(AV>K\;9C,>XPR/6Z4B2UFAENG>*]KS4!OL*3E3)(
M\8J-WQ.M7O@K1BH8!TH!Y8X7)RJ^MU7LD(4K!3L9]GS7XUH,&WM7E2*Y-3>M
M*Y7BXLRS"QLU?Q\F1Q+6?15][T*_>GM= 0?>:"QHX5%88CW)@$\#M0&3^1@\
M3IO"Y7^)&8E-&,8 P?!C.B#*66"34XA>+1.<ZLQP)XK[N>J'+MQ^;O56 (Y3
MXXR42V0#8-WU""+8++Z,\ML)M:,$AR_"P/"S:X3XXB,A1_M)@?Q6BV18(G0E
M]=TP7%PR= "-X6)<A2<:IQNJ3,@>G W,"V[*O0;#/O3%(G=:8]>BD#T=EI_A
M*-=\OV2>+N,53V9IKF,-]#7Y9(++/>'I2#&\9R"'9PM' ]W)W5L4H!8*U$L9
M'ZO?:#DL/H<EXWA(0"5A$T]]J[?!Y)(@0\K6(ZVQ^XI("6DL(7?$^2)F]*F1
MZ9RK&M45AG4 \MGM2WYEF5<7QV9JGTN#0PD:+B!D:MPRQVH "VU8<=G@\A U
M;PA&&$NVVK;L-)4$]T@]L]1Z(LA,!\+,W/SAI$OW7!)\X%!ZGC,5!'Z0!PM?
M.GG<PD_+V6;TA^8IY\?)-./>@$OB:>W\'2@O8));US<&!B'LF*C>=/?6M Y_
MD<FX+4F\HUS=U%V3369+)&.76-[W1(C'-!\H?#9[_((U"BF&::H;ARKR W^(
M0!N M]D@2#WL PPWM&)Y27A[E.] "4Z8G0OTKW8X&4#1YMOA5S3FX(>*%25H
M!FZ0'>IV83R(SSA6NWT(JTDM(&S4,--$4# @Q0@7;U.-@GEI74L!"Q=<-QT6
MI:FVSPOHR>H-K *=&\E[X8HT\LYUL 2-O/ZZ1_KD< !4X7])%>ZYK*?Y.%J-
M^?A%8+"Z0=4<^'5<\X3(4 8;=.NP5O3 KJ%V)JAPXH:!T(]<2UXJ#PGUHI$*
M>9DY.\O>N2:#,H(X Y%_&:Y*Z\*!XDBOD+5'KHE4OJ^VT\!T^E2EA4 @[-64
M8)UI'\/07=; Y&B8$F2![=9J(Z@LJ">\4<G7[:]3RZ7!H:K_Q:M:+Y.LN/QJ
M0_1-A]3)7F=HF2E#:[1)O\J=[(%"Q3<G$!3SDBS>DZ\SQ0PFU-<J)[.%AY<'
M]*FD9K\XLK;,1?"A[Z?]"-X5E1LT%1\SKV_J ;['$(I9.W28I@8;LC#O[_<2
M7<_U#%LCE, C"(5A0C>1<V-V4>L0X$AI4FNAH"Q&E0Z<#)\)\(S2@.2:X'4@
MY=RT(50BRN3O-A?4(5_ZL::PG9J><#_><X*\YDX2WWI,-]8BXU\/?/:15JGG
MN^3N8^*B]V2GQAYM@I<(CAZH4WQ!4QB1,[ C3WPC$9)M&ZU+ZNP<KRMQS[=S
MCI-L!@#_SBWT)NX9S1#'Y,ME\0)O#],V<2(-&J.NPR-CT&A=A]1VQU]\@ IH
M1)>G<1&8WD+@^0ZG*X<>]K3R.J),FX=(,^PUVS_@;7M?8<9HI_Q/>!/ 4W-5
MPN'J2&@FHN!PS",P$D66'BKNX<>S2!L:\YVVYQKB!Z@A_N5<0SS7$$^S/2:&
M9N_FP?Z, Y"%OYE.>YDS2#D\*#4H1RQV1MQ)@'?Z)Z?FMX\10/BCAQEVFNJW
M H^T1ID1.:WO6Y(@UPU&FL9:HY^O[CDLS_;@X+57%TVU';_Z[ LQAC5F+[ZZ
M>/KE'S9TF&+_XIF\R(=_A'ALGG[^Y"\P%@\G]\B1X[X+S8>BKW,,:B^5[B;%
M&/(.8OJO._H/+0 @_\ZQZ*0M6GQ=3/3OH!"=;E+IF.&L'\FA8 G M9OAARSV
M@'TC3.'@^PK-37X8>8F.^R(]B7GNSI$U>DSV0?/\F.<=]D@[[*=LRUMTM) *
M'Z9ET%Z& 04W&\C%I@'FN8[:6T?P:8'VHY(.F%+FUU/+<0ZY@ 03=HY WC:<
MD9(/[N/F&OUA(;47_09@4ON^ZPF,"7A!V+EZ&2:<L-R+T'@I(<WJFQMHN:Y;
M[/*]J46[""*8?:^4LDN=1&D"0,AQ7.1PJ*L&L)7&LL6:(,9BRSO<$AB4E-_5
MZ[Z[1-WAFQH9.>;].0R^ >EE%K\Q^>,\.ISWX$(!H1:3L7 !(BO<5*P%O' 5
M*H%I/@42:Z+0U*:,V$*(3>&E=$0);'M7;0[:2ZMO?"]GY+.S37@?-B'J"KK?
MXG 9.JKS-5+YI33@S!*$W="4E[!A01BZ%((CUX+6E[>NON>^%A;$U"/;T8!Z
M8BB+?8N]SW)I6$GMM*MZZ'2+&J//Z^BQUE$.A)!IATO:SX^VKR$48JHWXJ+<
MXQ90[&X1O(?@<*MU4U\I4/G#$I<.&=^R*7_#ULU2U :3\KFN0[A>EC[K[H=,
M CX/U'-]>O?C*JT%S_%KV+O#IEYK*UNX^;;N=_=HHDDI!ZB8Y\J^C&*$Z<E5
ME?QOL0C:,A2FL%P^$57)CQFQR@ LX(J>G5$55%*:YH)ZD,,6+]=ORRM,=2NI
M5-?/?)<E.V7U&BE_TMO-&,BUR2/F.7<E&_0G(DJWI#)^9&BHVZT]Y*;SX&O9
M.9UXP)74?:K]MJSXMM2+1]"XL*ZE63BJJ?BP9%7>A'%RO;U9_GSG7;G @#,1
MZVJ12%^KU2XDZ(G'&;M?X^_KQ&@L(2EH*1:&]<)U"]\2F%5Y/M8L?SXB'NN(
M>./6&;!QFV7*8@Y&0J%Q!IO$QKD8[1%@6S@<?$T87 FL^VJMM_#[?<&2AGU
MRO1S[MSCU JT8XH(K]'[/K5N:U<JA!S$E;JUACT0D2Z(T0RN&@$VB<P/\A6
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M<^OZ ZD'/+S6MR^?%ZMOOG,-,JXB N?5!CNSX3WBMC3T."W,]%07EQ&=.0,
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M8/2G[(&I=;N J-P/,6<F]Q0! \@M^2QZ<(YPK(V'/4G$T!I7]A<)"TOG%E&
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M[XUI'A%<)V'S#D'FB V^J3M1L9=ST.;TR>HU!>?\4R=\LNS) \4_>T&#=IO
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M[7XRM<+P(2!R=A!#Z?AIMZ:$OT)^5,1 KO".6A%QH*X>*LJWF$H&,YTQ+C*
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MV4/^=)TJXSGGQ@VC<%7>EBA3R340;$N5Q\BO-/C= #J3S-R@=0]HPO#0&64
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MJL$^Q8VIN*-P6*N^,CA#F08AW Y.6$:?.6 GA7:S7BKBPP[4AB9@6L*"2"^
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MT+^104KDOBI;:78_:FHXC5=%\V?$@+LBEYB?P+W*?F(KH$>S"#Y5&4]F'EZ
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M)%*72$7-J.+>3;DN-RURKP.+;@>.+9G(:T=(PUQ:7@7UN*U;9G=;LYBA-C8
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M=62U1BIQA(TJ"5I[>B\LSZN\:0Z3CWC@;O)%.K/D4;(-H<2%M&]*V, .<^]
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ML4Y^^>/S/']@MC-A\% H-?9\I,*["J$5ZV-'*;[8S:"Q:J24"U8@OV95L6%
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M5"Y11TYI3B#(4I6=,I<(U7*,/@&;<)LF1)> 1G" %.E%<J8M8V;#MC,[WHY
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MO[V7@E5#2&GSDM3NA$$^/H^N_*HMN$HT-SHZ#L'88-8@,ICK2!&4TW_W>P\
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MGD>@BQAH2!WG/+$X^#%$\ $4 <I7F7;3Z!CIFTX_FL_<W*.^(Y8@HFJ$;+/
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M55@ 2R^SZ_.K>;$.#S/):5DO*KU=8FE7Z[P%.;1"#H,?9Q".L-*-ZVXLGT*
M;RI@(Q.4A(+E^KF)E-+'51 !O:58"RR./0 _!B31Y2\G%#*:*%MBO0/;(%;.
M":97LE]M^1&?"WI'_%"SZPM2$:M1K>98+3[".)$LS@^7+#Q4@&@#[6WQ@Y00
MA9S($=&V0%HE-LY!926C$I'N2/OG 1JJ)] V1F[$_0"']K*I@XC>HR@B%;=5
M#&B.PC.#=2T!O#6$EPE=?DA5K_"@MX#2:U3L*:PR]-G.?T?"IW+CS"I;  (O
M2K#$-(+C@$X[@=SB8JB4K9I*LQEDA$O\:@?\.E@7*V9<["33"86;_H]5-<L
MY.01?8S,I@MZ!H+$=_BP;!3A)N+60=C-$2'0""+3E)I<FKT419U)MAV1)+9=
MK.%YHAK%]&9BY^KZP#0<HMLV26FA%$LRH$U./!FS&14C 8Y@XTE$CE3."(+
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MH<\E]H!$G1V_;V((\6OSUKB\,[K,>0H"QVBZ\41T$SL8650Y92M'U**ZUV[
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MQBUNV5?3QEU7W:BC8XNK_<7-#BE*Y8N')*T!Y0T#GT*$:'20GM?-F]9U#S?
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MK60A2B(L+2F59(D73) 4('EJ7$JQ=CWIMYSH'IHY=S'' (RYM@;M-/GF90[
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M\88R=!4IQ4\\%[3VA-LU,!X9"S95],K- U:DP9<?E[_*RNR?__;_4$L#!!0
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MLJK ':4/DX_EXD&6RZ>/,SI?WL[%Z_^[FCZ8I?#%TQ?=UNWW:361<2Q4EN5
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M3B'@LRS"01_#ET0XI>;1<@@G'_:S<=O8([O6R23+TE2)@@*4(LT)!:W#!!)
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MA-;O;DUF_5^;B7RRV4%F\26ENBE\\;GGB3;XH V$)9V+Z?RN]5*':9:C7%!
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M 5-)BHPE.7*YNO&&\ "7-<,@;$?NOG +3.F=F)K'C: U<J\WR+T_@YPSB]M
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M[T&ULS"><Z@"L]>V:C?1CG+UH&VK9\9N8\IL-(PV*@;R>@PU +X"I'V+-VP
M=2!P#P*L0_73<X$X4Q_]"_W>9>.>***T#:<*0)C$ .:I.4PR>ST2\S@1D(O<
MZ3C8LM_1T7E](<^WY>ZJ=/VD!Z;Z^3='*K>$WY*A_8,:FGAK/'=$;L^=HY^,
MU#_?1%KP(%GA'<'R19*6O0[+?6Y0'%":X^O]R_5\[,++3>3@!-*,IBK/ 8IC
M!:#@W-0^QT!FD,H\AQ)"Z^WFT1[&QC[K&C:-E)$6LPXZ=J_ELPODY9WGU? $
MYA%G9'H5^CFJ_545?W9;'+STSU&%CM4 .OY@7S_S1;G\(LO[MW5H<&W83""&
MI(!Z\L+4U.3EC $F<@:(2K!)PU(0"2>/LF0+>S_QPVY<OMCMS@+>MAHI@2:/
M>VU'K.5T]>X^ JCE+?25((6^BZ[1,?)%;RW0Z>$)?5I];W[,1[H8V OYM)*'
M/L1GGKVF]O:$\1C+F%.]1(L<0%/+DXF$ XIB(I)$92(NW(MN.ZW0@U7;[E]E
MVZF\]H@FZNUYC7N6T_8\%=M&GZ& ]JGIMO?;GA.,\U+6)PA;Z=D^*'-68$(Z
MJ^9@X7ZZNJ^V%PA*<I2F' ,],PN][/(<,/TG0 5.TI2IA,3I.M^O_<:^GS16
MG_)>&N AHK#D,OJ)=AK]W*5779\#_B1:M7Z.'AJE(OT+#ZDS>HZI)7N$&Z*!
MV*93(/II6X6?S9"LM>@.;FL];L+8#]<AZ8O6^@DQ+ U>!=0!;5[76C^:?4U+
MD[.PTENA.HQJ?3;',IKPG&<@5<046*(IP&G!@$I9AH7B6>;F9W>JH[&=1G1R
MFCUW$]MH<T[GAJT=H?E +#!E]0/+F9 N(>&)<DYV,RBI7%)VGS8N/M^/&+Z4
M5$A-.?4Q:)M'H_HDN9P^&AN@SJ?Q-"GR7,$LCP%'@@)(:6Q*-&JJ8!)QG.8Q
M+9P"B*QZ'1ME=/%W;^>Z-\W+T49@-\*PP]R./;PC&=[Z:0R<C8S1'XV449![
M9R> /#&,79^#THT3#/O<X_9R[UCKQ;U<WQ:_,P-KC"3C1 JQ@!02 6**((!$
M0N.5AT&:)C+):$%D*AU#K$_U-3;2:>\3U[)&G;#.P=0GT;4C&D^8!::7DW!Y
M]]6UP,-?G/3)GH8.C[ZD\I&HZ(NO]#PXFB^G8CI;+:>/6WD)7W_GLY60XHT6
MWESJKCI_E'WSZ<73\0;J&9%GC*>I*@ B* 8P%PA@I2#(BSPI,(NS0B$7O@DH
MZ]CX:EO2K=2@O6(*0@ZQY6'3. 8NM$W6;\S<#YS"H^GK5"J@I,,>786'_.!\
M:X N^^?/6)2[L>F;G+<O9&/12C'A*9(%%SG(3*Y';7K&@&"B_R4E+A#,]*X7
MNESWV78\S@O!U;R[*-";WR:Z^J$5WCUYAA7^=N0< M7 3-N(?"0YQG9V;2:C
M3G2_23%<P/*8!,.JV\&37KB <2S)A=/[/?EJDSE(;[X_+Q?\[]\6,_U^U50N
M6!\TZ^TQSHM$ B&Y ) C"2AA',@TQI@G(D;,*:[%MN.Q&9];<M<7:-66Y/_C
M'W&:H'^NZTW:1KHY#X0E<06 -S1Q[2';EIT)<0O@BHXOIK+M=EBF<@3C@*E<
MW_<;B/%F4<KIW?SEJBSEG#]]*>F\TKTU 2/U?\V:\P#QGZOFHO.]7'Y07^CW
MC^9N5/]BN2RG;%7[(WQ9?-3VX7PY(2RF>8:QWI1GFNY(ILR_*) L+O*8P"*5
M3DEY!Y5^;)S9*AGQ5LMHN5$LHFO-_$2&A/D>\CQ!4.422&*^AZQ( ".) )D2
M,,V)8E05;NZWH_TBAO'KM?PF',W_83\*NZ5XM ,=>#VW"%WJ/H(.@V@+A-H&
MV((AVN!P$QF_LX4RH4]Z7].@$6W#8?8X#2#AXZ&"CF/@J*HPLH\B-BOHL-A&
M>(45(E 9@^I"'NRZ-%WU=M[$O.S5K7O]799\JO>JY93+"8(HP3DF(!7F5E5P
MI7>-, 8HAH3E*BL$=TN2.)SL8S.BNC('=T8#*<*7=/7X&=@ME",=W,#+I$UQ
MA,JV.D*#@,GDW6!PI!1KAT-4 S%@T03_HS=4)06/DH^KO(+_(7&NN1! A)Z7
M_7N%"$WYP:VKH<:1VJA1+>L4-1.F4LR58B:F.@4PA00PG'*@_R<%SZE$.7$*
MV'(48&PW.6L)(R-BD\?'\3+>=0@L;]@# AMX<;"H?JI_M@.\Q[OTGKCYNB!W
M[7[86^^>X!Q<9?=MYYF,_XYR[0R_))-$,*%-_YSJ/PI9 !)C#C(2"\ZR N7(
MR<MI6/''N@60K9 CV 2X?0X#[0."#?*/M!58@_!C[@9ZC>%8-@1NPO]8>X)>
M ^-]6]!/BGYKYGNY?$FK;Q_+Q>-42/'BZ:N6Z>V\33\WO[OER^EC4RN,:*.?
M9T2!-,MB "63@)FJGFF6XE3FG*=%XK(GL.]Z;+L!<T+/M>C10RN[X2W5R1W1
MM>!N"Y;#6-@M-F$0#KQ0&'"-U-''+7!_,I)KLO\Y6@L?W5Z&V9G:W1'S1,L.
M'0]*J>Z [--ACQ9ZI\+8JV*^]BN"N4(J(0E@24P C%$,*(,QR/-"&^JR2%F>
M.P4DG.QJ;&;U1M*H$[5WH/89@"T/*[S %IA_>B+6)WW$!3#\I8@XU='0:2 N
M*'PDU<.E-ZZBBDH;7^9XHKG"U#21T9AJB@ \ARDP>20!1GD,L*G^F,5YJ@V=
M'C2QU\U(*:(R7NGNP=@GH'0BA"L &H8,JJB5\*9UY_!Y$GD6 [\<L-_)<\S_
M$XJ>F/NGGKXF2-HXZ#1Q-(9;5II>6E=TO?=Z(=6B;!T<OM#O)O!&$X[N0YLK
MY=/;I;ROWFMU]9M:==W379?-8)(F!44XHX!R(0&$IHYUS@5(LMR412F2'$N7
M[5% 6<>XGS()M"-6:]0EU5X:G?K$:8<98#M*&\FP!>;%'5^WR,SU:*-JM-&U
M&]'V^5K=FVA7O75"$-_!Y4$'P6MP>AA)GR&X/2CDQX/CPW;9\R;J=(@+17F"
M,<U )N($0*'7"BP9 HB(%,="%!Q#IUNC'R:ZZ//):"+'N@E7!Q#]$"%#VT+^
M4Q<P=-P/.,C^=+#(H;'$"KE'!P6+!_I8R@<Z%:^_F^N#3>:@.F%LM\/"(N:<
M0PBR#!< 2I(#EA<Q**#()62Q*)@3D5CT.39&:46.9"-S$UJW:*JT-!+WRL9L
M@[X=T7C&-##C='"VXM9H-H$.C<0!-K\. 'DK]WNYQX'+_5I#<%CNU_[5WAOF
MTD1GOY+-WV_G=1?KT.TV<;G>VO(DQCG@5*4 8BP!D0(!EN5ZYXLD44IUZ:2M
M=[\6'5M-GMW,T:'=6.KYTH=U+*&VWH7Z@F^P#64M:/13)_+/QK>C@7.3[L%W
MJGDWG/SM^6PZ'7K[Y@#$D9V8R]M^<C!O2EA*FA=<YAPDD&4 FAH3F,<(%&F*
M2,8+7$BG2)R3/8W- #('9V;_6_O(U:)>EWK9M2JH%Z ",\NQY,M!,J5>!"-0
M_N5GJIEY4=U+&9BOK6))Q>/]Y).\UX2S*FO'J@]J-Z?,)^,V]4%]U;91LWB*
M1.(L(TC;*50"R!,(B,H4$#B72A$ND]PJ\X%[UV-CCAWA3;CQ8KW&-BFJ2J,
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M@XCO2I_'NGJ>4I]GE#Y9Z_/<.WVOS]Z: S-JO/"E9B;:I?C*("<2<PXP)A+
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M%D+3GEG=LCC+DGJ%\]##(&N</R2Z5<YCB\^97_GR+5"6%E*D10&4"5V >J<
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MO#VY6#\ZC>J!O<)XZJ#]/MQKP=*'^9(L67MA#"](P@N1@ SJ MRL5"M+5B1
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M/2P2@!-" "Q%'%,L*<ZMJBO=Q$[M-*#6.C)J1[7>!^P)5CRK0X;!;KGK']S
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M;+4!I9@@,\@-"(4Q<.E%DJ$=0*ZMO1T\.DYX-A+KR."H5N]H@>',DY8LD##
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ME;."D$P"8;1QA7ME>>M:Y?TH;C*'Y]K,TZ-9OISV<M&3X7+#&!.5X E<J.U
MO(GUMHF!MTXD[9C1S<=&/);&<2W< 1%XYY2>H939J?7['5=UZ $YHVM&=[%[
M-S^BA<5[D*Q&MNYE6,S(_ZZO^M:+7&#(Q>@=.@\>"P7CT1D*QCV'K!4/*>>
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ML6['0Q;%G2TX8FG<72P?HD!.>'*S>!80RWJNK@L09320Z,N*:?016\]@&K)
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MG.J2:72Y6!O7;]<LG6I9@(^1MG<J)@F.U?WI!-K7"._?:Q@7VKMK>=^Z]$'
M?<GR=0%,O/=H BN@7+(U+JPCAWBAN-"60@<21]_ZX?JVM(U[<S,>1)OHJH=;
MFJ-9OGX-<,T?FBCOM4W20_&97"':6A2-\DCG!2+W7D0Z0;:^FWEXK7%O9(:'
MTA BW_M]S=Y.Z/U<W>&'3&+VP21BRUI4M<TB \^Y)6^$!6N<X8FSW>%TQXI;
M@<K\C*#:5_SC/]W:FK?J!TQ(=C$+.OF]\^39"DO;ACO:-ES)DI36]F9E[![0
MJBMN!2W[WP!:CQ9_!X'%G7PM[W@I,3$B,U6PEDG6XN!B)8F.3G45E$<1E5*Q
M]37)UL1M!4'W="$XK+9:6[@NGOX=Y3Q=OY>G+U)D='+EF?PA'_@]2,:(S_BV
M%\\A'NMEH009300,U=7+,4)T/D)1CNN(F')H'=@-^5CO1MQ^PRA</S#>S9=K
M14Q2S-RQB, )=K45G0,?? %D#DLLPC+1^D7++G1V<C^]+XIN6M;!5;;S64_[
M/<Z''-LQ33A;TL]_Q1G)=>>.*'=^3I,Q'C\DL)&).EMATR1GML;4WZ>KS\]/
MEZOY"2ZNC(KAW$>AP!7'0*5$:D\J '-2,!6X0M]ZIVY)VMZ&:[H,GSXMZK%^
MUA5MO>SF3I0Q1KP)#0F#)<^6(B>GZQ,QSW+RPNEH6AOIA^@9UQ -@95;-JF5
M-D:,,Y:+U>1YG2:'"Q+LZOOOX037I6HR:Q6S8I!9+&2LF87 0JP8,"F6)+S8
MJE$Q+7 %2?2W2Q3=M_;HK7,;:77>4,0C0^0]?CE=I,]AB4<D&MP\2+G.TEE9
M$ N80DX"Z-RME1DL@S.LGO0F*6,ETVZK1Y4_P,W6!(T#IC8ZGP^M@+$3^V_P
M&\X_?L9%^(*GJVE:OIZELS(PM-YRKBP0*W7>F^00##IP&9G741:I[8]<GA^L
M,1XT!M+FO+UH.TB!W6.0+S,V1C&MN>50:IY&H3$0N$\@,LM>%88VMBYA^A%-
MHS? ;GN$#:**#J#U R]QTY9S.OMTM%S6N6ZY7M\SPY&9VFJ86P053*H6/("5
MQ4LM-"NI]2R6'<CLTH?:$2>W6O\-J[1.6ZQM!L'M$?]?_??MQG<.&._?&'WG
MHS&HM0!1M =E(F%&&%8?SPAD.FCN6L>W0XSO7'_F"URFQ70]!&-CE7UVWOJ0
M0)K"*0YU]640G<DR6J:,,5FJUEW!'B"GJW&<C]'[W>,X]Q=Y!V?5O0/0GGVO
M3V\WT84HR+U(8$VH@U.\@)!]@*B%\<7&%)IW1]^"K+'1U @"VPZDVU$?/4.L
M,G06D/ @4K 4-TC:B:"L*>"=,B0W$S%S8UEIW5IN"[+&A5AS*&P]^W WO70
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MH/7AE**@M1N0YB<X887":RXU6!UK.%SYP"C!>-HR,DNA5/,9G-<H&/<IX9#
MV4/275_JGC]0FI<_9GFZ3.M2H/SJ='6ZV$CR? KSZ8R4=WWC['LAW&#M=I?)
MK04QS$6TDU(%6R*$).LHHCIZU<L %&0F&3E])[2_JVUY$7UWN#+%Y;EX7YQ>
MSKTE/S$*15ZC#))<QV@Y..4#<%-*SN1)HFB=NG@,?6.G,W9&QDWC-IA2.C@B
M[SKQ+Z+D<_[>8\U0UWU=7M'>#\?_A6$Q89HS:8L"J;#>58@(GD4.0?!Z]V\C
M>0,'<,RVHW;DJ:R#(6@+!VX =3X5X))8?Z>3YN.?>/P5?Z,(Z3.%1TZPXG.&
MXG0D'S:0>*-@D&-4*6*RLK3V G>E=>1)K5V!=E]5/B'(UNWX\<_YA,58I'*.
M3JH<0'%1P+%Z&8PVT:Y$G63K*5B/)''<A%YW -U%<4\-EP0TG$29L&1+&P]S
M[0'( GCG,H2B+ 5[%.&E86HB'T'DN*G /K'Y:.4],72^FI\N)B82(PD58!6I
M<HI!3.3O.^=TSJPV*6I=>/)8&L?-(':)S4>KKL?+D OF/LZ?X;LPS4>%5KM@
MSZ.H#R@8L(09%*N]L:5-D*02(FEID&W[<NZQ:X^;>AP<<8?0R!.RA9/,T6FO
M&9@<R ,16D (2!&=HL#.,_KM9I>\@]G <9N>=6?['J6J#EJ%5[[F-Q*\Y^Q<
M9A-^"[46<?7]<DB\9UJA-%"XQ-KP!2$*]"19%Q-SS,<P1-3]>$K'+HYIEK4\
M@*(ZL8CW<5E-_GM,./V*^>Z<%XH<=7 >N,\)E/(4LFE7('%F&0HGA!S"5=R9
MX+%3ZL,CZA$@;JO>)X3E6WDP1,^$P0*B/M=54EL(*/6ZAY>-4F8]2$IS%UK'
M-J_=(G@OI3XA\'[\<UYEO)SD6/RFNW[-CRFM''C!#)@Z*$6RF(3@(X'VG,;Q
MZQ4[!>M.2GQ*(*V)L@V'P4:;6"BUZ:P%%8*!6,-$D7S(#)-WO'53B<=3.7[9
M8Z] W4V13PBJ-8VQ85!E1X<")O!:.))GS. RCR"]D+I(+Z-N_5+ST42.7SK9
M*5!W4V,/.=![N+O*W/6<6PRUI:S1D"4=%\IZ!3$H#4X7$:.6VH7MAK7OLOKX
M)9@' N!A]/.$#&4=\>QR81FTC@$44QRJ]""''$HP]&W5^DG6MK2-FQ/MV"P^
M2FG-LJ-M*XF?A>,P2_CA,^+J^?SDRWQ6N;PLJ#U_'!ZNO O_'5=[=-S?<\46
M5<,MF6Y4*WR5I/>XG@9W5R]TSY5S.5,T4V0= N<HI(GK2? B<^=30=OZZF0[
MRMK-0[Z_'<'ZV7A@(07O)$3%. 5US(,3,0$3N5C/9:*HK_4[B2UI&S<!.@""
M[A^!W%!)'9S2VS3BB<SFHE0$5DA:2M0F%<E["):34^QJC-;ZI5?W/;*&P<,.
M#;,>HYR>\7:EXXK'K'E,"J1CM3-*=A DEY CYL"LSSFU?C_Q4S3,>A04=FB8
M]1B]= "U.Q]WGS??":I$%.0CA\J*- C.:0$NH$3E8M;-6](^0$ZGT-I5];=B
MBC9ZZ !2%Z(Y;PM&L4Y&$2 HFXA\H2"DXD 8)$MO50J\=6KO!@G]]\_:!SK[
MR+L#N-0 ZY0^[B8;0KJR?A5A@LFUAURB")VG.DS%Z^"4X[ZU(W\/*>/>I T-
MGQ;R[P!&KTX7LVE]T$LB>C7]5O]T;C\="M3)*'#&>5#1"8@A%$ GE1'$C2BR
M,9+NIV;<VZZAP=1("QW@J;; 62U.4]7,ZQG)[1.Q<LX+"A)0I "E"$M.)"OU
M1,8(-BJKM<Q.Z^9#41^@9]R+J>$-5"--=("J>V7UYJ*3A<W>""X92!U-W2<&
M EH!(MN@T9@0<NO2DA]3-:X'-6X>83?5] RV]0#K22HE,B,R,%]'5JM4(&JN
M@-NDD^6NM!]\\#!%G49X.^I_6W@]7AD=0.LHI=.3TTT2&8F(- V;2<)?CG&M
ML%D^.IDO5M-_KK]^+_,3JX*6/A?P25<O4XI:,""@),V=2+7(M;5OUHKV3J/*
M-G =1<'[]JH<UFK^CJN)<#I@8'3 K&><U9<U+FH/FA=;0F16A(.-*2!Z.HU,
M![:8CU7$$[U:IRVX.,7\\MN7.@>Y#G=_N_J,B^>;[L-77G\->-G^:!H.<?V^
MGV .>R%?VW@H38$/]T5#?9<)$3D#'Y'QS(R5XFE=R*]+L\XT4'MAT_>G*1P_
M/_N=]ND+_(K'\_5.I2V<*%9[/E^NEA/N#8^BE@5*61, ,5,,J"P89I2G'2L3
M+S_"Z\ZK/XF[]\> Y5JIW.#ZZ,/E7.]Z,FOS[XC/<(9ENEJ>[?I)--%+5BC@
M<S+5[IX!@O 1,-22Z5B(F]8IF8<I&M<]'!!Q RBD'WC1#BFT0TA+X?@5X@4W
M@3'A.-=@9+TV5IXVBTC$36T2ZJ3'U+R1[\,4C>OZ'0Y>+132 ;P^AF_K9_HU
M377.@JZ=;'QT(-9)4>DH-.+((42+W*F<3/-BO3O(&/="X@! VE?T':!G[=^>
M;8@K_NW%7I \%(<!M*Q3D@J%6E$7#LP%AUH9V?XUXL,4C7LA<0!,-53(V,]@
M;D131_=&4Q.9E3-*1@@Z"MHT9'R=P @L%'(7.2^(\C$._(^7'/?!RX&\]L:2
M[S3;4;,WJ^^O29ZSU?0K'OT9%GGYX?3D)"R^S\N'U3S]X^VZI_OR*-$/T,_N
MD=;8?;$6^8M&K#9*5%Q"]FVIV13"VIJE,T2O8\$/GVE#Q+ D=^OL'<OE0YEL
MDD\R@->*W'@?);BD#>&OH"DN6.=;-TK>C^*]7QK43WY6/_GJVD>+19A]PDTQ
MZ>6/G"V^5O&93M^>KI:K,*MS,=_/CX]?S1?UFQ/E-!D#]!"8U/5E)#D;(4O(
MWGECO2/)-I_?, @GXV92#HCF6Z\;Q@=&!ZYH0RELA@!- C'(0C(0+!;2"9UK
M05D+-@?/D+ZA76L+TYR)D=]9=(#,X3;+#C#9>9]\P<5TGC^LPF+5Q6[Y&_W@
M:OEZ]FY-UZ940/OLK&,<. L*5/0.8I2RAK):8T(K0^MH;P V1JXH^OEVS+Y0
MZ>%LJ:[QZ^62@J(7ZVG0&U[6;"^O^LTOO^$B39?UB35FF3%ZL 9U[8&::KXY
M IF#XJ-?IW-:;X9'4SENKK9'K ^KZ"[J2/85.\FYX+J6^F)33U!&KKT5=/S5
MCE7))(@A&["6"]KJ1L3N7*4[V!@WX]SC=A@9*C_%?KGM,7),)L;UA( <0=71
MW$&2")(5H3@M8RR].4J[!1:#9=)_PKVR'TSV#"Q>SOK8*V?':KT1.Q-"CBYQ
M%1QPXS*H8#6X^D!:>'2V)KAE\Q;7S9D8][;@)]PK^\&DAX"BG4[^CM-/G^FL
M._J*B_ )SQW3=XMIPJJO<J8O9*IH4V?0"FM!%4YV)=4.>)(<6)0ZM*\0/CR7
MXP;O/T<.> A _??9<A-M<LPV62BHR2X62UKDCGX)VM(9+J0SS?L\'8:UGR:7
M/ C"Q]F0CX+;T\D^+Q^54WQ00,&@B(+\@>*,!,62!I]5A!09"LV*+ZQY(NYP
M[/TTV>HN]N1(L'L*I^./1'/._7;2B<@2<I[K4%D$I3A"=$&!EK8.@?(ZXL'S
MA4TY_&DRZT]B7PX'OI]A:]Z1A7U0/BH6D:WE]:&W (6*@6?94UCB/"H1DFD^
M^.;0//XTF?XGL3V'!.!3V*"-7/T8LD@V6&"^ZI!)A%"<@UQ2E,B9B*;U2[*>
M(LNG<)G0Q78< 6X_W_7#PZ*Q'H5/B611V_G(PLFY-P*X#BY&7CP[O/O:AK6?
MYJKB*>S$(>#6[#P\Y"N+][A<$:?$_[K&YH_9=#7\:XMM%AW^U<6C6>_C]87S
M*?.D->3@-"C'R$53EO8.+X99&9&T\'.]OKAH];:[.[SI!<>M,T;0;@Z:C(W2
M1D'(7(%46D7KD@FV]7C<9L0_Z3<6C\'L_1,D#JG^#H*;#>7G3>JED=H$AT G
MI@3%C05G2AW"X93S.23/6K\,OT9 +V,C#@J"F_T'=M9(!W#:77"7;,]R[;SU
M>SBY:.(:5?0V>[#*UHWM"]19:Y!%#"5I1D',P>OI=N!C7'#O :MF^:)&.NX
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M9IP560$@2D(Y7(<1!MML94V58 %(2,0-5NG?PB;BH[$"LG/;A@L<4 ?I55I
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M4!P*-Y5EXI,CODC2?C=Q":ZJLP1EP6>-$I5'HXP0BJ,73_'L1Q*U&+,S46@
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M$R7"<FNJ>D]MMXEK'>I4(NN-76D7-N0*J4HEN+TLGRF9@R%FAD36ZHY-.;C
M,@;V=:+T*72#;ANZZ!1'P_#=TE,@K&R5:EKV<,M0%Y9Q,26;:(9)'>"J"-2?
MF)T!WU^A&M)"K)MI)9*4YIG,NP?;_JJ\T^.W7XX:)Y>I1D-*Z5(+.L,/70JP
M9D>MY0=8_L4\L?9R3^SN[^EL;U71>ZON4;J]/OO:&_:[EY?L*QZH>_%^O<?I
M+FXKZYQ8@TB+NC53(Z8P$1W!J2IU^<B'6W42PP\Z^[C\59YOW^B3"HU,XL;
M#L;&^"P4Q^:/$T>&,Y?/CZ5'I*";3O+CV8/A +:+4)/K(=%0U&7-IT='M:-F
M UDU@M%$CGFPYN(:<?%NY"Q>:S=K^_7FTLOU6F/IM=NZW:_56W_M7L'%/:BW
MG[[;VM'1X9UZW2564.P #!?.N/?[5FLKU8H$]8[KC!SQI+^D::.YT+8Y^XZM
ML^*!2'&!/_W9UKT0>+-VL)?YCO(J]9?K>FEPM]_I#Q]WP'3U9E6E5R6BWKS+
M.^X*UK;(I2L8^K%"L-A4RP##WRVUPG<2AW40^=T\S\'%V1UM%2R4X>49AB,P
MA(!C/'FL^%=&*I8!4G"^0OK)SGE,ARB]EZ$]^>';1M3C,;U:R;Y+:=4]_KV(
MS<,9HA>%3R(W^B),Y"\F404ILMCI1(HQZR:),BKW+E@ODSX]P*&5?@0.R*W(
M5VB,-X2/6XNUUH+V3'0(WRJ%^X/)(0])X-9B>#8+9<,@)(ADA"<UD>>&N& Z
M+S9502AL5MLT_LE"R0Q+-=O5AY:77]Z==R\ON]U-P\Q+WPZ=\?O7(5LOV/D%
M.Z_?TF>Q<\=S NCU?[S8P:*A%Z3Z@E0KS[]YG@6@>G%1>99]P:TON+5:_/.,
M<>MYIW]V?C$XVS38VAET=_JG;-#]T+OHL_Y%C34;%0CZKC$1G+T@]A\"AK(;
MH_4:)5-5!A_='<1O.LXY[_XO:+I!KP,JH7/.NI?#SK#+NO_XTAOVNI>@&6J?
M:]92_7?7V94PPYHF7")LF%?@B2"<R)GU\,.,GL7LH0-.1[U.!6;N5DVK/%P!
M'6R8 MK_Z0JH.DR*$.4?@TOPN0:;IGL^\6#NJE16]9IO+ 3>H!E>"8_RWK5*
M?1+]4DA[;+2IQ3IT3K6:KE7]WE]35S=8MDH7/W)*)0)= >"7#=""5OK&/LIO
M<GEP]ADCA4UBU95QW71.:X[K5H#%__F9#0068=&IANR<:H4ZXS&70?BDG+U+
M^;FY-%_59UD*<,&<_56R^/>>1SUU9:JG\<Q4.L)%'X3'0_8AYG@2@Q_D:V],
M1%J5WH2+9<JJ^-J\\8:/L88JS-;W9)Z3'!.<O@HW>Y2,'L(<[TPK?TR723 \
M._"D;!!C6FY:;IA] -7_J:<D-9A6<H0Q^>GZS!SX!A\:R!"]V"4')^1GKFN2
M]"M<%M]4LSBGW&EHIGIL+(+",6EIV9LB[B,K"2I5.- ^:M>:2G4OJ1S(V=1\
M*GKCP*C]96GL#[S8;M3V'GKO[4.N[_V@(3<;AHZK[RUW>-KUQS@\3Q=(>(9[
M'3JM_5WO8M@]_=B_.+_X0$'-7O]TC=6T/SO)O>A [SVM _V<\B)^OJNW=M'X
M*^2V_P@Q:3;6+29*TZZ)0?J ;>[I:C[>FTQF_'P$J2 \=V+7'\:SZU?M:^79
M(2;15"L^\@PY>DE-QD]GYM91I7#O2R[<L\N%>XG+K8[+[2^/R^V.?&<.OR;1
MU'W[_U!+ P04    " !X@:M6A[8N&T4(  !3)P  %@   &%D=FTM,C R,S S
M,S%E>#,Q,2YH=&W=6FU3&SD2_GZ_0FOJLJ3*[R\!#*'*,4ZMJPBPQ+GL?KJ2
M1ST>%3.C64ECX_WUVRV-L<%VXA3<!>##X!FU6JWN1T^W1G/RR]EE?_3GU8!%
M-HG9U9</Y\,^*U5JM:^M?JUV-CICOXT^G;-VM=Y@(\U3(ZU4*8]KM<%%B94B
M:[-NK3:;S:JS5E7I26UT72-5[5JLE(&JL*)T>D)/\ I<G/[KY)=*A9VI($\@
MM2S0P"T(EAN93MA7 >:&52J%5%]E<RTGD67->K/%OBI](Z?<MUMI8SA=Z#FI
M^?N3FAOD9*S$_/1$R"F3XGU)'ARVVYWF.V@?BF8; GYTU#Z@![P5=AH<^'\;
M:&0-Q7T?8^<QO"\E,JU$0.-W.^W,'L^DL%&W4:__N^3D3D]"E5H<3&-G_]/K
M6--DX=96>"PG:=?-I^2[+IH#%2O=W:N[OV-JJ80\D?&\^^M()F#8!<S8M4IX
M^FO98 PJ!K0,O:"1?P/:A.:YVYFW]P#UQ#*%A?V-)AD]N(WD6%K6:E0;]RW>
M;&N G@7]DXSM#ZY'PX_#?F\TO+Q@EQ_9Z+<!N[H>7O2'5[US-OACT/\R&OYG
M@$TH-;C>.J&$ZPE&TJJL^PY'?B[SN_IR_?E+[V+$1I?L\Z#O9MFJ-W$ZSSXT
M%(G/O>L/O8O!Y\KE'^>#/UFO/Z(8->OUYHZ!^)_;WMYH^[#,SGFNB7L^2A-$
MH,LL &UE.&<VXO;-7N?P>)<IN/$R+@025R6&T'9;=_"2J< !NI76SYMGH_IF
MK_&N?KQ^';*(3X%IF$J8(?7:2!KV4>F$->J5WYD*64],0><)^R"5A2!*T>2)
M!%-FPS1 M9VCU^"@YE8'?> &W:)2ELS93:IF,8@)E+V?-&1*6R84&I(JS%\X
M#I<IX^F<Y:G5.> \,*.YY(:NY"S!.RUYS$(>X"/-5((4;)676Q-((0!CN)Z3
M2,)O ,==T6GPF4!C<,C8948<@P0"J3$3HEB*W=$2 9K-(AE$S.1T6?:?@89"
M"4T@D2;&E$G9=R9MA!,T&03.0-*;H6E*X#01$>B4\7S5#:\%"JT?AP*P4*;H
M;(K;TKEEQ &*8[->:9=IB*N+4^&$OX,X%Z@3 [@*J)!+'<]9ANXGY!"BXG@)
MC2(JYL'(B#[A"K(R2>0Q"B >% ;-C5;8$W 3L3!6,[- BX:)-!;+.<LX/?1R
M:&5Y)>AF8<V:M:\E[NVM<1_=<]*;O<-FX^#8%)$MT@4M&16&$F_WS5OGP2'C
M&ERPT/ER' /YE $"9!Q+$U$/$DN0,8@UZ%Y@$HJ5P8SDN$2KV#B93*L !#XV
M;!]C) "C[@,QN TBGDZ ]7"97N<Q2C1:O-+H[(.WHM$1_L[?2JH44H\6TL]H
M+:^ R,>4;-EYH/#>0"$.1/-\B"R4H$SSB(QZT'Q&:.%;T7(&!FLR=)KCVN]'
MM$QI(."YV;T+\?$8,#K%2)[A5:Y1 2[7J32.!5 *4J>':IDE?ZQ2D(:8NW 7
M%+\,6;F@)VJ4R"5HBU&Q%&Z'9O*QD4)R[2H!Z1.1(\64-.6&DH-;(,9E$D<9
MN 5$@W!OYCIE''$6Y#$GJL-I.2.6209[^)2U2HSX:PPDB&2$_4$\@GR>%9S&
M.\)IY^6[AJK=%_[.X$) 3J4@S'"C4DX,QPWBC<H. A+78A%4A)GD8QE+.Z>T
MLVE8@KB+OPNM1^<]T96RQ1'I;3&A+-<90LNX/!D$2@MG@"M@)I!B^HL18=@"
M&4&71+ X\RA"B,L,N>RUX"C8BJ/!E,>Y6[OD9 A#K"#D%-UC-A0"=SEN!R[R
MMYMK P<;[(@\0JA!X;'*[78+=F%+?B<-5%Z%WZ],V7A1N+F5 -X3:(^+.@WP
M"B(OMC.(=^IZ<&B;4B1UU[(1 3_ &Y1D5!#DFD*PPN@;M";*6'Q.+RY0EPE0
MT5\Y)@14O;^E2XA8PA7]0+HP'*M:<#LLVGRE^9U=;[U5$3=WZ8^XP&$/A"-)
MYX^"P.:XC[J!N-AN/9 O/]I%C\3;LRJ7.T]?+KLW$6*!UO)RV1*+K")FN8(I
MYC^0$]>*G#OK.!8Z5FESEX;< U29X ;= GR#(\<*$QVU"XGV.27[B"ND)$.4
MA_^IW%HL!O@KEVB^ WZ>!FYG]O;U5\4]W,!202$QYK0?H)U%( $C5*20N^IT
M!OR&<H)/Z"XKN%+$O2U9;&9_*.Y%(>EW8QM6.J<W7 ;N%OI6C!0%#';!0&.=
M4?:)R6!6,GF"84)7N<DL]O&;=OVO*>EL+UM[F%M"C8NHC-X'M_0Q?NX=4Q'H
MLJ=FF4Y5/ 7BYY1/BE=ENF +2+)8S0%;9Y'R_,#OP0C#_B3)J[HU&+L[?\/9
MSW-[WWV&OG=<PS[QN0]4HU'V!VH+RZTKY O#QHART!6T+^:9@>[BQS'2=!;S
M>5>F;A37Z;B8XUA9JY)N!TV:$MUCOBX.*ISK?'-Q@'9T6&T>=.@,S:+SK%@,
M7!RO5=WQ6LV*];9F]>BHM;6U7FUL;?N6UDZU?7#X]%I;U>9AY\G5MEK5PW9[
M)[4UYUZ]$"A0T6PX*%JJG&.3\?1]J55Z@/QNG7FIQ1@_5[28R/?Z-+-;ZK5Z
MP$<K^"$@/1;__ZO1'1M_F-_/^P\]\>Y%SNK-7ANIUUT?'JYMG>G3Q'P'2!5\
MYE)KAJZA%UILX9.7Y.4+GL"WT?,*)[UV5ONI>E;]^:!Z22X<T9<QNP+G)4WL
M2N,N@6HR5X#W(PDA&]Q"D-,[)G;I]YK/!RLO#U9.8U=:'"W8(1[[5_[E*E;9
M:V%X^Z@XU%RQN:'$+L9WKTDRY3].Z_H#CBFL?;"U9$=7K=:77?@8*3*WZUV^
M\XU7<?6?F[D/WT[_ 5!+ P04    " !X@:M6I2C>+U4(  !H)P  %@   &%D
M=FTM,C R,S S,S%E>#,Q,BYH=&W=6FUSVK@6_GY_A9;,;=,9WLQ+&TB:&4K(
M+C-9DDWI].ZG.[(M@R:VY95D"/?7WT>2"21 2R;9;9I\(!@=24?G>?2<(]LG
MOYQ=]L=_7@W(5"<QN?KRZ6+8)Z5*K?:UV:_5SL9GY+?Q[Q>D5:U[9"QIJKCF
M(J5QK388E4AIJG76K=7F\WEUWJP*.:F-KVMFJ%8M%D*Q:JC#TNF)^06?C(:G
M_SKYI5(A9R+($Y9J$DA&-0M)KG@Z(5]#IFY(I5)8]46VD'PRU:11;S3)5R%O
M^(RZ=LUUS$Z7XYS4W/5)S4YRXHMP<7H2\AGAX<<2/Z+O.[[?;K0"/VAUVD<=
MK^T?A2W:COQ.D[8:__7@9 WFKH_2BYA]+"4\K4R9F;_;?)_IXSD/];3KU>O_
M+EF[TY-(I!J3271V7]T8&R-I=JLK-.:3M&O74W)=E\V!B(7L'M3MW[%IJ40T
MX?&B^W;,$Z;(B,W)M4AH^K:L@$%%,<DC9ZCX_QA\@GOV<N[\_8!Q8IZRI?]>
MPS@]N)URGVO2]*J-^QYO]S5 9)G\0<[V!]?CX?FPWQL/+T?D\IR,?QN0J^OA
MJ#^\ZEV0\^&HAZ_XUAN=D5Z_?_EE-!Z.?H4E.@VN=ZXOH7("8+7(N@;4E[+<
MJR_7G[_T1F,ROB2?!WV[Z&:]@>6\>*0,,)][UY]ZH\'GRN5_+@9_ H^Q@:Q1
MK^\FVGT@_G;?6UM]'Y;)!4]#2JYSGZ=*,YZ62<"DYM&"Z"G5;P[:1\?[K,%.
MF-$PA)!58A85HF%!P@P J%MI_KB%>M4W!][[^O'FYY!,Z8P1R6:<S2'%>LH5
M.1<R(5Z]\@<1$>F%,R;SA'SB0K-@FL+E"6>J3(9I@&';G=<0H,;. 'VB"F$1
M*4D6Y"85\YB%$U9V<9(L$U*34,"15""?81[*4T+3!<E3+7.&=2##V62'4%*2
MX$IR&I.(!OA)$I% DK5P=AL&*0N84E0NC$E";QCF71M3X;<0SF#*V&9*S&$,
M BZ1&6&6HCL\"9DD\RD/ID3EYF/5?\XD*P8Q"TBXBI%"33:><SW% E7& NN@
M&3>#:R+$,L$(!,5?K(?AM5"A^7@J,!+Q%,$VN*V"6P8/8(YFN=;.TPB[BYI"
M"M^#. \Q)@!<BV09X',9+TB&^!OJ&$K%\8H;!2SJP=2@7V@KM+*QR&,8@! "
MJ-GIE/4GH&I*HEC,U9(MDDVXTBCO-*'F1^<WO"RO@:Z6SFQX^UIP;^W$?7PO
M2&\.CAK>AV-5(%ND"[-E1!1Q7!ZJ=S:"0T(ELU@A]MR/F8DI82"('W,U-3V,
M60+%,*IAKD.N@EBH'/V,ED@1.] R*0(6XF=%#H%1R "Z V)P&TQI.F&DAVUZ
MG<>P\)JTXK4/F?/":X?NREUR4RJDCBQF?&+V\AJ''*;&E[TGBNY-%&$BL\Z'
MS(*%R31/R*@?&B^(+70G6\Z80E&&H%FM_3ZB99,& IJK_;L8/?89T"EF<@HO
M<HD!L%UG7%D1@!5+[3BFEEG)Q[H$2193"W<A\2O(RH4\F48.*8$O2L0\M"<V
ME?N*AYQ*6PEPEXBL**9FI%R9Y& WB+*9Q$H&CH1P"&<UVRFCX%F0Q]0H'99E
MG5@E&?1P*6L]T^*;SXPAQ C]6?@$\7E1=/+WI-/>VW>#5?MO_+W)!4+.>&@X
M0Y5(J5$XJL W4W88(E$9+D$%S3CU><SUPJ2=;=,:BEO\+;2.G?=,U\H6*Z2W
MQ8*R7&:@EK)I,@B$#*T#MH"9L!39+P;#T,(R0UUC@N+,L0@4YQFT[+7P*-C)
MH\&,QKG=NR;(+(I00/ 9PJ.V% )W.6X/+7*7VVL#2QMTA(XH5X'X(M>[/=A'
M+>F=-3/E5?3]RI3XR\+-[@3F(@%_+.IF@E> ?+A;05Q0-\$QQY0BJ=N6K0QX
MA&Z8)"."()<&@C5%WS)J(I3&[^;.!<92 0;Z*T="P-"'.[I$X!)V] /KPG%4
MM<R>L,SA*\WO_'KGO)I2=9?^C!98[K'0BJ2-1R%@"YRC;EA<'+<>V)>?'*(G
M\NU%E<OM/<OEM_L4RO8>1+CD:7FU88U^K'-EM7<-VH_(AAOES1UZ%"6.%E+=
M)2#[ X9,<#37C'U#'7V!%&?:0P[_[""'8!3$2!FQPW]3:"VW ?LKYW#?4CY/
M WLD>_?ZZ^$>3JZFE.# W)P$S)DBX P(%<GCKBZ=,WICLH%+Y38?V"+$WB=9
MGF(?A7M10KISV)8]3LV]+<7NMOA.CA2E"[H :%0899>2%/*1RA/ A%#9Q132
MNO6\_YK2S>Z"M8>L$DELHC*BS^S6!W[V[E(!=-F),D]G(IXQH\PIG10WR62A
M%BS)8K%@:)U/A=,'>H]&@/U9TE9U)QC[!W_+4Z"7=JO[#+&W6D-^IPL'E.>5
M[:.UI>/:5O"%7SY(SF0%[L4T4ZR[_'(,E<YBNNCRU$YB.QT72_2%UB+IMN'1
MS*@]$G7QB,)&SC473](Z1U6OV3 /TS1BI\/EQ,5SMJI]SE;3X69;H]KI=':V
MUJO>SK9OC=JNMHZ.GG_49K7A/;^SS6;UJ-/::]B:#:]<&A2D:'RP3-2F9(Y5
M1M./I6;I ?&[=>)9J^4</]:T6,CW^C2R6]-K_=&>V< /">FX^,]O1OO\^-/B
M?MI_&(GW/^6JWARTH+SV<^.QVLZE/@_H>W"J$#2;6C/$QMS*(LN@_$QA'M&$
M?9L^KW#1+X]/CXP>(/A!H1N;=V/V)<S/Q(G^E+.(G-^5=)?N5/ERJ/'\+/J[
MXVU'['*-V8(]$#B\<C=0$?P-&.QI:-7>6]UU+0S>/0FHFBT\MU3;Z^]L9<*]
ML=9U3SEF;.,MKI50VLJUONI"?:AEKC>[?.?%K^+3O8-FWX8[_3]02P,$%
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MKALYPSACRI*,:Y\SL<*HSEG=DLI<QLL4$QN)19Z:\-Z'7+(O2RZ9&=G*:'B
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M+Q\" &%D=FTM,C R,S S,S$N>'-D4$L! A0#%     @ >(&K5@_+EC.F%@
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M9'9M+3(P,C,P,S,Q97@S,C$N:'1M4$L! A0#%     @ >(&K5MY%J!G!!
M Q0  !8              ( !24$# &%D=FTM,C R,S S,S%E>#,R,BYH=&U0
52P4&      L "P#> @  /D8#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
